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i 
Summary 
Fusidic acid is a protein synthesis inhibitor commonly used to treat Gram-positive 
infections caused by pathogens such as Staphylococcus aureus. Gram-negative 
bacteria are intrinsically resistant due to their low permeability outer membrane and efflux 
pumps. UK optometrists are licenced to prescribe fusidic acid for the treatment of 
bacterial eye infections. However, 45 % cases of bacterial keratitis – a severe, sight-
threatening corneal infection – are caused by Gram-negative organisms. As some metal 
ions have been found to enhance the activity and extend the spectrum of established 
antimicrobial drugs, this work sought to investigate the efficacy of combining metal ions 
with fusidic acid as a potential reformulation strategy to repurpose fusidic acid as a broad 
spectrum, first line treatment for bacterial keratitis. The presence of Al3+, Cu2+ or Fe2+ 
ions was found to increase the activity of the fusidic acid sodium salt, sodium fusidate, 
against a selection of multi-drug resistant Gram-negative Escherichia coli, Klebsiella 
pneumoniae and Pseudomonas aeruginosa isolates, without reducing anti-S. aureus 
efficacy. P. aeruginosa was particularly susceptible to sodium fusidate with Al3+. There 
was no apparent link between the carriage of multi-drug resistance determinants and 
susceptibility to the combinations. With no evidence of spontaneous complexation, the 
mechanism of action against E. coli was determined to be reduced fusidate solubility 
enabling increased membrane access combined with the independent antimicrobial 
activity of metal ions. Proliferation of human corneal epithelial cells was less inhibited by 
Al3+, Cu2+ or Fe2+ than the Gram-negative reference strains, suggesting clinical 
selectivity. Unfortunately, the combinations were inactive against Gram-negatives in a 
novel rationalised simulated tear fluid, likely due to protein binding of both agents. 
However, future formulation optimisation may overcome this issue. Finally, the discovery 
of Al3+ and sodium fusidate activity against P. aeruginosa has prompted further research 
into the combined mechanism of action in this important opportunistic pathogen. 
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Chapter 1: Introduction 
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1.1 Overview 
Antimicrobial agents are regularly relied upon to prevent and treat bacterial infections, 
which would have been incapacitating or fatal not too many years ago. However, the 
diversity and rapid evolution of pathogenic organisms can limit the effectiveness of 
antimicrobial drugs and necessitates the continuous development of new anti-infective 
strategies. By exploiting the potential for co‐administration of agents to enhance the 
activity of previously approved antimicrobials, new therapeutic formulations with wider 
spectrums of activity may be developed and made available for human use in a shorter 
time frame than a completely novel drug could be. Such potential has already been 
demonstrated in the literature, and preliminary investigations at Cardiff University’s 
School of Pharmacy and Pharmaceutical Sciences have identified a promising 
combination of fusidic acid (FA) and ionic metals. This combination will form the basis of 
the present thesis which aims to understand the possible mechanisms and spectrum of 
activity of FA metal ion mixtures and assess their potential for clinical application in 
bacterial keratitis. 
1.2 Bacterial keratitis 
Keratitis is a serious sight-threatening inflammation of the cornea, usually occurring in 
response to infection. In most cases, keratitis is instigated by damage to the corneal 
epithelium due to traumatic injury, surgery, or, more commonly, abrasion such as that 
experienced during contact lens wear[1]. This allows pathogenic microbes to infiltrate the 
cornea, initiate infection and cause ulceration. While less common, keratitis can also be 
caused by microorganisms that are able to cross the intact corneal epithelial barrier[2]. 
Infectious keratitis can be bacterial, fungal, viral or protozoan and even polymicrobial. 
Prognosis, severity and treatment vary between causative organism and predisposing 
or concomitant factors. The focus of this work employing the antibacterial agent FA is 
bacterial keratitis. 
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1.2.1 Prevalence and predisposing factors 
Incidence of microbial keratitis in industrialised and cooler regions is lower than in tropical 
or developing countries. For example, rates of all-cause keratitis in temperate Minnesota 
during the late 1980s was 11 per 100,000 people per year[3] whereas in the early 1990s 
113 and 799 per 100,000 per year were reported in South India and Nepal, respectively. 
Based on the available incidence figures for these developing countries, the WHO 
estimates a burden of 1.5 to 2 million cases per year in Africa and Asia alone[4]. 
Incidence has significantly increased over time in industrialised countries due to 
widespread contact lens use[5]. There was a 435 % increase in annual cases between 
the 1950s and late 1980s in the Minnesota population[3] and by the late 1990s, incidence 
in northern California was 27.6 per 100,000 per year. However, from 2005 to 2015 in 
Queensland, Australia, microbial keratitis cases were less common at 6.6 per 100,000 
people per year[6]. Rates for bacterial keratitis alone are not accurately known as these 
population-based studies do not differentiate between infective agent. However, it is 
understood that bacterial pathogens predominate in industrialised, temperate regions, 
whereas fungi and parasites are more common in tropical and developing areas[1]. 
Even in regions with the highest prevalence, total incidence of microbial keratitis is 
substantially lower than most other ocular infections. For example, a conservative 
estimate for conjunctivitis caused solely by bacterial infection is >3,000 per 100,000 
people per year in Denmark[7]. However, complications in conjunctivitis are extremely 
rare[8] whereas even with effective treatment and excellent care, serious, vision-impairing 
complications occur in at least 5 % of bacterial keratitis cases[9]. 
Predisposing factors also vary by geographical region and population. Contact lens use 
is the most important risk for the development of bacterial keratitis in industrialised 
areas[1],[10]. This includes both day-time vision-correction or cosmetic lenses and 
overnight corneal-shaping orthokeratological lenses[10]. The risk is further compounded 
by poor lens hygiene, use during swimming or showering and long duration of wear due 
to increased likelihood of biofilm formation, contamination by environmental organisms 
or slowed clearing of potential pathogens, respectively[1]. In particular, extended wear of 
lenses increases chances of establishment of infection as the lens protects any microbes 
between it and the ocular surface from the sweeping action of blinking, allowing them to 
adhere[2]. In a study of keratitis in Taiwanese children – a population with a high 
prevalence of myopia – 34 % of cases were associated with soft contact lens wear and 
a further 19 % with orthokeratology[10]. 
4 
Conversely, traumatic injury is the most common cause of microbial keratitis in 
developing countries where agricultural occupations predominate[11],[12]. Table 1.1 
summarises rates of the most commonly reported predisposing factors identified in 
seven different studies of microbial keratitis. Industrialised countries see ≤20 % cases 
caused by traumatic injury[10],[13]–[15], whereas more than 45 % were related to trauma in 
an agricultural region of India[12]. 
Table 1.1 – Summary of variation in contribution of the four most commonly reported 
predisposing factors to initiation of microbial keratitis by country (%) 
 Hong 
Kong[16] * 
Taiwan[10] 
(paediatric) 
Australia[17] USA[13] * India[12] 
# 
France[14] 
# 
Switzerland[15] # 
Contact 
lens use 51.9 52.9 33.7 43.0 2.0 50.3 36.5 
Ocular 
surgery 5.1 4.4 NR 34.0 22.0 4.0 5.9 
Ocular 
trauma 12.6 16.2 36.4 13.0 46.6 15.0 20.0 
Ocular 
surface 
disease 
33.2 10.3 6.0 44.0 12.5 21.3 8.2 
Values do not total 100 % per country due to inclusion of other factors not summarised here. 
* Hong Kong and USA studies assigned patients to multiple categories. 
# Numbers from India, France and Switzerland are for bacterial keratitis only. 
NR: not reported 
Ocular surgery such as corneal transplant is also an important keratitis risk factor, along 
with pre-existing ocular surface disease. Both these conditions alter the normal structure 
and function of the corneal epithelium. Frequency of surgery-related keratitis varies by 
region whereas ocular surface disease appears to be the sole identified predisposing 
factor for approximately 10-20 % of keratitis cases globally. 
1.2.2 Symptoms, pathology and progression 
Bacterial keratitis presents as a combination of decreased visual acuity[1],[18],[19], 
photophobia[1],[18] and pain[1],[18],[19], often with redness of the eye[1],[18],[19] and discharge[18]. 
The discomfort experienced is usually a foreign body sensation rather than the gritty 
feeling common to other eye infections such as conjunctivitis[18]. However, not all 
symptoms are present in all patients[19]. On closer physical examination the affected eye 
can be found to exhibit corneal ulceration or stromal abscess with or without a hypopyon 
or localised oedema[20]. Presentation and progression can, but does not always, vary 
depending on the causative organism. Figure 1.1 illustrates various presentations and 
stages of keratitis caused by a variety of bacteria. 
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Figure 1.1 - Examples of bacterial keratitis presentation from the literature 
A: Streptococcus pneumoniae (Gram-positive) with an early uneven corneal infiltrate[21]; 
B: Klebsiella pneumoniae (Gram-negative) diffuse growth in a corneal graft[22]; 
C: Pseudomonas aeruginosa (Gram-negative) severe presentation illustrating large corneal 
infiltrate (top arrow) and hypopyon (bottom arrow)[1]; 
D: An unidentified Gram-negative in canine ulcerative keratitis nearing corneal perforation[23]. 
The infection starts with colonisation of an epithelial abrasion or defect by a microbial 
pathogen[24]. Once adhered, the organisms are able to migrate into the corneal stroma 
and trigger an inflammatory response. Figure 1.1A depicts an early uneven corneal 
infiltrate at the beginning of infection. This leads to ulceration (Figure 1.1C) and corneal 
degradation (Figure 1.1D) which can result in perforation and loss of the eye[1]. The 
rapidity and severity of progression varies by organism[24]. Fungal infections tend to 
advance more quickly than those of Gram-positive (GP) bacteria. However, keratitis 
caused by Gram-negative (GN) bacteria – and Pseudomonas aeruginosa in particular – 
can cause extensive inflammation, progress rapidly and result complete corneal 
destruction within as little as 24-48 h[20],[24].  
Bacteria are not only capable of melting the cornea by digesting collagen[25], they can 
also secrete agents which actively inhibit cell migration and therefore prevent healing of 
the epithelium[26]. Examples of organisms that have been shown to produce migration 
inhibitors include the GP Staphylococcus aureus and GNs Serratia marcescens and 
P. aeruginosa[26]. P. aeruginosa also produces multiple virulence factors which increase 
the severity of disease. These include a glycocalyx coating which provides protection 
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from phagocytosis, proteases which degrade the extracellular tissue structures and 
cause mammalian cell lysis, and exotoxins which destroy immunoglobulins, inhibit 
mammalian protein synthesis and induce apoptosis[19]. In addition, triggering of the 
immune response and ulceration contributes further to corneal damage, slowing healing 
and increasing chances of perforation[1]. If the infection goes uncontrolled, bacteria can 
also spread into the internal eye and cause endophthalmitis which even further 
complicates treatment and increases likelihood of resulting in enucleation[27]. Finally, 
while re-epithelialisation is indicative of successful treatment, the healed cornea 
frequently remains scarred which causes permanent reduction in visual acuity[28],[29]. 
1.2.3 Diagnosis 
Rapid and accurate diagnosis is essential to providing appropriate treatment in all types 
of microbial keratitis. Visualisation of the size, depth, location and shape of corneal 
infiltrates can be assessed using a slit lamp[1],[18]. These features, as well as the general 
condition of the surrounding eye tissues, may give indication to the cause of infection[1]. 
However, visual features vary widely and even highly trained corneal specialists are only 
able to distinguish bacterial from fungal aetiology 66 % of the time[21]. Alternatively, 
experienced practitioners can also use in vivo confocal microscopy to identify fungal or 
Acanthamoeba infections. However, bacterial cells are too small to be visualised via 
confocal microscopy and equipment availability and expertise is not widespread[1]. 
Corneal scrape for microscopy and culture is the gold standard for diagnosis of microbial 
keratitis[1],[18],[30]. Multiple corneal scrapes are performed using a needle or blade in order 
to recover and identify the causative organism(s). Each scrape is immediately used 
either to smear slides for staining and microscopy or to inoculate one of a variety of 
microbiological media. The smears and inoculations must be performed “patient-side” 
and, while the materials will be delivered to a laboratory for processing and interpretation, 
the required media and sampling skills need to be available to the consulted healthcare 
professional[1],[30]. Gram and Giemsa staining on receipt of the prepared slides can 
enable early indicative diagnosis of infective agent and, therefore, most appropriate initial 
treatment. However, the reliability of Gram stain results is directly linked to organism 
density in the smear which may be too low in scrapes from the early stages of disease 
or due to poor scraping and/or smearing technique[30]. The received cultures are 
incubated for at least 1-2 weeks as certain bacteria and other causers of microbial 
keratitis can be extremely slow growing in the laboratory[30]. Finally, antimicrobial 
7 
sensitivity testing is carried out on the recovered isolates in order to confirm drug 
selection and guide modification of the treatment regimen where necessary. 
Even with careful collection and processing, frequency of successful recovery of the 
infecting organism from a corneal scrape can be as low as 30-50 %[31]–[33]. Highest 
reported rates of positive microbial culture are only 65-85 %[15],[34],[35]. Lack of 
understanding of the cause of infection and the antimicrobial sensitivity profile can 
severely limit the healthcare provider’s ability to administer efficacious treatment. 
Alternative sample collection methods have been trialled in an attempt to increase the 
uptake and reliability of corneal culture. As an alternative to the healthcare professional 
undertaking multiple corneal scrapes and inoculating the required media patient-side, a 
single-use brush-like “ESwab” has been tested[36]. The ESwab is used to sample the 
corneal ulcer just once and placed in specialised transport medium which both maintains 
microbial viability and preserves nucleic acids for polymerase chain reaction (PCR) 
analysis. The ESwab sample is shipped directly to the microbiology laboratory for 
culturing and analysis. While the culture positive rate was no greater than the traditional 
method, the ESwab was found to minimise inadvertent growth of contaminants and be 
more cost-effective than the traditional scrape method. Another modified sample 
collection method is a corneal impression membrane[37]. A circular piece of sterile 
polytetrafluoroethylene (PTFE) membrane is carefully placed on the infected cornea for 
5 s to adsorb present microbes onto its hydrophilic surface. Similarly to the ESwab, the 
membrane is then immersed in transport medium and sent to the laboratory for 
processing. The authors found a significant increase in organism recovery with an 
impression membrane compared to using a surgical blade. 
However, regardless of the increased performance and convenience of these modified 
sample collection methods, the long turnaround time for culture and sensitivity testing 
can cause a severely detrimental delay to the initiation of effective treatment. 
Nevertheless, knowledge of antimicrobial susceptibility profiles is essential to 
management of the infection in the context of ever-increasing and evolving resistance in 
both bacterial and fungal pathogens. In order to address the need for both faster and 
more reliable confirmation of the causative organism, a number of PCR protocols have 
already been developed, with results often available within 24 h[1],[30]. Unlike microbial 
culture, these tests require only very small amounts of DNA to be recovered from a 
corneal sample and do not rely on the successful collection of viable organisms in order 
to obtain results. However, access to facilities and equipment necessary to carry out 
such tests and analyse results currently remains sparse. Construction of rapid diagnostic 
panels have also been suggested, such as a dot hybridisation assay[38]. In this method, 
bacterial DNA from corneal sampling is amplified by PCR, labelled with a UV-sensitive 
8 
marker and applied to a membrane embedded with organism-specific complimentary 
DNA probes. On exposure to UV light, positive dots become coloured indicating 
presence of the sought DNA and identifying the infecting organism. Such an assay may 
be more easily modified into a patient-side version than more comprehensive PCR 
analysis. This technique could theoretically also include known resistance genes in order 
to provide indicative antimicrobial susceptibility data. However, isolation and culture of 
the organism and determination of the minimum inhibitory concentration (MIC) of specific 
agents is likely to still be required in parallel, as bacteria and other pathogens often 
evolve novel resistance mechanisms which could otherwise go undetected. In addition, 
for many antimicrobials, resistance is rarely absolute and topical antimicrobial application 
can often surpass the MICs of organisms considered clinically resistant. 
1.2.4 Causative organisms 
A meta-analysis compiling bacterial causes of ocular infection demonstrated that the 
percentage of bacterial keratitis cases attributable to each species varied substantially 
by country[27]. The proportion of GN isolates reported in each study varied from <10 to 
>60 %. However, in 10 of 11 studies, P. aeruginosa was the most frequent GN isolate 
(in the report from the 11th country the percentage of infections caused by P. aeruginosa 
was equal to another GN organism, Escherichia coli, both accounting for 20 %). Table 
1.2 demonstrates a similarly wide variety in the ratio of GP:GN organisms isolated from 
bacterial keratitis both by country and reporting period in 24 additional observational 
studies from the literature. 
GP bacteria most often isolated from bacterial keratitis tend to be Staphylococcal and 
Streptococcal species, however, distribution varies by region[27]. The two most frequently 
isolated causative organisms in a 1996 Southern Californian study were Staphylococcus 
epidermidis (GP, a coagulase-negative Staphylococcus (CoNS)) and P. aeruginosa 
(GN), with isolation rates of 51.4 and 16.2 %, respectively[39]. Only a few years later in 
Northern California, S. aureus (GP) and CoNS accounted for 27.6 and 24.1 % of keratitis 
cases, respectively. In Florida around the same time, S. aureus was the most frequently 
found GP bacterium, isolated in 19.4 % of cases[40], and 25.2 % of cases were also 
caused by S. aureus in the Pittsburgh study[41]. Outside the USA, the two most common 
bacterial keratitis isolates have been reported as S. epidermidis (32.5 %) and 
Streptococcus pneumoniae (GP, 13.9 %) in a Central Indian study[12], S. pneumoniae 
(45.0 %) and P. aeruginosa (23.8 %) in South India, S. epidermidis (32.0 %) and 
S. aureus (21.3 %) in Switzerland[15], P. aeruginosa (49.4 %) and S. aureus (14.8 %) in 
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East Kent, and S. aureus, S. epidermidis, E. coli and P. aeruginosa all at 22.4 % in South 
Eastern Nigeria. While CoNS also accounted for the highest proportion of bacterial 
keratitis cases in a French study (32.8 %), the second most commonly isolated organism 
was the GP anaerobe, Propionibacterium acnes (10.1 %)[14]. Interestingly, P. acnes, was 
also found in 11.1 % of the Taiwanese paediatric cases during 2008-2012[10] and 7.2 % 
isolates during 15 years in St Louis[13] but does not appear to have been reported 
elsewhere. This wide variation in bacterial species isolated from keratitis cases is found 
throughout the literature, differing both by region and over time[33],[42]–[50]. 
Table 1.2 – Variation in percentage of bacterial keratitis cases caused by Gram-positive and 
Gram-negative organisms summarised from 24 observational studies 
Location Reporting period 
Percentage of bacterial keratitis 
isolates 
Gram-positive Gram-negative 
Vancouver, BC, Canada[34] 2006-2008 85.8 14.2 
Vancouver, BC, Canada[34] 2009-2011 72.0 28.0 
St Louis, Missouri, USA[13] 1999-2013 58.8 41.2 
Pittsburgh, Pennsylvania, USA[41] 1993-2012 53.7 46.3 
Southern Florida, USA[40] 1990-1998 49.0 51.0 
São Paulo, Brazil[32] 1975-2007 71.6 28.4 
Glasgow,UK[51] 1995-1998 84.0 16.0 
Glasgow,UK[51] 2004-2007 67.0 33.0 
London, UK[45] 1994-1999 54.7 45.3 
East Kent, UK[52] 1999-2008 38.9 61.1 
Lausanne, Switzerland[15] 1997-1998 76.0 24.0 
Izmir, Turkey[44] 1990-2005 88.6 11.4 
Mansoura Egpyt[31] 2013-2015 61.8 38.2 
Riyadh, Saudi Arabia[43] 2001-2002 79.1 20.9 
Hyderabad, Pakistan[53] 2011-2012 65.0 35.0 
Hyderabad, India[12] 1991-2001 82.1 17.9 
Hyderabad, India[42] 2007-2010 75.1 24.9 
Hyderabad, India[42] 2011-2014 85.5 14.5 
Shanghai, China[54] 2005-2010 51.9 48.1 
Taiwan[50] 1992-1996 49.1 50.9 
Taiwan[50] 1997-2001 32.5 77.5 
Taiwan[55] 2003-2007 46.2 53.8 
Taiwan[55] 2008-2012 54.8 45.2 
Taiwan[10] (paediatric cases only) 1998-2002 36.0 64.0 
Taiwan[10] (paediatric cases only) 2008-2012 52.9 47.1 
Adelaide, Australia[46] 1998-2003 70.1 29.9 
Sydney, Australia[17] 2001-2003 71.3 28.7 
Sydney, Australia[47] 2016 83.4 16.6 
Christchurch, New Zealand[48] 1997-2001 71.6 28.4 
Wellington, New Zealand[49] 2001-2005 82.5 17.5 
 
However, it is clear that regardless of the local ratio of GP:GN isolates, GN bacteria are 
consistently more common in contact lens-related keratitis than that of any other 
cause[10],[15],[16]. In a French investigation into the predisposing factors of bacterial 
keratitis, 30.5 % of contact lens-related cases were found to be caused by GN organisms 
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while GNs caused only 16.4 % of cases overall[14]. Perhaps more dramatically, the study 
from Florida found 50 % of bacterial corneal isolates from all cases to be GN whereas 
93 % of contact lens users were infected with GN organisms[40]. In another study 
comparing isolates from patients with various predisposing factors, authors found that 
43 % of contact lens users’ infections were caused by GN species whereas only 25 % of 
isolates from non-contact lens users were GN[15]. The ratio of GN to GP isolates has also 
been shown to increase within a population over time, approximately in line with contact 
lens use[52],[56],[57]. In addition, P. aeruginosa is the most commonly isolated GN bacterium 
in multiple studies of infectious keratitis[10],[13],[15],[27],[33],[39],[40] and is strongly correlated with 
both prior contact lens use and poor visual outcome[2],[10],[13],[16],[17],[58]. In a four year 
investigation in Central Saudi Arabia, 91.4 % of isolates were GP with only 6.0 % cases 
caused by P. aeruginosa. The authors suggested this relatively low rate of P. aeruginosa 
may be due to the rarity of contact lens use in the country’s dry climate[59]. Interestingly, 
however, despite 29.4 % of cases being contact lens-associated, no P. aeruginosa was 
found in a New Zealand North Island study[49], further illustrating the differences in 
isolates recovered worldwide. Other GN organisms such as S. marcescens, 
K. pneumoniae, E. coli and Moraxella species are also found in many studies, again with 
frequencies varying by location[27],[34],[39],[53],[57],[60]–[62]. 
1.2.5 Treatment strategy and limitations 
Initial treatment of all microbial keratitis cases must be aggressive to give the best 
chances of slowing progression and limiting further damage to the eye[20]. First line drugs 
are applied hourly for 5-7 days. Since less than 5 % of a dose applied to the ocular 
surface is retained in the cornea[63], very frequent administration is required in order to 
ensure continuously high enough concentrations to rapidly reduce microbial numbers. In 
the absence of laboratory results, broad-spectrum empirical treatment is initiated based 
on the presumptive diagnosis of a bacterial, yeast or filamentary fungal infection[20],[39].  
The current treatment strategy still in use in the UK is well summarised by Ong & Corbett, 
2015[1]. For bacterial keratitis, a fluoroquinolone, such as moxifloxacin 0.5 % or 
levofloxacin 0.5 %, is usually selected as the first line treatment. In severe cases, this is 
combined with a cephalosporin, for example cefuroxime 5 % or ceftazidime 5 %. 
Fluoroquinolones are inhibitors of DNA replication with good activity against most GN 
and GP aerobic bacteria[64], however, anaerobic organisms are more susceptible to some 
fluoroquinolone agents (e.g. moxifloxacin) than others (e.g. levofloxacin)[39],[65]. 
Cephalosporins are β-lactams which work by preventing cell wall peptidoglycan cross-
11 
linking[66]. Although cephalosporins are effective against both aerobic and anaerobic GP 
and GN isolates, GP isolates tend to be most sensitive to the first generation 
cephalosporins (e.g. cefuroxime) which have less activity against GN organisms while, 
conversely, GNs are more susceptible to third generation (e.g. ceftazidime) which are 
less active against GPs[66]. In addition, development and spread of antimicrobial 
resistance varies over time and by geographical region. Therefore, the exact agent or 
combination used initially will be informed by the healthcare provider’s current knowledge 
of potential ocular pathogens circulating locally and their resistance profiles. The course 
of infection is usually closely monitored, allowing therapy to be reviewed and modified 
based on clinical response as well as laboratory results once available[67]. 
However, empirical treatment does not always aid resolution[39] and use of ineffective 
agents can significantly extend the time taken for the cornea to heal once appropriate 
therapy is started[5]. Success of empirical treatment is also limited by the inevitable 
development and spread of antimicrobial resistance. Resistance to the cephalosporins 
and fluoroquinolones commonly used in keratitis has already been repeatedly 
observed[24],[40],[67]–[69] 
1.2.6 Antimicrobial resistance 
Continually increasing antimicrobial resistance poses a significant challenge to 
effectively managing and treating bacterial keratitis[70]. Where there is high incidence of 
resistance, empirical treatment cannot be relied upon to consistently slow or halt the 
infection and, in resistant cases, may not provide any clinical benefit. In addition, not only 
is the spectrum of bacteria capable of causing keratitis and their respective innate 
capacities to tolerate certain antimicrobials wide, the tendency to develop and harbour 
resistance also varies between species and changes over time. It is therefore evermore 
necessary to determine the antimicrobial susceptibility profile of corneal isolates, not only 
to direct treatment of the individual patient but also to understand and track local 
resistance patterns and inform future first line treatment[14],[70]. 
Bacteria can be resistant to antimicrobials by intrinsic and acquired mechanisms. 
Intrinsic resistance describes a universal phenotypic, metabolic or genetic feature of the 
bacterial species which renders the organism tolerant to an antimicrobial. For example, 
S. marcescens is intrinsically resistant to polymyxin B due to the innate structure of the 
lipopolysaccharides (LPS) of their outer membrane[71]. Acquired resistance occurs with 
genetic changes which enable the bacterium to produce a modified version of or 
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alternative to the antimicrobial target, different to the archetypal members of its species. 
These changes can either be as a result of mutations in the original gene on the 
chromosome or by gaining additional genes harboured on a plasmid. Plasmids are small, 
circular, non-essential, extra-chromosomal DNAs which often encode for multiple drug 
resistance genes and can be transferred between bacterial species. In addition to like-
for-like substitutions for the antimicrobial target, plasmids may also enable resistance by 
encoding enzymes which can inactivate the antimicrobial, efflux operons which allow the 
bacterium to pump the antimicrobial out of the cell or alternative uptake porins which 
prevent the antimicrobial entering the cell. For example, β-lactamase is a plasmid-
encoded enzyme which cleaves and inactivates β-lactam antimicrobials (penicillins)[72]. 
Intrinsic resistance limits the spectrum of use of individual antimicrobial drugs at the time 
of their introduction and throughout their lifecycle. On the other hand, both 
chromosomally acquired and plasmid-borne resistance develops in bacterial populations 
in response to exposure to an antimicrobial. This resistance emerges and spreads over 
time, gradually decreasing the drug’s usefulness.  
While the development of resistance could be limited by comprehensive antimicrobial 
stewardship, geographical and economical differences in drug availability, commonplace 
international travel and, in particular, variations in clinical and agricultural use policies 
combine to thwart such efforts[73]. Some studies have reported no increase in 
antimicrobial resistance and retention of high rates of susceptibility in bacterial keratitis 
isolates (comparison between 1998-2002 and 2008-2012 in Taiwan[10], comparison 
between 2006-2008 and 2009-2011 in Vancouver[34], over eleven years up to 2015 in 
Queensland[6] and over 15 years up to 2013 in Central India[13]). However, there is 
evidence of increasing resistance to fluoroquinolones in both GP and GN bacteria and 
the spread of extended-spectrum β-lactamases (ESBLs) threatens the effectiveness of 
cephalosporins. Table 1.3 illustrates the variety in fluoroquinolone and cephalosporin 
resistance levels in bacterial keratitis isolates globally over 35 years as snapshots from 
individual studies. 
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Table 1.3 - Summary of fluoroquinolone and cephalosporin resistance identified in 
bacterial keratitis isolates 
Location Reporting period Organism(s) 
Fluoroquinolones 
% resistant 
Cephalosporins 
% resistant 
San Francisco, 
California, USA[74] 1996-2015 
 
MSSA 
MRSA 
S. pneumoniae 
MSCoNS 
MRCoNS 
Pseudomonas sp. 
Serratia sp 
Moraxella sp 
MXF 
8.5 
90.5 
0.0 
33.3 
87.1 
3.4 
0.0 
0.0 
CIP 
7.7 
92.0 
- 
16.1 
81.3 
1.9 
0.0 
0.0 
OFX 
- 
- 
0.0 
0.0 
0.0 
- 
- 
- 
CEF 
0.0 
- 
- 
0.0 
83.0 
- 
- 
- 
CAZ 
- 
- 
- 
- 
- 
1.9 
0.0 
0.0 
Dallas, Texas, 
USA[75] 2000-2004 
 
CoNS 
S. aureus 
P. aeruginosa 
CIP/LVX 
33.3 
15.4 
0.0 
- 
Miami, Florida, 
USA[76] 1985-1987 P. aeruginosa 
OFX 
9.4 
CIP 
0.0 
TVA 
0.0 - 
Miami, Florida, 
USA[76] 1995-1999 P. aeruginosa 
OFX 
9.4 
CIP 
4.7 
TVA 
4.7 - 
Miami, Florida, 
USA[77] 1990-2001 S. pneumoniae 
LVX 
0.0 
OFX 
46.0 
CIP 
36.0 - 
Glasgow,UK[51] 1995-1998 
 
All GN 
All GP 
CIP 
0 
5 
CXM 
4 
61 
LEX 
61 
7 
Glasgow,UK[51] 2004-2007 
 
All GN 
All GP 
CIP 
0 
7 
CXM 
63 
9 
LEX 
51 
8 
Aba, Nigeria[78] 2005-2006 
 
S. aureus 
S. epidermidis 
S. pneumoniae 
E. coli 
K. pneumoniae 
P. aeruginosa 
OFX 
80 
70 
20 
80 
30 
20 
CIP 
20 
80 
90 
60 
20 
10 
LEX 
20 
20 
20 
50 
55 
80 
Mansoura, 
Egpyt[31] 2013-2015 
 
S. aureus 
S. epidermidis 
Streptococcus sp. 
P. aeruginosa 
K. pneumoniae 
CIP 
23.8 
25.0 
40.0 
16.7 
20.0 
OFX 
19.0 
12.5 
20.0 
25.0 
20.0 
GAT 
4.8 
0.0 
0.0 
25.0 
0.0 
MXF 
28.6 
27.5 
20.0 
16.7 
0.0 
CTX 
19.0 
12.5 
0.0 
33.3 
40.0 
Irbid, Jordan[79] 2005-2009 
 
All GN 
All GP 
CIP 
22.3 
22.0 
CEC 
55.6 
42.2 
CFM 
74.0 
68.9 
CEF 
68.8 
34.3 
CTX 
55.6 
15.7 
Riyadh, Saudi 
Arabia[43] 2001-2002 
 
S. pneumoniae 
S. aureus 
CoNS 
P. aeruginosa 
OFX 
0.0 
0.0 
0.0 
0.0 
CFZ 
38.5 
33.3 
72.4 
100 
CRO 
0.0 
- 
- 
- 
CAZ 
- 
- 
- 
0.0 
Hyderabad, 
Pakistan[53] 2011-2012 
All isolates (35 % 
GN) 
OFX 
21.3 
CIP 
26.3 
NOR 
27.5 
CFZ 
20.0 
Coimbatore, 
India[80] 2002 CoNS 
CIP 
40.0 
OFX 
31.4 
CFZ 
51.4 
CTX 
51.4 
Hyderabad, 
India[81] 2005-2008 All GP cocci 
CIP 
24.4 
OFX 
30.0 
MXF 
28.6 
GAT 
5.1 - 
Table 1.3 continued overleaf. 
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Table 1.3 continued - Summary of fluoroquinolone and cephalosporin resistance identified 
in bacterial keratitis isolates 
Location Reporting period Organism(s) 
Fluoroquinolones 
% resistant 
Cephalosporins 
 % resistant 
Hyderabad, 
India[42] 2007-2010 
 
S. pneumoniae 
S. aureus 
P. aeruginosa 
CIP 
5.5 
48.1 
4.1 
OFX 
1.3 
30.0 
4.0 
GAT 
5.9 
7.7 
2.0 
MXF 
0.0 
36.8 
4.7 
CEF 
0.0 
3.8 
- 
Hyderabad, 
India[42] 2011-2014 
 
S. pneumoniae 
S. aureus 
P. aeruginosa 
CIP 
3.3 
46.1 
10.9 
OFX 
0.8 
29.4 
9.1 
GAT 
2.4 
17.4 
8.5 
MXF 
1.9 
42.0 
13.4 
CEF 
0.8 
6.8 
- 
Trichy, India[62] 2005-2012 
 
S. epidermidis 
S. aureus 
S. pneumoniae 
P. aeruginosa 
CIP 
29.6 
23.4 
24.3 
17.1 
GAT 
6.2 
2.1 
5.0 
7.2 
MXF 
30.4 
26.6 
13.5 
7.9 
OFX 
19.5 
17.0 
13.6 
23.2 
- 
Shanghai, 
China[82] 2005-2010 
 
All GN 
All GP 
LVX 
0.0 
10.8 
CIP 
9.1 
13.2 
OFX 
18.2 
18.4 
FEP 
9.1 
6.9 
CAZ 
18.2 
6.9 
CFZ 
36.4 
13.8 
Taiwan[33] 1994-2005 
 
All GN 
All GP 
CIP 
1.2 
- 
CAZ 
2.7 
- 
CFZ 
80.0 
15.4 
Taiwan[55] 2003-2012 All GN CIP 6.3 
CAZ 
9.1 
Adelaide, 
Australia[46] 1998-2003 CoNS 
CIP 
0.0 
CEF 
35.0 
Queensland, 
Australia[6] 2005-2015 
 
All GN 
All GP 
unspecified 
1.5 
5.7 
1st gen 
29.5 
18.7 
3rd gen 
2.0 
5.9 
Sydney, 
Australia[83] 1998-2002 
 
S. aureus 
CoNS 
P. aeruginosa 
CIP 
16.7 
6.3 
0.0 
CEF 
0.0 
21.7 
- 
CAZ 
- 
- 
0.0 
Sydney, 
Australia[84] 2002-2003 
 
CoNS 
P. aeruginosa 
S. aureus 
CIP 
10.0 
0.0 
0.0 
CEF 
0.0 
100.0 
0.0 
Sydney, 
Australia[47] 2016 
 
S. aureus 
CoNS 
S. pneumoniae 
P. aeruginosa 
OFX/CIP  
7 
9 
40 
7 
CEF 
7 
9 
0 
- 
Brisbane, 
Australia[58] 1999-2004 
 
CoNS 
S. aureus 
S. pneumoniae 
P. aeruginosa 
CIP 
6 
5 
0 
0 
CEF 
34 
5 
0 
- 
CAZ/CTX 
- 
- 
- 
0 
Auckland, New 
Zealand[85] 2013-2014 
 
All GN 
All GP 
CIP 
0.0 
1.2 
CFZ 
0.0 
0.0 
CXM 
66.6 
- 
CAZ 
0.0 
0.0 
MSSA: methicillin-sensitive S. aureus, MRSA: methicillin-resistant S. aureus, 
MSCoNS: methicillin-sensitive CoNS, MRCoNS: methicillin-resistant CoNS 
CIP: ciprofloxacin, GAT: gatifloxacin, LVX: levofloxacin, MXF: moxifloxacin, NOR: norfloxacin, 
OFX: ofloxacin, TVA: trovafloxacin; CEC: cefaclor, CEF: cefalotin (cephalothin), CFZ: cefazolin, 
FEP: cefepime, CFM: cefixime, CTX: cefotaxime (cephotaxime), CAZ: ceftazidime, 
CRO: ceftriaxone, CXM: cefuroxime, LEX: cephalexin 
- : not reported  
15 
Fluoroquinolone resistance in S. aureus keratitis isolates was found to have increased 
from 11 % in 1990 to 28 % in 1998 in South Florida[40], however, P. aeruginosa remained 
susceptible over the same period. In Pittsburgh, overall GP resistance to ciprofloxacin 
and ofloxacin increased from 19.1 to 41.1 and 15.0 to 35.7 %, respectively, from 1993 to 
1997 while GN fluoroquinolone resistance remained constant at no more than 6 % 
throughout the study period[56]. At around the same time, P. aeruginosa resistance to 
ciprofloxacin emerged in Hyderabad, India, increasing from 0 % in 1992 to 20 % in 
1997[69]. Later, and nearly 600 miles South in Coimbatore, P. aeruginosa resistance to 
moxifloxacin dramatically increased over two years, from 19 % in 2007 to 52 % in 
2009[86]. Elsewhere in South India, fluoroquinolone resistance in both methicillin-
susceptible S. aureus (MSSA) and Enterobacteriaceae was found to rise between 2004 
and 2010[86]. Methicillin-resistant S. aureus (MRSA) ocular isolates with high levels of 
resistance to fluoroquinolones conferred by multiple mechanisms were found in Japan 
in 2003 and 2004[87] and emergence of ciprofloxacin resistance was identified in 
Melbourne, Australia with rates increasing from 0 % in 2000 to 6.6 % in 2014[88]. 
Cephalosporin resistance has also risen. S. aureus resistance to cefazolin was found to 
have increased from 23 to 40 % in North Carolina from 1997 to 2004 while P. aeruginosa 
remained susceptible to ceftazidime over the same period[89]. GN resistance to 
cefuroxime dramatically increased in Glasgow from 4 % in 1995-1998 to 63 % in 2004-
2007[51]. While it was already high in Oxford, it also increased between 1999-2004 and 
2004-2009 form 87.3 to 96.2 %[90]. GN resistance to ceftazidime emerged from 2000 to 
2015 in Toronto, with rates increasing to 20 %[35]. Interestingly, decreasing GN 
cefuroxime resistance was identified in Manchester with overall rates changing from 
51.8 % in 2004-2006 to 38.6 % in 2013-2015[91]. However, the proportion of GN 
infections caused by P. aeruginosa (which is intrinsically resistant to cefuroxime) 
decreased between these periods which may explain this shift. While most studies do 
not identify the mechanism of resistance, ESBL production is increasingly common in 
resistant GN organisms and likely to be present in many clinical settings. Between 7 and 
16 % of GN organisms isolated from ocular infections from Sep-2008 to Aug-2009 in 
Tirunelveli, South India produced at least one ESBL[92]. Of these, 53, 44 and 2 % of 
E. coli, K. pneumoniae and P. aeruginosa isolates, respectively, were ESBL producers. 
At the same institute between 2011 and 2014, 17 % of all GN ocular isolates produced 
ESBLs, including 17, 8 and 38 % of E. coli, K. pneumoniae and P. aeruginosa isolates, 
respectively[93]. Often due to co-localisation of other virulence factors, ESBL-producing 
and multi-drug resistant (MDR) GN organisms can cause particularly severe corneal 
disease with swifter progression, greater risk of corneal perforation and increased 
likelihood of surgical intervention[94],[95]. 
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While development of antimicrobial resistance cannot be circumvented, the availability 
of additional treatment options may aid the preservation of current fluoroquinolone and 
cephalosporin activity in bacterial keratitis. Fusidic acid (FA) is an old drug which can be 
effective in treating Staphylococcal keratitis[96]. More than 97 % of ocular MRSA isolates 
remain susceptible to FA despite resistance to other agents according to a study from 
2005-2015 in Hong Kong[97]. Furthermore, addition of corticosteroids to bacterial keratitis 
treatment regimens for the control of inflammation has been shown to reduce scarring[1] 
and FA is known to exert moderate anti-inflammatory activity[98]. 
1.3 Fusidic acid 
1.3.1 Discovery and introduction 
FA is a natural product and true antibiotic produced by the fungus Fusidium coccineum. 
The isolation was first reported in the early 1960’s by Godtfredsen et al of LEO 
Pharmaceutical Products, Denmark. The initial method of harvest required 120 h growth 
of the fungus at 24 °C in deep culture fermenters, the antibiotic being extracted directly 
from the growth medium after clarification[99].  
In its free acid form, FA is only sparingly soluble in water, however, the sodium salt, 
sodium fusidate (FNa) is considered soluble at concentrations up to 50 mg mL-1. The 
structure was elucidated in 1964 and confirmed to be steroidal but with an unusual chair-
boat-chair conformation[100]. Figure 1.2 illustrates the three-dimensional structure of FA 
compared to cholesterol. 
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Figure 1.2 – The 2D and 3D structures of fusidic acid and cholesterol 
A: fusidic acid 2D diagram and its 3D structure rotated along the steroid core axis by 90° 
revealing the boat-chair-boat conformation; 
B: cholesterol, a typical steroid with boat-boat-boat arrangement. 
Early reports confirmed FNa to be bacteriostatic against a number of GP organisms. 
Strains of S. aureus exhibited the most consistent susceptibility and required lower 
concentrations to be inhibited than other GP species, with MICs in the range of 
0.03 to 0.5 μg mL-1 and the majority being 0.25 μg mL-1 or less[101],[102]. Bactericidal 
activity was also found against S. aureus with 0.5 μg mL-1 killing 90 % of cells after 
15 h[101] and, where variation in minimum bactericidal concentration (MBC) was found, it 
fell within a range of 2 to 4 times that of the MIC[102]. The first investigation into clinical 
isolates in 1962 found only 4 of 200 penicillin resistant strains of S. aureus were also 
resistant to inhibition of growth by up to 1 μg mL-1 FNa[103]. FNa was also tested and 
shown to be active against Corynebacterium diphtheriae (the causative agent of 
diphtheria) and Clostridium tetani (tetanus)[99]. 
The initial in vivo investigations of FNa indicated an LD50 of 0.2 g kg-1 in mice and the 
drug proved to be well tolerated in rats inducing no pathological changes after oral 
administration of 0.4 g kg-1 for 6 months[99]. Soon afterwards, testing in human volunteers 
confirmed FNa to be antimicrobially active in the serum after administration of 20 mg kg-1 
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orally every 6 h, despite significant albumin and γ-globulin binding[103]. Trials in patients 
began almost immediately, and the developmental timeline was as follows: 
1962 In a controlled clinical trial in S. aureus burn infections, a higher proportion of 
wounds were cleared of infection by FNa (17/18) than with the methicillin 
comparator (10/15) or no-treatment control (1/18). However, post-treatment, 
resistant isolates were obtained from half the patients who received FNa, and 
these were also found as either colonisers or causes of infection in other patients 
on the same ward[104]. Conversely, in a case series from the same time, FNa was 
shown to be effective as monotherapy in the treatment of S. aureus 
gastroenteritis, upper respiratory tract infection, pneumonia and chronic 
osteomyelitis, with only one osteomyelitis isolate developing resistance to FA[103]. 
When used topically to clear intranasal S. aureus carriage, FNa out-performed 
the standard chlorhexidine treatment (68/77 patients), but strains isolated after 
re-establishment of carriage showed resistance to FA[103]. 
A single case report of particular interest was the successful treatment of 
septicaemia caused by Staphylococcus pyogenes. The patient’s infection had 
been largely unresponsive to a range of antimicrobials given both alone and in 
combination over the course of more than 4 months but was cleared by FNa[105]. 
1963 In a case series of 8 patients with extensive post-operative wound infections and 
osteomyelitis, FNa treatment combined with penicillin resulted in complete 
healing and sterilisation of the lesion site within 12 days in 5 cases[102]. 
Furthermore, favourable outcome was obtained for all but one patient and no 
induction of resistance was detected. Rapidity of healing was such the authors 
suggested FA may have a direct role in accelerating healing, independent of the 
antimicrobial activity. In another study, 5 days of oral FNa given to nurses with 
skin and soft tissue infections caused by S. aureus resistant to penicillin, 
streptomycin, tetracyclines and sulphonamides was very well tolerated[106]. 
Treatment resulted in cure in 13 of 16 cases, the final three recovering after an 
additional course required due to severity or complications. 
1967 FA was found to be well tolerated and effective in the treatment of children with 
a range of staphylococcal infections at 30 mg kg-1 [107]. 
1971 Oral FA 250 mg once daily in patients with chronic psoriasis (6 months to 5 years) 
was associated with definitive improvement in 12 out of 13[108]. However, the 
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author noted the possible influence of the placebo effect due to the role of 
emotional factors in psoriasis. 
1984 Oral FNa was shown to be non-inferior to the standard alternatives vancomycin 
and metronidazole in the treatment of Clostridium difficile antibiotic-associated 
colitis[109]. 
1987 FA 1 % viscous eye drops were shown to be safe and effective for the treatment 
of external eye infections in two clinical trials, with success rates of 85 and 
93 %[110],[111]. Both trials also reported lower rates of resistance to FA than to the 
comparator(s) in the causative strains, possibly the reason for increased cure. 
1989 In the first trial of FA in staphylococcal keratitis, 1 % suspension was found to be 
safe and effective, with open-label administration resulting in evidence of healing 
within 21 days for 85 % of patients[96]. 
1990 A Belgian study of S. aureus blood isolate susceptibility found 11.3 % to be 
resistant to oxacillin in vitro. However, for all but two isolates, the MBC of FA was 
1 to 2 mg L-1 which is well within the maintainable blood concentration during 
administration, indicating FNa to be of potential use in MRSA bacteraemia[112]. 
1994 First trial of FNa in the treatment of lepromatous leprosy was conducted. Dosing 
regimens of either 500 mg per day for 8 weeks or 750 mg per day for 4 weeks 
followed by 4 weeks 500 mg per day both showed slow but clinically relevant 
improvement during the course of the study. However, no cure was seen during 
the eight week treatment period[113].. 
2004 In a double-blind randomised controlled trial for the treatment of initial episodes 
of C. difficile-associated diarrhoea, FA was found to be an adequate alternative 
to metronidazole with no significant differences in reduction of toxin or clearance 
of bacterial load[114]. 
2005 FA viscous eye drops were approved for supply by optometrists in the UK[115]. 
2010 FA was assessed in vitro for potential use in the treatment of common sexually 
transmitted bacterial infections where resistance to standard antimicrobials is 
rising. Of 35 Neisseria gonorrhoeae and ten Chlamydia trachomatis isolates 
tested all were sensitive to FA with MICs ≤2 μg mL-1 [116]. 
2011 First reports from FA pharmacokinetic and clinical trials of a revised oral dosing 
regimen were published in preparation for licensing in the USA. The phase I trial 
confirmed the inclusion of a loading dose designed to optimise 
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pharmacodynamics was tell tolerated and achieved the desired stable plasma 
concentrations[117]. 
Subsequent clinical trial of the loading-dose initiated regimen in patients with 
acute bacterial skin and skin structure infections proved comparable to linezolid, 
the standard of care treatment[118]. The modified dosing regimen was 1500 mg 
twice per day on day 1, followed by 600 mg twice per day for 10 to 14 days. 
2015 With significant rise in frequency in incidence of MDR Acinetobacter baumannii 
infection, synergy between colistin and FA was investigated in vitro as a potential 
treatment[119]. FA not only prevented the emergence of colistin resistance, which 
was readily selected for with colistin alone, but synergy between 1 mg mL-1 FA 
and 0.06 mg mL-1 colistin was identified on chequerboard testing. 
Use of topical FA in the care of clean dermatologic procedures was 
retrospectively studied in comparison to petrolatum[120]. No significant differences 
were found in either the outcome or patient satisfaction between the two 
methods, indicating prophylactic topical FA is no more beneficial than non-
antimicrobial wound care in such cases and therefore not recommended for use. 
2016 A randomised trial of combined oral FA and rifampicin uncovered a previously 
undetected interaction[121]. FA plasma concentrations were significantly lowered 
in the presence of rifampicin and declined over time as treatment continued. The 
effect was thought to be due to rifampicin induction of cytochrome P450 3A4 
which increased metabolism and clearance of FA. 
2018 Oral FA was successfully used to clear MRSA from cystic fibrosis patients as part 
of a combined multi-drug and hygiene eradication protocol[122]. 
Knowledge regarding FA has been built slowly since its introduction, and in a manner 
quite different to methods used to satisfy modern standardised regulatory requirements. 
However, the accumulated data and experience has shown it to be a valuable drug, 
particularly in combination with other antibiotics for the treatment of serious MRSA 
infections[123]. In addition, information is being rapidly expanded by recent investigations 
and ongoing clinical trials to license FA in the USA.[124]–[126] 
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1.3.2 Current clinical use 
In the UK, both FA and FNa are available in a range of formulations in line with its various 
applications in staphylococcal infections. LEO Pharma, Berkshire, UK, are still the 
primary manufacturer of FA and FNa preparations in the UK. However, as the drug is 
off-patent, a number of generic versions are also available. Bacterial conjunctivitis, most 
commonly caused by S. aureus, is treated with 1 % viscous eye drops (Figure 1.3A). 
Skin infections, including impetigo, erythrasma, contact dermatitis and infected cuts 
caused by susceptible S. aureus can respond to 2 % cream or ointment (Figure 1.3B 
and C). For more serious skin infection, topical use is often administered in combination 
with systemic therapy. Oral FA is formulated as either 50 mg mL-1 suspension or 250 mg 
tablets (Figure 1.3D and Figure 1.3E). Oral administration is indicated in osteomyelitis, 
pneumonia, septicaemia and wound infections involving susceptible strains of S. aureus, 
including MRSA. Intravenous formulation is also available for use if oral therapy is 
inappropriate, such as in patients with reduced gastrointestinal absorption or lacking 
ability to swallow (Figure 1.3F). 
 
 
Figure 1.3 - Formulations of fusidic acid and sodium fusidate produced by LEO Pharma 
A: Fucithalmic, 1 % fusidic acid viscous eyedrops. B: Fucidin cream, 2 % fusidic acid.  
C: Fucidin ointment, 2 % sodium fusidate. D: Fusidin oral suspension, 50 mg mL-1 fusidic acid.  
E: Fucidin tablets, 250 mg sodium fusidate. F: Fucidin for intravenous injection, 50 mg mL-1 
sodium fusidate when mixed with 10 mL buffer solution. 
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1.3.3 Mechanism of action 
FA is a protein synthesis inhibitor, exerting its effect by halting the progression of peptide 
elongation at the tRNA translocation step. After initiation, the normal process of protein 
synthesis proceeds as elongation factor Tu (EG-Tu), complexed with GTP, activates a 
tRNA carrying the amino acid to be next joined to the growing peptide chain (Figure 1.4, 
box 1). The EG-Tu consumes GTP to assist with the docking of the aminoacyl-tRNA into 
the acceptor site (A site) of the ribosome and alignment of the tRNA anti-codon to the 
mRNA (Figure 1.4, box 2). A transpeptidation reaction between the newly arrived amino 
acid and C-terminal end of the developing peptide is catalysed by peptidyl transferase 
within the ribosome, transferring the growing chain onto the A site tRNA (Figure 1.4, 
box 3)[127]. Once transpeptidation has occurred, translocation begins with the tRNA in the 
A site shifting within the 50S subunit towards the peptidyl (P) site while the now 
deacylated tRNA in the P site shifts towards the exit (E) site (Figure 1.4, box 4)[128],[129]. 
This produces a substantial rotation of the 50S relative to the 30S subunit[130],[131]. 
Elongation factor G (EF-G), activated by another GTP, then catalyses a conformational 
change in the 30S subunit, allowing the mRNA to move through the ribosome and the 
associated tRNAs and peptide chain to complete their shift to their destination sites 
(Figure 1.4, box 5)[132],[133]. This process consumes the GTP complexed to EF-G, 
dissociating GDP from the elongation factor and allowing EF-G to dissociate from the 
ribosome[134]. The deacylated-tRNA at the E site is simultaneously released (Figure 1.4, 
box 6a)[135],[136]. 
FA interrupts protein synthesis by interfering with the translocation step by binding EF-G 
at the point of the EF-G•GTP complex docking onto the ribosome and inducing the 
conformational change (Figure 1.4, box 6b). GTP is consumed but FA stabilises the 
EF-G•GTP•ribosome complex, preventing the dissociation of GDP and consequently 
locking EF-G in place. This ultimately means the ribosome remains in the distorted 
translocation conformation, preventing a new aminoacyl-tRNA from docking into the A 
site to continue adding to the growing peptide (Figure 1.4, box 7)[132],[137]–[139]. 
As the interference of FA halts protein synthesis, its classification is bacteriostatic. The 
agent does not outright kill the bacterium and, if the FA concentration is reduced or the 
drug removed after initial exposure, bacterial cells can recover. However, after 8-15 h in 
the presence of FA, a high proportion of susceptible S. aureus will die due to lack of 
ability to produce new proteins in order to continue to maintain their cellular structures 
and functions[101],[103],[140]. 
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Figure 1.4 - Schematic of prokaryote protein synthesis and mechanism of fusidic acid inhibition 
The normal process of protein synthesis cycles through steps 1 to 6a. However, fusidic acid is able to halt protein synthesis by binding to elongation factor G (EF-G) while 
it is on the ribosome, preventing dissociation. 
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1.3.4 Limitations in bacterial keratitis 
As a clinically significant proportion of bacterial keratitis cases in the UK and worldwide 
are caused by GN bacteria, empirical treatment must be effective against a wide 
spectrum of organisms. FA alone is not clinically effective against GN infections and, 
therefore, is generally not used in the emergency treatment of keratitis. However, lack of 
efficacy is not due to a lack of the EF-G target. In fact, many investigations into FA 
mechanism of action have been carried out using the protein synthesis machinery 
isolated from the model GN organism E. coli[127],[128],[130],[133],[136]–[139]. Intrinsic GN 
resistance occurs because, while FA can readily cross the single phospholipid 
membrane of GP bacteria, the LPS-containing outer membrane (OM) of GN organisms 
poses a considerably greater barrier to large and lipophilic drugs[141],[142]. At the same 
time, GNs possess highly effective multi-drug efflux pumps which contribute to their 
extensive antimicrobial resistance by exporting any toxic molecules that do manage to 
enter the cell[141]–[145]. 
 
Figure 1.5 - Structure of the cell envelope in Gram-negative and Gram-positive bacteria 
Gram-negative organisms have a phospholipid inner cytoplasmic membrane, 7-8 nm layer of 
peptidoglycan and an outer membrane composed of a phospholipid inner leaflet and 
lipopolysaccharide-containing outer leaflet. Gram-positive organisms also exhibit a 
phospholipid cytoplasmic membrane but have no outer membrane and a much thicker 
20-80 nm peptidoglycan cell wall. Illustration not to scale. 
Figure 1.5 illustrates the comparative structures of the GN and GP cell envelope. As 
peptidoglycan is a porous lattice-like structure, the only barrier to the cell interior in GP 
organisms is the single phospholipid cytoplasmic membrane. Lipophilic compounds and 
the lipophilic portion of amphiphilic compounds readily associate with phospholipid 
membranes such as those encasing the bacterial cytoplasm[146]. This allows lipophilic 
and amphiphilic drugs to passively diffuse through to the internal surface of the 
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membrane and consequently access their intracellular targets. However, by comparison, 
cross-linking between the core regions of long LPS molecules and the consequent 
reduction in membrane fluidity substantially limits diffusion of lipophilic molecules 
through the asymmetrical GN OM[144],[147]. For example, the rate of steroid probe diffusion 
through the OM is only 1/100th of that through a standard phospholipid bilayer[148]. 
Therefore, to gain access to the GN cell interior, a drug molecule must first pass through 
the OM either via specific porin channels if hydrophilic[149] or by very slow diffusion if 
hydrophobic[147], then traverse the periplasmic space and finally make it through the 
cytoplasmic membrane. 
To further protect themselves, GN bacteria also employ efflux pumps to remove any 
harmful agents that manage to reach the periplasm or cytosol before they can 
accumulate and cause damage. In E. coli, periplasmic FA is expelled by the resistance 
nodulation division (RND) superfamily efflux pump, AcrAB-TolC[150],[151]. This multi-drug 
efflux pump is composed of six AcrA, three AcrB and three TolC proteins which together 
span both membranes and the periplasm[151]–[154] (Figure 1.6A). The TolC trimer forms an 
outer membrane protein (OMP) with an internal channel leading to the extracellular 
space. Three AcrBs form an inner membrane proton antiporter which protrudes into the 
periplasm and is responsible for recognition and movement of the efflux pump 
substrates. The hexamer of AcrA forms a funnel-like periplasmic membrane fusion 
protein between AcrB and TolC. On contact with a recognised substrate, the structure of 
a pore in AcrB changes from a resting loose “L” shape (Figure 1.6B) to the tight “T” state 
by employing H+ influx energy (Figure 1.6C). This structural shift scoops the toxic agent 
into the AcrB transport pore which subsequently cycles to an open “O” state. Through 
this series of dramatic conformational changes, the offending molecule is shunted though 
and out of AcrB and into the AcrA funnel. At the same time, the T and O conformations 
in AcrB modify the shape of AcrA which, in turn, pulls the TolC channel open like an iris, 
allowing the drug to pass directly into the extracellular space (Figure 1.6C). Once the 
substrate is expelled the efflux pump returns to the resting confirmation (Figure 1.6B)[153]. 
An additional subunit, AcrZ, is frequently found in association with the intracellular face 
of AcrB and its presence, while non-essential to efflux pump function, increases the 
spectrum of transported substrates[155]. 
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Figure 1.6 - Schematic representation of the superstructure and transportation mechanism 
of the E. coli AcrAB-TolC efflux pump, based on images in Wang et al, 2017[153] 
A: The tripartite AcrAB-TolC structure composed of the TolC outer membrane protein, AcrB 
inner membrane antiporter and AcrA periplasmic membrane fusion protein. 
B: Closed, resting conformation of AcrAB-TolC with the AcrB pore in the L position. 
C: Active transport by AcrAB-TolC. The AcrB pore receives the substrate as it changes to the T 
conformation under proton motive force. This structural shift induces conformational change 
in AcrA which pulls the TolC channel open. AcrB then cycles into the O confirmation, expelling 
the substrate through the AcrA-TolC channel and out of the cell. 
Other than FA, E. coli AcrAB-TolC, is known to be responsible for the efflux of many toxic 
and harmful substances. Substrates include a wide range of antimicrobials such as β-
lactams, macrolides and rifampicin as well as tetracyclines and chloramphenicol when 
complexed with AcrZ[142],[155]–[157]. In addition, AcrAB-TolC also effluxes detergents, 
cationic dyes, bile salts, fatty acids and solvents[142],[157]–[159]. While the proteins 
specifically isolated from E. coli have been heavily studied, identical AcrAB-TolC is also 
produced by other Enterobacteriaceae such as K. pneumoniae and Salmonella spp[142]. 
Homologous RND family efflux pumps are likewise found throughout GN bacteria, for 
example: MexAB-OprM and AdeIJK are responsible for expulsion of FA in 
P. aeruginosa[143] and A. baumannii, respectively[160]. 
Despite these intrinsic phenotypic resistance mechanisms, FA is an attractive option for 
potential reformulation in order to extend antimicrobial spectrum for three key reasons: 
1) EF-G is a ubiquitous target in GP and GN bacterial causes of keratitis[161]; 2) although 
genetic FA resistance can develop, rates in S. aureus appear to remain relatively stable 
during topical and ocular use[91],[162]; and, 3) UK optometrists are already licensed to 
prescribe FA for acute conjunctivitis[115],[163]. Co-formulation with an appropriate agent to 
overcome intrinsic FA resistance in GN organisms could provide a more effective 
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empirical option for keratitis, enabling a wide range of healthcare professionals to provide 
rapid and efficient treatment. Using an antimicrobial with a well-established safety profile 
can also minimise the need for extensive pre-clinical studies, clinical trials and de novo 
licensing. 
1.4 Antimicrobial development, drug repurposing and 
co-formulation 
1.4.1 Standard drug development 
Novel drugs take 10-17 years to make it from initial discovery in the laboratory to an 
approved medication available for use[164], currently at the cost of approximately $489 
million (not including post regulatory Phase IV observational studies or marketing 
costs)[165],[166]. In addition, the rate of failure of drug development projects at each stage 
is such that less than one new medication is successfully brought to market for every 40 
projects initiated[167] (Figure 1.7). 
After identification of a therapeutic concept, the standard drug development process 
begins by investigating potential drug targets. Approximately 60 % of initiated drug 
discovery projects successfully find an appropriate target. Large libraries of 100,000 or 
more compounds are screened for interaction with the target, usually utilising in silico 
modelling. This process takes 6 to 12 months and results in a substantially smaller library 
of around 100 to 1,000 compounds that may be suitable drug candidates. The next step 
is lead optimisation during which the selected compounds are tested for their in vitro 
interactions and efficacy at the target. In most cases, promising candidates go through 
multiple rounds of chemical modification in order to hone their specificity and activity. 
Seventy-five per cent of drug discovery projects which begin lead optimisation 
successfully produce about 3 optimised molecules for use in pre-clinical testing. 
However, 60 % of projects fail during pre-clinical testing, which is the first time the drug 
is investigated in vivo. Issues that derail the development process at this stage include 
lack of distribution to the target tissue (unsatisfactory pharmacodynamics), poor 
pharmacokinetic profile resulting in rapid elimination, or toxicity due to drug interactions 
with tissues, cells or receptors other than the intended target. 
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Figure 1.7 - Illustration of the classical drug development pipeline from target identification to regulatory approval, constructed based on data from Rang, 2006[167] 
The width of each trapezoid at the bottom compared to the top represents the proportion of projects estimated to successfully complete that step. Height of the 
trapezoid is proportionate to mean duration to complete the step. Less than one of every 40 drug development projects successfully brings a medication to market. 
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The largest expense in the drug development process are clinical trials. Clinical trials are 
stratified into four main phases, each involving greater numbers of subjects and closer 
to real-world situations than the last. Phase I trials are carried out in a small number of 
carefully selected healthy volunteers. First in man testing is performed to confirm the 
safety of the drug and formulation. This consists of an initial single small dose, followed 
by repeat dosing of incrementally larger amounts if results continue to be favourable. 
Pharmacodynamic and pharmacokinetic investigations are also performed during 
Phase I in order to inform development of suitable dosing regimens. 
The primary aim of Phase II trials is to confirm efficacy of the new drug in a select group 
of patients suffering from the target disease. These tests are generally carried out in a 
larger number of subjects and over a longer duration than Phase I, depending on the 
indication. Only 50 % of Phase II trials successfully confirm efficacy and tolerability of 
investigative new drugs in patients. However, if the outcome is positive, Phase III trials 
can be initiated. These studies recruit large numbers of patients with less strict inclusion 
criteria, resulting in a sample population which much more closely resembles the target 
population. Phase III trials are often double-blinded, where neither the patient nor the 
healthcare professional know whether the novel drug or a comparator (or sometimes a 
placebo) is being administered. Approximately 65 % of Phase III clinical trials yield 
results that sufficiently support the efficacy and safety of the tested agent. The new drug 
must been shown to meet strict criteria in order to be granted regulatory approval for 
marketing and use by the geographically appropriate body (e.g. the MHRA in the UK or 
the FDA in the USA)[166],[168]. Finally, Phase IV post-marketing observational studies are 
carried out in order to monitor safety in the wider population and inform regime 
modifications or potential contra-indications in sub-populations not included in the earlier 
phases. While these regulatory requirements do greatly contribute to the overall quality 
of available medications, complex application processes, differences between 
requirements in different countries, changes in regulatory rules and long approval times 
all extend the duration from novel drug discovery to clinical use[169]. 
1.4.2 The failing antimicrobial pipeline 
While this pipeline is very similar for drug development regardless of the therapeutic 
area, the long and expensive process is particularly detrimental in antimicrobial 
development. In the early days of antibiotics, lack of extensive regulatory control and 
approval allowed rapid development and introduction of novel agents[170],[171]. Alexander 
Fleming initially reported the discovery of penicillin in 1929[172], but it was introduced into 
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clinical use within 3 years of successful purification and demonstration of its activity in 
vivo by Chain et el[173]. Other antimicrobials were developed and put into use during the 
early years of penicillin, including streptomycin, chloramphenicol and doxycycline all 
before 1950[174]. In the United States, the infection-related death rate between 1937 and 
1953 dropped by 8.2% per year[175] – a nearly 3-fold decrease over 15 years. This gave 
rise to the golden age of antibiotics, where introduction of novel agents kept pace with 
and even surpassed the development of resistance. However, resistance was 
acknowledged as a potential problem soon after penicillin’s discovery[176]–[178] and 
Fleming was famously quoted in the New York Times on 26-Jun-1945, observing the 
dangers of poor antimicrobial stewardship: 
“The greatest possibility of evil in self-medication is the use of too 
small doses so that instead of clearing up infection, the microbes are 
educated to resist penicillin and a host of penicillin-fast organisms is 
bred out which can be passed to other individuals and from them to 
others until they reach someone who gets a septicaemia or a 
pneumonia which penicillin cannot save.” 
Now, 80 years after the discovery of penicillin, the widespread and often inappropriate 
use of antimicrobials in humans, companion animals and agriculture has produced 
increasingly resistant bacterial strains worldwide[174],[179],[180]. There are already many 
examples of extremely resistant pathogens. These include, but are by no means limited 
to, carbapenemase-producing Enterobacteriaceae[181], MDR hospital-acquired 
A. baumannii[182], and Mycobacterium tuberculosis resistant to all available 
antibiotics[183]. The rate of increase in antimicrobial resistance is such that it has been 
declared a global health emergency and new drugs or treatment strategies are 
desperately needed[184]. However, while resistance is the primary driver of this need, it 
also severely reduces the attractiveness of antimicrobial development as a 
pharmaceutical company investment. 
Exactly when and how resistance to a particular antimicrobial will occur cannot yet be 
adequately predicted[185],[186]. Figure 1.8 illustrates the variety in time elapsed between 
discovery and identification of clinical resistance for a selection of antimicrobials, which 
ranges from 5 to 60 years[187]. In vitro studies have been used to assess induction of 
resistance in an effort to predict the likely timeframes and mechanisms involved but fail 
to mimic occurrence of resistance in vivo or in clinical situations[188]. This is because the 
complex combinations of selective pressures bacteria experience in real life – 
transferring from host to environment to carrier and to host – are quite different and highly 
variable compared to the carefully controlled laboratory environment[185]. Large and 
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complex computational models are currently required in order to address this issue[186]. 
Until then, unlike drugs for chronic medical conditions, antimicrobials do not have an 
indefinite, or even defined, usable life and are highly likely to become obsolete[189]. In 
addition, novel antimicrobials are often reserved as treatments of last resort in order to 
limit development of resistance and are only administered for short periods at a time, 
which both reduce sales[189]. 
 
 
Figure 1.8 –Duration between antimicrobial discovery and development of clinical 
resistance (from Brooks & Brooks, 2014[187]) 
The useable lifetime of antimicrobial agents varies considerably with between 5 and 60 years 
passing between their discovery and the development of resistance. 
All these factors combine to make the development of novel antimicrobials unattractive 
to pharmaceutical companies as the investment to bring such a drug to market far 
outweighs the potential return[190],[191]. The pharmaceutical industry has consequently 
largely abandoned the antimicrobial market since the 1990s and this has resulted in an 
almost empty pipeline[192]. Figure 1.9 shows the decline in antimicrobial approvals in the 
USA from 1980 to 2014. The FDA has approved six new antimicrobial drugs since 2015, 
however, all are additions to current classes, including two cephalosporins and two 
glycopeptides[192]. The USA and many European countries have recently introduced 
market entry reward schemes which employ monetary incentives to stimulate 
pharmaceutical development of antimicrobial drugs[191],[193],[194]. However, due partly to 
the limited value of funding available, there is concern that the structure of these 
schemes may result in support being awarded for drugs reliant on only a small number 
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of mechanisms of action, leaving the market still vulnerable to the spread of 
unpredictable novel resistance mechanisms[195]. 
 
 
Figure 1.9 - Number of new systemic antibiotics approved by the FDA during each 5 year 
period since 1980 (from Ventola, 2015[169]) 
The number of new antibiotics developed and approved has decreased steadily over the past 
three decades (although four new drugs were approved in 2014), leaving fewer options to 
treat resistant bacteria. 
To help refill the empty pipeline and negate a large proportion of the development time 
and monetary investment, the repurposing of existing drugs is being taken up as an 
alternative route of antimicrobial discovery[196]–[199]. The principle is to discover or recover 
activity of already licensed or well characterised agents. This circumvents the often 
lengthy lead identification and optimisation processes and reduces the need for, or 
number of, costly pre-clinical toxicology and early Phase I studies. In addition, previously 
established safety data can aid the development and licensing processes. Repurposing 
of an existing agent can consequently take as little as 4 years (Figure 1.10). Reviving 
and reinstating old antimicrobials in this way is, therefore, a viable option to help fill the 
current gap in the novel antimicrobial drug pipeline[200],[201]. 
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Figure 1.10 – Comparison of de novo drug discovery timeline to that for drug repurposing 
(based on Ashburn & Thor, 2004[164]) 
After identification of a therapeutic concept, de novo drug discovery takes 10-17 years, up to 9 
years of which is dedicated to identifying the potential drug target, screening or designing 
molecules, optimisation to create a lead drug candidate and in vivo pre-clinical investigations. 
In contrast, drug repurposing begins by identifying a novel property of an existing therapeutic 
followed by legally acquiring the compound, which usually take up to 4 years combined. 
Agents discovered by either route are subsequently assessed through clinical trials before 
being registered for regulatory approval. However, depending on the similarity between the 
original and novel application and the quality of data previously generated, repurposed drugs 
may require relatively short clinical investigations to confirm efficacy in the new indication. 
1.4.3 Co-formulation to extend antimicrobial spectrum 
Co-administration – the administration of more than one antimicrobial drug concomitantly 
– has long been used to increase efficacy. Co-formulation can be used to combine fixed 
dosages of two or more antimicrobials in one preparation for easier co-administration. 
Combining antimicrobial agents can have multiple advantages over monotherapy. When 
combined, antimicrobial drugs can be more efficacious while used at standard dosages, 
thereby reducing chances of toxicity compared to using high-dose monotherapy to 
enhance efficacy; co-administration yields greater treatment success rates than 
monotherapy against infections clinically resistant to either of the individual agents; and, 
in particular, synergistic drug pairs can reduce the induction of resistance[187],[202]–[204]. 
However, co-administration of two or more antimicrobial drugs is not the only method to 
enhance activity. Adjuvants – often agents without antimicrobial activity in their own right 
– can be combined with antimicrobials in order to recover, extend or enhance activity of 
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the drug. There are three principal types of antimicrobial adjuvants: 1) an adjuvant that 
prevents the degradation or modification of the antimicrobial, 2) an adjuvant that 
increases intracellular entry or retention of the antimicrobial, or 3) an adjuvant that 
inhibits repair or alternative pathways which would allow tolerance to the 
antimicrobial[202].  
1.4.3.1 Synergy or potentiation between antimicrobial agents 
Trimethoprim and sulphamethoxazole was first established as an excellent synergistic 
combination for the treatment of N. gonorrhoeae infection (gonorrhoea) in 1967[205] and 
an effective option for hospital-acquired urinary tract infection in 1969[206]. The synergistic 
activity of trimethoprim and sulphonamide antimicrobials had previously been 
documented in vitro[207]. These agents are specific to two sequential enzymes in the 
bacterial folic acid biosynthesis pathway, a pathway which is essential to DNA replication 
and therefore growth. While each drug can be effective against a range of organisms 
when administered alone, the combination overcomes resistance to a single agent 
already present and induces significantly less additional resistance compared to single-
agent exposure. This combination has since been produced as a single formulation and 
continues to be successfully used in the treatment of urinary tract infections. 
Synergy between the fluoroquinolone levofloxacin and vancomycin or teicoplanin (both 
peptidoglycan synthesis inhibitors) has also been found in vitro against S. pneumoniae 
(GP)[208]. However, the combined activity of levofloxacin with either rifampicin (an RNA 
synthesis inhibitor) or FA was indifferent against the same panel of organisms. 
The use of phage (bacterial viruses) in combination with established antimicrobials has 
gained traction over the last 10 years[209]. While synergy has been identified in some 
pairings, others appear to antagonise each other. However, studies using successful 
pairs have indicated reduced rates of resistance induction to both the antimicrobial and 
the bacteriophage in vitro and good efficacy in vivo. 
1.4.3.2 Prevention of antimicrobial degradation 
An excellent example of activity recovery is the story of clavulanic acid. In 1976, a novel 
β-lactam was isolated from Streptomyces clavuligerus but, rather than having direct 
antimicrobial properties, was found to be a β-lactamase inhibitor[210]. Shortly after 
discovery, clavulanic acid was tested in vitro in combination with various penicillins and 
restoration of activity against β-lactamase-producing strains was identified[211],[212]. Within 
six years of discovery, trials of clavulanic acid combined with amoxicillin in patients with 
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complicated[213] and urinary tract[214] infections caused by β-lactamase producers were 
completed and confirmed excellent tolerability and favourable outcome. The combination 
was licensed by GlaxoSmithKline as Augmentin and is still on the market today. 
Following the same principle, a number of combination formulations of carbapenem 
(another class of β-lactams with broader spectrum but increasing resistance) or 
cephalosporin and ESBL-inhibitor are now also available[202]. These include imipenem-
relebactam and meropenem-vaborbactam which recover carbapenem activity against 
non-susceptible Enterobacteriaceae and P. aeruginosa[215], and ceftazidime–avibactam 
and ceftolozane–tazobactam which both have potent activity against clinical MDR ESBL-
producing isolates of E. coli, K. pneumoniae and P. aeruginosa[216]. 
1.4.3.3 Increasing antimicrobial access to its target 
Low molecular weight antimicrobial peptides are produced as part of the innate immune 
systems of most lifeforms and many structural analogues and peptides of novel design 
have been shown to exhibit antimicrobial activity in their own right[217]. In addition, these 
synthetic and semi-synthetic antimicrobial peptides can synergise with a variety of 
traditional antimicrobial drugs both in vitro and in vivo. Colistin is an old antimicrobial 
peptide which has been revived for last-line treatment of MDR GN infections, often in 
combination with a carbapenem[218]. Novel antimicrobial peptides are also in 
development specifically for their ability to synergise with other agents. For example, one 
novel antimicrobial peptide has been shown to eradicate 99.9 % of S. aureus from a 
mouse wound infection model after a single dose when combined with levofloxacin[219]. 
Oligo-acyl-lysyls (OAKs) also mimic host antimicrobial peptides and synergise with 
rifampicin in vitro[220]. In the presence of 5 μg mL-1 OAK, the MIC of rifampicin against 
E. coli reduced from 8 μg mL-1 to 0.004 μg mL-1. However, similarly to other antimicrobial 
peptides, preliminary toxicology and pharmacokinetic investigations in mice have shown 
OAKs are not well absorbed after oral administration. Nevertheless, subcutaneous 
injection of OAKs 1 h after oral rifampicin doubled survival of K. pneumoniae infected-
mice compared to rifampicin alone[220]. However, not all peptide and drug combinations 
produce predictable synergy based on the currently understood mechanisms of action. 
For example, membrane permeabilising agents are known to enhance fluoroquinolone 
activity against GN organisms but one study found no evidence of increased 
ciprofloxacin activity in vitro when combined with any of a variety well-characterised 
antimicrobial peptides known to disrupt the OM[221]. 
Natural products have also been investigated as potentiators of antimicrobial drugs. 
Eugenol, the major component of clove oil, has been shown to synergise with a broad 
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spectrum of antimicrobials against GN bacteria in vitro by disrupting the OM[222]. A 
number of plant extract compounds have also been found to synergise with various 
antimicrobials to prevent and eradicate biofilms, possibly by disrupting the extracellular 
matrix which is usually impenetrable to most antimicrobials[223]. Combinations of 
antimicrobials and enzymes are also under investigation for the same purpose of 
combating biofilms[224]. 
1.4.4 Desirable mechanisms of agents for co-formulation with fusidic acid 
Since low OM permeability and efflux are the intrinsic resistance determinants in GN 
bacteria, agents which target one or both of these phenotypes may be useful for 
co-formulation with FA. 
1.4.4.1 Membrane permeabilisation 
Membrane permeabilisation is a promising potential option to extend the spectrum of 
classically anti-GP lipophilic drugs to cover GN organisms. Polymyxin B nonapeptide has 
long been known to sensitise E. coli to hydrophobic antimicrobials and synergises with 
FA[225]. Other small synthetic cationic peptides that can permeabilise the OM also 
synergise with hydrophobic drugs against GN bacteria[226],[227]. In particular, colistin has 
been shown to strongly enhance the activity of FA against MDR A. baumannii, as 
previously mentioned in Section 1.3.1[119]. Another novel antimicrobial peptide, SPR741, 
has been shown to synergise with several hydrophobic antimicrobials including FA 
against E. coli, K. pneumoniae and A. baumannii reference strains, and is currently in 
clinical development[228],[229]. These are potentially promising agents for co-formulation 
with FA. However, polymyxins are currently reserved as last-line antibiotics for otherwise 
resistant GN infections and their use may therefore need to be limited in order to delay 
induction of resistance as far as possible. High-throughput screening methods have even 
been developed and successfully employed to test and identify a wide variety of agents 
capable of permeabilising the E. coli cellular envelope[230]. One peptide unrelated to the 
polymyxins identified via this method was able to reduce the FA MIC from 500 to 
16 µg mL-1. 
Sodium hexametaphosphate, a phosphate polymer and metal chelator, is another agent 
which sensitises GN organisms to FA and other hydrophobic drugs in a synergistic 
manner[231]. Other metal chelators are also known to increase OM permeability by 
scavenging the Mg2+ and Ca2+ responsible for LPS cross-linking, increasing membrane 
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fluidity and consequently enhancing cellular uptake of hydrophobic agents[232]. 
Unfortunately, systemic administration of metal chelators is known to cause retinal 
damage due to local depletion of Cu and Zn[233] and sodium hexametaphosphate 
specifically is an ocular irritant[234]. However, identification of additional agents that can 
selectively destabilise bacterial OMs could provide a suitable option for coadministration 
with FA. 
1.4.4.2 Efflux inhibition 
A variety of AcrAB-TolC efflux pump inhibitors have been discovered and investigated in 
vitro[142],[235]. However, the ability of each inhibitor to recover the activity of an otherwise 
effluxed antimicrobial varies, which is thought to depend on the individual ArcB binding 
site of each agent[142]. There have been no reports of efflux inhibitors combined with FA. 
In addition, high concentrations of these inhibitors are generally needed in order to 
achieve adequate AcrAB-TolC inactivation. However, if inhibition comparable to the 
deletion of the acrAB locus could be achieved, E. coli sensitivity to FA would potentially 
be increased by more than 100-fold[150]. Despite the challenges presented by efflux over-
expression, the search for effective inhibitors goes on. Recent investigations have 
identified novel metabolites from Actinomyces spp. capable of sensitising GN bacteria to 
classically GP antibiotics such as rifampicin and linezolid by competing for efflux[236]. 
1.4.5 Metals as antimicrobial adjuvants 
Many metals are essential micronutrients to biological processes in all life forms[237]. Iron, 
for example, is an important element for the correct structure and activity of multiple 
enzymes. Most bacteria gather iron by producing molecules known as siderophores 
(from the Greek for “iron bearer”) which are excreted, chelate extracellular Fe3+ and are 
then internalised as an Fe-complex by dedicated receptors[238]. The removal of iron from 
the intracellular siderophore as Fe2+ is catalysed by specific enzymes and carefully 
controlled to prevent release of free, reactive iron ions. Nevertheless, when bacteria are 
exposed to high concentrations of iron or other metal ions, homeostasis systems can 
become saturated leaving cells vulnerable to the detrimental effects of these reactive 
ions.  
Throughout history, metals and their solutions have been naturally selected as a means 
to prevent and treat infections, even prior to understanding of the cause. Copper and 
silver vessels were used in ancient Egypt (2000 BC) and ancient Greece (400 BC) to 
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keep safe drinking water[239],[240]. This principle was also adopted by early American 
pioneers who placed copper or silver coins in water barrels[241]. Ancient medical 
applications of metals have included copper oxide and malachite for skin conditions by 
the Aztecs and silver plates to aid wound healing by Macedonians[239],[240]. Possibly the 
first published evidence of medical silver nitrate use is in a Roman pharmacopoeia dated 
69 BC[240]. By the nineteenth century, anti-infectious metal use was widely documented, 
including such applications as copper salts for rabies prophylaxis and the treatment of 
infected ulcers[242], silver sutures to reduce “muco-purulent secretion” and promote 
healing in the repair of vaginal tears postpartum[243] and mercury(II) chloride as a 
disinfection agent after exposure to faecal matter from patients with cholera and 
typhoid[244]. Bordeaux Mixture, a combination of copper sulphate and calcium hydroxide 
(lime), was discovered in the late nineteenth century and commercialised as a fungicide 
for grape vine mildew[245]. The use of metals to control microbial growth has been 
continued to modern times. Comparatively recent discoveries such as the Bordeaux 
Mixture see ongoing commercial success while metallic copper touch surfaces have 
been shown to positively contribute to infection control in healthcare settings[246],[247]. 
Metal ions can be well tolerated in humans and are present in a variety of drugs in clinical 
use, particularly as anticancer agents[248]. They have also been employed in vaccine 
formulation in order to enhance efficacy[249]. Over the past 15-20 years, the use of metals 
either as nanoparticles, free ions or to form complexes has been investigated as a means 
to increased activity of antimicrobial drugs. 
1.4.5.1 Nanoparticles 
A variety of metal and metal-based nanoparticles have been found to be active against 
many microbial species and some exhibit synergy with established antimicrobial 
drugs[250]. Addition of ZnO nanoparticles at subinhibitory concentrations can enhance the 
activity of ciprofloxacin against clinical isolates of both S. aureus and E. coli[251]. 
However, the authors found that the same nanoparticle concentration had no effect on, 
or was even detrimental to, the antimicrobial activity of a wide variety of other drugs 
tested. Ag+ nanoparticles have also been shown to synergise with several antimicrobials, 
most notably with colistin against a resistant E. coli strain and penicillin against a 
resistant S. aureus strain[252]. In another investigation, MDR isolates of E. coli and 
K. pneumoniae were re-sensitised to cephalosporins, ciprofloxacin and gentamicin by 
Ag+ nanoparticles[253]. However, there are concerns over the environmental impact of 
nanoparticles[254], including the induction of antimicrobial resistance gene transfer 
between bacterial species when released into the environment[255]. 
39 
1.4.5.2 Metal complexation 
Metal complexes of antimicrobials can be synthesised by chemical manipulation 
processes or may occur in aqueous, biological or other environments spontaneously. 
Metal-fluoroquinolone complexes have been investigated extensively[256]. Magnesium, 
as well as the antimicrobial metal ions Mn2+, Zn2+, Fe3+ and Al3+, were originally reported 
to reduce the activity of fluoroquinolones in a concentration-dependent manner due to 
spontaneous metal-drug binding in aqueous solutions[257],[258]. However, Co2+, Ni2+, Cu2+ 
and even Zn2+ complexes of ciprofloxacin exhibit very similar in vitro antimicrobial 
activities to the standard sodium salt against a wide range of bacterial species and 
strains[259]. Pd2+ and Pt2+ complexes of ciprofloxacin, levofloxacin, ofloxacin, sparfloxacin, 
and gatifloxacin have also been shown to retain antimicrobial activity against 
M. tuberculosis[260]. Many other combinations of metals and fluoroquinolone have been 
synthesised[261]–[263]. In addition, most metal cations were found to enhance rather than 
reduce fluoroquinolone solubility when buffered to a range of physiologically relevant 
pHs[264], therefore indicating that the early reports of determinantal metal interaction may 
have been due to the specific artificial experimental conditions. 
A Cu-tobramycin complex has been shown to have equal anti-P. aeruginosa activity to 
tobramycin[265]. However, the complex exhibited enhanced anti-inflammatory effects in 
vitro compared to the parent drug, giving an important advantage for the potential 
treatment of pulmonary infection in cystic fibrosis patients[265]. Pd2+ complexes of anti-
tuberculosis drugs capreomycin, kanamycin and ofloxacin have also been generated 
and found to be slightly more active than the parent compounds against intracellular 
M. tuberculosis in vitro[266]. 
A silver salt of FA, silver fusidate, has been investigated and found to have similar 
antimicrobial activity per mg as FNa[267]. However, as the molecular mass of silver is 
approximately 5 times that of sodium, the molar activity of silver fusidate is actually 
slightly greater than FNa, likely due to the additional antimicrobial activity of dissociated 
Ag+ ions. 
The mechanism of action of most metal-antimicrobial complexes appear to be the same 
as the parent antimicrobial. Where enhanced activity is seen, this is thought to be due to 
either the dissociation of the complex affording the additional antimicrobial effect of free 
metal ions or due to alterations in uptake of the complex compared to the free drug. 
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1.4.5.3 Free metal ions 
While metal-drug complexation essentially leads to a novel chemical entity, co-
formulation of free metal ions and antimicrobial drug may enhance activity by combining 
mechanisms of action as a two (or more) pronged attack. Many metal ions exhibit 
antimicrobial activity, but only a few have been investigated as potential adjuvants. The 
presence of Ag+ ions has been shown to synergise with bactericidal antimicrobials 
against E. coli, greatly increasing the activity of otherwise sub-lethal concentrations of 
gentamicin, ampicillin and ofloxacin[268]. Studies in a mouse model of urinary tract 
infection also confirmed the gentamicin and Ag+ ion combination to be effective at killing 
bacteria in vivo. Another study found that Ag+, and to a lesser extent Cu2+, was able to 
enhance the activity of gentamicin against E. coli, whereas Fe2+, Co2+, Zn2+ and Ni2+ were 
not[269]. Ag+ was found to allow gentamicin to bypass one of the steps in its usual uptake 
mechanism and accumulate intracellularly more rapidly. Tobramycin, another 
aminoglycoside, has also been shown to be potentiated by Ag+ ions against 
P. aeruginosa biofilms[270]. In addition, Cu2+ ions have been found to inactive the 
important ESBL New Delhi metallo-β-lactamase 1 (NDM-1)[271]. When combined with 
carbapenems in vitro, Cu2+ ions synergised against an NDM-1-producing strain of E. coli, 
recovering the activity of the antimicrobial. 
While systemic administration of most metal ions is inadvisable due to toxicity as well as 
poor distribution, topical application is less likely to suffer these challenges. Issues with 
absorption and distribution are largely overcome when an antimicrobial is applied directly 
to the site of infection. In addition, generalised toxicity becomes far less likely and any 
risk of localised problems can be weighed against the benefits of treatment[187].  
Metal ions can both disrupt bacterial membranes and denature proteins[272], potentially 
synergising with FA by targeting both the impermeable OM and active efflux pumps. In 
addition, topical administration to the eye is likely to avert the systemic toxicity common 
to oral or other exposure routes. Repurposing of FA as a GN antimicrobial could be 
effectively achieved by co-formulation with metal ions and is yet to be explored. 
Therefore, this work sought to investigate the combined in vitro antimicrobial activity of 
FA and metal ions as a potential treatment bacterial keratitis.  
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1.5 Hypothesis and aims 
It was hypothesised that one or more antimicrobial metal ion(s) would enhance the 
activity of FA against GN bacteria without reducing anti-GP efficacy. In addition, the 
combination would exhibit low toxicity against mammalian cells and good activity in a 
simulated tear fluid mimicking the ocular environment. 
The primary aims of the work presented in this thesis were: 
1) To identify metal ion(s) which increase FA activity against GN organisms 
without decreasing its anti-GP efficacy. 
2) To determine whether the key mode of combined activity is via spontaneous 
complexion, action against dual antimicrobial targets or another mechanism. 
3) To investigate whether activity of combination(s) extends to multiple GN 
species and resistant isolates. 
4) To characterise toxicity of combination(s) against human corneal epithelial 
cells. 
5) To assess antimicrobial activity of combination(s) in a simulated tear fluid.
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Chapter 2: General methodology 
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The methods presented here outline procedures used for experimentation reported in 
multiple Chapters and the materials listed were used throughout this thesis. Specific 
method details are described within the relevant chapter. Appropriate personal and 
environmental safety procedures were followed, and precautions taken throughout the 
work, as detailed in Appendix A. 
2.1 Test agent stock solution preparation and storage 
Stock solutions of metal salts were prepared in HPLC-grade water (Fisher Scientific, 
Loughborough, UK) and filter sterilised (0.22 µm PES). Aluminium sulphate hydrate 
(Al2(SO4)3•H2O), cobalt(II) sulphate heptahydrate (CoSO4•7H2O), copper(II) sulphate 
anhydrous (CuSO4), manganese(II) sulphate monohydrate (MnSO4•H2O), iron(II) 
sulphate heptahydrate (FeSO4•7H2O), nickel(II) sulphate hexahydrate (NiSO4•6H2O), 
zinc(II) sulphate heptahydrate (ZnSO4•7H2O), copper(II) D-gluconate (Cu D-glu), 
copper(II) chloride anhydrous (CuCl2), copper(II) nitrate hemipentahydrate 
(Cu(NO3)2•2.5H2O), sodium D-gluconate (Na D-glu) and sodium chloride (NaCl) were 
purchased from Sigma Aldrich (Gillingham, UK). Palladium(II) sulphate dihydrate 
(PdSO4•2H2O) and sodium sulphate anhydrous (Na2SO4) were from Fisher Scientific 
(Loughborough, UK). For Al2(SO4)3, CoSO4, CuSO4, MnSO4, NiSO4, ZnSO4, CuCl2, 
Cu(NO3)2, and Cu D-glu the final concentration of metal ions was adjusted to 400 mM 
and the solutions stored at room temperature for up to one month. As PdSO4 is not 
soluble in aqueous solution, a 40 mM stock was prepared in 160 mM NaCl (affording a 
1:4 molar ratio of Pd2+ and Cl-) to enable the formation of water-soluble sodium 
tetrachloropalladate complexes. A volume of NaCl stock solution without PdSO4 was 
reserved for use as a control for the effects of NaCl at concentrations equivalent to those 
present in PdSO4 tests. PdSO4 and NaCl stock solutions were kept at room temperature 
for no more than two weeks. Due to instability in aqueous solution (see Section 3.3.3), 
fresh 400 mM FeSO4 solution was prepared and used within 30 min for each experiment. 
Na2SO4 stock solution was prepared at a concentration of 400 mM for use as a control 
for the effects of sulphate.  
Sodium fusidate (fusidic acid sodium salt, FNa) was purchased from Sigma Aldrich 
(Gillingham, UK) and HPLC-grade absolute ethanol (EtOH) from Fisher Scientific 
(Loughborough, UK). A 51.2 mM FNa stock solution was prepared in 50 % v/v EtOH[273] 
by first dissolving the appropriate mass of FNa in absolute EtOH followed by dilution with 
HPLC-grade water. The resulting solution was filter sterilised through 0.22 µm PES and 
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stored for up to a month at room temperature as solubility is reduced at cooler 
temperatures. 
2.2 Sources, storage and maintenance of bacterial strains 
2.2.1 Source of strains 
Escherichia coli, National Collection of Type Cultures (NCTC) strain reference 10418, 
Staphylococcus aureus NCTC 12973 Klebsiella pneumoniae NCTC 9633 and 
Pseudomonas aeruginosa NCTC 13359 were obtained from glycerol stocks produced 
from NCTC sourced samples (Salisbury, England) and frozen at -80 °C. 
E. coli NCTC 10418 and S. aureus NCTC 12973 were chosen for the initial testing as 
both are well-characterised representatives of GN and GP organisms, respectively. In 
addition, both strains exhibit wild-type susceptibility to fusidic acid and were the British 
Society of Antimicrobial Chemotherapy (BSAC) recommended control strains for 
determining antimicrobial susceptibility at the time of the initial work[274]–[276]. 
K. pneumoniae NCTC 9633 and P. aeruginosa NCTC 13359 (also known in the 
American Type Culture Collection (ATCC) as ATCC 13883 and ATCC 15542, 
respectively) were selected as reference strains during testing of multi-drug resistant 
(MDR) plasmid-harbouring isolates (Chapter 6) as both are type strains exhibiting wild-
type susceptibilities[277],[278]. The MDR isolates of E. coli, K. pneumoniae and 
P. aeruginosa were provided by the School of Medicine on agar plates.  
2.2.2 Preparation of initial glycerol stocks 
A 10 µL inoculation loop of frozen glycerol stock or three to five morphologically identical 
colonies from MDR culture plates was transferred to sterile, room temperature phosphate 
buffered saline (PBS,10 mM, pH 7.4, Fisher Scientific, Loughborough, UK), and vortexed 
for 20 s. The resulting bacterial suspension was streaked onto nutrient agar (NA) plates 
prepared from nutrient agar powder (Thermo Scientific Oxoid, Basingstoke, UK) per the 
manufacturer’s instructions and incubated at 37 °C for 18-24 h. Plates were checked 
visually for uncontaminated growth. Three to five morphologically identical colonies were 
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suspended in 20 mL prepared and autoclaved nutrient broth No. 1 (NB, Thermo Scientific 
Oxoid, Basingstoke, UK) and incubated for 18±2 h at 37 °C and 120 rpm. The bacterial 
culture was mixed with an equal volume sterile 20 % v/v glycerol (Sigma Aldrich, 
Gillingham, UK) and stored in 1 mL aliquots at -80 °C. Stock viability and purity was 
confirmed after three days by inoculating NB with three random samples of each 
organism followed by subculture on NA. 
2.2.3 Maintenance of stocks and cultures 
Frozen glycerol stocks were maintained following the seed lot method[279]. For each 
organism, twelve of the originally prepared glycerol stocks were reserved as the seed lot 
and the remainder used as working lot. As the supply of working lot reached depletion, 
a new batch of working lot was produced from one of the seed lot stocks. In order to 
replenish the frozen working lot, NB was inoculated with one rapidly thawed seed lot 
glycerol stock and incubated at 37 °C and 120 rpm for 18±2 h. The bacterial culture was 
mixed with an equal volume sterile 20 % v/v glycerol and 1 mL aliquots frozen at -80 °C 
as the new working stock. In this way, each glycerol stock used for experimentation was 
a minimal number of passages from the original NCTC isolate, avoiding any large genetic 
variation which may occur with repeated culture. 
Working agar cultures of each organism were produced once monthly by reviving one 
rapidly thawed working lot glycerol stock in nutrient broth incubated at 37 °C and 120 rpm 
for 18±2 h. Disposable inoculation loops were used to streak 10 µL bacterial culture onto 
NA plates. Plates were incubated at 37 °C for 18-24 h and the resulting working cultures 
stored agar side up at 4 °C for a maximum of 6 weeks. 
2.3 Enumeration of bacteria 
Bacteria were enumerated as colony forming units (CFU). CFU counts were performed 
using the Miles & Misra method[280], as summarised in Figure 2.1. Briefly, serial 10-fold 
dilutions of a bacterial suspension were performed in PBS and 10 µL aliquots plated onto 
NA in triplicate. After drying for 10-15 min at room temperature, the plates were incubated 
at 37 °C for 18-24 h. The mean number colonies in the least dilute suspension where 
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discrete colonies could be counted was used to calculate the CFU mL-1 in the original 
bacterial suspension using the following formula: 
𝑠𝑠 = (𝑛𝑛� × 10−𝑑𝑑) × 100 
Where 𝑠𝑠 = CFU mL-1 in the original bacterial suspension, 𝑛𝑛� = mean discrete CFU per 
10 µL aliquot and 𝑑𝑑 = dilution number. 
 
Figure 2.1 – The dilution and plating steps in the Miles & Misra method[280] 
Up to seven 10-fold serial dilutions were performed in PBS and 10 μL of the each of the 
suspensions of interest dropped on nutrient agar in triplicate. Plates were allowed to dry at 
room temperature for 10-15 min then incubated at 37 °C for 18-24 h. 
The number of dilutions in the series was varied depending on the nature of the 
investigation. For example, for confirmatory enumeration of a 5±3 x 105 CFU mL-1 
inoculum only three dilutions were performed and the 10-2 and 10-3 plated whereas seven 
dilutions were performed and plated for kill-time assays. 
2.4 Determination of minimum inhibitory and minimum 
bactericidal concentrations by microdilution 
Microdilution was selected as the most appropriate method to ascertain single agent 
antimicrobial activities[281]. Firstly, unlike agar diffusion-based methods (disc diffusion or 
well diffusion), microdilution enables determination of the minimum inhibitory 
concentrations (MICs) of agents. Secondly, by employing 96-well plates, microdilution is 
comparatively high-throughput testing, requiring less set-up time and fewer resources 
compared to the more traditional macrodilution method. Finally, while agar dilution can 
also be used for accurate and very high-throughput MIC determination, the employment 
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of a microplate reader enables precise quantification of growth inhibition in each well of 
the microdilution assay. This allows analysis of effects of sub-MIC agent concentrations 
on bacterial growth, which is particularly useful in assessment of metal ions since many 
are micronutrients. 
The method used was based on that published by the Clinical and Laboratory Standards 
Institute (CLSI)[282], with modifications as directed by the chequerboard assay 
optimisation (see Chapter 3). Three to five colonies from working agar cultures were 
used to inoculate fresh NA plates and incubated at 37 °C overnight. Serial dilutions of 
test agents were performed using 100 µL sterile filtered (0.22 µm) HPLC-grade water 
per well in sterile un-coated flat-bottomed 96 well plates (Corning Costar, New York, 
USA). At least one agent-free control well (HPLC-grade water only) was included on 
each plate. Bacteria were picked from the overnight growth and suspended in 3 mL 
sterile HPLC-grade water. HPLC-grade water was used in place of the usual PBS to 
prevent the formation of insoluble metal phosphate precipitates. The optical density (OD) 
of the bacterial suspension at 625 nm was adjusted to approximately 1 × 108 CFU mL-1 
for the particular organism using a Jenway 6305 spectrophotometer and semi-micro 
polystyrene cuvettes giving a 1 cm path length, based on OD : CFU mL-1 calibration 
curves constructed previously. The resulting suspension was diluted 1/100 in double 
strength NB, of which, 100 µL was used to inoculate each well to a final concentration of 
5±3 × 105 CFU mL-1 [282]. Double strength NB was employed so that the final 1:1 mixture 
of test agent in aqueous solution and bacterial inoculum would be in standard 
concentration NB. Immediately after inoculation, a separate designated control well was 
used to perform a drop count in order to confirm the initial number of CFU mL-1 in each 
test plate. A 10 µL aliquot from the inoculum control well was serially diluted in PBS, of 
which 10 µL aliquots were plated onto NA and incubated overnight at 37 °C. Blank 96 
well plates, each with identical agent dilutions to a test plate, were also prepared using 
sterile double strength NB. Blank plates enabled baseline correction against any 
colouration caused by the test agents over the concentrations used. All test and blank 
plates were wrapped in plastic to reduce evaporation and incubated for 18±2 h at 35 °C 
and 120 rpm. 
Providing the drop count results confirmed the inoculum to be within the accepted range, 
a Tecan Infinite F200 PRO spectrophotometric microplate reader was used to measure 
the absorbance in each well of the test and blank plates at 595 nm (wavelength filter 
accuracy ±10 nm[283]) with 5 flashes from a single central beam. Plates were read in 
triplicate with each read being preceded by 30 s orbital shaking at an amplitude of 6 mm. 
Shaking and read repetition was used for two reasons: 1) to minimise the impact of any 
precipitate on final values as multiple reads allowed averaging of dense and less dense 
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areas (this occurred infrequently and was borne from necessity for a small number of 
wells in certain chequerboards (see Chapter 3)), and 2) to enable erroneous single read 
data to be removed before further processing, e.g. bubbles or dust particles located in 
the transmittance path during one of the three reads. 
Absorbance data was used to calculate baseline-corrected well-by-well percentage 
growth inhibition as follows. The mean absorbance reads for the test plate were 
background corrected for growth medium, 96 well plate material and test agent 
absorbance by subtracting blank plate read values of corresponding wells. Percentage 
bacterial growth inhibition in each test condition of the 96 well plate was calculated using 
background-corrected absorbance values (𝑐𝑐𝑐𝑐) as: 
𝑝𝑝𝑝𝑝𝑝𝑝𝑐𝑐𝑝𝑝𝑛𝑛𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 𝑖𝑖𝑛𝑛ℎ𝑖𝑖𝑖𝑖𝑖𝑖𝑝𝑝𝑖𝑖𝑖𝑖𝑛𝑛 = (1 − 𝑐𝑐𝑐𝑐𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑤𝑤𝑡𝑡𝑤𝑤𝑤𝑤
𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑡𝑡𝑐𝑐𝑐𝑐𝑤𝑤 𝑤𝑤𝑡𝑡𝑤𝑤𝑤𝑤) × 100 
Where 𝑐𝑐𝑐𝑐𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑤𝑤𝑡𝑡𝑤𝑤𝑤𝑤 = the mean background-corrected absorbance value for a particular 
test well, and 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑡𝑡𝑐𝑐𝑐𝑐𝑤𝑤 𝑤𝑤𝑡𝑡𝑤𝑤𝑤𝑤 = the mean background-corrected absorbance value for the 
agent free control well, representative of 100 % (maximal) growth. 
Minimum bactericidal concentrations (MBCs) were also determined by plating 20 µL 
aliquots from wells with ≥90 % inhibition (as calculated using the above formula) onto NA 
and checking for growth of viable organisms after 18-24 h incubation at 37 °C.  
All experiments were performed in triplicate using three independent bacterial 
suspensions. The MIC90 of each test agent was determined as the lowest concentration 
needed to produce a mean of at least 90 % growth inhibition and the MBC as the lowest 
concentration to result in no growth on agar in any replicate. 
2.5 The chequerboard assay 
The chequerboard assay enables evaluation of the combined antimicrobial efficacy of 
two agents by determining the fractional inhibitory concentration index (FICI) as a 
measure of synergy or antagonism[284]. This assay was employed to assess the 
bacteriostatic activity of FNa combined with a range of metal salts. All tests were carried 
out in sterile un-coated flat-bottomed 96 well plates. Chequerboard assays were 
prepared using two-fold serial dilutions of the two test agents on opposing axes, as 
illustrated for FNa and metal sulphate in Figure 2.2. The highest concentration of FNa 
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and metal salt were both four times their respective MIC90 for the organism being tested 
(as determined by preliminary microdilution data and within agent solubility limits) in 
order to enable detection of and differentiation between any antagonistic and 
suppressive combinations[201]. Dilutions of all agents were prepared in sterile filtered 
HPLC-grade water, mixed in the 96 well plate and allowed to stand for 60±15 min before 
inoculation. Single agent, positive and sterility controls were also included. 
As described for the microdilution assay (Section 2.4), 96 well plates were set up in pairs. 
One of each pair of prepared plates was inoculated to a final concentration of 
5±3 × 105 CFU mL-1 and the inoculum confirmed by drop count on NA. The other plate 
of each pair was set up as a blank by adding sterile double strength NB. Plates were 
incubated, wrapped in plastic, for 18±2 h at 35 °C and 120 rpm. After confirmation of 
initial inoculum, absorbance at 595 nm was measured using a Tecan Infinite F200 PRO 
microplate reader. Reads were carried out in triplicate, each after 30 s orbital shaking 
and the data used to calculate well-by-well baseline-corrected percentage growth 
inhibition. Minimum bactericidal concentrations (MBCs) of the combinations were also 
determined by plating aliquots from wells with ≥90 % inhibition onto NA and checking for 
growth of viable organisms after 18-24 h incubation at 37 °C. Each chequerboard assay 
was performed in triplicate using an independent bacterial suspension for each replicate. 
 
Figure 2.2 - Illustration of typical chequerboard assay set-up 
Sodium fusidate is shown in orange and metal salt in cyan, with greater colour intensity 
representing higher concentration. Nutrient broth without the test organism was added to 
sterility control wells in order to verify the reagents employed were free from contamination. 
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Figure 2.3 - Selection of wells from hypothetical chequerboard results for FIC90I calculation 
Shaded wells represent bacterial growth inhibited by <10 %. Metal salt MIC90 well is 
highlighted in cyan, sodium fusidate in orange and the combined MIC90 in purple. 
The mean lowest FIC90I (fractional 90 % inhibitory concentration index)[285] for each 
chequerboard triplicate was used to determine whether a synergistic (FICI ≤0.5) or 
antagonistic (FICI >4.0) interaction occurred between the test agents[286] and quantify the 
extent. The FIC90I was calculated for each replicate as follows: 
𝐹𝐹𝐹𝐹𝐶𝐶90𝐹𝐹 = 𝐹𝐹𝐹𝐹𝐶𝐶90(𝑐𝑐) + 𝐹𝐹𝐹𝐹𝐶𝐶90(𝐵𝐵) 
Where: 
𝐹𝐹𝐹𝐹𝐶𝐶90(𝑐𝑐) = 𝑀𝑀𝐹𝐹𝐶𝐶90(𝑐𝑐) 𝑖𝑖𝑛𝑛 𝑐𝑐𝑖𝑖𝑐𝑐𝑖𝑖𝑖𝑖𝑛𝑛𝑝𝑝𝑝𝑝𝑖𝑖𝑖𝑖𝑛𝑛𝑀𝑀𝐹𝐹𝐶𝐶90(𝑐𝑐) 𝑝𝑝𝑎𝑎𝑖𝑖𝑛𝑛𝑝𝑝         𝑝𝑝𝑛𝑛𝑑𝑑       𝐹𝐹𝐹𝐹𝐶𝐶90(𝐵𝐵) = 𝑀𝑀𝐹𝐹𝐶𝐶90(𝐵𝐵) 𝑖𝑖𝑛𝑛 𝑐𝑐𝑖𝑖𝑐𝑐𝑖𝑖𝑖𝑖𝑛𝑛𝑝𝑝𝑝𝑝𝑖𝑖𝑖𝑖𝑛𝑛𝑀𝑀𝐹𝐹𝐶𝐶90(𝐵𝐵) 𝑝𝑝𝑎𝑎𝑖𝑖𝑛𝑛𝑝𝑝    
FIC90s (fractional 90 % inhibitory concentrations) were calculated from three individual 
wells within each replicate: 1) the MIC90 of the metal salt alone, 2) the MIC90 of FNa 
alone, and 3) the well where the combined lowest concentration of the two agents 
produced ≥90 % inhibition, as illustrated in Figure 2.3. This method provides a calculated 
FIC90I closer to the true value than other approaches, while also accounting for any day-
to-day variation in MIC90[221]. 
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Figure 2.4 – Schematic representation of isobolograms produced by synergistic, additive, 
antagonistic and suppressive antimicrobial combinations 
Based on summaries provided in Cottarel & Wierzbowski, 2007[202] and Bollenbach, 2015[201]. 
Interactions were also assessed graphically by constructing isobolograms – plots of the 
concentration of one agent required to produce inhibition when in combination with 
another agent. In the example in Figure 2.4 the agent concentrations have been 
converted to % of their respective MICs. This data transformation was used when 
comparing agents with different MIC90s to facilitate visual comparison on the same graph. 
The shape of the isobologram indicates the nature of the interaction. No interaction 
results in additive effects and a straight line between MICs[201],[202],[284]. Synergy and 
antagonism between agents produce inward and outward bows between the MICs, 
respectively[201],[202],[284]. Suppression, an extreme form of antagonism, is defined as the 
presence of one agent increasing the MIC of the other and results in the plot forming a 
peak which exceeds at least one of the agent’s MIC[201]. The use of isobologram plots 
aided distinction between antagonistic and suppressive combinations for which there is 
no standard using the FICI. 
Further data were extracted and analysed from chequerboard results in line with the 
nature of specific investigations, the details of which are provided in the chapters that 
follow. 
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2.6 Fusidic acid quantification by RP-HPLC 
Two reversed phase high performance liquid chromatography (RP-HPLC) methods were 
employed to determine the concentration of fusidate. While separation method 1 
performed well for most applications and was employed for the majority of assays, peaks 
were insufficiently resolved when components from bacterial cells were present (see 
Appendix C). Therefore, a substantially longer, gradient elution method – separation 
method 2 – was used for the analysis of such samples. 
For both methods, the HPLC system was composed of a G1379B Degasser, G1311A 
QuatPump, G1313A ALS autosampler and G1314A VWD UV detector, all from Agilent, 
and fitted with a 5 μm Gemini-NX C18 4.6 x 250 mm column as the stationary phase. 
Agilent ChemStation for LC systems (revision B.04.02 SP1) was used for system control 
and data visualisation and processing. Calibration curves were constructed for both 
methods (see Appendix B). 
Acetonitrile (ACN), >98 %, HPLC-grade water, gradient grade methanol (MeOH) and 
glacial acetic acid were purchased from Fisher Scientific (Loughborough, UK). 
Phosphoric acid (H3PO4), >85 % in water, was from Sigma Aldrich (Gillingham, UK). All 
chemicals were used as received. 
2.6.1 Separation method 1 
Separation method 1 was based on that reported by Curbete & Salgado[287], employing 
an isocratic mobile phase of 72:28 v/v ACN : 1 % aqueous acetic acid, injection volume 
of 20 μL and flow rate of 1 mL min-1. The detection wavelength was optimised to 235 nm 
(see Section 5.3.1.1) and the analysis run time was 10 min per sample.  
2.6.2 Separation method 2 
Separation method 2 was a gradient method with a 60 min analysis run time, based on 
that reported by Byrne et al[288]. This was employed when method 1 yielded insufficient 
peak resolution, for example: due to additional, overlapping peaks produced by high 
concentrations of bacterial cell components. 
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Mobile phase A was 16:21:21:42 v/v/v/v MeOH : 10 g L-1 H3PO4 : H2O : ACN and mobile 
phase B was 24:5:5:66 v/v/v/v MeOH : 10 g L-1 H3PO4 : H2O : ACN. The gradient is 
described in Table 2.1. The flow rate was 0.7 mL min-1 and injection volume 50 μL with 
a detection wavelength also of 235 nm. 
Table 2.1 - Mobile phase gradient for HPLC method 2 
Time (min) % A % B 
START 95 5 
20.00 95 5 
45.00 0 100 
50.00 95 5 
60.00 STOP - 
2.7 Determination of FA solubility 
Solubility of FNa at various concentrations was determined in 1 mL volumes of the solute 
of interest in sterile 2 mL centrifuge tubes. After equilibration duration and temperature 
suitable to the investigation, solutions were centrifuged in a Heraeus Fresco 17 (Fisher 
Scientific, Loughborough, UK) at 17,000 x g (13,300 rpm) for 20 min to pellet any non-
solubilised particles. Five hundred microliters of clear supernatant were carefully pipetted 
from each tube immediately after centrifugation and transferred to a prepared brown 
glass HPLC vial. When equilibration was performed in an incubator (35 or 37 °C), the 
centrifuge was pre-warmed and maintained at the appropriate temperature throughout 
and supernatant samples were mixed with 500 μL EtOH to prevent precipitation of 
fusidate while at room temperature. Supernatant samples were analysed using 
RP-HPLC separation method 1 and resulting peak areas were converted to fusidate 
concentration using the inverted linear regression equation (Appendix B), correcting for 
additional dilution with EtOH where necessary. 
2.8 Measurement of solution pH 
Unless otherwise specified, all pH measurements were made using an HI-99165 pH 
meter fitted with an FC242D amplified electrode, accuracy ±0.2 pH units (Hanna 
Instruments, Leighton Buzzard, UK). Two-point calibration of the instrument was 
performed no more than 20 min prior to each batch of readings. The read accuracy was 
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checked using standard pH 4.01 and pH 7.01 buffers (Fisher Scientific, Loughborough, 
UK) between every 6-8 measurements.  
2.9 Statistical analysis 
Data was assumed to be normally distributed for the purposes of statistical analysis and 
a p value of ≤0.05 was considered significant. All statistical analyses were carried out 
using Microsoft Office Excel 365 software, version 1902 (Microsoft Corporation, 
Redmond, Washington, USA). Statistical tests were selected based on the specific 
nature of each inquiry and data set, the details of which are provided within each Chapter.
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Chapter 3: Optimisation of the 
microdilution and 
chequerboard assays 
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3.1 Introduction 
Standardised microdilution assays against non-fastidious bacteria are carried out in the 
rich medium cation-adjusted Müller-Hinton broth (CAMHB)[282]. Consistent employment 
of CAMHB enables valuable, reproducible and directly comparable antimicrobial 
susceptibility testing to be performed across multiple laboratories and countries[289]. 
However, such standardisation may not always be helpful when searching for novel 
topical agents or combinations[290]. The nutritional environment of CAMHB is tailored to 
support rapid bacterial growth. While this is an advantage for standard diagnostic 
susceptibility testing, it does not reflect the conditions during infection. In fact, 
antimicrobial susceptibility testing in media mimicking tissue fluid has illustrated marked 
changes in the minimal inhibitory concentrations compared to CAMHB. For example, 
azithromycin was found to be highly active against A. baumannii in the mammalian 
culture medium RPMI, while the same strains are classified as resistant in CAMHB[291]. 
In addition, the same authors found that both the susceptibility of A. baumannii to 
azithromycin and synergy of azithromycin with minocycline observed in RPMI in vitro 
was replicated in a mouse model of pneumonia[291]. Conversely, a range of both GN and 
GP uropathogens exhibited similar fluoroquinolone minimum inhibitory concentrations 
(MICs) when grown in synthetic urine as in CAMHB[292]. It appears that these variations 
are, at least in part, linked to bacterial growth rate, with slower growth corresponding to 
increased susceptibility[293]. This is likely to be compounded by concomitant stressors 
and antimicrobial solution chemistry. However, while these factors complicate in vitro 
determination of the clinical effectiveness of antimicrobial agents, they may not be as 
problematic when considered during drug discovery or development. In particular, the 
increasing number and sophistication of options for topical formulations enable greater 
manipulation and control of the delivered agent(s) to answer specific developmental 
questions. For example, a co-polymer of ɑ-cyclodextrin and chitosan has been used to 
solubilise the antifungal agent econazole, increasing the concentration delivered to the 
cornea by more than 600 times[294], while semi-synthetic vesicles have been developed 
to adhere and deliver encapsulated drugs to specific tissues[295]. Hence, once the 
mechanism of action of an antimicrobial has been understood in a particular artificial 
environment, formulation chemistry can be used to modulate the delivery and efficacy in 
situ. The focus of this initial optimisation work was therefore to determine conditions that 
enabled the most sensitive detection of potential synergy between FNa and metal ions 
against GN bacteria. Since preliminary results from prior work carried out in our 
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laboratory (not shown) indicated potential enhancement of FNa activity against E. coli 
NCTC 10418 in the presence of CuSO4, this organism and agent combination was 
employed for optimisation. 
3.1.1 Aims and objectives 
Aim: to optimise the chequerboard assay for use in the study of the combined 
antimicrobial activity of FNa and metal ions, with a focus on GN-bacteria. 
Objectives: 
1) To select an appropriate bacteriological medium for detection of antimicrobial 
interactions between FNa and Cu2+ against E. coli NCTC 10418. 
2) To determine the MIC90 of FNa against E. coli NCTC 10418 and S. aureus 
NCTC 12973 and thereby select appropriate concentration ranges for use in 
chequerboard assays. 
3) To determine the MIC90 and MBCs of eight metal sulphates against E. coli 
NCTC 10418 and S. aureus NCTC 12973 and select appropriate concentration 
ranges for use in chequerboard assays. 
4) To determine the impact of EtOH, sulphate counterion and NaCl, at 
concentrations equivalent to those present in FNa and metal ion dilutions, 
respectively, on the growth of E. coli NCTC 10418 and S. aureus NCTC 12973. 
3.2 Methods 
3.2.1 Selection of bacteriological medium 
An initial pilot investigation to identify indicative MICs and appropriate concentration 
ranges for FNa and CuSO4 was conducted using the standard bacteriological medium 
for antimicrobial testing: CAMHB[282]. Müller-Hinton broth (MHB) powder (Sigma Aldrich, 
Gillingham, UK) was prepared in deionised water and sterilised by autoclaving per the 
manufacturer’s instructions. Stock solutions of 7.5 g L-1 CaCl2•2H2O and 10 g L-1 
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MgCl2•6H2O were prepared in deionised water and filter sterilised. After autoclaved MHB 
had cooled to room temperature, stock solutions were used to adjust the concentration 
of Ca2+ and Mg2+ cations to 20-25 and 10-12.5 mg L-1, respectively[282]. Serial two-fold 
dilutions of FNa and CuSO4 were prepared in CAMHB in a sterile un-coated flat-
bottomed 96 well plate. The plate was inoculated with E. coli NCTC 10418 suspended in 
CAMHB to a final concentration of 5±3 × 105 CFU mL-1 and incubated for 18±2 h at 35 °C 
and 120 rpm. After incubation, plates were inspected visually to determine the indicative 
MIC of each agent and select prospective concentration ranges for use. 
To compare bacteriological media, chequerboard assays were set up generally following 
the method described in Chapter 2, page 49. FNa and CuSO4 dilutions were performed 
in HPLC-grade water then transferred to six sterile un-coated flat-bottomed 96 well 
plates. E. coli NCTC 10418 suspended in double strength CAMHB (with 40-50 and 20-
25 mg L-1 Ca2+ and Mg2+, respectively), Miller’s lysogeny broth (LB, Fisher Scientific, 
Loughborough, UK), or NB was used to inoculate three of the prepared plates with 
5±3 × 105 CFU mL-1. Sterile double-strength CAMHB, LB or NB was added to the 
remaining three plates as blanks. The final formulation of each bacteriological medium 
is detailed in Table 3.1. 
Table 3.1 - Composition of bacteriological media 
Medium name Ingredients (g L-1) 
Cation adjusted Müller-Hinton 
broth (CAMHB)[282] 
Beef infusion solids, 2.0 
Casein hydrolysate, 17.5 
Starch, 1.5 
Ca2+, 20-25 mg L-1 
Mg2+, 10-12.5 mg L-1  
Miller’s lysogeny broth (LB)[296] 
Tryptone, 10. 
Yeast extract, 5.0 
NaCl, 10.0 
Nutrient broth No. 1 (NB)[297] 
Lab-Lemco beef extract, 1.0 
Peptone, 5.0 
Yeast extract, 2.0 
NaCl, 5.0 
 
All 96 well plates were incubated for 18±2 h at 35 °C and 120 rpm, wrapped in plastic to 
reduce evaporation. Absorbance at 595 nm in all wells was measured and background 
corrected % inhibition calculated as previously described in Chapter 2, page 49. The 
experiment was performed in triplicate using an independent bacterial suspension for 
each replicate. The number of wells resulting in precipitation of higher concentration 
agents, lowest achievable MIC90s and mean standard deviation (SD) % inhibition in each 
well (as a measure of reproducibility between replicates) were assessed in order to select 
an appropriate broth for ongoing use. 
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3.2.2 Effect of low concentration ethanol on bacterial growth 
Due to limited solubility in aqueous solution, standard laboratory practice is to prepare 
an initial FNa stock solution in EtOH[273]. However, EtOH can denature proteins and 
therefore disrupt bacterial growth[298]. The effect of low concentrations of EtOH on growth 
of S. aureus NCTC 12973 and E. coli NCTC 10418 in the chosen bacteriological medium 
was therefore investigated. This was performed using EtOH concentrations equivalent 
to those present in dilutions of a 51.2 mM FNa stock solution in 50 % v/v EtOH. 
The concentration range of FNa for use with S. aureus NCTC 12973 in the chosen broth 
was optimised by first testing the range selected for E. coli NCTC 10418 and then further 
extending the two-fold dilutions. Once the FNa concentration range was determined for 
both organisms, dilution series of equivalent concentrations of EtOH were prepared in 
96 well plates and inoculated with 5±3 × 105 CFU mL-1 of E. coli NCTC 10418 or 
S. aureus NCTC 12973. Percentage inhibition was determined after incubation for 
18±2 h at 35 °C and 120 rpm as for other investigations. The 95 % confidence intervals 
(95 % CI) were calculated for each EtOH concentration to determine whether there was 
a statistically significant difference in inhibition compared to the EtOH-free control 
(p ≤0.05). 
3.2.3 Metal ion MIC90s, MBCs and concentration range selection 
The MIC90 and MBC of the sulphates of Al3+, Co2+, Cu2+, Fe2+, Mn2+, Ni2+, Pd2+ and Zn2+ 
against E. coli NCTC 10418 and S. aureus NCTC 12973 was determined using the 
microdilution method described in Section 2.4. Stock solutions of metal sulphates were 
prepared and stored as described in Section 2.1. All metal ions were initially tested using 
two-fold dilutions from a maximum concentration of 10 mM. This concentration range 
was selected based on experience with Cu2+ during initial chequerboard optimisation 
(Section 3.3.1). If the MIC90 could not be identified in this range, a lower or higher starting 
concentration was selected as appropriate and the assay repeated. Each experiment 
was carried out in triplicate. The MIC90s were used to select the concentration range of 
each metal to be used for chequerboard testing as a highest concentration of two or four 
times the MIC90 followed by five two-fold dilutions. Where the MIC90 varied between 
organisms, the E. coli MIC90 was used as a basis for range calculation because of the 
focus on anti-GN efficacy. 
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3.2.4 The effects of sodium sulphate and sodium chloride on bacterial 
growth and sodium fusidate activity 
It was important to validate that any modulation of microbiological activity was due to the 
metal ions, and not the sulphate counterion. Therefore, once the chequerboard 
concentration ranges were selected, the effect of sulphate was investigated using 
sodium sulphate (Na2SO4). Na2SO4 was selected as concentrations of Na+ up to 850 mM 
and 2.3 M have been found to be non-inhibitory to the growth of E. coli and S. aureus, 
respectively[299]. The microdilution assay was used to determine % inhibition of E. coli 
NCTC 10418 and S. aureus NCTC 12973 produced by Na2SO4 at concentrations 
equivalent to sulphate present in the highest selected metal sulphate concentration 
ranges, in triplicate. In addition, the microdilution assay using NaCl was also carried out 
in triplicate in order to assess the effect of NaCl equivalent to concentrations present in 
Pd2+ solutions. The 95 % CIs were calculated for each Na2SO4 and NaCl concentration 
to determine whether there was a statistically significant difference compared to the 
control (p ≤0.05).  
Finally, the effect of sulphate and NaCl on activity of FNa against E. coli NCTC 10418 
and S. aureus NCTC 12973 was assessed by chequerboard assay, as described in 
Chapter 2, Section 2.5. The highest concentration of FNa tested against E. coli and 
S. aureus was 1280 and 10 µM, respectively, whereas both organisms were exposed to 
a maximum of 10 mM Na2SO4 or 5 mM NaCl. FNa MIC90 and MBC values with and 
without the various concentrations of Na2SO4 or NaCl were compared. The absolute 
difference between % inhibition caused by combinations of FNa and sodium salt and the 
same concentration of FNa alone was calculated in the presence of each Na2SO4 or 
NaCl concentration in three separate replicates. Absolute inhibition differences of ± <5 % 
were considered negligible. The 95 % CIs were used to determine whether differences 
in inhibition of ± ≥5 % were statistically significant (p ≤0.05). 
63 
3.3 Results 
3.3.1 Bacteriological medium selection 
Initial MICs of 5 mM CuSO4 and 1280 µM FNa against E. coli NCTC 10418 were visually 
determined from the pilot investigation in CAMHB. However, precipitation of FNa in 
CAMHB was apparent in wells containing >1280 µM of the drug. Concentration ranges 
of 0.156 to 5 mM CuSO4 and 2.5 to 1280 µM FNa were therefore selected for 
chequerboard bacteriological medium optimisation. 
Broth comparison chequerboard results analysed using the microplate reader are 
presented as mean % inhibition heatmaps in  
Figure 3.1. Precipitation of FNa was apparent in high concentration wells in all broths 
tested, as indicated by pink shading, and these wells were excluded from the analysis. 
The MIC90 of FNa against E. coli NCTC 10418 in CAMHB was found to be >1280 µM on 
spectrophotometric assessment which was greater than that visually determined in the 
pilot test. A concentration of 1280 µM FNa produced a mean 86.0 % inhibition. Since 
precipitation of FNa was observed in the pilot test with concentrations of >1280 µM and 
the MIC90 fell within this range, CAMHB was rejected as an option suitable for 
chequerboard analysis of FNa and metal salt combinations against GN organisms. FNa 
MIC90s in LB and NB were 80 and 320 µM, respectively, and no precipitation of FNa 
alone was detected in these broths at concentrations up to and including 1280 µM. 
Precipitation in both LB and NB was apparent at the highest combined concentrations of 
the agents tested. However, concentrations of FNa and CuSO4 involved in precipitation 
were several times higher than the respective and combined MIC90s. 
The MIC90 of CuSO4 alone against E. coli NCTC 10418 was found to be at least 8 times 
higher in LB than NB, at >5 and 1.25 mM, respectively. The mean of the SDs for all 
analysed wells were quite similar at 0.93 % with LB and 1.11 % with NB, indicating 
similar inter-replicate reproducibility with both broths. However, NB was selected based 
on the lower CuSO4 MIC90 and consequent reduced requirement for resources.  
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Figure 3.1 - E. coli NCTC 10418 growth heatmaps in the presence of sodium fusidate and 
copper(II) sulphate combinations in three media: cation adjusted Müller-Hinton broth 
(CAMHB), Miller’s lysogeny broth (LB) and nutrient broth No. 1 (NB) 
Colour density of shading corresponds to percentage inhibition in each well, as indicated in 
the key. Pink wells indicate presence of precipitation. 
(n = 3) 
3.3.2 Effect of low concentration ethanol 
The MIC90 of FNa against S. aureus NCTC 12973 in NB was found to be 312.5 nM. As 
the purpose of chequerboard testing against S. aureus was to confirm absence of 
adverse effects of the presence of metals on the activity of FNa (to which S. aureus is 
already sensitive), the FNa concentration range selected was 19.5 nM to 10 µM to allow 
detection of both decreased and increased inhibition. The FNa concentration range for 
E. coli was maintained at 2.5 to 1280 µM, as determined above. 
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Figure 3.2 - Inhibition of S. aureus NCTC 12973 by ethanol concentrations equivalent to 
those present in sodium fusidate test dilutions 
Arrow indicates sodium fusidate MIC90. 
 (n = 3, error bars = 95 % CI, * = p ≤0.05) 
 
Figure 3.3 - Inhibition of E. coli NCTC 12973 by ethanol concentrations equivalent to those 
present in sodium fusidate test dilutions 
Arrow indicates sodium fusidate MIC90. 
(n = 3, error bars = 95 % CI, * = p ≤0.05) 
Inhibition of S. aureus NCTC 12973 and E. coli NCTC 10418 by EtOH in NB at 
concentrations relevant to the corresponding FNa test ranges is presented in Figure 3.2 
and Figure 3.3, respectively. The equivalent FNa concentration is shown on the x axis 
for ease of interpretation of the impact of EtOH in direct relation to the chequerboard FNa 
concentration range. For reference, dilution of a 51.2 mM stock solution of FNa in 
50 % v/v EtOH equates to 1.25 % EtOH being present with 1280 µM FNa, 0.00980 % 
with 10 µM and 0.000305 % with 0.313 µM. 
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The 95 % CIs indicated small but significant enhancement of S. aureus growth in the 
presence of EtOH concentrations equivalent to those present with 0.625 µM FNa and 
below, illustrated by negative inhibition values ranging from -10.7 to -2.8 % (p <0.05, 
Figure 3.2). However, since the S. aureus MIC90 of FNa falls within this range (0.313 µM), 
the small growth-enhancing effect of low concentration EtOH alone appears to be 
overcome by the much larger inhibitory effects of FNa. S. aureus growth was inhibited 
by EtOH equivalent to 2.5 and 10 µM FNa dilutions by 2.8 and 7.5 %, respectively 
(p <0.05). However, inhibition by FNa at these concentrations of 4- and 32-times the 
MIC90, respectively, was already determined to be >95 %. 
There was no significant impact on growth of E. coli in NB in the presence of EtOH 
concentrations equivalent to those present with 5 to 640 µM FNa, inclusive (p >0.05, Figure 
3.3). Interestingly, when exposed to EtOH alone at concentrations equal to those present in 
the lowest and highest FNa dilutions tested (2.5 and 1280 µM), the calculated inhibition of 
E. coli was significantly different from the control, at -4.6 and -11.8 % (p <0.05), 
respectively, indicating increased cell density compared to the EtOH-free control. However, 
since 2.5 and >95 % E. coli inhibition was already confirmed in the presence of 2.5 and 
1280 µM FNa, respectively ( 
Figure 3.1 in Section 3.3.1), this phenomenon with EtOH alone appears to have a 
negligible impact on the interpretation of the effects of FNa. 
3.3.3 The instability of Fe2+ in aqueous solution 
On initial preparation, stock solutions of FeSO4 in sterile HPLC-grade water were pale 
green in colour, due to the presence of Fe2+ ions. However, over time in aqueous solution 
and after incubation for 18±2 h in bacteriological media, an orange-brown colour and 
precipitate developed. Figure 3.4 illustrates the concentration-dependent colour change 
and precipitation after incubation in nutrient broth. 
Iron ions are well known for their ability to be readily oxidised or reduced between Fe2+ 
and Fe3+ and to exist as multiple species of both divalent and trivalent ions in aqueous 
solution, including bacteriological media. For example, after 24 h incubation in LB, Fe2+ 
precipitates as Fe3O4 and Fe3+ as Fe(OH)2.7Cl0.3[300]. However, while it is unknown 
whether these insoluble products are responsible for or involved in the antimicrobial 
activity of iron, concentrations at which they appear to form in NB (≥2.5 mM) are 
bactericidal to both E. coli and S. aureus. 
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Figure 3.4 - Wells containing iron(II) sulphate in sterile nutrient broth after incubation for 
18±2 h at 35 °C and 120 rpm illustrating precipitation and colour change indicative of 
generation of heterogenous iron species 
Precipitate (cloudiness) and colour change (orange-brown, Fe3+) developed during incubation 
of ≥2.5 mM iron(II) sulphate in nutrient broth. No precipitation or colour change occurred 
with ≤1.25 mM. Left image is photographed over a black background to enhance visualisation 
of the precipitate and right over a white background for visualisation of the colour change. 
3.3.4 Metal ion MIC90s, MBCs and concentration range selection 
The MIC90 and MBC of each metal ion against E. coli NCTC 10418 and S. aureus NCTC 
12973 are displayed in Table 3.2. In all cases, the MIC90 against the two organisms fell 
within one two-fold dilution of each other. Where determined, the MBCs were also 
similar, except Al3+ which killed E. coli at 2.5 mM while S. aureus was able to survive in 
the presence of at least 10 mM. There was no significant difference between growth of 
E. coli NCTC 10418 or S. aureus NCTC 12973 in the presence of NaCl concentrations 
equal to those found in Pd2+ dilutions and the controls (p >0.05). 
 
Table 3.2 – MIC90 and MBC of antimicrobial metal sulphates against E. coli NCTC 10418 and 
S. aureus NCTC 12973 after 18±2 h incubation in nutrient broth at 35 °C and 120 rpm 
 E. coli NCTC 10418 S. aureus NCTC 12973 
 MIC90 (mM) MBC (mM) MIC90 (mM) MBC (mM) 
Aluminium as sulphate 2.5 2.5 2.5 >10 
Cobalt(II) sulphate 0.156 0.313 0.156 0.625 
Copper(II) sulphate 1.25 2.5 2.5 2.5 
Iron* sulphate 2.5 2.5 2.5 2.5 
Manganese(II) sulphate 2.5 >10 1.25 >10 
Nickel(II) sulphate 0.625 1.25 0.313 2.5 
Palladium(II) sulphate 0.625 1.25 1.25 1.25 
Zinc(II) sulphate 0.313 0.625 0.156 >0.625 
*Colour change on mixing and incubation with broth indicates heterogeneous iron species are 
generated (see Figure 3.4 in Section 3.3.3) 
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In combination with values from the literature, the determined MIC90s illustrated effect of 
growth medium on the antimicrobial activity of metal ions. For example, the lowest 
reported MICs of Co2+ are 1 mM in LB against E. coli[301] and 3 mM in tryptone soy broth 
(TSB) against S. aureus[302], both >6 times the MIC90 determined in NB (Table 3.2). The 
Zn2+ MIC90s in NB were also many times lower than the reported MICs in richer growth 
media of 3.73 in CAMHB against E. coli[303] and 5 mM in TSB against S. aureus[302]. 
Conversely, the MIC90s of Pd2+ in NB were higher than reported values in minimal media 
of 0.015 against E. coli and 0.2 mM against S. aureus[304] while the reported MICs in LB 
were only approximately two to four times those found in NB at 2.82 and 2.24 mM, 
respectively[305]. Interestingly, Al3+ MIC against E. coli has been reported to be only one 
two-fold dilution higher than that found in NB at 5 mM in Lennox LB [300] and very similar 
to in NB at 2 mM in a mineral salts medium[306]. However, reported Cu2+ MICs against 
E. coli were 1 mM in minimal medium[306], 4[301] or 5[271] mM in LB, 10 mM in MHB[307] and 
12 mM on brain heart infusion (BHI) agar[308]. Overall, metal ion MIC values in NB are 
lower than in rich bacteriological media such as LB or MHB, but higher than those in 
minimal media, indicating that lower nutrient content increases metal ion susceptibility. 
These differences reflect previously reported data comparing antimicrobial activity and 
growth medium composition[309],[310]. 
Based on MIC90 results in NB, concentration ranges for use in chequerboards were 
selected as follows: 0.3125 to 10 mM Al3+, 19.5 to 625 µM Co2+, 0.156 to 5 mM Cu2+, 
0.313 to 10 mM Fe2+, 0.313 to 10 mM Mn2+, 0.781 to 2.5 mM Ni2+, 0.391 to 1.25 mM 
Pd2+, and 19.5 to 625 µM Zn2+. 
3.3.5 Effects of sodium sulphate alone on bacterial growth 
Na2SO4 concentrations of 0.313 to 10 mM were selected for investigation (Figure 3.5). 
There was no significant difference between growth of E. coli NCTC 10418 in the 
presence of any concentration of Na2SO4 tested (p >0.05) except 2.5 mM. At this 
concentration Na2SO4 inhibited E. coli growth by 1.9 % which, while small, was 
statistically significant (p ≤0.05). S. aureus NCTC 12973 was not affected by the 
presence of 0.313 to 1.25 mM Na2SO4, inclusive (p >0.05), however, 2.5, 5 and 10 mM 
inhibited 6.9, 9.8 and 19.7 % of growth, respectively (p ≤0.05). Consequently, the 
determined MIC90s of 2.5 mM Al3+, Cu2+ and Fe2+/3+ could have been influenced by the 
additional inhibition caused by 3.75, 2.5 and 2.5 mM sulphate, respectively. However, 
the MIC90 of these metal sulphates inhibited S. aureus growth by 100 ± 0, 97.4 ± 4.1 and 
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100 ± 0 % (95 % CI), respectively. Therefore, normalisation to inhibition caused by the 
presence of 2.5 to 5 mM Na2SO4 still results in >90 % attributable to the metal ions.  
 
Figure 3.5 - Inhibitory effect of sodium sulphate on the growth E. coli NCTC 10418 and 
S. aureus NCTC 12973 in nutrient broth after incubation for 18±2 h 
(n = 3, error bars = 95 % CI, * = p≤0.05) 
3.3.6 Sodium fusidate activity in the presence of sodium sulphate 
 
Figure 3.6 - Difference in inhibition of S. aureus NCTC 12973 by sodium fusidate in the 
presence of sodium sulphate compared to sodium fusidate alone 
Sodium fusidate concentrations up to 4 x MIC90 are shown. 
(n = 3, error bars = 95 % CI, * = difference ±≥5 % and p≤0.05) 
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The MIC90 and MBC of FNa against S. aureus NCTC 12973 were not affected by the 
presence of any concentration of Na2SO4 tested. However, statistically significant 
differences in the inhibition produced by sub-MIC90 concentrations of FNa with and 
without Na2SO4 were identified (p ≤0.05, Figure 3.6). Inhibition by 78.1 nM FNa (0.25 x 
MIC90) was reduced by 8.8 and 6.4 % when combined with 0.313 and 1.25 mM Na2SO4, 
respectively, whereas it was increased by 15.6 % by 10 mM. The inhibition produced by 
39.1 and 19.5 nM FNa was also increased by 6.3 and 7.0, 11.4 and 9.3, and 19.0 and 
17.5 % in the presence of 2.5, 5 and 10 mM Na2SO4, respectively. 
The MIC90 against E. coli NCTC 10418 was also unaffected in the presence of ≤1.25 mM 
Na2SO4. With 2.5, 5 and 10 mM Na2SO4 the FNa MIC90 against E. coli was reduced by 
one two-fold dilution to 160 µM, however, only in the presence of 10 mM was the 
inhibition ≥5 % and statistically different to that produced by FNa alone (p <0.05, Figure 
3.7). Na2SO4 at 10 mM also significantly increased the antimicrobial activity of 80, 40, 20 
and 10 µM FNa by 7.5, 12.9, 18.2 and 5.9 %, respectively (p <0.05), and at 5 and 2.5 mM 
added 6.3 and 6.6 % to growth inhibition by 20 µM FNa (p <0.05). The MBC of FNa 
against E. coli was above the tested concentration range >1280 µM and therefore not 
assessed. 
 
Figure 3.7 - Difference in inhibition of E. coli NCTC 10418 in the presence of sulphate and 
sodium fusidate compared to sodium fusidate alone 
(n = 3, error bars = 95 % CI, * = difference ±≥5 % and p≤0.05) 
The inhibitory effects of sulphate combined with FNa against S. aureus NCTC 12973 
and E. coli NCTC 10418 were found to occur at concentrations at or above those present 
with the MIC90 of metal ions. Sulphate-normalised % inhibition of metal ions at MIC90 was 
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still ≥90 %. Therefore, this activity was considered to have no impact on the interpretation 
of chequerboard results. 
3.3.7 Effect of sodium chloride on bacterial growth and the activity of 
sodium fusidate 
NaCl at concentrations present in Pd2+ dilutions were found to have little effect on the 
interpretation of results. No significant differences in growth of either E. coli NCTC 10418 
or S. aureus NCTC 12973 were found between any NaCl concentration tested and 
agent-free controls. Significant differences of ≥5 % in growth inhibition between FNa 
alone and in the presence of NaCl were detected against both organisms. E. coli NCTC 
10418 was inhibited by an additional 5.7 % by 40 µM FNa when combined with 2.5 mM 
NaCl. However, this NaCl concentration was equivalent to that present with 0.625 Pd2+ 
which caused >98 % growth inhibition, therefore indicating no interference with 
determination of the E. coli MIC90. When 78.1 and 39.1 nM FNa were each combined 
with 5 mM NaCl against S. aureus NCTC 12973, growth inhibition was increased by 11.6 
and 16.6 %, respectively. This NaCl concentration was equivalent to that present with 
1.25 mM Pd2+, the S. aureus MIC90 and, more notably, MBC, therefore being unlikely to 
have any impact on interpretation. 
3.4 Conclusions 
NB was found to be the most appropriate medium for conducting chequerboards of FNa 
and metal salts against GN bacteria and was therefore employed for all microdilution-
based assays against all organisms. Selection was based on lower E. coli NCTC 10418 
MIC90 of CuSO4 compared to LB and CAMHB, reproducibility between replicates and 
lack of FNa precipitation at critical concentrations. 
Low concentration EtOH in NB was found to exhibit some small but significant impacts 
on the growth of both S. aureus NCTC 12973 and E. coli NCTC 10418. In particular, the 
growth of S. aureus was enhanced by EtOH concentrations equivalent to those present 
in sub-MIC90 FNa dilutions by up to 4.8 %. However, these effects appeared to have a 
negligible influence on the antimicrobial performance of FNa and the interpretation of 
MIC90 values, therefore, FNa dilutions prepared from 51.2 mM stock solution in 50 % v/v 
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EtOH were determined to be suitable for use in microdilution and chequerboard assays 
without further adjustment. 
The chequerboard and microdilution assays were therefore successfully optimised for 
the study of the antimicrobial activity of metal ions, FNa and both combined. The finalised 
microdilution and chequerboard methods presented in Chapter 2, Sections 2.4 and 2.5, 
respectively.
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Chapter 4: Antimicrobial activity of 
sodium fusidate combined 
with metal ions 
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4.1 Introduction 
As previously discussed in Chapter 1, FNa inhibits bacterial growth by targeting the 
prokaryotic elongation factor EF-G and preventing protein synthesis. While GN 
organisms do not lack the EF-G target, they are intrinsically resistant to FNa due to a 
combination of a low permeability OM and multi-drug efflux pumps. Formulations of FA 
and FNa are already licensed for and frequently used in the treatment of conjunctivitis. 
Repurposing FNa for use in both GP and GN keratitis is therefore an attractive drug 
development option as the safety and efficacy in ocular use is already established. Metal 
ions are well known to exhibit a range of antimicrobial and chemical properties. One or 
more antimicrobial mechanism of metal ions may exert a co-operative effect to overcome 
intrinsic FNa resistance and render GN organisms susceptible to its protein synthesis 
inhibitory effects. Metal ions were therefore selected for investigation into extending the 
antimicrobial spectrum of FNa by co-formulation. 
4.1.1 Metal ions of interest for combining with sodium fusidate 
Metal ions exert their antimicrobial effect by targeting multiple bacterial structures and 
systems. These include damaging proteins by displacing native ions, disrupting iron-
sulphur (Fe-S) clusters or binding and denaturing polypeptides; damaging membranes 
by attacking embedded proteins, peroxidising lipids or altering crosslinking and fluidity; 
damaging nucleic acids by binding amino acid residues or causing strand breaks; 
interfering with ribosomal function by ion displacement or structural damage; and 
generalised oxidative stress via the generation of reactive oxygen species (ROS) or 
saturation of ROS management systems[272]. The specific mechanisms of metal ion 
antimicrobial activity have taken many years to elucidate and some metals are better 
understood than others. As discussed in Section 1.4.4, increased OM permeabilisation 
and inhibition of efflux are likely to be effective strategies to overcome intrinsic FNa 
tolerance in GN bacteria. However, other features, such as induction of oxidative stress 
or the ability to synchronously interfere with protein synthesis, may also help increase 
drug activity.  
Inclusion criteria for elemental metal ion selection in this work was essentially based on 
whether their established antimicrobial mechanisms had the potential to produce a co-
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operative effect with FNa. Consequently, the following 8 metal ions were selected: Al3+, 
Co2+, Cu2+, Fe2+, Mn2+, Ni2+, Pd2+ and Zn2+. The unique combinations of each metal ion’s 
targets are detailed in Sections 4.1.1.1 to 4.1.1.8 below and summarised in Table 4.1. 
Overlap between antimicrobial mechanisms was chosen to support potential 
identification of metal ion targets necessary or detrimental to effective combination with 
FNa. 
Table 4.1 – Summary of known antimicrobial targets and mechanisms of metal ions 
selected for investigation in combination with sodium fusidate 
Metal 
Known antimicrobial targets and mechanisms 
oxidative 
stress DNA RNA ribosomes 
intracellular 
proteins membranes 
Al3+       
Co2+       
Cu2+       
Fe2+       
Mn2+       
Ni2+       
Pd2+       
Zn2+       
 
4.1.1.1 Aluminium 
Al3+ is believed to be non-essential to biological systems and is not spontaneously taken 
up into bacterial cells[300],[311],[312]. However, Al3+ ions are able to exert an antimicrobial 
effect by damaging external cell structures: trivalent Al3+ can outcompete both Ca2+ and 
Mg2+ for phosphate functional groups leading to misfolding of membrane proteins and 
disruption of lipopolysaccharide (LPS) and phospholipid organisation in GN 
bacteria[300],[313],[314]. This may also lead to alterations in transmembrane potential[315] as 
well as acceleration of lipid peroxidation in the presence of reactive iron[316]. Al3+ is also 
thought to be able to hijack Fe3+ uptake systems, compromising Fe homeostasis and 
limiting production of essential Fe-containing enzymes[237]. At sub-bactericidal 
concentrations, the presence of Al3+ specifically induces GN membrane stress reporter 
genes[300] as well as enhanced expression of flagellin[317] and an enzyme involved in the 
production of modified, cation-resistant lipid A[318],[319]. 
Al3+ is also toxic to GP bacteria via similar mechanisms as occur in GNs, causing damage 
to membrane proteins and phospholipids[320]. However, the GP bactericidal effect of Al3+-
containing solutions is not as rapid or dramatic as against GN organisms[321]. This may 
be because Al3+ readily adsorbs onto carboxyl and phosphate sites of the exposed GP 
cell wall peptidoglycan[322], thereby reducing the local concentration freely able to access 
and damage the membrane components. The overall antimicrobial mechanism of Al3+ 
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follows a similar pattern in both GN and GP organisms: damage initially decreases 
function and stability of the cell membrane(s) inhibiting active growth and this, if too 
extensive for rapid repair, results in increased permeability, consequent leakage of 
intracellular material and cell death. 
Al3+ may be able to enhance FNa anti-GN activity by producing both increased 
intracellular access through destabilised OM and decreased efflux pump function due to 
cell surface protein damage and disruption of the required IM PMF. 
4.1.1.2 Cobalt 
Co2+ is an essential nutrient required for the proper function of cobalamin-dependent 
enzymes[161]. As such, bacteria exhibit specific uptake and homeostasis mechanisms to 
acquire and manage intracellular Co2+. However, excess Co2+ can interfere with essential 
cellular processes, including the assembly and stability of Fe-S cluster- and haem-
containing proteins, Fe2+ uptake and normal redox status disturbance[323]–[326]. In E. coli, 
Co2+ is acquired via the major cobalt importer CorA[323], cobalamin uptake[327] or as a 
citrate-coupled complex by replacing the preferred Mg2+ [328]. When present in excess, 
Co2+ can also out-compete Fe2+ and Ni2+ uptake via FeoB and NikA, respectively[324]. 
Exposure to increased Co2+ induces the expression of the Co2+ and Ni2+ efflux encoding 
gene rcnA via RcnR[329] while feoB and nikA expression is stopped[324]. If these measures 
fail to adequately reduce intracellular Co2+ levels, the assembly of Fe-S enzymes is 
compromised. In the presence of excess Co2+, scaffold proteins, responsible for transient 
assembly of Fe-S clusters and transfer to the target protein, can erroneously replace 
approximately half of Fe2+ in the immature Fe-S assemblies with Co2+ [323]. These inactive 
mixed Co-Fe-S clusters are then transferred to the target enzymes resulting in an 
inoperative product[323]. Processes dependent upon Fe-S proteins include gene 
regulation, tRNA turnover, DNA maintenance and, crucially, respiration[324]. In order to 
limit the impact on overall cell function, the expression of Fe-S biogenesis genes is 
increased in response to Co2+ exposure, presumably to compensate for the proportion 
of miss-assembled enzymes in essential pathways, and non-essential Fe-S-dependent 
pathways and proteins are downregulated[324]. However, Co2+ can also disrupt complete 
and fully-functional Fe-S proteins by displacing Fe[323]. This is further confounded by the 
reduction of intracellular Fe2+ via Co2+-induced reversal of Fur repression and 
consequent ferrichrome reductase (fhuF) expression[330], preventing Fe-S cluster 
recovery. 
While Co2+ plays no role in the generation of reactive oxygen species inside bacteria[331] 
and appears to inhibit Fe2+-H2O2-mediated lipid peroxidation[332], it can indirectly produce 
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oxidative stress. Glutathione (GSH), an antioxidant, is able to chelate intracellular Co2+. 
Strangely, the GSH•Co2+ complex acts as a pro-oxidant, catalysing the formation of •OH 
and singlet oxygen from H2O2 via a Fenton-type reaction[325]. These reactive oxygen 
species can cleave DNA. In addition, Co2+ has been found to inhibit E. coli protein 
synthesis[333] by direct interference with ribosomal subunit assembly[334] which may be 
due lack of differentiation between Co2+ and Zn2+ when either ion is present in excess[335]. 
Finally, Co2+ can also inhibit RNA synthesis in E. coli[333]. 
Co2+ is an interesting option for combination with FNa due potential synergy between 
each agent’s mechanism of protein synthesis inhibition. Furthermore, disruption of Fe-S 
cluster-dependent enzymes and pathways or additional oxidative stress may further limit 
survivability when in combination with protein synthesis inhibition. 
4.1.1.3 Copper 
Cu2+ is also an essential micronutrient utilised as a cofactor in many bacterial enzymes 
including cytochrome oxidases and oxygenases[161],[336]. Homeostasis in E. coli is 
primarily governed by two chromosomal operons: cue (copper efflux) and cus (copper 
sensing)[337]. CueR regulates expression of Cu management genes by binding to the 
promotor of copA (a P-type ATPase which exports Cu+ to the periplasm[338]) and cueO 
(a periplasmic oxygen-dependent multi-copper oxidase which oxidises Cu+ to the less 
damaging Cu2+) in the presence of elevated intracellular Cu+. (Any free ions in the 
cytoplasm are the more reactive Cu+ due to the reducing intracellular environment[339].) 
However, these systems can become overwhelmed in the presence of excess 
extracellular Cu2+, leading to toxicity. The first and most deleterious effect of Cu2+ 
overload appears to be the disruption of Fe-S clusters in dehydratases[340]. Dehydratases 
are essential to the branched chain amino acid biosynthesis pathway required for growth, 
as well as various other metabolic functions. Cu+ displaces Fe2+ from the Fe-S cluster, 
leading to enzyme dysfunction and degradation. Dehydratases appear to be particularly 
susceptible to Cu+ attack due to the exposed nature of their Fe-S clusters whereas the 
function of enzymes with occluded clusters is not affected[340]. Cu2+ has also been found 
to interfere with the biosynthesis of haem by inhibiting an Fe-S cluster-containing 
decarboxylase of one of the porphyrins upstream of Fe2+ incorporation. This results in 
loss of the enzymes catalase and peroxidase which in turn decreases ROS defences[341]. 
This is interesting, since the generation of intracellular ROS was long disputed as a direct 
mechanism of Cu+ toxicity. It appears that Fe2+ released from damaged Fe-S clusters 
may initiate ROS production[340], while abrogation of detoxifying enzymes exacerbates 
the situation. As with other metal ions, the majority of free intracellular Cu+ is sequestered 
by GSH[340]. While the GSH pool within cells is very large and unlikely to become 
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saturated by Cu+, even when exposed to toxic concentrations[342], reduced reserves may 
have a knock-on effect on the ability of the cell to manage its redox homeostasis. This is 
likely to result in increased susceptibility to ROS generated by released Fe2+ in the same 
way that exposure to combined Cu2+ and H2O2 was found to produce high levels of 
intracellular •OH radicals in E. coli[343]. Therefore, oxidative stress can play a role in Cu2+ 
toxicity, but it is mediated via the accumulative effects of other mechanisms rather than 
direct redox cycling. However, almost all unbound copper ions are found in the 
periplasm[339] and here they can damage both membranes by causing lipid peroxidation 
via a cyclical redox reaction[332],[336] and interfere with the structure and function of 
periplasmic and membrane proteins[342]. 
The propensity of Cu2+ to readily bind to antimicrobial drugs has long been employed for 
the detection and differentiation of sulphonamides[344]. A number of these complexes 
have been shown to retain their antimicrobial activity in vitro[345],[346]. Cu2+, along with a 
number of other divalent cations, has also been shown to spontaneously form complexes 
with a variety of cephalosporins, however, none have been found with increased 
activity[347]–[349]. Conversely, the Cu-complex of the fluoroquinolone ciprofloxacin is 
equally activity as the parent drug[259],[350],[351], whereas Cu-enrofloxacin has been shown 
to be about twice as effective as equivalent ionic mixtures or free enrofloxacin alone[352]. 
The combination of permeability-altering membrane damage and disruption of essential 
metabolic pathways caused by Cu2+ may enhance FNa activity by increasing entry into 
the cell while decreasing growth capacity. In addition, disruption of membrane and 
periplasmic proteins may damage AcrAB-TolC, reducing or preventing efflux. 
Alternatively, complex formation may enhance activity by preventing efflux or enabling 
direct delivery of Cu2+ into the cytoplasm. 
4.1.1.4 Iron 
Iron is the most abundantly available and biologically utilised metal on Earth, essential 
to all forms of life[353]. Its importance is such that all animals flood their exposed mucosal 
surfaces with Fe-sequestering proteins to limit the availability of Fe to potential 
pathogens, a function known as “nutritional immunity”[353]. Interestingly, some bacteria 
express receptors capable of obtaining Fe2+ via siderophores and other Fe-bound 
proteins that are produced by other organisms in order overcome Fe-limited 
conditions[354]. Despite the necessity and extensive measures to overcome any scarcity 
of Fe, exposure to high concentrations can be very damaging to bacterial cells. 
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ROS generation and the resulting oxidative stress is believed to be the primary 
mechanism of Fe toxicity. All homeostatic processes are geared to utilising gathered Fe 
while preventing any uncontrolled reactivity. However, free ions accumulated during 
overload readily react with endogenous respiration products H2O2 and O2- in a cyclical 
manner[336],[355] (Figure 4.1). Fe2+ reduces H2O2 to produce OH- and highly reactive and 
damaging •OH. The resulting Fe3+ is then readily reduced back to Fe2+ by O2-, 
perpetuating the cycle. Excess •OH reacts with biological macromolecules, primarily 
damaging DNA and proteins[300]. In addition, Fe2+ and Fe3+ can directly catalyse the 
oxidation of proteins[300] and membrane lipid peroxidation[332],[336]. 
 
Figure 4.1 – Cyclical production of hydroxyl radicals via the Fenton reaction[336] 
Fe3+ is reduced by O2- to Fe2+. Fe2+ reduces H2O2 to OH- and highly reactive •OH, oxidising to 
Fe3+ in the process. 
The combination of membrane and protein damage may be advantageous to FNa activity 
by facilitating entry into the cell and reducing efflux, respectively. In addition, 
considerable oxidative stress may limit bacterial resources for induced AcrAB-TolC 
expression while, vice versa, stalling of protein synthesis would prevent replenishment 
of damaged proteins and free radical scavengers. 
4.1.1.5 Manganese 
While Mn2+ is also a micronutrient, it too can cause damage to an array of bacterial 
systems when present in excess. Extracellular Mn2+ outcompetes Mg2+ for uptake when 
at a high relative concentration ratio[328] and, when the internal concentration ratio shifts, 
Mn2+ displaces Mg2+ at multiple intracellular locations including enzymatic active sites 
and structural positions in ribosomal RNA (rRNA) folding[356]. It can also cause errors 
during DNA replication by displacing Mg2+ at the DNA polymerase I active site, reducing 
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nucleotide alignment fidelity[357],[358]. Since the homeostasis of Mn2+ and Fe2+ are linked 
(primarily via the Fur operon), excess Mn2+ inhibits the synthesis of haem and Fe-S 
clusters by inducing the depletion of intracellular Fe2+ and out-competing available Fe2+ 
for inclusion in these structures[359],[360]. The consequent inactivation of key enzymes 
results in disruption of both the TCA (Krebs) cycle and electron transport chain – the two 
pathways for ATP generation[360]. In addition, Mn2+ stress is inhibitory to E. coli cell 
division, producing a filamentous morphology void of septation due to downregulation of 
penicillin binding protein 3 (PBP3) expression[361]. 
Any of these modes of toxicity could potentially synergise with FNa activity, however, 
Mn2+-induced ribosomal misfolding coupled with protein synthesis stalling by FNa could 
be particularly effective at inhibiting bacterial growth. 
4.1.1.6 Nickel 
Ni2+ is another essential micronutrient required structurally or catalytically for the correct 
function of multiple enzymes[161],[337]. However, when in excess, Ni2+ can displace Zn2+ 
from its binding sites in enzymes and metalloproteins. For example, the structurally 
essential Zn2+ of E. coli fructose-1,6-bisphosphate aldolase is readily replaced by surplus 
Ni2+, abolishing enzymatic activity[362]. This enzyme is essential for utilisation of glucose 
and fructose as an energy source and, therefore, its disruption is thought to be a key 
mechanism of Ni2+ toxicity in limited carbon-source environments. GSH-associated ROS 
generation occurs with Ni2+ in the same way as with Co2+ [336]. In addition, and unlike 
Co2+, Ni2+ enhances Fe2+-mediated lipid peroxidation[332], however, this does not appear 
to be sufficient to damage membranes under standard laboratory growth conditions 
without iron supplementation[363]. Ni2+ is able to denature proteins by catalysing 
spontaneous disulphide bond formation[331] and can also reduce RNA synthesis[333]. This 
combination of antimicrobial mechanisms could work to prevent FNa efflux by denaturing 
AcrAB-TolC components while reducing mRNA available for transcription, limiting 
energy utilisation and overloading the cells with oxidative stress. 
4.1.1.7 Palladium 
In response to the success of the Pt-based anticancer agent cisplatin and the similarity 
between Pt2+ and Pd2+ coordination chemistry, a wide variety of Pd-complexes have 
been studied for their anticancer[364]–[367], antimicrobial[368]–[371] and antiviral[372] efficacies. 
Pd readily forms complexes with ligands containing N, S, P and/or O co-ordination sites. 
In many cases, such complexation has been found to increase the biological activity of 
the parent molecule. For example, the antimicrobial activity of a variety of quinolones 
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was increased approximately 5-fold against a number of bacterial species including 
E. coli and P. aeruginosa by complexation with Pd[373]. Complexation with Pd has also 
been shown to dramatically increase the efficacy of tetracycline against TetA efflux-
mediated resistant E. coli[374] indicating that the complex retains antimicrobial activity but 
resists efflux. Pd also spontaneously binds β-lactams[375], fluoroquinolones[376],[377] and 
cephalosporins[378],[379], but these properties are employed in drug quantification assays 
and the complexes have not been tested for antimicrobial activity. 
Pd2+ ions have been less extensively investigated as antimicrobial agents. However, at 
500 mg L-1 Pd2+ can completely eradicate 7 day old biofilms of A. baumannii, 
K. pneumoniae and E. faecalis[380] and the same investigators found Pd2+ to be more 
active against planktonic bacterial cells than the more popularly investigated metal ions, 
Ag+ and Cu2+. In addition, unlike their Pt2+ counterparts, Pd2+ ions have been 
demonstrated to not be genotoxic to either E. coli cells or human peripheral 
lymphocytes[381]. Pd nanoparticles also exhibited antimicrobial properties, possibly via 
membrane damage and ROS generation[382]. However, Pd2+ ions appear to be more 
bactericidal in water suspension than nanoparticles at equimolar concentrations[383]. 
While this data is interesting, the precise mechanism of Pd2+ antimicrobial activity has 
not been fully investigated. PdCl4 has been shown to irreversibly inactivate some 
enzymes by binding to critically positioned sulphhydryl groups and/or cystine and other 
amino acid residues[384],[385]. Pd2+ is also known to increase the production of hydroxyl 
radicals in the presence of Fe2+, but cannot catalyse the Fenton reaction alone[386], and 
Pd2+-induced membrane damage has been indicated in one environmental GN 
species[387]. Finally, Pd2+ has been found to have high affinity to bind the phosphate 
backbone of DNA where it can generate damaging •OH. 
Pd2+ has potential to work well with FNa against E. coli by either forming a novel complex 
which resists AcrAB-TolC efflux or by causing synergistic membrane, enzyme or DNA 
damage. 
4.1.1.8 Zinc 
Ionic zinc only occurs as Zn2+. Similar to Al3+, Zn2+ causes membrane damage in E. coli 
and induces membrane stress responses, increased flagellum production and 
upregulation of genes involved in processing and modification of LPS lipid A[388]–[394] as 
well as proteins required for anchoring LPS to peptidoglycan[395]. This damage results in 
increased membrane permeability[396] which could facilitate greater internalisation of 
FNa. Zn2+ overload inhibits essential Fe-S cluster biosynthesis by preventing assembly 
proteins binding Fe2+ [397]. In addition, the presence of excess Zn2+ inhibits detoxification 
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of ROS by replacing Fe2+ in the haem clusters of catalases, inactivating the enzymatic 
activity[331]. Like Co2+ and Ni2+, Zn2+ has also been shown to inhibit RNA synthesis in 
E. coli[333]. However, Zn2+ is also a bacterial micronutrient therefore its specific 
homeostatic mechanisms must be overcome by exposure to concentrations in excess of 
that which the cell can manage. Nevertheless, the combination of increased membrane 
permeability and decreased RNA levels is promising for combination with FNa. These 
mechanisms could overcome the normally limited FNa access through the OM and 
contribute to the antibiotic’s protein synthesis inhibition by reducing the amount of mRNA 
available for translation. Furthermore, Zn2+ has been shown to reduce expression of 
E. coli virulence factors[396],[398] which would be particularly advantageous in the treatment 
and clearing of infection. 
4.1.2 Selection of methods for assessment of antimicrobial activity 
Antibacterial substances can be considered in three categories based on the 
combination of their overarching mode of action and application: biocidal agents for 
external and environmental use, bactericidal drugs, and bacteriostatic drugs. Fast-acting 
biocidal agents rapidly kill bacteria and other organisms. Biocides are important in 
applications such as surface disinfection in healthcare settings but are unsuitable for 
systemic or prolonged topical use in humans and other animals. The maximum in-use 
contact time for such formulations is generally 1 min or less, during which a 3 log10 
reduction must occur in order for a disinfectant to be considered effective[399]. Bactericidal 
antimicrobial drugs can be administered to humans and other animals and kill actively 
growing bacteria while causing minimal damage to the infected host. These are often 
used for severe or systemic infections and in immunocompromised patients[400]. Finally, 
bacteriostatic agents effectively aid eradication of a localised microbial infection by 
preventing further growth of the causative organisms, allowing the previously inundated 
immune system to regain control. 
As biocides are potentially used against metabolically inactive organisms on surfaces, 
their mechanism of action often involves causing physically disruptive damage to the 
cellular structure such as breaking open cell membranes[401]. Conversely, bacteriostatic 
and bactericidal agents tend to target and halt microorganism-specific metabolic 
processes, preventing their growth or cell maintenance[400]. Therefore, information on the 
bacteriostatic and bactericidal efficacy of metal ion and FNa combinations must be 
determined in order to assess their potential as novel topical antimicrobial formulations. 
Various assays can be utilised in order to assess the capability of agents or combinations 
83 
to act in these ways. Additional consideration with regards to assessment of whether the 
presence of either agent enhances or reduces the activity of the other must also be 
made. 
As previously discussed in Chapter 3, the chequerboard assay was selected and 
optimised for the assessment of combined bacteriostatic efficacy of metal ions and FNa. 
This method can also be used to detect changes in efficacy of bactericidal antimicrobials. 
The effects of different metal counter-ions on the bacteriostatic activity of a 
representative metal ion in combination with FNa was also investigated using this 
method. A qualitative suspension test was used to initially assess whether biocidal 
activity was exerted by the combination of FNa and a representative metal ion. The 
suspension test was carried out in a range of solvents in order to investigate the effects 
of their variation on biocidal efficacy results. Finally, a kill kinetics assay was used to 
detect differences in speed of bacterial killing over time between a representative 
combination and each agent alone. 
4.1.3 Aims and objectives 
Aims: to identify metal ions which can enhance the antimicrobial activity of FNa and 
characterise whether the relationship(s) in vitro are bacteriostatic, bactericidal or 
biocidal, with particular interest in anti-GN efficacy. 
Objectives: 
1) To identify metal ions exhibiting bacteriostatic synergy in combination with FNa 
against E. coli and S. aureus reference strains. 
2) To determine whether the counter-ion influences the combined bacteriostatic 
activity of a representative metal ion (Cu2+) synergistic with FNa. 
3) To investigate whether bacteriostatic synergy against E. coli correlates with 
biocidal activity of a representative metal ion (Cu2+) and FNa. 
4) To investigate whether the presence of FNa effects the E. coli kill kinetics of a 
biocidal metal ion (Cu2+), representative of metals that synergise with FNa. 
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4.2 Methods 
4.2.1 Bacteriostatic and bactericidal activity of sodium fusidate combined 
with metal salts 
The chequerboard assay, as described in Chapter 2, Section 2.5, was used to test the 
activity of FNa against E. coli NCTC 10418 and S. aureus NCTC 12973 in combination 
with the following metal salts: Al2(SO4)3, CoSO4, CuSO4, FeSO4, MnSO4, NiSO4, PdSO4, 
ZnSO4, CuCl2, Cu(NO3)2, and Cu D-glu. The highest concentration of FNa tested against 
E. coli and S. aureus was 1280 and 10 µM, respectively. Concentration ranges for the 
metal sulphates were selected as described in Section 3.3.4, page 67. CuCl2, Cu(NO3)2, 
and Cu D-glu were used at the same concentrations as determined for CuSO4. 
Percentage inhibition, MIC90s, MBCs and FIC90Is were calculated as previously 
described (Sections 2.4 and 2.5). 
The activity profiles of each metal sulphate and FNa combination were visually compared 
by plotting isobolograms of the concentration of FNa required to produce ≥90 % inhibition 
against each metal concentration, both converted to a percentage of their respective 
MIC90. FNa and metal sulphate FIC90Is were assessed for synergy and antagonism. 
Finally, the concentration of FNa needed to produce ≥90 % growth inhibition in the 
presence of metal sulphates at 25 and 12.5 % of their respective MIC90s was determined 
from the chequerboard data and the fold reduction of FNa MIC90 calculated. Statistical 
significance of FNa MIC90 changes were ascertained using the 95 % CI (p ≤0.05). 
Comparison between activities of the different Cu(II) salts combined with FNa was 
performed in order to assess the effects of the different counter-ions. FIC90Is were 
calculated and compared. In addition, isobolograms of the concentration of FNa required 
to produce ≥90 % inhibition plotted against each metal concentration were constructed 
and the area under the curve (AUC) calculated to numerically compare the combined 
activity. Statistical significance of differences between AUCs with each Cu(II) salt was 
determined using the 95 % CI (p ≤0.05). 
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4.2.2 Biocidal capability of sodium fusidate combined with copper(II) 
sulphate against E. coli 
Biocidal capability of FNa and CuSO4 was qualitatively investigated in a range of solvents 
against E. coli NCTC 10418 in order to determine whether the combination was able to 
enhance killing in the absence of bacteriological medium. The following solvent solutions 
were tested: PBS, HPLC grade water, 10 % v/v dimethyl sulphoxide (DMSO, Fisher 
Scientific, Loughborough, UK) in HPLC grade water and 10 % v/v MeOH in HPLC grade 
water. Prepared solvent solutions were sterilised by filtration (0.22 µm). Stock solutions 
of CuSO4 and FNa were prepared in each solvent with one exception: CuSO4 in sterile 
deionised water was used as a stock solution for tests in PBS to prevent formation and 
precipitation of insoluble copper phosphates[402]. While PBS was included as an 
experimental solvent in order investigate whether this interaction had any effect on 
antimicrobial activity with FNa, the possibility of precipitation prior to exposure was 
avoided. 
All tests were carried out in sterile un-coated round-bottomed 96 well plates. For each 
agent, serial 10-fold dilutions were made using the test solvent solution. Final well 
concentrations of CuSO4 ranged from 0.01 µM to 100 mM and FNa concentrations from 
1 µM to 10 mM. CuSO4 and FNa dilutions were added to the 96 well plate with their 
concentration gradients on opposing axes, as for the chequerboard assay, and mixed by 
gentle pipetting. Prepared plates were allowed to stand at 20 °C for 15-20 min and then 
inoculated with a suspension of E. coli NCTC 10418 in the test solvent solution to a final 
concentration of 5±3 x 105 CFU mL-1. After inoculation, the plates were wrapped in 
laboratory film to reduce evaporation and left on a benchtop at 20 °C in a temperature 
controlled room for 6 h. Bacterial survival was determined qualitatively by plating a 
triplicate of 20 µL aliquots from every well onto NA and checking for growth of viable 
organisms after 18-24 h incubation at 37 °C. Resulting growth was categorised as 
present or absent. 
The concentration of CuSO4 required to produce complete killing in combination with 
each concentration of FNa was determined. In order to differentiate from the minimum 
bactericidal concentration (MBC) as determined by the microdilution or chequerboard 
assays in bacteriological growth medium, this 6 h 20 °C biocidal concentration was 
named the minimum complete-kill concentration (MCKC). The MCKC of CuSO4 
combined with FNa was plotted against FNa concentration and the 95 % CIs used to 
determine statistically significant differences (p ≤0.05). 
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4.2.3 Effect of sodium fusidate on kill kinetics of copper(II) sulphate 
against E. coli 
Kill-time assays were performed to investigate whether the presence of FNa had any 
impact on E. coli NCTC 10418 bactericidal kinetics by CuSO4. Test solutions 
investigated were 1 mM FNa, 1 mM CuSO4, 1 mM FNa + 1 mM CuSO4, 2 mM FNa, 
2 mM CuSO4 and 2 mM FNa + 2 mM CuSO4. Bacteria were suspended in sterile HPLC 
grade water and added to the test solutions and agent-free control to achieve an initial 
concentration of 1±5 x 107 CFU mL-1. CFU counts were performed using the Miles & 
Misra method[280] (see Section 2.3, page 46) immediately following inoculation and after 
10 min, 30 min, 1 h, 2 h, 6 h and 24 h exposure at 20 °C in a temperature controlled 
room. The log10 reduction was calculated for each replicate at each time point by 
subtracting the post-exposure log10 CFU mL-1 from the initial log10 CFU mL-1. Bacterial 
survival in the presence of FNa was compared to that in the paired agent-free controls 
using the 95 % CIs and statistically significant differences identified (p ≤0.05). The log10 
reduction values for CuSO4 alone and FNa + CuSO4 were normalised to their paired 
agent-free and FNa alone controls, respectively. Statistically significant differences 
between CuSO4 alone and in combination with FNa at each time point were assessed 
by comparing 95 % CIs (p ≤0.05). 
4.3 Results 
4.3.1 Combined bacteriostatic activity of sodium fusidate and metal ions 
The MIC90s of FNa against E. coli NCTC 10418 and S. aureus NCTC 12973 were 
confirmed to be 320 µM and 312.5 nM, respectively, as previously determined during 
chequerboard optimisation (see Sections 3.3.1 and 3.3.2, pages 63 and 64).  
4.3.1.1 FIC90Is between metal ions and sodium fusidate 
The FIC90Is for Al3+, Fe2+ and Cu2+ with FNa against E. coli NCTC 10418 were found to 
be 0.229, 0.375 and 0.425, respectively, indicating synergy (Table 4.2). Conversely, Zn2+ 
and Mn2+ were antagonistic to FNa activity against E. coli, with FIC90Is of 4.250 and 
10.125, respectively. Interestingly, FIC90Is for all five of these metal ions combined with 
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FNa against S. aureus fell within the indifference range, demonstrating little impact on 
anti-S. aureus FNa activity by their presence. Pd2+, however, strongly antagonised FNa 
against S. aureus, with an FIC90I of 48.125, but did not affect E. coli susceptibility. Finally, 
Co2+ and Ni2+ exhibited neither FNa synergy nor antagonism against either organism.  
Table 4.2 - FIC90I for antimicrobial metal ions in combination with sodium fusidate against 
E. coli NCTC 10418 and S. aureus NCTC 12973, in order of anti-E. coli efficacy 
 FIC90I 
 E. coli NCTC 10418 S. aureus NCTC 12973 
Aluminium sulphate 0.229 $ 0.833 
Iron(II) sulphate 0.375 $ 1.250 
Copper(II) sulphate 0.425 $ 0.875 
Cobalt(II) sulphate 0.594 1.250 
Nickel(II) sulphate 0.628 0.525 
Palladium(II) sulphate 1.250 48.125 # 
Zinc(II) sulphate 4.250 # 1.500 
Manganese(II) sulphate 10.125 # 0.725 
green $ = synergy (FICI ≤ 0.5), red # = antagonism (FICI > 4.0), grey = indifference (n = 3) 
4.3.1.2 Metal ion and sodium fusidate isobolograms 
Isobolograms for E. coli NCTC 10418 and S. aureus NCTC 12973 are shown in Figure 
4.2 and Figure 4.3, respectively. None of the metal ion MIC90s were increased by the 
presence of any concentration of FNa against either organism. 
The E. coli isobologram (Figure 4.2) demonstrated that FNa activity was suppressed by 
Zn2+ and Mn2, as indicated by the peaked shape of the curves. The presence of each 
concentration of Zn2+ and Mn2+ investigated increased the FNa MIC90 to more than twice 
the MIC90 of FA when alone. The isobolograms for Al3+, Cu2+ and Fe2+ illustrated synergy 
with FNa, as indicated by the FIC90Is.  Interestingly, the curve for Ni2+ also suggested a 
moderate synergy which may be reflected by the FIC90I of 0.628. At 50 % its MIC90, Pd2+ 
appeared to be purely additive to FNa activity, while antagonism occurred at some of the 
lower concentrations which also aligns with its FIC90I of 1.250 (since an FICI of 1 is 
absolute additivity). Conversely, Co2+ appeared to exhibit synergy at 50 % its MIC90 but 
antagonism at all lower concentrations, despite an FIC90I of 0.594. 
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Figure 4.2 - Combined metal and sodium fusidate MIC90s against E. coli NCTC 10418 
Data is presented as % individual agent MIC90 to allow visual comparison between metals. 
Each point illustrates mean % sodium fusidate MIC90 required in combination with set metal 
concentration to produce 90 % inhibition. Insert is for clearer visualisation of otherwise 
obscured activity profiles. The dashed black line represents the line of additivity. 
(n = 3, error bars = SD) 
Figure 4.3 illustrates that the Pd2+ antagonism of FNa against S. aureus indicated by the 
FIC90I of 48.125 was also suppression. The isobolograms of FNa with Al3+, Mn2+ and Ni2+ 
closely followed the line of additivity while FIC90Is of 0.833, 0.725 and 0.525, respectively, 
would suggest more difference between them. Similarly, the curve for Fe2+ illustrated 
synergy with FNa at 50 and 25 % the metal MIC90 while Cu2+ was synergistic only at 
50 % MIC90 but their FIC90Is of 1.250 and 0.875, respectively, could suggest the inverse. 
However, Co2+ and Zn2+ curves indicated antagonism to FNa which FIC90Is of 1.250 and 
1.500, respectively, also hinted. 
While FICI cut-offs can be used to differentiate synergy, antagonism and indifference, 
the isobologram curves provide useful additional detail. This enables identification of 
suppressive combinations and information on particular concentrations of one agent 
which can enhance or antagonise the antimicrobial, activity of another. 
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Figure 4.3 - Combined metal and sodium fusidate MIC90s against S. aureus NCTC 12973 
Data is presented as % individual agent MIC90 to allow visual comparison between metals. 
Each point illustrates mean % sodium fusidate MIC90 required in combination with set metal 
concentration to produce 90 % inhibition. Insert is for clearer visualisation of otherwise 
obscured activity profiles. The dashed black line represents the line of additivity. 
(n = 3, error bars = SD) 
4.3.1.3 Effect of sub-MIC90 metal ion concentrations on sodium fusidate MIC90 
Figure 4.4 summarises fold reduction in FNa MIC90 against E. coli NCTC 10418 and 
S. aureus NCTC 12973 in the presence of 25 and 12.5 % of each metal ion MIC90. No 
statistically significant change in the MIC90 of FNa against S. aureus was found when 
combined with either concentration of Al3+, Co2+, Cu2+, Mn2+, Ni2+ or Zn2+ (p >0.05). There 
was also no significant change with 12.5 % the Fe2+ MIC90 (p >0.05) but, as observed on 
the isobologram (Figure 4.3), with 25 % Fe2+ MIC90 the concentration of FNa required to 
produce ≥90 % inhibition decreased by a mean 2.67-fold (p ≤0.05). The presence of Pd2+ 
at 25 and 12.5 % its MIC90 produced a 0.04- and 0.03-fold reduction (equal to 25- and 
33.3- fold increases, respectively) in FNa MIC90 against S. aureus (p ≤0.05), further 
illustrating the suppressive interaction. 
-1,000
0
1,000
2,000
3,000
4,000
5,000
6,000
7,000
8,000
0 20 40 60 80 100
%
 so
di
um
 fu
sid
at
e 
M
IC
90
% metal sulphate MIC90
Al Co Cu Fe Mn Ni Pd Zn
0
20
40
60
80
100
120
0 20 40 60 80 100
90 
 
Figure 4.4 – Sodium fusidate MIC90 fold reduction in the presence of 25 or 12.5 % metal ion 
MIC90s 
E + 25 % = E. coli NCTC 10418 in the presence of 25 % metal ion MIC90 
E + 12.5 % = E. coli NCTC 10418 in the presence of 12.5 % metal ion MIC90 
S + 25 % = S. aureus NCTC 12973 in the presence of 25 % metal ion MIC90 
S + 1.25 % = S. aureus NCTC 12973 in the presence of 12.5 % metal ion MIC90 
* = reduction in sodium fusidate MIC90, † = increase in sodium fusidate MIC90 (p≤0.05 for both) 
NF = not found. (n = 3, error bars = 95 % CI, y axis is log10 scale) 
Only Co2+ and Pd2+ failed to exhibit statistically significant effect on FNa MIC90 against 
E. coli (p >0.05). Fold reductions of FNa MIC90 in the presence of Al3+, Cu2+ and Fe2+ at 
25 and 12.5 % the metal MIC90 all fell within the ranges 4.0 to 8.0 and 3.3 to 4.0, 
respectively (p ≤0.05). Ni2+ decreased the FNa MIC90 to a lesser degree, by 2.0- and 
1.67-fold when present at 25 and 12.5 % its MIC90 (p ≤0.05). Both Mn2+ and Zn2+ had the 
opposite effect, increasing the MIC90 by between 3- to 6-fold at both concentrations 
investigated (p ≤0.05). 
4.3.2 Effect of the counter-ion on bacteriostatic activity of sodium fusidate 
combined with copper(II) 
4.3.2.1 Copper(II) salt and sodium fusidate FIC90Is 
The MIC90 and MBC of Cu2+ against each organism did not vary with counter-ion. When 
assessed by FIC90I, the anion also had no effect on the antimicrobial interaction between 
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Cu2+ and FNa against either E. coli NCTC 10418 or S. aureus NCTC 12973 (Table 4.3). 
While there was some variation in FIC90I values, all indicated synergy against E. coli and 
an indifferent effect against S. aureus.  
 
Table 4.3 - FIC90I for copper(II) salts in combination with sodium fusidate against E. coli 
NCTC 10418 and S. aureus NCTC 12973 
 FIC90I 
 E. coli NCTC 10418 S. aureus NCTC 12973 
Copper(II) sulphate 0.375 $ 1.250 
Copper(II) chloride 0.375 $ 0.563 
Copper(II) D-gluconate 0.375 $ 0.708 
Copper(II) nitrate 0.458 $ 0.917 
green $ = synergy (FICI ≤ 0.5), red # = antagonism (FICI > 4.0), grey = indifference (n = 3) 
4.3.2.2 Isobologram analysis for sodium fusidate and copper(II) salts 
 
Figure 4.5 – Combined MIC90s of sodium fusidate and copper(II) salts against E. coli 
NCTC 10418 
The dashed black line represents the line of additivity. 
(n = 3, error bars = SD) 
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Table 4.4 – Area under the isobologram curves for copper(II) salts combined with sodium 
fusidate against E. coli NCTC 10418 
Salt AUC (95 % CI) 
D-gluconate 56.25 (56.25 – 56.25) 
chloride 60.42 (53.75 – 67.08) 
nitrate 66.67 (56.53 – 76.81) 
sulphate 75.00 (75.00 – 75.00) 
 
The isobolograms for all copper(II) salts tested with FNa were indicative of synergy 
against E. coli NCTC 10418 (Figure 4.5). However, comparison of AUCs illustrated some 
significant differences between total efficacy of the copper(II) salts ( 
Table 4.4). FNa with Cu D-glu and CuCl2 produced isobologram AUCs of 56.25 and 
60.42, respectively, both of which were significantly smaller than 75.0 with CuSO4 
(p ≤0.05) indicating greater antimicrobial efficacy. The AUC for Cu D-glu was also 
significantly smaller (p ≤0.05) than that with Cu(NO3)2 which fell between CuCl2 and 
CuSO4 at 66.67.  
Table 4.4 lists the copper(II) salts in approximate order of efficacy in combination with 
FNa against E. coli. 
 
Figure 4.6 - Combined MIC90s of sodium fusidate and copper(II) salts against S. aureus 
NCTC 12973 
The dashed black line represents the line of additivity. 
(n = 3, error bars = SD) 
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Table 4.5 – Area under the isobologram curves for copper(II) salts combined with sodium 
fusidate against S. aureus NCTC 12973 
Salt AUC (95 % CI) 
chloride 0.189 (0.110 – 0.268) 
nitrate 0.267 (0.117 – 0.416) 
D-gluconate 0.287 (0.112 – 0.462) 
sulphate 0.421 (0.328 – 0.514) 
 
Figure 4.6 illustrates that both CuCl2 and Cu D-glu synergise with FNa against S. aureus 
NCTC 12973 on isobologram assessment. The curve with Cu(NO3)2 also fell primarily 
below the line of additivity suggesting possible synergy while CuSO4 is least active.  
Table 4.5 lists the copper(II) salts in approximate order of efficacy in combination with 
FNa against S. aureus. As against E. coli, FNa combined with CuSO4 produced the 
largest AUC against S. aureus indicating it was the least active of the copper(II) salts 
tested. CuCl2 produced the most S. aureus inhibition in combination with FNa with an 
AUC significantly smaller than CuSO4 (p ≤0.05). Cu(NO3)2 and Cu D-glu fell between 
CuCl2 and CuSO4 and were not significantly different to one another or either of the 
extremes (p >0.05). The combined antimicrobial activity of metal salts and FNa therefore 
appears to be slightly affected by different counter-ions. 
4.3.3 Investigations into bactericidal activity of sodium fusidate combined 
with copper(II) sulphate 
4.3.3.1 Combined MBCs of metal ions and sodium fusidate 
For all metal ions tested, the MBC against E. coli NCTC 10418 and S. aureus NCTC 
12973 was not modulated by the presence of any concentration of FNa. Similarly, the 
FNa MBC against S. aureus NCTC 12973 remained the same in the presence of most 
metals. The exceptions were Pd2+, which increased the FNa MBC to 10 µM when present 
at 39.1 µM and to >10 µM at ≥78.1 µM, and Ni2+, which decreased the FNa MBC by one 
two-fold dilution when at ≥625 µM. Although the MBC of FNa alone against E. coli NCTC 
10418 could not be determined, Al3+ and Fe2+ both produced a combined MBC of 625 µM 
metal ions and 320 µM FNa. No other metals lowered the FNa MBC to within the 
detectable range. 
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4.3.3.2 Biocidal capability of sodium fusidate combined with copper(II) sulphate 
against E. coli 
The 6 h minimum complete-kill concentration (MCKC) of CuSO4 alone against E. coli 
NCTC 10418 showed a high level of variability between solvents, ranging from 0.83 μM 
in 10 % MeOH to 23.3 mM in PBS (Table 4.6) with a statistically significant difference 
between all solvents (p ≤0.05). None of the agent-free solvents or any concentration of 
FNa tested alone was biocidal in any of the solvents over the same exposure period. 
Table 4.6 - MCKC of copper(II) sulphate against E. coli NCTC 10418 after 6 h room 
temperature incubation in a range of solvents 
Solvent CuSO4 MCKC (μM ± SD) 
10 % MeOH 0.833 ± 0.236 
HPLC grade water 2.33 ± 1.89 
10 % DMSO 350.00 ± 212.13 
PBS 23,333.33 ± 18856.18 
 
Figure 4.7 - Concentrations of copper(II) sulphate required to kill E. coli NCTC 10418 in the 
presence of sodium fusidate after 6 h exposure in a range of solvents 
(n = 3, error bars = SD) 
The MCKC of CuSO4 in the presence of a range of FNa concentrations is presented in 
Figure 4.7. Regardless of solvent, the concentration of CuSO4 needed for biocidal activity 
in combination with 10 mM FNa was higher than with ≤1 mM FNa, however, the 
difference was not statistically significant in PBS. In 10 % DMSO there appeared to be a 
pattern of decreasing CuSO4 MCKC as FNa concentration increased from 1 μM to 
100 μM, followed by an increase with FNa from 100 μM to 5 mM. A similar but less 
pronounced trend was also suggested in 10 % MeOH, whereas CuSO4 MCKCs in HPLC 
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grade water and PBS remained constant in the presence of ≤0.5 and ≤1 mM FNa, 
respectively. 
4.3.3.3 E. coli kill-time kinetics of combined copper(II) sulphate and sodium 
fusidate 
There was no significant difference between E. coli NCTC 10418 survival in 1 or 2 mM 
FNa and the paired agent-free controls at each time point (p >0.05). Mean log10 reduction 
across all controls and time points was 0.28, ranging from -0.28 to 1.38, whereas log10 
of the initial CFU concentration was 6.90 (range 6.34 to 7.46). 
Complete killing was achieved by all CuSO4-containing solutions within 4 h (Figure 4.8). 
After 10 min, 30 min and 1 h exposure, there was no significant difference between 
proportion of E. coli killed by CuSO4 alone or in the presence of FNa at the same 
concentration (p >0.05). However, there were some differences in efficacy of the different 
concentrations. After 30 min and 1 h exposure, 1 mM CuSO4 alone killed 61.9 and 
63.2 % E. coli cells whereas 2 mM killed only 35.2 and 48.0 %, respectively (p ≤0.05). 
The mean log10 reduction at 10 min was also greater with 1 mM than 2 mM CuSO4, 
however, this difference was not significant. When combined with equimolar FNa, 2 mM 
CuSO4 killed only 22.2 % E. coli after 30 min but 1 mM killed 56.5 % (p ≤0.05). In 
addition, 49.2 % E. coli was killed after 2 h exposure to 2 mM FNa combined with 2 mM 
CuSO4 which demonstrated significantly reduced biocidal efficacy compared to 74.9 % 
produced by the same concentration of CuSO4 alone. 
 
Figure 4.8 - Percentage of log10 E. coli NCTC 10418 killed by copper(II)sulphate with or 
without sodium fusidate in HPLC grade water at 20 °C 
Individual replicate values were normalised to their paired metal-free controls. 
(n = 3, error bars = 95 % CI) 
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4.4 Discussion 
4.4.1 Links between antimicrobial mechanisms of metal ions and their 
effect on sodium fusidate activity 
Not all antimicrobially active metal ions tested had the same effect on bacteriostatic 
efficacy when combined with FNa. Since metal ions exert their activity via different 
routes, variability in FNa-combined activity profile could be due to the differences in 
individual metal ion modes of action. 
4.4.1.1 Metal ions antagonistic and suppressive to sodium fusidate anti-E. coli 
activity 
Based on known antimicrobial mechanisms (as detailed in Section 4.1.1), it appears that 
metal ions which reduce FNa activity against E. coli may be capable of enhancing efflux. 
Mn2+ suppressed the activity of FNa against E. coli producing an FIC90I of 10.125 (Table 
4.2, page 87) and increased the concentration of FNa required to inhibit growth when 
present at any of the sub-MIC90 concentrations tested (Figure 4.2, page 88). Conversely, 
Mn2+ had very little effect on the activity of FNa against S. aureus (Figure 4.3, page 89). 
While there are no reports on the specific effects of Mn2+ on efflux activity, exposure to 
sub-inhibitory concentrations is known to upregulate many cellular processes in E. coli 
including electron transport, ribosomal turnover, cell division and membrane 
biogenesis[360]. On the other hand, effects on S. aureus are strictly limited to 
downregulation of Mn2+ uptake and upregulation of Mn2+ efflux[403] affording effective 
homeostasis. Mn2+ is a micronutrient which is known to be utilised by E. coli in direct 
detoxification of ROS[337], and as a co-factor to both superoxide dismutase which 
detoxifies oxygen radicals[161] and the penicillin binding protein complex which catalyses 
the final peptidoglycan cross-linking step in cell wall assembly[404]. It is also required as 
a co-factor in ubiquinone-8 (Q8) biosynthesis[404],[405]. Q8 is the substrate for all three 
respiratory cytochrome complexes (ubiquinone oxidases) in the E. coli electron transport 
chain[406] which produces the inner membrane PMF[407]. PMF is not only utilised in ATP 
production but also many membrane functions including powering AcrB, the substrate 
recognition and extrusion subunit of the FNa efflux pump[142],[408]. The presence of Mn2+ 
may, therefore, also enable increased AcrAB-TolC activity due to the upregulated 
electron transport activity. A wide variety of metabolites have also been shown to 
increase expression of AcrAB-TolC[409], therefore, enhancement of any of the many 
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metabolic pathways Mn2+ induces may further contribute to increased FNa efflux while 
enhancing bacterial growth. 
Zn2+ was also suppressive to anti-E. coli activity of FNa with an FIC90I of 4.250 (Table 
4.2, page 87). Like Mn2+, Zn2+ is also a co-factor for Q8 biosynthesis[404],[405] which may 
increase AcrAB-TolC activity. In addition, Zn2+ induces expression of MdtABC-TolC, 
another RND efflux pump[388]. MdtABC-TolC can export Zn2+ as well as a range of 
antimicrobial compounds, bile salts and surfactants[151]. There is also evidence that FNa 
can be an MdtABC-TolC substrate[410]. The expression of MdtABC-TolC is usually at a 
much lower level than AcrAB-TolC with the latter being responsible for the bulk of FNa 
efflux[410]. However, induction of MdtABC-TolC expression by Zn2+ may be substantial 
enough to contribute to FNa tolerance. In addition, the ability of Zn2+ to interfere with 
translation by targeting RNA and ribosomes may trigger increased transcription and 
ribosomal production or turnover. This could contribute to lowered FNa susceptibility by 
increasing translation and releasing FNa from stalled ribosomes. Sub-MIC Zn2+ has also 
been shown to elicit a heterogeneous response in E. coli populations, resulting in stalled 
growth or death of some cells while others already expressing Zn2+ exporters continue 
to reproduce[411]. This may explain why Zn2+ was not found to be as effective an FNa 
suppressant as Mn2+ in these experiments despite additional mechanisms which may 
afford tolerance. Finally, Zn2+ neither enhanced nor reduced FNa activity against 
S. aureus when at sub-MIC90 concentrations, which aligns with the less complex 
homeostasis mechanisms present in GP organisms[412]. 
4.4.1.2 Metal ions eliciting neither an antagonistic nor synergistic effect when 
combined with sodium fusidate against E. coli 
Pd2+ did not suppress or enhance anti-E. coli FNa activity (Figure 4.2, page 88). There 
was evidence of antagonism at lower Pd2+ concentrations on the isobologram while at 
50 % the MIC90, the combined activity with FNa was strictly additive. It is likely that on 
exposure to lower concentrations the induced stress response in E. coli can compensate 
for any Pd2+-related damage leaving only the inhibitory effects of FNa to be observed. 
Furthermore, the additivity of inhibition caused by 50 % Pd2+ MIC90 and FNa indicates 
there is unlikely to be any interaction or cross-over between the two agents’ mechanisms 
of anti-E. coli activity. Conversely, Pd2+ was very suppressive to the activity of FNa 
against S. aureus, producing an FIC90I of 48.125 (Table 4.2, page 87 and Figure 4.3, 
page 89). There is a possibility that Pd2+ can induce an undiscovered metabolic pathway 
or cellular process able to afford high-level resistance to FNa in S. aureus. However, the 
observed bacterial growth was enhanced to such an extent and the mechanism of FNa 
activity is well enough understood that it seems unlikely the suppression was due to the 
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biochemical activity of Pd2+ alone. A more plausible explanation may be due to a 
combination of Pd2+ properties. Firstly, the presence of the metal ions and induction of 
stress responses increases the growth rate of S. aureus. Secondly, since Pd2+ is well 
known to form complexes at N, S, P and/or O co-ordination sites, Pd2+ may 
spontaneously co-ordinate fusidate, forming complexes unable to diffuse through the 
bacterial membrane and effectively concealing FNa from the bacterial cells. 
Concentration combinations of 2:1, 1:1 and 1:2 FNa : Pd2+ were particularly ineffective, 
which may be indicative of binding ratios. Alternatively, Pd2+ may bind to the exposed 
peptidoglycan of the GP cells, possibly trapping FNa to prevent its access to the cell. 
The latter scenario may be more likely since no antagonistic or suppressive effects were 
observed against E. coli with its shielded cell wall. 
The combination of FNa and Co2+ was neither synergistic nor antagonistic against E. coli 
with an FIC90I of 0.594 (Table 4.2, page 87). However, the isobologram suggested a 
biphasic activity (Figure 4.2, page 88). The highest sub-MIC90 Co2+ concentration 
lowered the FNa MIC90 while 25 % Co2+ MIC90 and below had no effect on the 
concentration of FNa required to produce inhibition. This may be explained by the 
bacterium’s ability to maintain both FNa efflux and Co2+ homeostasis in the presence of 
the lower Co2+ concentrations but not at 50 % MIC90. At this concentration, the combined 
requirements for FNa and Co2+ efflux likely overwhelms ATP production capacity and 
available reserves, compounded by the effects of Co2+ on the normal aerobic electron 
transport chain respiration[326], the function of Fe-containing enzymes[323] and ROS 
generation[325], along with FNa inhibition of protein synthesis. S. aureus displayed less 
sensitivity to the addition of Co2+ at 50 % MIC90 (Figure 4.3, page 89), possibly because 
of its lack of FNa efflux pump allowing sole defensive investment in Co2+ removal. 
However, sub-MIC90 Co2+ concentrations tested did moderately reduce the FNa MIC90. 
The most likely explanation is the competition for ATP and other resources between 
ribosome turnover and Co2+ homeostasis. 
Ni2+ was neither antagonistic not synergistic to FNa activity against either organism, with 
FIC90Is of 0.628 for E. coli and 0.525 for S. aureus (Table 4.2, page 87). Nonetheless, 
the isobologram did reveal some enhancement of activity against E. coli compared to the 
line of absolute additivity (Figure 4.2, page 88). Both Co2+ and Ni2+ exert their 
antimicrobial activity via protein disruption, DNA damage, transcription inhibition and 
ROS generation. Both are also managed by the same metal homeostasis systems and 
effluxed by RcnA. However, although Co2+ also interferes with ribosome assembly while 
Ni2+ does not, Ni2+ has been show to produce ROS inside E. coli cells at a significantly 
higher rate than Co2+ [331]. Increased oxidative stress may explain the greater impact on 
FNa MIC90 in the presence of more sub-MIC90 Ni2+ concentrations compared to Co2+. 
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4.4.1.3 Metal ions that synergise with sodium fusidate against E. coli 
Cu2+, Fe2+ and Al3+ all synergised with FNa against E. coli with FIC90Is of 0.425, 0.375 
and 0.229, respectively (Table 4.2, page 87). All three also target the lipids of bacterial 
membranes. This suggests that membrane damage and the resulting permeability 
changes enhances FNa activity against GN organisms, as hypothesised. In addition, 
Cu2+, Fe2+ and Al3+ can all cause protein damage. While there are no reports of 
membrane-specific protein damage by Cu2+ or Fe2+, if these ions can injure intracellular 
proteins, they can presumably do the same to membrane proteins via the same 
mechanisms. Such protein damage may contribute to membrane disorganisation or 
efflux pump inhibition. 
However, Pd2+ and Zn2+ also cause membrane and protein damage and did not 
synergise with FNa against E. coli. The binding chemistry of Pd2+ may explain its lack of 
synergistic activity with FNa. Once Pd2+ injures the OM and accesses the periplasmic 
space, it may be adsorbed onto the cell wall peptidoglycan, as hypothesised for 
S. aureus. This could mean FNa can more readily access the periplasm and migrate 
through the IM, resulting in the additive effect of the combination observed against 
E. coli. Al3+ is also known to be adsorbed onto peptidoglycan and exhibited similar 
antimicrobial efficacy to Pd2+ when combined with FNa at equivalent concentrations. 
However, insufficient data was generated to draw an adequate comparison between 
equimolar Al3+ and Pd2+ due to the differences in MIC90s and consequent concentration 
ranges utilised experimentally. Zn2+, on the other hand, suppressed FNa activity against 
E. coli despite being known to cause damage to membrane lipids. The possible 
mechanisms of FNa activity suppression by Zn2+ have already been discussed (Section 
4.4.1.1) and their impact is clearly sufficient to overcome the presumably detrimental 
membrane damage. 
Both Cu2+ and Fe2+ are also known to generate ROS, as discussed in Sections 4.1.1.3 
and 4.1.1.4, which puts considerable stress on the bacterial cell. However, Al3+ is not 
known to do the same, but synergises more strongly with FNa than either Cu2+ or Fe2+. 
The combined efficacy of FNa and metal ions is clearly more complex than the sum of 
their antimicrobial mechanisms. 
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Figure 4.9 - Known antimicrobial targets or mechanisms of metal ions and their ranked 
co-operativity with sodium fusidate against E. coli NCTC 10418 
 
Figure 4.9 was constructed to illustrate the lack of clear correlation between known metal 
ion mechanisms and their ability to enhance FNa activity against E. coli. It appears that 
membrane damage, possibly to both lipids and proteins, is likely to contribute to the 
combined activity but cannot solely explain the interactions. As already indicated, 
antimicrobial metal ion mechanisms are complex and multi-faceted. In addition to the 
specific targets and processes discussed, generalised stressors can influence bacterial 
responses to metal ions. Reduced pH is one such stressor which may be particularly 
relevant with the limited buffering of NB used in these experiments. 
4.4.2 Effect of the copper(II) salt counter-ion on anti-E. coli activity in 
combination with sodium fusidate 
In combination with FNa, Cu D-glu was more effective against E. coli than Cu(NO3)2 or 
CuSO4 (Figure 4.5, page 91). This may be because E. coli can utilise gluconate as a 
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carbon source by switching on the Entner-Doudoroff pathway[413]. It has been long 
established that antimicrobial activity tends to be most potent during the log phase of 
bacterial growth, where cells are growing and dividing at their maximum rate[414],[415]. 
Somewhat paradoxically, the increased metabolic activity afforded by the addition of 
gluconate may therefore result in greater FNa-mediated inhibition of E. coli growth. 
Alternatively, differences in pH of the Cu2+ salts in NB may influence the antimicrobial 
effect by exerting various degrees of concomitant acidic stress. 
CuSO4 was the least efficacious of the four salts tested against S. aureus when 
combined with FNa (Figure 4.6, page 92). As observed during chequerboard optimisation 
(see Chapter 3, Section 3.3.5), S. aureus exhibited some sensitivity to high 
concentrations of Na2SO4. In an inverse manner to the hypothesised effects of gluconate 
on E. coli growth, concurrent growth inhibition by another agent could reduce FNa 
efficacy. On the other hand, this may be another manifestation of the differences in pH 
produced by the Cu(II) salts in NB. If CuSO4 is the least acidic Cu(II) salt in NB it will 
exert less acid stress than the other salts. This could result in less growth inhibition 
overall by eliminating or reducing the impact of acid stress on the combined antimicrobial 
activity. In addition, GP tolerance of acidic environments is generally greater than GN 
which may explain the differences in susceptibility patterns between species. 
4.4.3 Anti-E. coli biocidal activity of copper(II) sulphate and sodium 
fusidate 
No bactericidal synergy was found with Cu2+ and FNa against either E. coli or S. aureus 
by chequerboard assay. However, the biocidal efficacy against E. coli was investigated 
in order to explore the effects of FNa and various solvents on Cu2+ activity.  
4.4.3.1 Effect of sodium fusidate on the biocidal activity of copper(II) sulphate 
The observed degree of E. coli killing by combined 1 mM FNa and 1 mM Cu2+ at each 
timepoint was no greater than that by the same concentration of Cu2+ alone (Figure 4.8, 
page 95). This indicates that the biocidal activity of the 1 mM combination in room 
temperature water was due solely to the activity of Cu2+ and there was no modulation by 
the presence of FNa. This is to be expected since the bacteriostatic effects of FNa are 
only observed against growing organisms while bacteria suspended in water are likely 
to have a very slow or inactive metabolism. Interestingly, 2 mM Cu2+ alone was not as 
effective as 1 mM after 30 min or 1 h (p <0.05). The higher Cu2+ concentration may be 
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less injurious at first because it is likely to induce a more rapid upregulation of 
homeostatic mechanisms in response to the greater initial influx of Cu2+ into the cell. 
However, by 2 h, the cells become just as overwhelmed as those with a slower response 
on exposure to 1 mM (p >0.05). Interestingly, after 2 h exposure, 2 mM FNa and 2 mM 
Cu2+ was significantly less effective than 2 mM Cu2+ alone (p <0.05), indicating a 
protective effect of FNa. This may be through membrane stabilisation. FNa is known to 
readily incorporate into lipid bilayers[416]–[418] and at the higher concentration of 2 mM, 
FNa inclusion could be sufficient to protect membrane integrity and reduce disruption by 
Cu2+. 
4.4.3.2 Effects of different solvents on biocidal activity of copper(II) sulphate 
combined with sodium fusidate 
Despite differences between the tested solvents, the 6 h exposure biocidal activity of 
Cu2+ against E. coli was also modulated by higher concentrations of FNa in all but one 
(Figure 4.7, page 94). Only in PBS was there no effect of FNa concentration on the 
amount of Cu2+ required to kill E. coli (p >0.05). This was likely due to the relative 
ineffectiveness of Cu2+ in PBS, presumably because of phosphate binding producing an 
antimicrobially inactive precipitate.  
Compared to water, Cu2+ was more effective at killing E. coli in 10 % MeOH and less 
effective in 10 % DMSO (p <0.05). Increased Cu2+ efficacy in 10 % MeOH is likely due 
to the effect of MeOH on the E. coli OM. MeOH and other alcohols are known to increase 
the fluidity of phospholipid membranes[419],[420]. Increased fluidity results in increased 
permeability and would therefore facilitate Cu2+ entry to the periplasm. The addition of 
≤1 mM FNa had no impact on Cu2+ activity in 10 % MeOH (p >0.05), whereas >1 mM 
reduced Cu2+ efficacy (p <0.05). This again implies a membrane stabilising effect 
induced by FNa at higher concentrations. DMSO is also known to penetrate and stabilise 
phospholipid bilayers[421]–[423]. This characteristic, in contrast to the destabilising effect of 
MeOH, likely explains the decreased sensitivity of E. coli to Cu2+ in 10 % DMSO 
compared to 10 % MeOH. FNa concentrations of >1 mM appeared to have a similar 
membrane stabilising effect in 10 % DMSO to those observed in water or 10 % MeOH, 
necessitating higher Cu2+ to kill E. coli than with lower FNa concentrations. However, the 
presence of 0.05 to 1 mM FNa resulted in reduced Cu2+ tolerance compared to <0.05 or 
>1 mM FNa in 10 % DMSO. While unexpected, this may be an artefact of interaction 
between DMSO and FNa within the membranes resulting in less stabilisation and more 
Cu2+ access. These observations highlight the complexities and dependency of 
antimicrobial activity on the solvent or growth medium. 
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4.5 Conclusions 
The major conclusions drawn from the work in this Chapter can be summarised as 
follows: 
1) Al3+, Fe2+ and Cu2+ exhibit bacteriostatic synergy in combination with FNa 
against E. coli NCTC 10418, an organism intrinsically resistant to FNa. 
2) None of the eight metal ions tested synergised with FNa against FNa-sensitive 
S. aureus NCTC 12973. 
3) No bactericidal or biocidal synergy was detected against either E. coli 
NCTC 10418 or S. aureus NCTC 12973. 
4) The counter-ion may impact bacteriostatic synergy between metal salts and 
FNa against E. coli NCTC 10418 due to impact on pH or bacterial utilisation. 
5) The mechanism of anti-E. coli synergy with FNa appears to involve metal ion-
mediated membrane damage; however, the role of other factors such as pH 
require further examination.
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Chapter 5: Sodium fusidate solution 
chemistry and effect on anti-
E. coli activity 
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5.1 Introduction 
As discussed in Chapter 4, the mechanism of the antimicrobial synergy discovered 
between FNa and the metal ions Al3+, Fe2+ and Cu2+ is unclear. We have already 
established that metal ions exhibit multiple antimicrobial mechanisms independently 
(Chapter 4) but can also form complexes that sometimes increase the activity of 
antimicrobial agents (Chapter 1). In addition, metal ions can lower the pH of aqueous 
solutions which may cause pH stress in bacteria, affect the solvation of FNa or both. In 
this Chapter, the role of chemistry-based factors in the anti-E. coli activity of FNa and 
metal ion combinations are explored. 
5.1.1 Spontaneous complexation between metal ions and antimicrobials 
Al3+ has well known and extensive binding properties and is used commercially as a 
mordant in fixing dyes to fabrics and binds to organic molecules such as 
polyphenolics[424]. Al3+ readily coordinates O-donor sites[425] and has been found to form 
complexes with the cephalosporin cefodizime[426] and the fluoroquinolones ciprofloxacin 
and norfloxacin[427], all without altering their antimicrobial efficacy. In fact, Al3+ complexes 
of ciprofloxacin and norfloxacin were shown to be much more soluble than the parent 
drugs, a characteristic advantageous to systemic administration[428]. Coordination 
complexes of Cu2+ have been much more thoroughly explored than those of Al3+. In 
particular, Cu2+ spontaneously complexes several antimicrobial drugs in aqueous 
solution at room or physiological temperatures, including streptomycin[429], cycloserine 
and novobiocin[430], ciprofloxacin[259],[350],[351] and a variety of cephalosporins[347]. Many of 
these complexes were also found to have at least equal activity to the parent drug when 
tested against a diverse panel of GP and GN bacteria[259],[350],[351],[429],[430]. However, the 
efficacy of cephalosporins against both GP and GN organisms was reduced by Cu2+ 
complexation[347], presumably due to structural changes resulting in lower affinity for the 
PBP binding site. The same workers found that Fe-cephalosporin complexes also 
spontaneously formed in aqueous solution, but with similar antimicrobial results[347]. Fe2+ 
also spontaneously complexes ciprofloxacin in room temperature water-EtOH 
mixture[431]. Other Fe2+ complexes of antimicrobials have been generated and studied for 
their efficacy; however, synthesis was carried out in organic solvents or dry 
alcohols[426],[431], presumably to maintain the preferred Fe species. 
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The observed synergy between FNa and Al3+, Cu2+ and Fe2+ could be due to similar 
spontaneous formation of coordination complexes. Such a complex may be more active 
than the parent via several mechanisms. For example, complexation may modify drug 
solubility which could enhance membrane passage by creating a system with increased 
thermodynamic activity. It may also modulate transport of the parent drug, if relatively 
weak, the complex may dissociate intracellularly, delivering the toxic metal to vulnerable 
macromolecules. Conversely, a strong complex may resist efflux due to its modified 
structure or shielded features normally recognised by AcrB. The mechanism may also 
be a combination of all of these, and other scenarios. 
 
 
Figure 5.1 - Example of ITC output data for an exothermic complexation reaction between 
silver ions and the antimicrobial cefuroxime 
The upper panel shows the enthalpy change at each injection over time and the lower panel 
shows the integrated enthalpy curve points normalized per mole of injectant as a function of 
molar ratio. Image from Möhler et al, 2017[432]. 
Investigations into interactions between metal ions and FNa were therefore required in 
order to determine whether spontaneous complexation may play a role in their combined 
antimicrobial activity. Cu2+ was selected over the other two synergistic metal ions since 
it exhibits lower reactivity with metal surfaces (such as those found in delicate isothermal 
calorimetry equipment) compared to Al3+ and superior aqueous stability compared to 
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Fe2+. Initially, ultraviolet-visible light (UV-Vis) spectrophotometry was used to collect the 
absorption spectra of aqueous mixtures of CuSO4 and FNa in order to detect shifts 
indicative of spontaneous complex formation[433]. Isothermal titration calorimetry (ITC) 
was then employed to investigate whether a complexation reaction between FNa and 
Cu2+ occurred on mixing. ITC can be used to identify and characterise molecular 
interactions by measuring the enthalpy change as heat liberated or absorbed on 
binding[434]–[436]. The technique has many applications and has been employed in the 
biochemical sciences to characterise interactions such as potential drug ligand-receptor 
binding properties[437] and enzyme kinetics[438],[439]. Figure 5.1 illustrates the ITC results 
from a typical exothermic complexation interaction[432]. 
5.1.2 Potential effects of metal ion-mediated pH reduction 
5.1.2.1 Bacterial response to pH stress 
A feature common to many metal ions is that they are innately acidic. The reduction in 
pH when metal ions are in aqueous solution can give rise to pH stress and potentially 
death in a microbe. Multiple acid tolerance or acid resistance (AR) systems are employed 
by bacteria to respond to various combinations and degrees of acid stress conditions, 
many of which have been extensively studied in E. coli. At very low pH (≤2.5), bacterial 
growth ceases and one or more of four AR systems (AR1-4) is expressed, depending on 
the exposure conditions and preceding environment[440],[441]. While AR1 is not well 
characterised, key components of AR2, AR3 and AR4 are amino acid decarboxylases 
which consume intracellular protons by employing them to convert glutamate, arginine 
and lysine to glutamine, agmatine and cadaverine, respectively; along with a 
corresponding amino acid-amine antiporter[440]–[442]. However, even small fluctuations in 
external pH rapidly alter the periplasmic pH to similar values, indicating that the OM is 
permeable to protons[441],[442]. Whether this OM permeability is due to movement through 
ion channels, directly through the bilayer or a combination is yet to be determined. Low 
pH can produce ionic changes in proteins and cause them to unfold by protonating amino 
acid residues and causing them to repel one another[442]. Since the pH in the periplasm 
is effectively contiguous with the external environment, E. coli relies on chaperone 
proteins HdeA and HdeB to survive and recover from pH stress. HdeA and HdeB interact 
with acid-damaged proteins to prevent their aggregation and deliver them to other 
periplasmic chaperones responsible for refolding once the pH has returned to neutral[442]. 
When initially exposed to moderately low external pH (down to pH 5), the cytoplasmic 
pH also drops but then rapidly recovers[441],[442]. The rapidity of this equilibration indicates 
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it is likely due to the buffering capacity of the cytosol or conformational switching of ion 
transporters rather than slower a transcriptional response[441],[442]. The IM also has lower 
permeability to protons compared to the OM due to the presence of cyclopropane fatty 
acids. E. coli upregulates expression of cyclopropane fatty acid synthase in response to 
acid stress, increasing the IM cyclopropane fatty acid content to minimise acid-mediated 
damage[442]. 
Alterations in IM composition could presumably change its permeability to FNa. In 
addition, damage to the periplasmic portion of AcrAB-TolC would reduce the efficacy of 
FNa efflux. 
5.1.2.2 Sodium fusidate solubility at reduced pH 
In addition to the direct effects on the bacterial cell, lowered pH is likely to affect the 
solubility of FNa. FA is a weak acid with a pKa of 5.35[443]. This means that as solution 
pH is lowered to below 5.35, the dissociation equilibration favours a higher proportion of 
protonated fusidate increasing its thermodynamic activity, as described by the 
Henderson-Hasselbalch equation[444],[445]. Fully protonated fusidate (which is 
undissociated FA) is non-polar and therefore insoluble in polar solvents such as water 
and bacteriological media which leads to precipitation. However, non-polar molecules 
are lipophilic and FA has been shown to solubilise in membrane lipids as efficiently as 
bile salts[446]. Therefore, lowered pH could effectively drive fully protonated FA into, and 
consequently across, the bacterial OM. Interestingly, free fatty acids that are fully 
protonated in moderately reduced external pH (e.g. octanoic acid (C8) with a pKa of 4.89) 
have been found to exert intracellular pH stress by permeating membranes and 
deprotonating in response to the neutral pH inside the cell[447]. Fully protonated FA may 
well exhibit the same behaviour. 
Most of this chapter therefore focusses on investigations into the pH of metal salts in 
bacteriological media, the solubility of FNa in these environments and whether a 
relationship between FNa solubility and anti-E. coli activity can be characterised 
mathematically. Finally, the association of fusidate with E. coli cells under a selection of 
representative exposure conditions is measured directly. 
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5.1.3 Aims and objectives 
Aims: to investigate the complexation and physical chemistry of synergistic metal ion and 
FNa mixtures and characterise the role of these interactions in the combined anti-GN 
efficacy. 
Objectives: 
1) To determine whether a representative metal ion (Cu2+) spontaneously 
complexes FNa in aqueous solution. 
2) To investigate the impact of pH on the anti-E. coli activity of FNa, with and 
without metal ions. 
3) To characterise the relationship between FNa solubility and its anti-E. coli 
activity, with and without metal ions. 
4) To investigate the effect of reduced solubility on association of FNa with E. coli 
cells. 
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5.2 Methods 
5.2.1 Investigations into interactions between fusidate and copper(II) ions 
5.2.1.1 Ultraviolet-visible light (UV-Vis) spectrophotometric analysis 
Stock solutions of 400 μM FNa and 1 mM CuSO4 were prepared separately in HPLC-
grade water. The full scanning range of the Agilent Cary 60 UV-Vis spectrophotometer 
was employed (190-1100 nm), performed at a scan rate of 200 nm min-1 and intervals of 
0.15 nm. A standard quartz cuvette with a 1 cm path length was first filled with a 1 in 2 
dilution of the FNa stock solution (final concentration 200 μM) to a total volume of 
3500 μL and the absorbance spectrum measured. An aliquot of 100 μL was removed 
from the cuvette and replaced with 50 μL 400 μM FNa solution and 50 μL 1 mM CuSO4 
solution, and the cuvette inverted several times before the spectrum was read. This 
process was repeated to titrate with increasing CuSO4 concentration, while maintaining 
200 μM FNa. Collected spectra were used to produce extinction curves by correcting 
against absorbance of FNa alone and assessed graphically to determine wavelength 
ranges of interest. 
The effect of pH on extinction curve absorbance shift was also investigated. As an 
alternative to the use of a buffering agent, due to the limitations presented in Sections 
5.2.1.2 and 5.3.1.2, putative complex formation with Cu D-glu at both native and near-
neutral pH was also assessed by UV-Vis spectrophotometry. A separate Cu D-glu 2 mM 
stock solution aliquot was adjusted to pH 7.3 by addition of NaOH flakes (Fisher 
Scientific, Loughborough, UK). Mixtures of 100 µM FNa with 1 mM Cu D-glu were 
prepared using the pH adjusted and a pH unadjusted stock solution. A mixture of 100 µM 
FNa with pH unadjusted 1 mM CuSO4 was also prepared. The 200-600 nm UV-Vis 
absorbance spectrum of each of the mixtures and 100 µM FNa alone was measured as 
described above. FNa extinction curves were determined for each mixture and compared 
graphically. 
5.2.1.2 Isothermal titration calorimetry (ITC) 
ITC was performed using an iTC200 Microcalorimeter (MicroCal, Northampton, MA, USA). 
Data generated was imported into the MicroCal Origin software for analysis. Prior to use 
the instrument performance was validated using a standardised protocol for the reaction 
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between ethylenediaminetetraacetic acid (EDTA) and calcium chloride (CaCl2), as 
provided by the manufacturer (see Appendix D). 
Cu2+ is known to form complexes and otherwise adversely interact with components of 
many common buffering solutions[448]. 3-(N-morpholino)propanesulfonic acid (MOPS), a 
buffer not complexed by metal ions[448],[449], was therefore selected for the preparation of 
CuSO4 and FNa solutions. However, lack of FNa solubility in ≥10 mM MOPS prohibited 
the use of this buffer altogether (see Section 5.3.1.2 of Results). Attempts were 
subsequently made to adjust the pH of an un-buffered aqueous solution of 1 mM FNa to 
match the unadjusted pH of un-buffered aqueous 10 mM CuSO4 and vice versa using 
dropwise addition of 1 M HCl or 1 M NaOH (Fisher Scientific, Loughborough, UK) without 
success. Finally, since similar antimicrobial synergy with other Cu2+ salts in combination 
with FNa had been observed (see Chapter 4, Section 4.3.2, page 90), pH adjustment of 
un-buffered aqueous solutions of CuCl2, Cu(NO3)2 and Cu D-glu was also attempted. 
To investigate the nature of the possible interaction between Cu2+ and FNa, ITC was 
performed against 1 mM FNa with a variety of injectants: 10 mM CuSO4, 10 mM Cu D-
glu (pH unadjusted), 10 mM Cu D-glu (increased pH), 10 mM sodium D-gluconate (Na2 
D-glu) and dilute sulphuric acid (H2SO4, Fisher Scientific, Loughborough, UK). Cu D-glu 
was used as an alternative Cu2+ source since it was found to be amenable to pH 
adjustment (see Section 5.3.1.1 of Results). Na2 D-glu was tested to determine any 
interaction between FNa and D-gluconate. H2SO4 was use in an attempt to investigate 
the effect of reduced pH without Cu2+ ions. All solutions were prepared in 1 % v/v EtOH 
which was selected to maintain FNa dissolution. 
The ITC run parameters were based on those used in the performance validation assay: 
25 °C cell temperature, injection interval of 150 s, and 20 injections with initial injection 
of 0.4 μL over 0.8 s and subsequent injections of 2 μL over 4 s. However, a slower 
stirring speed of 100 rpm was employed to prevent frothing of the FNa solution observed 
at higher speeds used in preliminary runs. The reference cell was filled with 1 % v/v 
EtOH. 
All test solutions were prepared approximately 24 h in advance of the ITC experiments 
to ensure equilibration at the time of use. Shortly after the initiation of each ITC run, the 
pH of aliquots of the same solutions used was measured and a mixture of the pair was 
prepared at the final ratio and same concentrations as produced by the ITC. The pH of 
each mixture was measured after equilibration at room temperature for 12-24 h. Each 
complete test – ITC run and pH measurements – was performed in duplicate or triplicate. 
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5.2.2 Relationship between broth pH and sodium fusidate anti-E. coli 
activity, with and without metal ions 
5.2.2.1 Metal sulphate pH measurements 
The pH of 1 mL samples of metal sulphates in NB were measured after 18±2 h incubation 
at 35 °C and 120 rpm, mimicking the antimicrobial test conditions. The metal sulphate 
broth solutions were prepared in triplicate at concentrations equal to those previously 
investigated for antimicrobial activity. The pH measurements were used in combination 
with previously generated E. coli inhibition data (Chapter 4) to probe the relationships 
between pH and activity. 
5.2.2.2 Anti-E. coli activity of sodium fusidate in pH adjusted broth 
The pH of 100 mL volumes of NB was adjusted to between 4.2 and 7.0 at 0.2±0.05 unit 
increments by drop-wise addition of 0.5 M H2SO4 and filter sterilised. The pH-adjusted 
broths were then used to perform a modified chequerboard assay in order to assess the 
activity of FNa at different pHs but without the presence of additional metal ions. Two-
fold dilutions of FNa were prepared in each pH adjusted broth and 100 µL aliquots of 
each series transferred to one row of a flat-bottomed 96 well plate. Solutions were 
thoroughly mixed between dilution steps and before transfer to the 96 well plate in order 
to ensure any precipitate present was suspended as evenly as possible. A 
1 × 108 CFU mL-1 suspension of E. coli NCTC 10418, prepared as previously described 
(see Section 2.4), was diluted 1/100 into an aliquot of pH-adjusted broth and rapidly used 
to inoculate the corresponding row of the prepared 96 well plate with 100 µL aliquots. 
This process was repeated for each pH adjusted broth. After incubation at 35 °C and 
120 rpm for 18±2 h, absorbance in each well was used to calculate the % inhibition. The 
experiment was performed in triplicate. 
5.2.2.3 Copper(II) in combination with sodium fusidate at neutral pH 
In order to probe whether the activity of FNa in combination with Cu2+ (as a representative 
synergistic metal) was primarily due to the pH change produced by the metal salt, 
chequerboard assays were carried out using a range of Cu2+ concentrations all adjusted 
to neutral pH. Cu D-glu was used in this experiment because all but the lowest 
concentrations of CuSO4 required were previously found to precipitate in aqueous 
solution if the pH was raised above ~5.5 (see Section 5.3.1.2). Since in previous 
chequerboard experiments Cu D-glu was found to be slightly more effective than CuSO4 
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when in combination with FNa (see Section 4.3.2), the unadjusted Cu D-glu 
chequerboard results were used as a comparator. 
Serial two-fold dilutions of Cu D-glu were prepared in NB and the pH of each adjusted to 
pH 7.2±0.1 using 1 M NaOH. The pH-adjusted Cu D-glu broth solutions were filter 
sterilised and used to prepare serial dilutions of FNa in a 96 well plate in chequerboard 
format. As for the pH adjusted broth chequerboard described in Section 5.2.2.2, bacterial 
suspensions were prepared in each pH-adjusted Cu D-glu broth dilution and used to 
inoculate all wells with 5±3 x 105 CFU mL-1 E. coli NCTC 10418. Plates were incubated 
at 35 °C and 120 rpm for 18±2 h and the absorbance in each well used to calculate % 
inhibition. The experiment was performed in triplicate. 
As described for the comparisons between different copper(II) salts in Chapter 4 (page 
4.2.184), isobolograms of the concentration of FNa required to produce ≥90 % inhibition 
plotted against each Cu2+ concentration were constructed and the AUC calculated to 
compare the combined activity. Statistically significant differences between AUCs with 
pH-adjusted Cu D-glu and the unadjusted comparator were determined using 95 % CIs 
(p ≤0.05). 
5.2.3 The effect of broth pH on sodium fusidate solubility, with and without 
metal ions 
5.2.3.1 Preliminary test for pH-induced precipitation of sodium fusidate in 
nutrient broth 
In order to determine whether lowered pH may be associated with increased aggregation 
and precipitation of FNa under antimicrobial test conditions, solutions of 2.56 mM FNa 
were prepared in aliquots of standard NB (pH 7.2±0.2) or NB which had been adjusted 
to pH 5.0 using 1 M H2SO4. After equilibration at room temperature for 1 h, syringe filters 
(0.22 μm PES) were used to remove any large aggregates and the resulting solution re-
adjusted to pH 7.2 by drop-wise addition of 1 M NaOH. One solution of FNa in 
unadjusted NB was also filtered to determine the presence of similarly sized precipitate 
in standard broth and another used as an un-filtered, unadjusted control. 
Two-fold dilutions of the final FNa broth solutions were carried out in standard NB in flat-
bottomed 96 well microtiter plates. Plates were inoculated with S. aureus NCTC 12973 
to a final concentration of 5±3 x 105 CFU mL-1 and incubated at 35 °C and 120 rpm for 
18±2 h. As described for similar assays, the absorbance of the resulting growth was 
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measured at 595 nm using a Tecan Infinite PRO microtiter plate reader and the % 
inhibition in each well calculated. The mean % inhibition from three biological replicates 
was plotted against the dilution number. An estimation of the FNa concentration in the 
pH adjusted broth was made by shifting the resulting curve to fit that of the control. The 
95 % CIs were used to determine statistically significant differences (p ≤0.05). 
5.2.3.2 Assessment of sodium fusidate stability at reduced pH 
Solutions of 2.5 mM FNa were prepared in 3 mL aliquots of standard NB (native 
pH 7.2±0.2), NB which had been adjusted to pH 5.0 using H2SO4, NB with 625 µM ZnSO4 
or 2.5 mM CuSO4 in duplicate. One of each pair was prepared for immediate HPLC 
analysis: one drop of NaOH was added to acidic solutions (pH 5 NB and NB with CuSO4) 
in order to dissolve precipitated FNa and an equal volume of water was added to the 
others (standard NB and NB with ZnSO4). Solutions were transferred to individual HPLC 
autosampler vials. The other of each pair was incubated at 35 °C and 120 rpm for 18±2 h 
and the same neutralisation and control steps were performed. All samples were 
analysed by RP-HPLC separation method 2 (Section 2.6.2) which was specifically 
developed for the assessment of fusidic acid stability[288]. Chromatograms of 0 h and 
post-incubation samples were compared and differences in degradation products 
identified. 
5.2.3.3 Solubility of sodium fusidate at reduced pH and with metal ions 
The pH of seven 100 mL volumes of NB was lowered to between approximately 4.4 and 
6.8 at intervals of 0.4±0.05 units using dropwise addition of 1 mM H2SO4. Serial two-fold 
dilutions of FNa stock solution were performed in each pH adjusted broth and unadjusted 
nutrient broth control to produce concentrations from 2.5 to 1,280 μM, the same range 
as used in E. coli chequerboard assays. In triplicate, separate 1 mL aliquots were 
equilibrated at room temperature (20 °C) for 1.5±0.5 h and at 35 °C and 120 rpm for 
18±2 h to represent point of inoculation and end of incubation, respectively. Post-
equilibration processing was as described in Section 2.7, as appropriate for the 
incubation temperature. Additional triplicate 1 mL samples of each test broth and control 
were equilibrated under the same conditions in order to verify the pH. FNa solubility was 
determined after 1.5±0.5 h at 20 °C and 18±2 h at 35 °C and 95 % CIs used to determine 
statistically significant differences (p ≤0.05). 
To investigate FNa solubility in NB with metal sulphates, serial two-fold dilutions of metal 
sulphates were made in HPLC-grade water and mixed 1:1 with 2560 μM FNa (2.5 % v/v 
EtOH) in double concentration NB. The resulting mixtures contained 1280 μM FNa and 
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metal sulphate at concentrations of one two-fold dilution above the MIC90, the MIC90 and 
the next three lower concentrations used in E. coli chequerboard assays. As for pH 
adjusted broth experiments, two triplicate sets of aliquots were equilibrated at 20 °C for 
1.5±0.5 h and at 35 °C and 120 rpm for 18±2 h for HPLC analysis and pH verification. 
FNa solubility in NB with Cu D-glu at unadjusted native pH and at pH 7.2 was also 
investigated. Serial two-fold dilutions of Cu D-glu were performed in standard NB in 
duplicate. The pH of one set of dilutions was adjusted to pH 7.2±0.1 using 1 M NaOH 
and filter sterilised. FNa was added to each of the pH adjusted and unadjusted dilutions 
to a final concentration of 1280 μM and two sets of triplicate aliquots were incubated at 
35 °C and 120 rpm for 18±2 h for HPLC analysis and pH verification. 
Finally, the effect of different broths on FNa solubility in the presence of CuSO4 was 
assessed. Serial two-fold dilutions of CuSO4 prepared in HPLC-grade water were mixed 
with 2560 μM FNa in double concentration LB or CAMHB and aliquots incubated at 35 °C 
and 120 rpm for 18±2 h. 
All solutions for quantification of dissolved FNa were processed as described in Section 
2.7, and analysed by HPLC separation method 1 (Section 2.6.2). 
5.2.4 Modelling correlations between sodium fusidate solubility and anti-
E. coli activity 
Microsoft® Excel® (MSO Professional Plus 2016, Microsoft Corporation, WA, USA) was 
used to detect and characterise correlations between FNa solubility after 18±2 h at 35 °C 
and activity against E. coli NCTC 10418 in pH adjusted broth. Data for 1280 μM solubility 
and 20 μM activity were fitted to exponential, polynomial and linear equations and the 
strongest correlation determined. 
The selected equation was applied to solubility data for 1280 μM FNa in the presence of 
metal sulphates in order to predict inhibition of E. coli by 20 μM FNa under the same 
conditions. A modified model, accounting for the inhibitory effect of each metal 
concentration alone, was also applied by adding the paired value recorded within the 
same replicate to the previously predicted inhibition. The predictive accuracy of each 
model was assessed using the 95 % CIs to determine statistically significant differences 
between observed and predicted data points (p ≤0.05) and by calculating the absolute 
difference in mean observed vs mean predicted inhibition at each metal concentration. 
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The accuracy of both models at predicting E. coli inhibition in the presence of Cu D-glu, 
with and without pH adjustment, and in LB or CAMHB was assessed in the same way. 
5.2.5 Quantification of sodium fusidate associated with E. coli cells 
A simple method, based on that of Lemire et al. (2011)[450], was employed to determine 
the amount of FNa associated with E. coli cells after exposure in the presence of metal 
ions or reduced pH.  
E. coli NCTC 10418 was grown overnight on NA. Four separate 40 mL volumes of 
standard NB were inoculated using disposable plastic loops touched to three to five 
morphologically identical colonies and incubated at 35 °C and 120 rpm for 18 to 24 h. 
The grown cultures were centrifuged in a Heraeus Megafuge 8R centrifuge (Thermo 
Scientific, Osterode am Harz, Germany) for 20 min at 3260 x g (4500 rpm) at room 
temperature. Meanwhile, 25 mL volumes of each exposure broth were prepared: NB with 
312.5 µM CuSO4, NB with 625 µM MnSO4, NB adjusted to pH 6.0±0.2 and standard NB 
at native pH as a control. The adjustment of NB to pH 6 was achieved by dropwise 
addition of 1 M H2SO4 followed by filter sterilisation (0.22 µm) before use. Other exposure 
broths were prepared aseptically throughout. FNa stock solution was added to each 
exposure broth to a final concentration of 160 µM. 
The supernatants of the four centrifuged E. coli cultures were decanted and each 
bacterial pellet resuspended in 10 mL of one of the exposure broths. Resuspended 
viable bacteria were immediately enumerated using the Miles & Misra[280] drop counting 
technique, as described in Section 2.3, and incubated at 35 °C and 120 rpm for 30 min. 
Separate sterile 10 mL volumes of each exposure broth were incubated in the same way. 
Samples of the remaining exposure broths were taken for quantification of FNa initial 
concentration by HPLC. 
After the 30 min exposure period, viable bacteria were again enumerated by drop count. 
Both the exposed E. coli and uninoculated exposure broth controls were centrifuged for 
20 min at 3260 x g and 4 °C (pre-cooled). This temperature was selected in order to halt 
or reduce any further bacterial replication. Supernatants were carefully decanted. The 
bacterial pellets were thoroughly resuspended in 1 mL water and a third drop count 
performed. One mL water was also used to thoroughly rinse the bottom of each bacteria-
free control tube in order to dissolve or suspend any FNa present. The resuspensions 
and controls were mixed 1:1 with EtOH in 2 mL centrifuge tubes, sealed to prevent 
evaporation and incubated at room temperature for 30-45 min in order to kill bacteria and 
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fully dissolve FNa (see Appendix C). Syringe filters (0.22 µm) were used to prepare each 
mixture for HPLC. FNa was quantified using RP-HPLC separation method 2 (Section 
2.6.2). The experiment was carried out in triplicate. 
HPLC and drop count data were used to calculate mean FNa in pg per 106 E. coli cells. 
Results were normalised to FNa precipitated in the same broth conditions without 
bacteria present. The 95 % CIs were used to determine statistically significant 
differences (p ≤0.05). 
5.3 Results 
5.3.1 Investigations into interactions between fusidate and copper(II) ions 
5.3.1.1 UV-Vis spectrophotometric analysis of sodium fusidate and copper(II) 
The FNa-normalised absorbance spectra of 200 μM FNa titrated with increasing 
concentrations of CuSO4 in aqueous solution are presented in Figure 5.2. Absorbance 
in the ranges of approximately 205 to 215 nm and 250 to 270 nm were found to increase 
with increased CuSO4 concentration, whereas absorbance between approximately 235 
and 240 nm decreased.  
Extinction spectra were produced for 100 μM FNa mixed with 1 mM either pH-unadjusted 
CuSO4, pH-unadjusted Cu D-glu or Cu D-glu adjusted to neutral pH (Figure 5.3). The 
mixture containing pH-unadjusted Cu D-glu produced the highest peak at approximately 
250 nm. The native pH of 2 mM Cu D-glu was the lowest of the three Cu2+ salt solutions 
at 4.9. Conversely, no discernible peak was produced by pH 7.3 Cu D-glu combined with 
FNa. The peak from pH 5.4 CuSO4 was not as large as that with pH unadjusted pH 4.9 
Cu D-glu. This indicated that the observed absorbance shifts were likely due to FNa 
precipitation as pH was lowered, rather than spontaneous formation of a Cu-fusidate 
complex. 
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Figure 5.2 – Absorbance spectra of 200 μM sodium fusidate titrated with increasing concentrations of copper(II) sulphate in aqueous solution 
Darker colour = greater copper(II) sulphate concentration (range = 15-600 μM). Spectra are normalised to 200 μM sodium fusidate absorbance. 
Insert included for visualisation of otherwise obscured area of interest. 
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Figure 5.3 - UV-Vis extinction curves illustrating pH-dependent changes in sodium fusidate 
precipitation on mixing with copper(II) salts 
Quoted pH is that of the 2 mM copper(II) salt solution prior to mixing. Neutral pH results in 
very little absorbance shift when the two agents are mixed resulting in no detectable 
extinction spectrum peak. (n = 3) 
5.3.1.2 Effect of pH on the interaction between fusidate and copper(II) by ITC 
ITC instrument performance was successfully validated using the EDTA-CaCl2 standard 
prior to each set of experiments (see Appendix D). ITC experimentation is generally 
performed in buffered solutions in order to ensure pH matching between the injectant 
and receiving sample. If the pH is not closely matched, the resulting enthalpy of mixing 
can interfere with detection of molecular interactions. However, it was not possible to 
carry out buffered ITC experimentation with FNa and Cu2+ ions due to solubility 
limitations. FNa was found to be insoluble in ≥10 mM aqueous MOPS. Dissolution of up 
to 4.5 mM FNa was achieved with a combination of 10 mM MOPS and 40 % EtOH, 
however, CuSO4 was insoluble in this buffer-alcohol mixture. In lieu of identification of 
an effective buffer, adjustment of aqueous solutions of FNa and Cu2+ salts to the same 
pH was investigated. Addition of HCl to 1 mM FNa in 1 % v/v EtOH generated a white 
precipitate at pH ~5.8. When the pH of 10 mM CuSO4 was increased using NaOH, a 
dense, bright blue precipitate formed at pH ~5.2. Similar precipitation was seen on 
attempted pH increase of CuCl2 and Cu(NO3)2 solutions. However, the pH of up to 96 mM 
Cu D-glu was successfully raised to over 8.5 with no visually detectable precipitation 
indicating this salt was alone in remaining dissolved at increased pH. Cu D-glu was 
therefore employed to investigate the interactions between FNa and Cu2+ in aqueous 
solution at equal pH. The results presented here comprise of one representative run per 
test condition (Figure 5.4 and Figure 5.5). Other replicates can be found in Appendix D. 
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Figure 5.4 – ITC thermograms of sodium fusidate with copper(II) sulphate (A), copper(II) D-
gluconate at native pH (B), copper(II) gluconate at pH 6.12 (C) and sodium D-gluconate (D) 
The upper panels show enthalpy change at each injection over time and the lower panels 
show the integrated enthalpy curve points normalized per mole of injectant as a function of 
molar ratio. Note difference between scale in A/B and C/D. 
A 
C 
B 
D 
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Table 5.1 – The pH of each initial individual solution used in ITC experiments and an 
equilibrated mixture at the same final ratio 
Injectant Initial pH Equilibrated 
mixture pH Injectant Sodium 
fusidate 
aliquot 
CuSO4 4.77 6.42 5.77 
Cu D-glu (native pH) 4.46 6.53 5.10 
Cu D-glu (adjusted) 6.12 6.39 6.55 
Na2 D-glu 6.43 6.34 6.67 
H2SO4 4.75 6.33 6.43 
 
The enthalpy change peaks (Figure 5.4, upper panels) on interaction between FNa and 
both CuSO4 (A) and Cu D-glu (B) at their native pHs were too wide for quantitative data 
interpretation. However, qualitative assessment of the tailing shape along with width of 
these peaks was indicative of precipitation. The pH of the test solutions are listed in Table 
5.1. The reaction with Cu D-glu (Figure 5.4B) reached completion after fewer injections 
than with CuSO4 (Figure 5.4A). In addition, the Cu D-glu injectant solution was a lower 
pH than CuSO4 (Table 5.1). Combined, these facts indicated a pH-related precipitation 
of FNa, since the lower initial pH Cu D-glu would have lowered the pH of the receiving 
FNa solution more rapidly than CuSO4. Indeed, the pH of the final mixture of FNa and 
Cu D-glu was lower than FNa and CuSO4 at 5.10 compared to 5.77, respectively. 
Precipitation of FNa in a pH-dependent manner was further supported by the lack of net 
enthalpy change when Cu D-glu adjusted to pH 6.12 (Figure 5.4C) or Na2 D-glu (Figure 
5.4D, native pH equal to that of the FNa solution) was titrated against FNa. These results 
illustrated no interaction between Cu2+, the D-gluconate ion or Na+ and FNa. 
A dilute H2SO4 solution of pH 4.75, equal to the test solution of CuSO4 ±0.02 units, was 
also titrated against FNa in an attempt to confirm the effect of reduced pH without metal 
ions. However, addition of diluted H2SO4 to FNa resulted no significant pH change. The 
equilibrated mixture at their final test concentrations was very similar to the native pH of 
the original FNa solution at pH 6.43 (Table 5.1). As would therefore be expected, there 
was also no net enthalpy change during ITC with the same concentration of H2SO4 
(Figure 5.5). 
123 
 
Figure 5.5 - ITC thermogram of sodium fusidate with dilute sulphuric acid 
The upper panel shows enthalpy change at each injection over time and the lower panel 
shows the integrated enthalpy curve points normalized per mole of injectant as a function of 
molar ratio. 
5.3.2 Relationship between pH and sodium fusidate activity against E. coli 
5.3.2.1 Metal sulphate pH in nutrient broth and inhibition of E. coli 
Since Cu2+-related pH change was identified as a modulator of FNa solubility, the 
inhibition of E. coli NCTC 10418 by metal sulphates alone was first plotted against the 
pH of the same metal sulphate and concentration in NB after 18±2 h incubation at 35 °C 
(Figure 5.6). The pH of NB was also adjusted using dropwise addition of 1 M H2SO4 to 
determine pH effect without added metal ions. 
Where the pH of a metal sulphate in broth was <6.0, E. coli inhibition was >90 % for all 
metals tested. With pH adjustment using sulphuric acid alone, this degree of inhibition 
was only seen at pH ~4.4; inhibition at ~4.6 and 4.8 was 26.7 and 8.5 %, respectively, 
and ≤5.0 % at pH ~5.0 and above. For data points corresponding to metal sulphate 
concentrations below the MIC90, there was an apparent trend between pH and inhibition 
by Al3+, Co2+, Cu2+, Fe2+, Ni2+ & Pd2+. At their lowest concentrations, the pH of Al3+, Fe2+ 
and Ni2+ were >6.75 in nutrient broth and growth of E. coli was not inhibited by their 
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presence. Conversely, Cu2+ and Pd2+ inhibited growth at every concentration tested, 
despite their lowest concentrations having minimal impact on broth pH. Co2+, Mn2+ and 
Zn2+ had very little effect on broth pH at any concentration tested, their respective MIC90s 
being pH 7.02, 7.08 and 7.13. 
 
Figure 5.6 - Relationship between pH of metal sulphates in nutrient broth and inhibition of 
E. coli NCTC 10418 
(n = 3, vertical error bars = SD, horizontal error bars = SD + pH electrode accuracy) 
5.3.2.2 Relationship between broth pH and inhibition of E. coli by sodium 
fusidate 
There was no significant difference between the recorded pH of any metal sulphate in 
NB with or without FNa. A sub-inhibitory FNa concentration of 20 µM (6.25 % MIC90) was 
selected for representative comparison of the combined effects of metal sulphate, pH 
and antibiotic and to investigate whether pH alone may dictate the anti-E. coli efficacy of 
FNa. Figure 5.7 illustrates inhibition of E. coli by 20 µM FNa in the presence of metal 
sulphates or in pH adjusted NB, plotted against pH. 
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Figure 5.7 - Relationship between pH of 
metal sulphates in nutrient broth and 
inhibition of E. coli NCTC 10418 by 20 μM 
(6.25 % MIC90) sodium fusidate 
 
A: all metal sulphates tested. 
 
B: only metal sulphates found to synergise 
with sodium fusidate. 
 
Concentrations of metal sulphates are two-
fold dilutions. Broth pH was adjusted by 
dropwise addition of 0.5 M sulphuric acid 
until target pH±0.15 was achieved. 
Dotted line denotes degree of inhibition by 
sodium fusidate alone. 
 
(n = 3, error bars = SD)
Sulphates that were suppressive to FNa activity, Zn2+ and Mn2+, produced a pH change 
of ≤0.25 units, and did not exhibit any correlation between pH and inhibition of E. coli 
(Figure 5.7A). Combinations of FNa with Co2+, Ni2+ or Pd2+ were determined as 
antimicrobially indifferent – neither synergistic nor antagonistic/suppressive. Despite 
lowering the pH to <6.5 at their most antimicrobially active concentrations, lower 
concentrations of both Ni2+ and Pd2+ enhanced bacterial growth when combined with 
FNa compared to FNa alone. However, while Co2+ had little effect on broth pH at any 
sodium fusidate alone
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concentration tested, its antimicrobial activity in combination with FNa was consistently 
higher than the effects of the equivalent metal-free pH-adjusted broth. 
Inhibition vs pH data for only the metal sulphates that were found to synergise with FNa 
are shown in Figure 5.7B. A trend was apparent between pH and the activity of Al3+, Cu2+ 
and Fe2+ in combination with FNa. Where similar pH was produced by the metal dilutions, 
there was no significant difference between their combined activity with 20 µM FNa 
(p ≥0.05). However, FNa with metal ions generally produced 10-20 % additional 
inhibition compared to FNa in NB adjusted to the same pH using H2SO4. Similar patterns 
were observed for the metals and pH-adjusted broths at all sub-inhibitory concentrations 
of FNa tested. 
5.3.2.3 Copper(II) in combination with sodium fusidate at neutral pH 
 
Figure 5.8 - Inhibition of E.coli NCTC 10418 by 20 μM sodium fusidate in the presence of 
copper(II) D-gluconate at unadjusted and neutral pH 
(n = 3, error bars = SD) 
Next, the effect of Cu2+ ions combined with FNa at neutral pH was assessed to determine 
whether neutralisation of metal acidity negated enhancement of FNa activity. Figure 5.8 
illustrates the inhibition of E. coli NCTC 10418 by 20 μM FNa and a range of Cu D-glu 
concentrations with (dark blue) and without (turquoise) pH adjustment to 7.2±0.1. 
Without pH adjustment, the MIC90 of Cu D-glu with 20 μM FNa was 625 μM, however, 
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when the pH was adjusted to ~7.2 the MIC90 increased 4-fold to 2.5 mM. The Cu D-glu 
MBC also increased from 1.25 mM at native pH to 10 mM at pH 7.2. Furthermore, 
increasing of pH to neutral significantly reduced the percentage inhibition produced by 
all <2.5 mM concentrations Cu D-glu in combination with 20 μM FNa (p ≤0.05). 
 
Figure 5.9 - Combined MIC90s of sodium fusidate and copper(II) D-gluconate at unadjusted 
native pH and neutral pH 7.2 against E. coli NCTC 10418 
The dashed black line represents the line of additivity. 
(n = 3, error bars = SD) 
Comparison of the isobolograms for FNa with unadjusted and pH 7.2 Cu D-glu further 
illustrated reduced antimicrobial activity of the neutralised solutions (Figure 5.9). 
Statistically significant differences in isobologram AUCs were found: 56.25 ± 0 with pH-
unadjusted and 187.50 ± 0 with pH 7.2 Cu D-glu (p <0.05). 
5.3.3 Sodium fusidate solubility and anti-E. coli activity 
5.3.3.1 Preliminary confirmation of pH-induced precipitation of sodium fusidate 
in nutrient broth 
FNa-sensitive S. aureus NCTC 12973 was used to detect changes in FNa concentration 
after filtration of precipitate generated at pH 5.0. No significant difference was found 
between the inhibition of S. aureus caused by dilutions of filtered and unfiltered 2.56 mM 
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FNa prepared in standard NB at native pH (p >0.05, Figure 5.10). This indicates there 
was little aggregation of FNa in NB at pH 7.2 and any aggregates present must have 
been <0.22 μm. However, from dilution number 12 to 17, there was significant difference 
between the effect of dilutions prepared from filtered pH 5.0 FNa broth solution returned 
to pH 7.2 and the unadjusted control. Reduced inhibition of S. aureus by the filtered 
pH 5.0 solution indicates that filtration of the low-pH solution through a 0.22 μm 
membrane lowered the FNa concentration by removing large aggregates. This was also 
supported cloudiness observed in the pH 5.0 broth on addition of 2.56 mM FNa and 
clarity after filtration. 
 
Figure 5.10 - Inhibition of S. aureus NCTC 12973 by sodium fusidate remaining after 
removal of large aggregates by filtration 
Dilution number 15 equates to 78.125 nM sodium fusidate in unadjusted filtered broth and 
the control. The pH 5.0 broth was adjusted back to 7.2 after filtration of aggregates. 
(n = 3, error bars = 95 % CI) 
The pH 5.0 inhibition plot was aligned with the activity of known FNa concentration 
against S. aureus by shifting the data by two dilutions (Figure 5.11). There was no 
significant difference between activity of known concentrations of 39.1, 19.5 or 9.8 nM 
FNa and that of the FNa present in the aligned filtered pH 5.0 broth (p <0.05). As the 
shift of two two-fold dilutions equated to a four-fold difference in concentration, this 
implies that approximately 75 % of the FNa originally added to the pH 5.0 broth was 
removed by filtration, likely having formed aggregates of ≥0.22 μm. 
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Figure 5.11 – Alignment of data for S. aureus NCTC 12973 inhibition by sodium fusidate 
after exclusion of large aggregates induced by lowered pH to unadjusted control 
Shifting the data for inhibition caused by sodium fusidate remaining in filtered pH 5.0 broth by 
two dilutions and comparison to controls allowed for estimation of sodium fusidate 
concentration. 
 (n = 3, error bars = 95 % CI) 
5.3.3.2 Assessment of sodium fusidate stability at reduced pH 
To first assess whether phenomenon of pH-related FNa activity may be due to 
degradation of the drug into products more active against GN bacteria, a stability-
indicating RP-HPLC method (separation method 2) was used to determine whether acid 
hydrolysis of FNa may occur under reduced pH conditions. Chromatograms for FNa in 
broth and in 50 % EtOH after 18 h incubation at 35 °C were aligned with the example 
provided by Byrne et al., 2015[288], the authors of the RP-HPLC method (Figure 5.12). 
Retention times observed were not identical to those reported due to differences in 
employed column length and material, however, the majority of fusidate breakdown 
products could be presumptively detected. (Assignment of fusidate peak had been 
previously verified during calibration curve construction, see Appendix B.) 
Figure 5.13 displays example overlaid FNa chromatograms generated immediately after 
mixing and after 18 h incubation at 35 °C. The y axis upper bounds are limited to 100 
mAU in order to allow visualisation of the smaller degradation product peaks. In standard 
NB, some FNa degradation occurred over the 18 h incubation period, as illustrated by 
the increased peak areas for 11-didehydrofusidic acid at approximately 25 and 16-
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epideacetylfusidic acid at 30 min (Figure 5.13A). A similar degree and pattern of 
degradation was observed with 625 µM ZnSO4 (Figure 5.13C). Conversely, lowered pH 
reduced this degradation, with or without the presence of antimicrobial metal ions. Figure 
5.13B and D illustrate reduced FNa degradation in NB adjusted to pH 5.0 using H2SO4 
and NB with 2.5 mM CuSO4 (producing pH 5.11), respectively, compared to the 
unadjusted control, A. The results therefore suggest lowered pH may have a protective, 
stabilising effect on FNa in some conditions and, at least, does not induce hydrolysis or 
otherwise increase degradation. 
 
Figure 5.12 - Alignment of raw sodium fusidate 18 h stability chromatograms (lower panel) 
with published, annotated example from Byrne et al., 2015[288] (upper panel) 
Peak identification, as given in Byrne et al., 2015[288]: 1. Betamethasone.2. 24,25-Dihydro-
24,25-dihydroxyfusidic acid. 3. 24,25-Dihydro-24,25-dihydroxyfusidic acid 21,25-lactone. 4. 
Betamethasone-17-valerate. 5. (24R)-24,25-dihydro-24,25-dihydroxyfusidic acid-21,24-
lactone. 6. 26-Hydroxyfusidic acid. 7. (24S)-24,25-dihydro-24,25-dihydroxyfusidic acid-21,24-
lactone. 8. Betamethasone-21-valerate. 9. 26-Oxofusidic acid. 10. 3- Didehydrofusidic acid. 11. 
11-Didehydrofusidic acid. 12. 16-Epideacetylfusidic acid. 13. Fusidic acid. 14. 16-
epideacetylfusidic acid-21,16-lactone. 15. Deacetylfusidic acid-21,16- lactone. 16. 11-
Deoxyfusidic acid. U, unknown impurity. While quantification of derivatives was not the aim of 
this work, their presence and relative abundance could be compared. 
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Figure 5.13 - Example stability-indicating RP-HPLC overlay chromatograms produced by 2.5 mM sodium fusidate before and after incubation for 18 h at 35 °C 
A: standard nutrient broth; B: nutrient broth adjusted to pH 5 using sulphuric acid; C: nutrient broth with 625 µM zinc(II) sulphate (pH 6.96); D: nutrient broth with 
2.5 mM copper(II) sulphate (pH 5.11). Peak annotation: 11DA = 11-didehydrofusidic acid, 16EA = 16-epideacetylfusidic acid, F = fusidate. 
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5.3.3.3 Sodium fusidate solubility in pH adjusted nutrient broth and correlation 
with anti-E. coli activity 
5.3.3.3.1 Sodium fusidate solubility in pH adjusted broth 
 
Figure 5.14 - Concentration of sodium fusidate remaining in solution after equilibration in 
pH adjusted nutrient broths for 1.5±0.5 h at 20 °C 
(n = 3, error bars = SD) 
Table 5.2 - Correlation slopes and R2 values for relationship between initial sodium fusidate 
concentration and concentration in solution after equilibrium at 20 °C for 1.5±0.5 h in pH 
adjusted nutrient broth 
Broth pH Initial : post-equilibrium sodium 
fusidate correlation slope (4 d.p.) 
Initial : post-equilibrium 
sodium fusidate R2 (4 d.p.) 
4.39 0.0360 0.8533 
4.87 0.2174 0.9635 
5.19 0.3859 0.9790 
5.60 0.6522 0.9873 
5.98 0.8358 0.9889 
6.41 0.9409 0.9994 
6.78 0.9301 0.9997 
7.24 (control) 0.9968 0.9999 
 
The solubility of FNa in NB adjusted to different pHs was investigated in order to assess 
whether this correlated with enhanced anti-E. coli activity. Figure 5.14 illustrates the 
relationship between FNa remaining in solution after equilibrium for 1.5±0.5 h at 20 °C 
and initial FNa concentration at each broth pH, as determined by RP-HPLC. The 
correlations between initially added FNa and that remaining in solution at each pH tested 
are listed in Table 5.2. At pH 4.87 and above, the correlations between initial and post 
0
200
400
600
800
1000
1200
1400
0 160 320 480 640 800 960 1120 1280
so
di
um
 fu
sid
at
e 
in
 so
lu
tio
n 
af
te
r 
eq
ui
lib
ria
tio
n 
(µ
M
)
initial sodium fusidate added (µM)
pH 4.39 pH 4.87 pH 5.19 pH 5.60
pH 5.98 pH 6.41 pH 6.78 pH 7.24 (control)
133 
equilibration FNa concentrations were very strong (R2 > 0.96). The FNa saturation point 
in NB did not appear to be met at pH 4.87 and above using any of the concentrations 
tested. Due to the stock solution preparation method, EtOH was present in proportion to 
FNa concentration (1.25 % v/v with 1280 μM) which likely effected solubility, however, 
this was identical to the composition of dilutions used in all antimicrobial testing and 
therefore directly representative of conditions at the point of inoculation. 
At pH 4.39, the correlation between initial FNa concentration and that remaining in 
solution was markedly reduced compared to higher pHs, with an R2 of 0.85 compared to 
>0.96. The concentration in solution after equilibration was only 28.7, 35.3, 38.3, 41.8, 
49.3 and 71.1 μM when 40, 80, 160, 320, 640 and 1280 μM FNa had initially been added, 
respectively. A strong correlation with EtOH concentration in the respective dilution was 
also found (R2 = 0.98), suggesting that the EtOH-free solubility of FNa in pH 4.4 broth at 
20 °C was below the 28.7 μM observed when 0.039 % v/v EtOH was present. 
 
Figure 5.15 - Percentage of different initial sodium fusidate concentrations remaining in 
solution after 1-2 h equilibration at 20 °C in nutrient broth at a range of pHs 
(n = 3, vertical error bars = SD, horizontal error bars = SD + pH electrode accuracy) 
The nature of the relationship between FNa remaining in solution and NB pH varied 
depending on the initial FNa (and EtOH) added (Figure 5.15). With 1280 μM, (1.25 % v/v 
EtOH) there was a possibly sigmoid-like correlation between pH and FNa remaining in 
solution, with a linear portion between pH 4.8 and 6.0 (R2 = 1.00) and maximal solubility 
apparently reached at pH 6.4 where there was no significant difference between FNa in 
solution at pH 6.8 (p >0.05). There was a similar pattern in correlation between pH and 
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FNa remaining in solution after addition of 640 (0.625) and 320 μM (0.313 % v/v EtOH). 
Both exhibited linear relationships between pH 4.8 and 6.0 (R2 = 0.99 and 0.98, 
respectively) where maximal solubility was reached. With 160 and 80 μM FNa (0.156 
and 0.078 % v/v EtOH, respectively), maximal solubility was reached at pH 5.2 after a 
possible linear relationship from pH 4.4. There was no apparent correlation between pH 
and FNa remaining in solution when only 40 μM (0.039 % v/v EtOH) was initially added, 
with between 26.7 and 34.3 μM detected at all pHs tested. In addition, solubility of 
1280 μM FNa in pH 4.87 and 5.19 broths was 24.6 and 41.1 %, respectively, which, 
given the trend of decreasing solubility with increasing initial FNa concentration, directly 
supports the estimated 75 % precipitation of 2560 μM in pH 5.0 broth observed in Section 
5.3.3.1. 
 
Figure 5.16 - Concentration of sodium fusidate remaining in solution after equilibration in 
pH adjusted nutrient broth for 18±2 h at 35 °C and 120 rpm 
(n = 3, error bars = SD) 
Table 5.3 - Correlation slopes and R2 values for relationship between initial sodium fusidate 
concentration and concentration in solution after equilibrium at 35 °C for 18±2 h in pH 
adjusted nutrient broth 
Broth pH Initial : post-equilibrium sodium 
fusidate correlation slope (4 d.p.) 
Initial : post-equilibrium 
sodium fusidate R2 (4 d.p.) 
4.37 0.0256 0.9890 
4.85 0.1914 0.9620 
5.18 0.3264 0.9875 
5.58 0.5615 0.9843 
5.95 0.7113 0.9842 
6.39 0.9273 0.9973 
6.79 0.9689 0.9992 
7.11 (control) 1.0043 1.0000 
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Figure 5.16 illustrates the relationships between FNa remaining in solution after 18±2 h 
at 35 °C and initial FNa concentration, which were similar to those observed at 20 °C 
(Figure 5.14). The correlation slopes and R2s between initially added FNa and that 
remaining in solution at each pH tested are listed in Table 5.3. The correlation between 
initial and post-equilibration FNa concentration was very strong for every pH, with R2 
>0.98 for all but pH 4.8 which was 0.96. As with 1.5±0.5 h equilibration at 20 °C (Table 
5.2), an equally strong correlation (R2 = 0.99) was found between FNa remaining in 
solution after 18±2 h equilibration in pH 4.4 broth at 35 °C and EtOH concentration in the 
respective dilution. 
 
Figure 5.17 - Percentage of different initial sodium fusidate concentrations remaining in 
solution after 18±2 h equilibration at 35 °C in nutrient broth at a range of pHs 
(n = 3, vertical error bars = SD, horizontal error bars = SD + pH electrode accuracy) 
As found at 20 °C, the relationship between pH and FNa remaining in solution after 
equilibration at 35 °C varied depending on the initial amount of FNa added (Figure 5.17). 
Sigmoidal correlations were apparent with 1280 (1.25 %), 640 (0.625 %) and 320 μM 
(0.313 % v/v EtOH) FNa. However, the pH range of the linear portions differed between 
initially added FNa (and EtOH) concentration, being from pH 4.8 to 6.4 (R2 = 1.00), 4.8 
to 6.0 (R2 = 1.00) and 4.8 to 5.6 (R2 = 1.00) with 1280, 640 and 320 μM, respectively. 
Maximal solubility with 640 and 320 μM FNa (0.625 and 0.313 % v/v EtOH) was reached 
at pH 6.4 and 6.0, respectively. With 1280 μM FNa (1.25 % v/v EtOH), the saturation 
point did not appear to be met and, although the concentration increment decreased 
beyond pH 6.4, there were significant differences in dissolved FNa at pH 6.4, 6.8 and 
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the pH 7.1 control (p ≤0.05). Similar solubility patterns for 160, 80 and 40 μM FNa to 
those observed after 1.5±0.5 h at 20 °C were found after equilibration at 35 °C. 
The reduced differences detected in FNa solubility at lower initial concentrations maybe 
due to limitations in the ability of the processing method to remove undissolved drug from 
solution when there is high thermodynamic activity and low total concentration, rather 
than actual differences in solubility between starting concentrations. At low 
concentrations where aggregates do not form the duration of the fully protonated state 
is too short to result in any precipitation of FNa, consequently preventing removal of any 
undissolved fraction despite its presence. As such, an initial FNa concentration of 
1280 μM was used in all subsequent testing. 
 
Figure 5.18 - Comparison of sodium fusidate solubility in pH adjusted nutrient broth after 
1.5±0.5 h at 20 °C and 18±2 h at 35 °C 
(n = 3, error bars = 95 % CI, * = p <0.05) 
There were small but statistically significant (p <0.05) differences between FNa solubility 
after equilibration 1.5±0.5 h at 20 °C and 18±2 h at 35 °C in pH adjusted nutrient broth 
(Figure 5.18). At pH 6.8 and below, apparent FNa solubility was lower after incubation at 
35 °C for 18 h than 1.5±0.5 h at room temperature. In order to more closely represent 
conditions in microbiological assays, data for 35 °C solubility was selected for use in all 
further analyses. 
  
0%
20%
40%
60%
80%
100%
120%
pH 4.4 pH 4.8 pH 5.2 pH 5.6 pH 6.0 pH 6.4 pH 6.8 control
so
di
um
 fu
sid
at
e 
so
lu
bi
lit
y
20 °C 35 °C
*
*
*
*
*
* * *
137 
5.3.3.3.2 Relationship between sodium fusidate solubility and anti-E. coli activity 
in pH adjusted nutrient broth 
 
 
 
Figure 5.19 - Linear (A), exponential (B) and polynomial (C) modelling of the relationship 
between sodium fusidate solubility and its impact on growth of E. coli NCTC 10418 
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Data for solubility of 1280 μM FNa after equilibration for 18±2 h at 35 °C was selected 
for further correlation investigations as, in addition to being representative of 
microbiological test conditions, this initial concentration yielded the widest and most well 
distributed range of values over the investigated pH range, thereby enhancing the 
sensitivity of potential trend detection. After an initial analysis (not shown), E. coli data 
was inverted from % inhibition to % maximal growth in order to more effectively utilise 
Excel® trendline functions. Growth in the presence of 20 μM was selected for modelling 
as the variation in FNa activity across broth pH similarly exhibited a wide variation. 
Figure 5.19 illustrates the three mathematical descriptions for the relationship between 
FNa solubility and its effect of E. coli growth. While removal of data points corresponding 
to solubility below 55 % from the analysis achieved an R2 of 0.809, a linear correlation 
was not observed (Figure 5.19Error! Reference source not found.A). A strong 
correlation was identified as an exponential plot, with R2 = 0.963 (Figure 5.19B), 
however, data points corresponding to no bacterial growth could not be included due to 
limitations in Excel® exponential fitting function. The use of this formula in relationship 
modelling would therefore be limited to solubilities of ≥36 % which correspond to >0 % 
maximal growth and would not be able to predict 100 % inhibition. However, the 
relationship was similarly well described by a fifth order polynomial equation (R2 = 0.967, 
Figure 5.19C) which allowed inclusion of all data points in the fitting calculations. The 
following formula, derived from the polynomial curve in Figure 5.19C, was therefore used 
as the basis for modelling the relationship between inhibition of E. coli growth by 20 μM 
FNa and solubility of 1280 μM FNa: 
𝑐𝑐 = 1 − ((4.83 × 𝑆𝑆5) − (6.35 × 𝑆𝑆4) + (2.49 × 𝑆𝑆3) − (0.19 × 𝑆𝑆2) − (0.02 × 𝑆𝑆1)) 
Where 𝑐𝑐: activity of 20 μM FNa as % inhibition of E. coli NCTC 10418, and 𝑆𝑆: % solubility 
of 1280 μM FNa. 
5.3.3.4 Sodium fusidate solubility in nutrient broth with metal sulphates and 
correlation with anti-E. coli activity 
5.3.3.4.1 Solubility of sodium fusidate with metal sulphates in nutrient broth 
Percentage solubility of 1280 μM FNa in NB with metal sulphates after 1.5±0.5 h at 20 °C 
and 18±2 h at 35 °C are shown in Figure 5.20. In the presence of the two suppressive 
metals, Mn2+ and Zn2+, FNa exhibited more than 95 % solubility regardless of the metal 
concentration or the incubation temperature and duration. However, FNa solubility in NB 
in the presence of the other metals was dependent both on metal concentration and 
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incubation conditions. In particular, the solubility of FNa with Fe2+ reduced dramatically 
after incubation at 35 °C, consistent with the pH reduction and precipitation observed 
previously. Since differences in FNa solubility between equilibration conditions occurred 
and replicating the microbiological incubation environment was important to building a 
predictive model, FNa solubility data for 18±2 h at 35 °C was selected for further use. 
 
 
Figure 5.20 - Solubility of 1280 μM sodium fusidate in nutrient broth with metal sulphates 
after incubation for 1.5±0.5 h at 20 °C (blue) or 18±2 h at 35 °C (red) 
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(n = 3, error bars = SD) 
In order to assess whether the effect on solubility was a direct function of broth pH 
change induced by the metal sulphate, the % 1280 μM FNa remaining in solution in the 
presence of the highest metal concentration tested was plotted against the pH for each 
equilibration condition. Data for 1280 μM FNa solubility in metal-free pH adjusted nutrient 
broth was included in the same graphs in order to assess whether solubility in the 
presence of metal sulphates aligned with the previously observed correlation with broth 
pH (Figure 5.21). FNa solubility in NB in the presence of other metal sulphates 
conformed well to the data for pH adjusted broth without metals. 
 
Figure 5.21 - Comparison of solubility of 1280 μM sodium fusidate in pH adjusted nutrient 
broth (open circles) and nutrient broth with metal sulphates (labelled closed circles) after 
equilibration for 18±2 h at 35 °C 
(n = 3, vertical error bars = SD, horizontal error bars = SD + pH electrode accuracy) 
5.3.3.4.2 Predictability of anti-E. coli activity of sodium fusidate based on 
solubility in nutrient broth with metal sulphates 
The equation derived in Section 5.3.3.3.2 from Figure 5.19C was applied to the data for 
1280 μM FNa solubility in the presence of metal sulphates in order to test the modelling 
accuracy. The resulting predictions for E. coli inhibition by 20 μM FNa are referred to as 
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“predicted  (i)”. A modified model, including addition of the inhibitory effect of each metal 
concentration alone, was also applied and its outputs referred to as “predicted  (ii)”. 
 
Figure 5.22 - Comparison of observed inhibition with two methods of predicting inhibition 
of E. coli NCTC 10418 by 20 μM sodium fusidate in the presence of aluminium as sulphate 
in nutrient broth 
(n = 3, error bars = 95 % CI, * = p <0.05) 
Four of the five predictions for the combined anti-E. coli activity of Al3+ and FNa using 
model (i) were not significantly different to the observed values (p >0.05, Figure 5.22). 
Predicted inhibition by 1.25 mM Al3+ combined with 20 μM FNa was 88.3 % whereas the 
observed value was 100 %. In addition, while not statistically different, mean predicted 
inhibition by FNa with 0.625 mM was 39.8 % while the observed inhibition was 16.9 % 
more at 56.7 %. When the activity of Al3+ alone was accounted for using model (ii) there 
was no improvement to the accuracy and predictions for both 1.25 and 0.625 mM were 
significantly different to those observed. 
E. coli inhibition by 20 μM FNa with Co2+ predicted by (i) was significantly different to that 
observed for all but the lowest tested concentration (p <0.05, Figure 5.23). This was 
because pH, and therefore solubility of FNa, varied very little between the Co2+ 
concentrations in nutrient broth. When the activity of Co2+ alone was added, resulting 
predicted (ii) values more closely tracked the observed inhibition. However, there were 
still significant differences between observed and predicted inhibition with two Co2+ 
concentrations. Predicted (ii) inhibition with 0.078 mM Co2+ was 100 % whereas the 
observed inhibition was 94.2 % and with 0.039 mM predicted was 84.7 and observed 
35.1 %. 
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.  
Figure 5.23 - Comparison of observed inhibition with two methods of predicting inhibition 
of E. coli NCTC 10418 by 20 μM sodium fusidate in the presence of cobalt(II) sulphate in 
nutrient broth 
(n = 3, error bars = 95 % CI, * = p <0.05) 
 
Figure 5.24 - Comparison of observed inhibition with two methods of predicting inhibition 
of E. coli NCTC 10418 by 20 μM sodium fusidate in the presence of copper(II) sulphate in 
nutrient broth 
(n = 3, error bars = 95 % CI, * = p <0.05) 
Both models accurately predicted four of the five inhibition values for FNa and Cu2+ 
(Figure 5.24). Interestingly, inclusion of activity of Cu2+ alone using method (ii) gave the 
most accurate prediction for activity of 20 μM with 0.625 mM Cu2+ at 84.8 % inhibition 
compared to 85.0 % observed, while method (i) based on FNa solubility alone gave the 
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most accurate prediction for activity with 0.156 mM Cu2+ at 31.3 % compared to 29.0 % 
observed. In addition, the observed inhibition produced by FNa with 0.313 mM Cu2+ was 
54.4 %, falling between the predictions made by each model (33.4 % by (i) and 67.4 % 
by (ii)). It therefore appears that the activity of 20 μM FNa in the presence of Cu2+ can 
be described differently depending on the concentration of metal present. 
 
Figure 5.25 - Comparison of observed inhibition with two methods of predicting inhibition 
of E. coli NCTC 10418 by 20 μM sodium fusidate in the presence of iron(II) sulphate in 
nutrient broth 
(n = 3, error bars = 95 % CI, * = p <0.05) 
Predicted inhibition of E. coli by FNa in the presence of Fe2+ calculated by either method 
was not significantly different to that observed (p >0.05, Figure 5.25) at all concentrations 
other than 0.625 mM. However, both methods significantly underestimated the inhibition 
produced by 20 μM FNa with 0.625 mM Fe2+ (p <0.05). Observed inhibition was 82.5 % 
whereas predicted values were 35.3 and 29.1 % by method (i) and (ii), respectively. 
Values for predicted E. coli inhibition by 20 μM FNa in the presence of Mn2+ were closer 
to observed values when the activity of the metal alone was included in the calculations 
(predicted (ii), Figure 5.26). Without inclusion of metal activity, inhibition predicted by 
method (i) was significantly different to observed (p <0.05) except with 1.25 mM Mn2+. 
Conversely, using method (ii) only the prediction for 20 μM FNa with 0.313 mM Mn2+ was 
significantly different to that observed. 
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Figure 5.26 - Comparison of observed inhibition with two methods of predicting inhibition 
of E. coli NCTC 10418 by 20 μM sodium fusidate in the presence of manganese(II) sulphate 
in nutrient broth 
(n = 3, error bars = 95 % CI, * = p <0.05) 
 
Figure 5.27 - Comparison of observed inhibition with two methods of predicting inhibition 
of E. coli NCTC 10418 by 20 μM sodium fusidate in the presence of nickel(II) sulphate in 
nutrient broth 
(n = 3, error bars = 95 % CI, * = p <0.05) 
E. coli inhibition by 20 μM FNa in the presence of Ni2+ was also more accurately 
predicted when the activity of the metal alone was accounted for using method (ii) (Figure 
5.27). The only significant difference between inhibition observed and that predicted by 
model (ii) was with 0.313 mM Ni2+ with values of 89.8 and 98.7 %, respectively. 
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Predictions of FNa activity when combined with Pd2+ were not accurate with either 
method (Figure 5.28). The predicted values were significantly greater than observed 
activity of 20 μM FNa with 0.313, 0.156 and 0.078 mM Pd2+. This may be explained by 
the tendency of Pd2+ to spontaneously form complexes which could reduce antimicrobial 
activity of FNa without proportionately effecting its solubility. 
 
Figure 5.28 - Comparison of observed inhibition with two methods of predicting inhibition 
of E. coli NCTC 10418 by 20 μM sodium fusidate in the presence of palladium(II) sulphate in 
nutrient broth 
(n = 3, error bars = 95 % CI, * = p <0.05) 
 
Figure 5.29 - Comparison of observed inhibition with two methods of predicting inhibition 
of E. coli NCTC 10418 by 20 μM sodium fusidate in the presence of zinc(II) sulphate in 
nutrient broth 
(n = 3, error bars = 95 % CI, * = p <0.05) 
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The combined activity of FNa and Zn2+ was also poorly predicted by both models (Figure 
5.29). None of the values produced by model (i) accurately described the observed 
inhibition (p <0.05). While model (ii) yielded predictions closer to the observed values, 
there was only no significant difference between observed and predicted activity for 
20 μM FNa with 0.625 mM Zn2+ (p >0.05). 
The absolute differences between the mean observed and mean predicted inhibition of 
E. coli are summarised for model (i) and (ii) in Table 5.4 and Table 5.5, respectively. 
Overall, model (ii) was found to yield greater predictive accuracy than (i), with a mean of 
total differences of 10.1 compared to 25.5 %. However, while model (ii) more accurately 
predicted the activity of FNa with metal sulphates at their MIC90 and above, some metals 
were better described by model (i) when below these concentrations. For example, the 
difference between model (i) predictions for FNa activity with 12.5 % MIC90 of Cu2+ and 
Fe2+ and observed inhibition were only 2.3 and 1.8 %, respectively. However, when the 
observed effect of the same concentration of metal alone was included in the calculations 
as model (ii), the differences increased to 28.4 and 7.2 %. In contrast, predictions of 
activity with 12.5 % MIC90 Co2+ or Ni2+ were closer to the observed values when the effect 
of the metal alone was included. 
 
Table 5.4 - Difference between observed E. coli NCTC 10418 inhibition by 20 µM sodium 
fusidate in the presence of metal sulphates and that predicted by model (i) 
Metal 
concentration 
(% MIC90) 
Al3+ Co2+ Cu2+ Fe2+ Mn2+ Ni2+ Pd2+ Zn2+ mean 
200 0.0% 66.1% 0.0% 0.0% 38.9% 9.6% 0.0% 61.5% 22.0% 
100 0.1% 64.5% 0.9% 0.0% 59.5% 66.0% 10.6% 62.6% 33.0% 
50 11.7% 59.2% 38.5% 3.5% 14.4% 64.0% 22.2% 15.0% 28.6% 
25 17.0% 30.9% 21.0% 47.2% 20.0% 6.3% 20.4% 34.9% 24.7% 
12.5 8.2% 16.6% 2.3% 1.8% 54.9% 9.1% 15.0% 30.3% 17.3% 
mean 7.4% 47.5% 12.5% 10.5% 37.6% 31.0% 13.7% 40.9% 25.1% 
 
Table 5.5 - Difference between observed E. coli NCTC 10418 inhibition by 20 µM sodium 
fusidate in the presence of metal sulphates and that predicted by model (ii) 
Metal 
concentration 
(% MIC90) 
Al3+ Co2+ Cu2+ Fe2+ Mn2+ Ni2+ Pd2+ Zn2+ mean 
200 0.0% 0.0% 0.0% 0.0% 0.9% 1.0% 0.0% 0.1% 0.3% 
100 0.0% 0.0% 0.1% 0.0% 0.2% 0.1% 1.2% 6.6% 1.0% 
50 9.5% 5.8% 0.3% 0.0% 25.9% 9.0% 27.7% 19.9% 12.2% 
25 18.1% 18.7% 13.0% 56.4% 2.9% 5.4% 28.1% 23.5% 20.8% 
12.5 6.0% 9.3% 28.4% 7.2% 33.8% 2.8% 21.0% 21.5% 16.3% 
mean 6.7% 6.8% 8.3% 12.7% 12.7% 3.7% 15.6% 14.3% 10.1% 
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The reduced solubility of FNa clearly plays a major role in its increased activity against 
E. coli when in combination with metal sulphates. However, these comparisons indicate 
that FNa solubility is not the sole determinant of activity of the combinations. In fact, while 
the independent antimicrobial activity of the metal generally contributes to combination 
efficacy, there are nuances with each metal suggesting the influence of other factors 
such as interplay between the various metabolic processes and survival mechanisms 
induced by each agent. 
5.3.3.5 Predictability of anti-E. coli activity of sodium fusidate based on solubility 
in with other copper(II) salts and in other broths 
The solubility of 1280 μM FNa (data not shown) in NB with Cu D-glu at unadjusted pH, 
NB with Cu D-glu adjusted to pH 7.2, LB with CuSO4 and CAMHB with CuSO4 was used 
to predict anti-E. coli activity of 20 μM FNa in the same conditions with models (i) and 
(ii). 
5.3.3.5.1 Copper(II) D-gluconate in nutrient broth at native and neutral pH 
 
Figure 5.30 - Comparison of observed inhibition with two methods of predicting inhibition 
of E. coli NCTC 10418 by 20 μM sodium fusidate in the presence of copper(II) D-gluconate in 
nutrient broth at unadjusted native pH 
(n = 3, error bars = 95 % CI, * = p <0.05) 
The activity of 20 μM FNa with Cu D-glu against E. coli was accurately predicted by 
model (ii) for four of the five Cu2+ concentrations investigated (p >0.05, Figure 5.30). 
However, an additional 19.2 % inhibition was observed with 0.313 mM Cu2+ compared 
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to the (ii) prediction (p <0.05). The difference between observed inhibition and that 
predicted by model (i) was statistically significant with both 0.625 and 0.313 mM Cu2+ 
(p<0.05) at 23.9 and 49.6 %, respectively.  
 
Figure 5.31 - Comparison of observed inhibition with two methods of predicting inhibition 
of E. coli NCTC 10418 by 20 μM sodium fusidate in the presence of copper(II) D-gluconate in 
nutrient broth adjusted to pH 7.2 
(n = 3, error bars = 95 % CI, * = p <0.05) 
Model (i) was unable to predict the anti-E. coli activity of 20 μM FNa combined with any 
concentration of Cu D-glu tested when the pH was adjusted to 7.2 (p <0.05, Figure 5.31). 
This was because solubility of 1280 μM FNa was 100 % in all pH 7.2 NB solutions of Cu 
D-glu corresponding to a prediction of 24.4 % inhibition by 20 μM FNa in the same 
conditions. Inclusion of the activity of Cu D-glu alone at pH 7.2 increased the accuracy, 
reducing the mean difference between observed and predicted to 15.0 % with model (ii) 
compared to 55.1 % with (i). However, there were large and significant differences 
between the observed and predicted values with 1.25, 0.625, and 0.313 mM, with the 
actual inhibition being 40.5, 15.6 and 13.1 % higher than predicted by model (ii), 
respectively. While the activity of FNa combined with Cu D-glu in NB without pH 
adjustment correlated well with the additive effects of reduced FNa solubility and the 
activity of Cu D-glu alone, the results with the same combinations at pH 7.2 suggest a 
more complex mode of combined activity as the presence of Cu2+ enhances FNa activity 
beyond the effect of reduced solubility with independent metal activity. 
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5.3.3.5.2 Copper(II) sulphate in LB and cation adjusted Müller-Hinton broth 
The models for solubility-based anti-E. coli activity of FNa were derived from 
observations in NB. Since bacterial growth and metabolism varies between media, 
predictions for activity in other broths using the same models can be expected to be 
limited. Indeed, while models (i) and (ii) both accurately predicted concentrations of 
CuSO4 that would produce 100 % inhibition of E. coli growth when combined with 20 μM 
FNa in LB (p >0.05, Figure 5.32), neither was successful at other concentrations. The 
mean difference between predicted and observed inhibition at the three lowest 
concentrations were 47.4 % with model (i) and 30.1 % with model (ii). 
 
Figure 5.32 - Comparison of observed inhibition with two methods of predicting inhibition 
of E. coli NCTC 10418 by 20 μM sodium fusidate in the presence of copper(II) sulphate in 
Miller’s lysogeny broth 
(n = 3, error bars = 95 % CI, * = p <0.05) 
Interestingly, predictions in CAMHB were closer to observed values than those for LB 
(Figure 5.33). The total mean difference between observed and predicted values was 
11.2 % with model (i) and 8.7 % with model (ii), despite nearly all predictions being 
significantly different to the observed inhibition (p <0.05). In particular, the pattern of 
predicted inhibition using (ii) was similar to that observed. CAMHB is supplemented with 
additional Ca2+ and Mg2+ to support increased bacterial growth which may be the cause 
of the observed inhibition being consistently lower than that predicted by model (ii). 
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Figure 5.33 - Comparison of observed inhibition with two methods of predicting inhibition 
of E. coli NCTC 10418 by 20 μM sodium fusidate in the presence of copper(II) sulphate in 
cation adjusted Müller-Hinton broth 
(n = 3, error bars = 95 % CI, * = p <0.05) 
5.3.4 Association of sodium fusidate with E. coli cells 
The number of viable bacteria present at the end of the exposure period was selected 
for calculation of FNa per 106 cells since no significant difference was found between 
this and the number of viable E. coli NCTC 10418 initially exposed or recovered from the 
bacterial pellets (p >0.05). 
After exposure to 160 µM, 206.8 pg FNa was associated with E. coli NCTC 10418 per 
106 cells (Figure 5.34). In the presence of CuSO4, this value was greater at 278.6 ng FNa 
per 106 cells and with MnSO4 it was lower at 143.8 ng per 106 cells. However, there was 
no statistically significant difference between the amount of FNa recovered from E. coli 
exposed to FNa in the presence of CuSO4, MnSO4 or the control due to variability 
between replicates (p >0.05). In contrast, 1197.4 pg FNa per 106 cells was recovered 
from E. coli exposed to FNa in pH 6 broth (mean pH 5.94±0.20 SD) which was 
significantly more than all other conditions (p <0.05). 
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Figure 5.34 – Sodium fusidate per million E. coli NCTC 10418 cells recovered from bacterial 
pellet after exposure to 160 µM in nutrient broth in the presence of metal ions or reduced 
pH for 30 min at 35 °C and 120 rpm 
(n = 3, error bars = 95 % CI) 
Table 5.6 lists the activity and solubility of FNa compared to the amount recovered under 
the same conditions. While a relationship could not be described mathematically using 
only 4 data points, it was apparent that FNa activity against E. coli increased with 
increasing FNa recovery. This suggests that the greater activity of FNa at lower pH is at 
least in part due to more FNa being associated with the E. coli cells under these 
conditions. Interestingly, while a relationship between solubility or pH and FNa recovered 
was apparent for the control, Cu2+ and pH 6.0 broth, the Mn2+ appeared to be 
inconsistent. This could simply have been because of limitations in the sensitivity of the 
assay. However, as Mn2+ enhanced E. coli growth and was suppressive to FNa activity, 
an alternative explanation may involve induction of increased efflux by the metal, 
reducing total associated FNa disproportionately to its solubility. 
 
Table 5.6 - Comparison of sodium fusidate recovered from E. coli NCTC 1014 to its activity 
and solubility under the same conditions, ordered by mass recovered 
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1280 µM 
sodium 
fusidate 
Solution pH 
625 µM 
MnSO4 
143.8 54.1 % 99.9 % 7.17 
control 
(pH 7.2) 206.8 88.7 % 100 % 7.20 
312.5 µM 
CuSO4 
278.6 95.2 % 98.2 % 6.95 
pH 6.0 
broth 1197.4 99.6 % 71.6 % 6.00 
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5.4 Discussion 
5.4.1 Precipitation (and not complexation) of sodium fusidate in the 
presence of copper(II) ions 
UV-Vis analysis demonstrated decreased absorbance at the FA lambda max as 
increasing concentrations of CuSO4 were mixed with FNa (Figure 5.2, page 119). This 
correlated with common titration spectra findings for complex formation – the free drug 
absorbance reduces as it is coordinated by metal ions[451]. However, ITC did not indicate 
a complexation interaction. An example of the ITC profile generated by complexation is 
shown in Figure 5.1, page 107, illustrating a sigmoidal relationship between molar ratio 
and enthalpy per mole of injectant[432]. ITC thermograms of CuSO4 or Cu D-glu at their 
native pH titrated against FNa corresponded to precipitation (Figure 5.4A&B, page 121), 
with tailed enthalpy peaks of progressively decreasing size. Further, evidence of an 
enthalpy change is almost entirely eradicated when there is no pH drop on Cu2+ addition 
(Figure 5.4C, page 121) indicating that the precipitation is pH- rather than metal ion-
mediated. The absorbance reduction in the UV-Vis spectrum at approximately FNa λmax 
on titration with CuSO4 can therefore be determined to be due to precipitation lowering 
the dissolved FNa concentration rather than complexation. This is supported by the 
observed elimination of absorbance change with adjustment of the Cu D-glu solution to 
neutral (Figure 5.3, page 120). If Cu2+ was complexing FNa it would be more likely to 
occur at higher, less acidic pH since this would encourage deprotonation of FNa and 
increased interaction with Cu2+ [429], but this is not the case. In addition, visual precipitate 
of FNa was filtered out of broth adjusted to pH 5 which lowered the effectiveness against 
S. aureus by 75 % (Figure 5.10, page 128) and this was not due to breakdown of FNa 
(Figure 5.13, page 131). These findings confirm lack of Cu2+ complexation and illustrate 
FNa precipitation at reduced pH. While this does not directly confirm other synergistic 
metals do not exert their efficacy by complexation, the trends in activity with pH and 
solubility discussed below indicate this is the most likely scenario. 
5.4.2 Relationship between broth pH and sodium fusidate solubility 
Figure 5.8 (page 125) illustrates the apparent relationship between broth pH and the 
activity of FNa against E. coli. While the pattern was consistent for synergistic metals, 
those that are additive or suppressive to FNa activity did not correlate, despite also 
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changing pH in some cases. In addition, the inhibition produced by FNa in pH-adjusted 
broth was consistently lower than when with metal ions at the same pH. Since the pH 
reduction produced by CuSO4 had already been found to cause FNa precipitation in 
water (Section 5.3.1), it was hypothesised that this apparent relationship may have been 
due to changes in FNa solubility. Indeed, the solubility of FNa was found to strongly 
correlate with broth pH, both with and without metal ions after 1.5±0.5 h at 20 °C and 
18±2 h at 35 °C (Section 5.3.3.3). As the pKa of FA is 5.35[443], the lower pHs will result 
in a higher proportion of the molecules being fully protonated and therefore insoluble. At 
lower pHs, % solubility is also seen to decrease as FNa concentration increases. FNa is 
known to aggregate in aqueous solutions by forming dimers with hydrophobic regions 
turned inwards which subsequently coalesce into much larger structures. The degree of 
aggregation is known to be related to at least the total concentration of FNa, presence 
of excess counter ions, temperature and the activity of buffers[443],[446],[452],[453]. In addition, 
the Schulze-Hardy rule describes increased aggregation with increased counter ion 
valency[454], which supports the particularly low FNa solubility observed with Al3+ (Figure 
5.21, page 140). When the initial concentration of FNa is sufficient to result in 
aggregation, a large proportion of the undissolved fraction will be shielded and therefore 
stabilised in the precipitated form as only the surface area of aggregates would readily 
be able to be re-dissolved. Conversely, at lower concentrations where aggregation is not 
significant, all of the drug present can be readily accessed by the surrounding solvent 
and continuously de-protonated/protonated, even during and after high speed 
centrifugation to remove any precipitate. The duration of the fully protonated state is likely 
too short to result in any precipitation of drug when the initial concentration is low, 
consequently preventing removal of any undissolved fraction despite its presence. 
The lower solubility after equilibration at 35 °C for 18±2 h than 20 °C for 1.5±0.5 h at 
pHs 4.4 to 6.0 (Figure 5.18, page 136) may be due to greater loss of EtOH from the 
incubated samples. The rate of EtOH evaporation has also been shown to be higher for 
low concentration aqueous solutions due to the preferential adsorption of EtOH to the 
air-liquid interface[455]. In fact, the evaporation rate increases in rapidity inversely to the 
EtOH concentration remaining in solution, with the mass transfer coefficient increasing 
from 26.1, 47.8 to 71.2 m h-1 as concentration decreases from 5.38, 2.01 to 0.64 % v/v. 
The combination of this phenomenon with increased temperature and/or different 
equilibration durations could result in less EtOH in solution in the incubated samples than 
those at 20 °C. As it acts to increase sodium fusidate solubility, this reduction in EtOH in 
solution would result in increased precipitation of sodium fusidate. Conversely, at 
pHs 6.4 and 6.8, solubility at 35 is greater than at 20 °C which reflects the usually 
expected trend due to greater kinetic energy at higher temperature. It appears that at 
these pHs the increased kinetic energy sufficiently overcomes the effects of EtOH loss 
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allowing greater solubility than seen at lower pHs. Finally, there was no significant 
difference between solubility of the various initial concentrations in control broth – it 
seems that the effects of excess hydrogen ions, EtOH loss and increased energy are in 
balance to produce the same % solubility at both temperatures. 
5.4.3 Predicting anti-E. coli activity of sodium fusidate based on its 
solubility 
As complex aqueous solutions can often take a considerable period of time to reach 
equilibration and all antimicrobial activity studies were performed at 35 °C for 18±2 h, it 
can be reasoned that solubility data for solutions equilibrated in these conditions are 
likely to be more reliable and representative of the antimicrobial assay than data from 
1.5±0.5 h equilibration at 20 °C. In addition, the longer equilibration period yielded more 
consistent pH and solubility results, particularly for unstable Fe2+ (Figure 5.20, page 139). 
When the calculated activity of reduced solubility FNa and known activity of metal ions 
alone were summed using model (ii) (Table 5.5, page 146), predictions were more similar 
to observed activity against E. coli than if independent metal ion activity was omitted 
(model (i), Table 5.4, page 146). The mean difference between predicted and observed 
inhibition was 25.1 %, range 0 – 66.1 % with 17/40 differences being >20 %, when metal 
activity was not included (model (i)). This reduced to 10.1 %, range 0 – 56.4 % with 9/40 
differences being >20 % when the effect of the metal alone was accounted for with model 
(ii). This suggests that the combined activity of FNa and metal ions against E. coli is 
primarily a product of the additive effects of reduced FNa solubility and metal ion 
antimicrobial action. However, other factors such as synergising effects of pH stress 
(Section 5.1.2.1, page 108) and the change in pH and consequent FNa solubility during 
the course of incubation observed with some metals (Figure 5.20, page 139) may both 
contribute to explaining the inconsistencies in predictions and complicate formulation of 
a more accurate model. 
5.4.3.1 Metal sulphates in nutrient broth 
5.4.3.1.1 Sodium fusidate with synergistic aluminium, copper(II) or iron(II) 
Agreement between the observed inhibition of E. coli NCTC 10418 and that predicted by 
model (ii) was higher than model (i) for both Al3+ (Figure 5.22, page 141) and Cu2+ (Figure 
5.24, page 142) with 20 µM FNa. However, since sub-MIC90 Al3+ alone had only a small 
impact on bacterial growth (± ≤2.2 % compared to the agent-free control), there was no 
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significant differences between the predicted combination activities from the two models 
(p >0.05). While the observed activity of 0.313 and ≥2.5 mM Al3+ combined with 20 µM 
FNa was as predicted, observed E. coli inhibition by 0.625 and 1.25 mM was significantly 
more than that predicted. This implies some additional factor may be involved in the 
combined activity, perhaps the effects of pH stress. Since Al3+ and low pH both cause 
membrane damage (see Sections 4.1.1.1 and 5.1.2.1), their combined effects at these 
concentrations may synergise with 20 µM FNa by increasing intracellular access. 
Interestingly, observed activity of 20 µM FNa with ≥0.313 mM Cu2+ was best described 
by the sum of reduced solubility FNa activity and Cu2+ (model (ii), p >0.05). Conversely, 
prediction based on the relationship between solubility FNa without accounting for metal 
ion activity (model (i)) was more accurate for 20 µM FNa and 0.156 mM Cu2+ (p >0.05, 
Figure 5.24, page 142). This pattern suggests that the proposed additive activity of FNa 
at reduced solubility and metal ions against E. coli occurs with Cu2+ concentrations of 
≥0.313 mM. Below this Cu2+ concentration, E. coli appears to be impervious to the effects 
of Cu2+ when in the presence of 20 µM FNa. Previous observations indicated that higher 
concentrations of ≥1 mM FNa stabilised the bacterial membrane and reduced sensitivity 
to Cu2+ in water (Chapter 4, Section 4.3.3.2). The lower FNa concentration investigated 
here may be able to aid E. coli in resisting the effects of lower concentrations of Cu2+ in 
NB in the same way, which could account for activity of the combination being lower than 
that predicted by model (ii). Alternatively, exposure to either agent at very low sub-MIC90 
may induce processes providing cross-resistance or enhancing overall viability and 
growth. In either case the similarity between predicted anti-E. coli activity of FNa at 
equivalent solubility alone and that observed in response to the combination of 20 µM 
FNa and 0.156 mM Cu2+ is likely to be coincidental. 
Models (i) and (ii) gave similarly accurate predictions for the activity of Fe2+ with 20 µM 
FNa (p >0.05, Figure 5.25, page 143). Only the observed activity of 0.625 mM Fe2+ 
combined with 20 µM FNa was significantly greater than predicted inhibition (p <0.05), 
exhibiting an extra 47.2 and 56.4 % than predicted by model (i) and (ii), respectively. This 
concentration may represent the tipping point between manageable levels of Fe-
mediated ROS generation, membrane disruption and other redox damage while still 
being able to simultaneously efflux 20 µM FNa when only 0.313 mM Fe2+ is present, and 
E. coli homeostasis mechanisms being overwhelmed by 0.625 mM Fe2+. 
5.4.3.1.2 Sodium fusidate with indifferent cobalt(II), nickel(II) or palladium(II) 
The combined activity of 20 µM FNa and Co2+ (Figure 5.23, page 142) or Ni2+ (Figure 
5.27, page 144) could not be accurately predicted using model (i). Since the pH of the 
tested concentrations of each metal had very little effect on the pH of nutrient broth, FNa 
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solubility was similar for all (except 1.25 mM Ni2+ which produced pH 5.97). However, 
when the activity of the metal ions alone was also included in the calculations, the 
predicted inhibition closely corresponded to that observed. The predictions for E. coli 
inhibition by 20 µM FNa with 0.078 or 0.039 mM Co2+ were higher than that observed 
(p <0.05). This may be due to the micronutrient role of Co2+ as discussed in Section 
4.4.1.2. Only the prediction for 0.313 mM Ni2+ with 20 µM FNa was higher than that 
observed, likely due to similar reasons (see Section 4.4.1.2). Conversely, the predicted 
E. coli inhibition by the three lowest concentrations of Pd2+, 0.313, 0.156 and 0.078 mM, 
combined with 20 µM FNa by both models was significantly higher than that observed 
(p <0.05, Figure 5.28, page 145). This finding may support complexation between Pd2+ 
and FNa, as hypothesised in Chapter 4. At the lower concentrations of Pd2+, coordination 
of FNa may remove enough free metal ions from solution that the detectable 
antimicrobial effect attributable to them is reduced, while no FNa can penetrate the 
bacterial cell to exert its effect either. At higher Pd2+ concentrations, all FNa is again 
complexed and cannot enter the cells, however, there is enough free Pd2+ to cause 
considerable bacterial damage. In addition, 100 % inhibition is observed with the higher 
Pd2+ concentrations due to the additional pH stress exerted rather than free, active FNa. 
5.4.3.1.3  Sodium fusidate with antagonistic manganese(II) or zinc(II) 
The anti-E. coli activity of 20 µM FNa with both Mn2+ (Figure 5.26, page 144) and Zn2+ 
(Figure 5.29, page 145) was more accurately predicted with inclusion of the effects of 
metal ions alone by model (ii). The only significant difference between observed activity 
of 20 µM FNa in the presence of Mn2+ and that predicted was with 0.313 mM Mn2+. The 
growth of E. coli was enhanced by 20 % by 0.313 mM Mn2+ when alone and by the 
combination of 0.313 mM Mn2+ and 20 µM FNa. As discussed in Section 4.4.1.1, Mn2+ is 
a micronutrient for E. coli and may enhance AcrAB-TolC expression and function, which 
explains the growth enhancement in the presence of the combination. In addition, while 
NB can support growth of most non-fastidious bacteria, it is notoriously lacking in certain 
areas of "nutrition", including Mn2+ with concentrations of less than 1 μM[456]. Therefore, 
an additional low concentration of 0.313 mM Mn2+ alone enhances E. coli growth as a 
micronutrient while higher concentrations are inhibitory. The anti-E. coli activity of 20 µM 
FNa with Zn2+ predicted by both models was quite different to that observed (Figure 5.29, 
page 145). While the inclusion of activity of Zn2+ when alone improved accuracy for 0.625 
and 0.313 mM Zn2+, both models overestimated combined activity with ≤0.156 mM Zn2+. 
This is likely to be for similar reasons as with Mn2+ and discussed for Zn2+ in Section 
4.4.1.1, namely increased AcrAB-TolC activity, MdtABC-TolC induction and greater 
ribosomal turnover. 
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5.4.3.2 Copper(II) D-gluconate in nutrient broth at native and neutral pH 
The observed activity of 20 μM FNa combined with Cu D-glu at native pH against E. coli 
was very similar to that predicted by model (ii) (Figure 5.30, page 147). Interestingly, 
however, and in contrast to CuSO4, the observed inhibition with 0.313 mM Cu D-glu was 
significantly higher than that predicted (p <0.05). As discussed in Section 4.4.2, this may 
be because E. coli can utilise gluconate as a carbon source[457] and the resulting increase 
in bacterial metabolism allows greater FNa-mediated inhibition. At neutral pH, there is 
more disparity between the observed combined activity of 20 μM FNa with Cu D-glu and 
that predicted by model (ii) (Figure 5.31, page 148). The model (ii) predictions – which 
include the activity of the metal salt alone under the same conditions – were closer to 
observed inhibition than the model (i) predictions. However, the inhibition predicted by 
model (ii) for 20 μM FNa with ≤1.25 mM Cu D-glu at pH 7.2 was significantly lower than 
that observed. This is likely to be due to the same gluconate-metabolism and FNa activity 
combination as hypothesised for 20 μM FNa with 0.313 mM Cu D-glu at native pH. In 
addition, the phenomenon was observed at higher Cu2+ concentrations when adjusted 
to pH 7.2, presumably because neutralisation reduced pH stress, thereby allowing 
additional growth and its subsequent inhibition by FNa. 
5.4.3.3 Copper(II) sulphate in LB and cation adjusted Müller-Hinton broth 
Prediction of the anti-E. coli activity of FNa and Cu2+ in other broths using the models 
based on growth in NB was attempted. Accuracy was not anticipated since differences 
in nutritional composition of growth media alter bacterial growth characteristics and 
therefore the degree of inhibition. However, in some cases the activity of 20 μM FNa and 
Cu2+ could be predicted based on the solubility of 1280 μM FNa and activity of Cu2+ alone 
in LB and CAMHB. In LB (Figure 5.32, page 149), 5 and 2.5 mM CuSO4 was observed 
to produce 100 % inhibition and this was accurately predicted by both models. At lower 
CuSO4 concentrations, the predictions were consistently lower than observed inhibition, 
however, they followed a similar downward trend with Cu2+ concentration. In CAMHB 
(Figure 5.33, page 150), model (ii) predictions followed the same trend as observed 
inhibition but were approximately 10-15 % higher for all Cu2+ concentrations except 
2.5 mM. Since Ca2+ and Mg2+ with which CAMHB is supplemented both play a role in 
membrane structure and fluidity, the lower observed inhibition may be due to additional 
permeability to FNa afforded by cation adjustment compared to NB. Alternatively, the 
differences could also simply be due to different growth and metabolism exhibited by 
E. coli in each medium composition. However, the results in LB and CAMHB do indicate 
that the combined activity of FNa and metal ions in other bacteriological media also 
correlated with FNa solubility and the independent activity of the metal ions. More 
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accurate models of prediction could therefore be arrived at by studying the 
solubility : activity relationship of FNa in these broths over a range of pHs. 
5.4.4 Association of sodium fusidate with E. coli cells in the presence of 
metal ions or reduced pH 
Reduction of NB pH to 6.0 significantly increased the amount of FNa that associated with 
E. coli NCTC 10418 cells after exposure to 160 µM for 30 min at 35 °C and 120 rpm 
(p <0.05, Figure 5.34, page 151). No significant differences were detected between FNa 
association with E. coli in standard control NB, NB with 625 µM Mn2+ or NB with 312.5 µM 
Cu2+ (p >0.05). However, there was a correlation between E. coli inhibition by FNa after 
18±2 h at 35 °C and 120 rpm and the amount of FNa associated with cells after 30 min 
under the same conditions. While Cu2+ could have been expected to have a greater effect 
on FNa association with E. coli due to synergy between the agents, the 312.5 µM 
selected for use did not have a dramatic impact on NB pH, reducing it only to 6.95. This 
concentration, 25 % MIC90, was selected to avoid viability loss during exposure. In 
addition, the overall assay may not have been sensitive enough detect significant 
differences. A longer exposure period may increase sensitivity but also introduces 
additional variables due to differences in inhibition and consequent bacterial growth rate 
between conditions, leading to greater disparity between the final number of bacteria 
present. Alternatively, greater starting cell numbers in a larger volume of broth could 
increase sensitivity by resulting in higher yield of total FNa. 
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5.5 Conclusions 
The conclusions drawn from the work in this Chapter can be summarised as follows: 
1) Cu2+ does not spontaneously complex FNa in order to enhance its activity 
against E. coli NCTC 10418. 
2) Reduced pH decreases FNa solubility and increases activity against E. coli 
NCTC 10418. 
3) The anti-E. coli synergy of Al3+, Cu2+ and Fe2+ with FNa are primarily due to 
the additive effects of pH-meditated reduction in FNa solubility and metal ion 
antimicrobial activity. 
4) Reduced pH and FNa solubility increases the association of FNa with E. coli 
NCTC 10418 cells. 
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Chapter 6: Activity of sodium fusidate 
and metal ion combinations 
against Gram-negative multi-
drug resistant isolates 
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6.1 Introduction 
E. coli serves as a valuable model GN organism for early antimicrobial activity studies; 
however, as discussed in Chapter 1, the most common cause of GN bacterial keratitis is 
Pseudomonas aeruginosa. Several other GN species have also been reported to infect 
the cornea with geographically variable frequency, including Klebsiella 
pneumoniae[31],[78]. In addition, while reference strains used in the laboratory generally do 
not harbour multiple drug resistance mechanisms, multi-drug resistance (MDR) is 
becoming increasingly common in both environmental and clinical P. aeruginosa and 
K. pneumoniae isolates[70],[74],[75],[78]. In contrast to laboratory reference strains, novel GN 
isolates frequently harbour plasmids carrying many MDR genes and also exhibit 
additional genetic and phenotypic changes to aid their survival and virulence. Such 
isolates can, therefore, be more representative of the possible resistance profiles and 
metabolic abilities of organisms likely to be involved in spontaneous clinical cases than 
standard reference strains. In addition, clinical and environmental MDR isolates can be 
used to check for cross-resistance with other antimicrobial classes and provide an 
indication of overall susceptibility of the wider bacterial population. 
Like E. coli, K. pneumoniae is a member of the Enterobacteriaceae family and both 
species are facultative anaerobic residents of the mammalian gastrointestinal tract. 
Conversely, P. aeruginosa is an obligate aerobe found in water and the soil and belongs 
to the Pseudomonadaceae family. However, all three species are opportunistic human 
pathogens and intrinsically resistant to FNa. K. pneumoniae achieves FNa resistance by 
expressing AcrAB-TolC[142], the same efflux pump utilised by E. coli, while P. aeruginosa 
produces an homologous RND family pump: MexAB-OprM[143]. As for other GN species, 
resistance to FNa lies in preventing intracellular accumulation by efficient expulsion of 
the drug rather than absence of the EF-G target. 
The known mechanisms of metal ion activities against GN organisms were discussed in 
Chapter 4. While phenotypic and metabolic differences between species may alter metal 
ion susceptibility and MIC values, high-level resistance is most commonly conferred by 
acquired genetic material. Metal resistance genes are frequently found in MDR bacterial 
strains and this could result in lower efficacy of the metal ion and FNa combinations 
compared to the comparatively sensitive E. coli reference strain. Nonetheless, since 
metal ion damage to the OM appears to be a key to the combined activity, metal 
resistance mechanisms which protect internal targets may be ineffectual in preventing 
163 
FNa entry and accumulation. On the other hand, there are known differences between 
the structure of Enterobacteriaceae and Pseudomonadaceae membranes which may 
manifest differences in sensitivity to FNa combined with metal ions. For example, the 
P. aeruginosa OM is devoid of the large general porins found in Enterobacteriaceae but 
instead contains only small substrate-specific membrane channels[458]. Since the smaller 
membrane channels both exclude large molecules and contribute to greater OM stability, 
this difference is thought to account for the very low permeability of the P. aeruginosa 
OM at only 8 % that of E. coli[458]. 
In this Chapter the sensitivities of several MDR isolates of K. pneumoniae, P. aeruginosa 
and E. coli to metal ions, FNa and combinations was investigated and compared to their 
reference strains in order to determine whether metal ions can also enhance FNa activity 
against highly resistant GN organisms capable of causing keratitis. 
6.1.1 Aim and objectives 
Aim: to determine if metal ions can enhance FNa activity against MDR isolates of GN 
organisms which cause keratitis. 
Objectives: 
1) To determine sensitivity of E. coli, K. pneumoniae and P. aeruginosa MDR 
isolates to antimicrobial metal ions. 
2) To investigate the effects of metal ions on FNa activity against E. coli, 
K. pneumoniae and P. aeruginosa MDR isolates. 
3) To identify the metal ion(s) which are most effective at enhancing FNa activity 
against E. coli, K. pneumoniae and P. aeruginosa MDR isolates. 
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6.2 Methods 
6.2.1 Sources and maintenance of bacterial strains 
Standard reference strains K. pneumoniae NCTC 9633 and P. aeruginosa NCTC 13359 
were obtained from glycerol stocks of NCTC-sourced samples and frozen at -80 °C as 
described in Section 2.2.  
Four MDR plasmid-harbouring clinical isolates each of E. coli, K. pneumoniae and 
P. aeruginosa were kindly gifted by Dr Jonathan Tyrrell, selected at random from the 
Prof Timothy Walsh collection held at Cardiff University School of Medicine (Table 6.1). 
Glycerol stocks and working agar cultures were prepared and maintained for all strains 
as described in Section 2.2. 
Table 6.1 – Multi-drug resistant Gram-negative isolates provided by Prof Walsh 
laboratories 
Species Isolate 
reference 
Source 
location 
Number of genes conferring resistance to: 
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E. coli TWE1 India 11 8 - - 1 1 2 - 2 
TWE2 India 10 5 - - 1 1 2 - 2 
TWE3 India 4 4 1 - 1 1 2 - 1 
TWE4 India 7 5 1 - 1 1 3 - 1 
K. pneumoniae TWK1 UK 3 4 3 1 1 1 2 1 1 
TWK2 UK * 
TWK3 Egypt 8 4 4 - - - 1 1 1 
TWK4 Egypt 7 5 3 - 2 1 1 1 1 
P. aeruginosa TWP1 UK 3 3 1 - 1 - 2 1 - 
TWP2 Egypt 13 4 2 - 3 1 2 1 - 
TWP3 Egypt 11 4 1 1 1 - 2 1 1 
TWP4 Egypt 5 3 1 - 1 - 1 - - 
*sequencing data unavailable; multi-drug resistance phenotype identified experimentally. 
6.2.2 Susceptibility testing 
The MIC90s of FNa and sulphates of Al3+, Co2+, Cu2+, Fe2+, Mn2+, Ni2+, Pd2+ and Zn2+ 
against E. coli, K. pneumoniae and P. aeruginosa MDR isolates and K. pneumoniae and 
P. aeruginosa reference strains were determined by microdilution, as described in 
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Section 2.4. MBCs of metal ions (as sulphates) were also measured, as described in 
Section 2.4. 
As previous experimentation yielded significant enhancement of FNa activity against 
E. coli NCTC 10418 in the presence of synergistic and additive metal ions at ¼ their 
MIC90 (see Section 4.3.1), microdilution was subsequently used to characterise the 
activity of FNa in combination with ¼ the modal MIC90 of Al3+, Co2+, Cu2+, Fe2+ and Ni2+ 
(as sulphates) against the MDR and reference strains. Where appropriate, results 
previously generated for E. coli NCTC 10418 and S. aureus NCTC 12973 (presented in 
Section 4.3.1) were included in the comparison and analysis. 
6.2.3 Data analysis 
In both sets of experiments, the absorbance at 595 nm was used to calculate percentage 
inhibition and MIC90s as previously described (see Section 2.4). Modal MIC90s of metal 
ions were calculated for each species and across all species. In diagnostic microbiology, 
an MIC difference of one two-fold dilution difference is considered acceptable margin of 
error[282]. However, data in this study were subjected to statistical analysis and 
differences observed between 95 % CIs considered significant (p <0.05). 
Since FNa and each of the metal ions affected the growth of individual bacterial strains 
differently, the absorbance data was also used to calculate the AUC for bacterial growth 
with FNa in the presence of each metal ion as a percentage of the AUC for growth with 
FNa alone. This analysis allowed direct comparison between strains, accounting for 
differences in individual agent susceptibility and was calculated as follows: Growth 
density in each well was calculated as a percentage of that with the corresponding FNa-
free control, the metal ion alone thereby being assigned maximal or 100 % growth. The 
AUC for percentage maximal growth from 5 to 1280 µM FNa was determined for each 
metal ion and paired metal-free control of FNa alone. The AUCs with metal ions were 
then converted to percentage of the paired AUC for FNa alone. Mean percentage FNa 
AUCs were calculated from the triplicate experiments and the 95 % CI used to determine 
statistically significant differences (p <0.05). 
FIC90s were calculated for each organism and metal ion combination by dividing the FNa 
MIC90 in the presence of metal sulphate by the MIC90 of FNa alone. Fold reductions in 
FNa MIC90 were used for graphical comparison and calculated by dividing the MIC90 of 
FNa alone by the MIC90 of FNa in the presence of each metal ion. 
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6.3 Results 
6.3.1 Metal ion activity against Gram-negative MDR isolates 
The MIC90s and MBCs of metal ions as sulphates against all tested strains are provided 
in Table 6.2. The MIC90s of each metal ion across the bacterial strains varied no more 
than four-fold. While there were some exceptions, detailed below, each metal ion MBC 
against a strain was generally no more than four-fold greater than the MIC90. 
All but two Al3+ MIC90s were 2.5 mM (p >0.05). The exceptions were an MDR isolate of 
K. pneumoniae, TWK4, and the P. aeruginosa reference strain, NCTC 13359 which were 
two-fold higher and lower at 5 and 1.25 mM, respectively (p <0.05). MBCs of Al3+ varied 
between 2.5 and >10 mM. The modal MBCs against E. coli and K. pneumoniae strains 
were both 5 mM, whereas the modal MBC against P. aeruginosa was 10 mM. S. aureus 
was also particularly resistant to killing by Al3+, and survived in the presence of 10 mM, 
the highest concentration tested. 
Co2+ susceptibility was more variable than that of Al3+, however, species-specific patterns 
were apparent. K. pneumoniae strains were particularly susceptible to growth inhibition 
by Co2+, with a modal MIC90 of 0.078 mM (p <0.05). However, the MBC against reference 
strain NCTC 9633 was 0.625 mM and all MDR K. pneumoniae isolates were able to 
survive in the presence of this concentration. In contrast, the modal MIC90 of Co2+ against 
E. coli, also a member of the Enterobacteriaceae family, was four times greater at 
0.313 mM (p <0.05) while the modal MBC was 0.625 mM. Susceptibility of P. aeruginosa 
fell between the other species with a modal MIC90 of 0.156 mM which was significantly 
greater than K. pneumoniae (p <0.05) but no different to E. coli (p >0.05), and MBC of 
0.625 mM. 
MIC90s for Cu2+ were lowest against E. coli, with a modal value of 1.25 mM. In opposition 
to their relative responses to Co2+, K. pneumoniae were more resistant to inhibition by 
Cu2+ than E. coli (p <0.05), with a modal MIC90 of 2.5 mM Cu2+. Similarly, the modal 
MBCs against E. coli and K. pneumoniae were 2.5 and 5 mM, respectively. 
P. aeruginosa susceptibility again lay between the two Enterobacteriaceae, with a higher 
modal MIC90 than E. coli at 2.5 mM Cu2+ (p <0.05) which was not significantly to the 
MIC90 against K. pneumoniae isolates (p >0.05). 
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Table 6.2 – MIC90s and MBCs (in parentheses) of metal ions against MDR bacterial isolates and their reference strains (mM) 
  Al3+ Co2+ Cu2+ Fe2+ Mn2+ Ni2+ Pd2+ Zn2+ 
E.
 co
li 
NCTC 10418 2.5 (2.5) 0.156 (0.313) 1.25 (2.5) 2.5 (2.5) 2.5 (>10) 0.625 (1.25) 0.625 (1.25) 0.3125 (0.625) 
TWE1 2.5 (2.5) 0.313 (>0.625) 1.25 (2.5) 2.5 (2.5) 5 (5) 1.25 (2.5) 0.625 (0.625) 0.625 (0.625) 
TWE2 2.5 (2.5) 0.313 (>0.625) 1.25 (1.25) 2.5 (2.5) 5 (5) 0.625 (2.5) 0.625 (0.625) 0.3125 (0.625) 
TWE3 2.5 (5) 0.156 (0.625) 1.25 (2.5) 2.5 (2.5) 2.5 (5) 0.625 (2.5) 0.625 (0.625) 0.3125 (0.625) 
TWE4 2.5 (5) 0.625 (0.625) 2.5 (2.5) 2.5 (2.5) 5 (5) 2.5 (2.5) 0.625 (1.25) 0.3125 (0.625) 
E. coli mode 
 2.5 (2.5) 0.313 (0.625) 1.25 (2.5) 2.5 (2.5) 5 (5) 0.625 (2.5) 0.625 (0.625) 0.3125 (0.625) 
K.
 p
ne
um
on
ia
e 
NCTC 9633 2.5 (5) 0.0781 (0.625) 5 (5) 2.5 (2.5) 2.5 (5) 0.625 (1.25) 0.625 (0.625) 0.3125 (0.625) 
TWK1 2.5 (5) 0.0781 (>0.625) 2.5 (5) 2.5 (2.5) 2.5 (5) 0.625 (1.25) 0.625 (0.625) 0.625 (0.625) 
TWK2 2.5 (2.5) 0.0781 (>0.625) 2.5 (5) 2.5 (2.5) 2.5 (5) 0.625 (2.5) 0.625 (1.25) 0.625 (0.625) 
TWK3 2.5 (2.5) 0.0781 (>0.625) 5 (5) 2.5 (2.5) 2.5 (5) 0.625 (1.25) 1.25 (1.25) 0.3125 (0.625) 
TWK4 5 (5) 0.156 (>0.625) 2.5 (5) 2.5 (2.5) 2.5 (5) 1.25 (2.5) 1.25 (1.25) 0.3125 (0.625) 
K. pneumoniae 
mode 2.5 (5) 0.0781 (>0.625) 2.5 (5) 2.5 (2.5) 2.5 (5) 0.625 (1.25) 0.625 (1.25) 0.3125 (0.625) 
P.
 a
er
ug
in
os
a 
NCTC 13359 1.25 (2.5) 0.156 (>0.625) 2.5 (2.5) 1.25 (1.25) 2.5 (5) 1.25 (>2.5) 1.25 (1.25) 1.25 (1.25) 
TWP1 2.5 (10) 0.156 (0.625) 2.5 (5) 1.25 (5) 2.5 (10) 1.25 (>2.5) 1.25 (>1.25) 1.25 (10) 
TWP2 2.5 (>10) 0.156 (0.625) 2.5 (2.5) 1.25 (2.5) 2.5 (10) 0.625 (>2.5) 1.25 (>1.25) 1.25 (5) 
TWP3 2.5 (10) 0.313 (0.625) 2.5 (5) 1.25 (1.25) 2.5 (10) 0.625 (>2.5) 1.25 (>1.25) 1.25 (10) 
TWP4 2.5 (5) 0.156 (0.625) 2.5 (2.5) 0.625 (1.25) 1.25 (>10) 0.625 (>2.5) 1.25 (1.25) 1.25 (10) 
P. aeruginosa 
mode 2.5 (10) 0.156 (0.625) 2.5 (2.5) 1.25 (1.25) 2.5 (10) 0.625 (>2.5) 1.25 (>1.25) 1.25 (10) 
S.
 a
ur
eu
s 
NCTC 12973 2.5 (>10) 0.0781 (0.625) 2.5 (2.5) 2.5 (2.5) 1.25 (>10) 0.313 (2.5) 1.25 (1.25) 0.156 (>0.625) 
OVERALL MODE 2.5 (5) 0.156 (0.625) 2.5 (2.5) 2.5 (2.5) 2.5 (5) 0.625 (2.5) 0.625* (1.25) 0.3125 (0.625) 
Modal values for each species are given in bold. Modal values across all species are given in bold and underlined. Data for Gram-positive S. aureus NCTC 12973 is also 
included. *Modal value across all species could not be determined, the mode for Gram-negatives only is given. (n = 3)
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Fe2+ activity was consistent against E. coli and K. pneumoniae with the modal MIC90s 
and MBCs both being 2.5 mM against every strain (p >0.05) and no variation between 
replicates. S. aureus NCTC 12973 was also susceptible to the same concentration. 
However, the modal MIC90 and MBC of Fe2+ against P. aeruginosa were both statistically  
significantly lower at 1.25 mM (p <0.05), and there was some variation in susceptibility 
between isolates. In particular, the small colony variant (SCV) MDR isolate TWP1 was 
able to survive in higher concentrations of Fe2+ than all other bacterial strains tested, 
resulting in an MBC 5 mM (p <0.05) despite an MIC90 of 1.25 mM. The growth of TWP4 
– another MDR isolate but with normal colony phenotype – was also inhibited by only 
0.625 mM Fe2+ (p <0.05) but the MBC was only one two-fold dilution greater at 1.25 mM. 
There was no variation between the response of K. pneumoniae to Mn2+ with MIC90s and 
MBCs of 2.5 and 5 mM, respectively, for all five strains tested (p >0.05). E. coli strains 
were less susceptible to growth inhibition and the modal MIC90 and MBC were both 5 mM 
Mn2+ but there was no significant difference between isolates or to K. pneumoniae 
(p >0.05). However, interestingly, the E. coli reference strain exhibited greater resistance 
to cidal action than the MDR isolates, resulting in an MIC90 of 2.5 mM but MBC of >10 mM 
(p <0.05). The modal MIC90 and MBC of Mn2+ against P. aeruginosa were 2.5 and 
10 mM, respectively, indicating this species were less susceptible to killing by Mn2+ than 
the others tested. 
P. aeruginosa was also less susceptible to the bactericidal effect of Ni2+ than both E. coli 
and K. pneumoniae (p <0.05). Modal MBCs of Ni2+ were 2.5 and 1.25 mM against E. coli 
and K. pneumoniae, respectively, and >2.5 mM against P. aeruginosa. However, all 
species were similarly susceptible to growth inhibition with modal MIC90s of 0.625 mM 
with no statistically significant difference between them (p >0.05). 
Ten of the 16 bacterial strains tested were found to be killed by the same concentration 
of Pd2+ that produced apparent 90 % inhibition. All MIC90s of Pd2+ against E. coli were 
0.625 mM and modal MBC was also 0.625 mM (p >0.05). K. pneumonia strains were 
overall slightly less susceptible than E. coli, with the MIC90 against two MDR isolates 
being 1.25 mM and a modal MBC of 1.25 mM. The MIC90 against all P. aeruginosa 
strains was 1.25 mM and three MDR isolates were able to survive in the presence of this 
concentration making the MBC >1.25 mM. 
The modal MIC90 and MBC of Zn2+ for E. coli and K. pneumoniae strains were both 0.313 
and 0.625 mM, respectively, with no statistically significant difference between strains 
(p >0.05). P. aeruginosa isolates were less susceptible to Zn2+ compared to both of the 
Enterobacteriaceae (p <0.05) with a modal MIC90 and MBC of 1.25 and 10 mM, 
respectively. 
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Overall, E. coli strains were the most susceptible to metal ions, closely followed by 
K. pneumoniae then P. aeruginosa. However, there were some notable exceptions. The 
variations between both MIC90s and MBCs against the bacterial species as a whole and 
the differences between strains within species likely reflects phenotypic and genetic 
differences which alter susceptibility. 
6.3.2 Activity of sodium fusidate combined with metal ions against Gram-
negative MDR isolates 
Figure 6.1 illustrates the AUC for bacterial growth in the presence of metal ion and FNa 
combinations as a percentage of that with the same concentration range of FNa alone. 
Mn2+, Pd2+ and Zn2+ were not tested in combination with FNa against MDR isolates and 
their reference strains due to suppression previously identified against E. coli NCTC 
10418 or S. aureus NCTC 12973 (see Section 4.3.1). 
Al3+ and Fe2+ were the more effective than Co2+, Cu2+ and Ni2+ at reducing the AUC for 
bacterial growth when combined with FNa against every strain (p <0.05). Co2+ and Ni2+ 
had the least additional antimicrobial effect, and Cu2+ moderately reduced growth. No 
growth AUCs with FNa in the presence of Co2+ or Ni2+ were significantly less than 80 % 
of FNa alone (p >0.05). In fact, in some cases, growth was greater with the metals than 
without. However, the growth-reducing effects of Al3+, Fe2+ and Cu2+ were significant. 
In all but one case, AUCs for growth in the presence of FNa and Al3+ were <20 % those 
of FNa alone (p <0.05). The exception was the E. coli reference strain NCTC 10418 with 
a growth AUC for with Al3+ of 21.8 % of FNa alone. There was no significant difference 
between FNa alone-standardised growth AUCs for FNa with Al3+ against the MDR 
isolates of E. coli (p >0.05) except between the upper and lower values for TWE3 at 
8.3 % and TWE4 at 2.0 %. FNa with Al3+ growth AUCs for K. pneumoniae were all within 
a range of 8.2 to 16.8 % FNa alone. There was no significant difference between the 
MDR isolates, however, growth of the reference strain NCTC 9633 was significantly less 
reduced than three of them (p <0.05). There was no significant difference between 
P. aeruginosa strains (p >0.05) and all FNa with Al3+ growth AUCs were between 0.1 and 
1.0 % FNa alone. 
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Figure 6.1 – AUCs of metal ion-normalised bacterial growth with sodium fusidate in the presence of metal ions 
Data is presented as percentage paired AUC of growth with sodium fusidate alone to allow direct comparison between organisms with variable sodium fusidate 
susceptibility. Metal ion concentrations are 0.25 x modal MIC90: 0.625 mM Al3+, 0.0391 mM Co2+, 0.625 mM Cu2+, 0.625 mM Fe2+ and 0.156 mM Ni2+.  
(n = 3, error bars = 95 % CI)
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A similar pattern was observed for Fe2+. P. aeruginosa growth AUCs for Fe2+ with FNa 
were the overall smallest percentage of growth AUCs with FNa alone, ranging from 0.4 
to 3.4 %. The only significant difference between P. aeruginosa strains was that TWP2 
growth was reduced more than TWP3 (p <0.05). E. coli MDR isolates were similarly 
affected, exhibiting FNa with Fe2+ growth AUCs of 1.1 to 4.5 % FNa alone and no 
significant difference between them (p >0.05). E. coli reference strain NCTC 10418 was 
again less dramatically impacted by the presence of metal than the MDR isolates 
(p <0.05), which may indicate that this isolate is not a good model for population 
behaviour. Interestingly, growth of K. pneumoniae was significantly less reduced by the 
presence of Fe2+ with FNa compared to E. coli and P. aeruginosa (p <0.05). However, 
the growth AUC for FNa with Fe2+ for all MDR isolates was less than 15 % the 
corresponding AUC for FNa alone while that of the reference strain, NCTC 9633, was 
21.9 %. 
While Cu2+ was effective at reducing the FNa growth AUCs for almost all strains, its 
impact was less than that of Al3+ or Fe2+. The growth of E. coli MDR isolates was reduced 
more than almost all the other bacterial strains. FNa with Cu2+ growth AUCs were 
between 30.1 and 34.0 % of FNa alone for TWE2, TWE3 and TWE4 with no significant 
difference between them (p >0.05). TWE1 had an AUC with Cu2+ of 19.4 % and 
NCTC 10418 was 63.8 % FNa alone, both of which were significantly different to the 
other strains and each other (p <0.05). Cu2+ had less influence on K. pneumoniae growth 
with FNa with all AUCs being between 45.7 and 60.9 % FNa alone. Four of the five 
P. aeruginosa strains exhibited similar susceptibility with AUCs of 44.1 to 66.1 % FNa 
alone, except TWP4 which was 95.8 % and not significantly different to FNa alone 
(p >0.05). 
6.3.3 The effect of metal ions on sodium fusidate MIC90s 
The MIC90 of FNa alone and with each metal ion (as sulphate) against all strains tested 
is listed in Table 6.3 along with the FNa FIC90s for the combinations. MDR isolates were 
significantly less susceptible to FNa than the originally tested GN model organism, E. coli 
NCTC 10418, with the modal MIC90 against all being 1280 or 2560 µM (p <0.05).  
In the presence of 0.625 mM Al3+, the MIC90 of FNa against E. coli NCTC 10418 was 
reduced from 320 to 40 µM (p <0.05). The FNa MIC90s against MDR isolates of E. coli 
were reduced from 2560 or 1280 µM to 40 to 160 µM by the inclusion of Al3+ (p <0.05). 
The mean FNa FIC90 against E. coli was 0.0688. While the MIC90 of FNa against 
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K. pneumoniae ranged from 320-2560 µM, the presence of Al3+ reduced it to one eighth 
against every strain tested (p <0.05). Addition of 0.625 mM Al3+, had the largest effect 
on the MIC90 of FNa against P. aeruginosa compared to other species (p <0.05). Alone, 
the MIC90 of FNa was 2560 µM against all strains but in the presence of Al3+, every strain 
of P. aeruginosa was ≥90 % inhibited by 5 µM FNa, the lowest concentration tested. The 
FNa FIC90 was therefore ≤0.00195 against P. aeruginosa. The mean FIC90 of FNa with 
0.625 mM Al3+ against all GN organisms tested was 0.0652. 
Table 6.3 – Sodium fusidate MIC90s (µM) and FIC90s (in parentheses) with metal ions 
Species Strain MIC90 (FIC90) control with Al with Co with Cu with Fe  with Ni 
S. aureus NCTC 12973 0.3125 0.3125 
(1) 
0.15625 
(0.5) 
0.3125 
(1) 
0.15625 
(0.5) 
0.3125 
(1) 
E. coli NCTC 10418 320 40 
(0.125) 
160 
(0.5) 
40 
(0.125) 
40 
(0.125) 
160 
(0.5) 
TWE1 2560 80 
(0.0313) 
2560 
(1) 
320 
(0.125) 
10 
(0.0039) 
2560 
(1) 
TWE2 2560 80 
(0.0313) 
2560 
(1) 
320 
(0.125) 
5 
(0.0020) 
2560 
(1) 
TWE3 1280 160 
(0.125) 
1280 
(1) 
320 
(0.25) 
40 
(0.0313) 
1280  
(1) 
TWE4 1280 40 
(0.0313) 
1280 
(1) 
640 
(0.5) 
20 
(0.0156) 
1280 
(1) 
Species FIC90 mean 
 
0.0688 0.900 0.225 0.0355 0.900 
K. pneumoniae NCTC 9633 640 80 
(0.125) 
640 
(1) 
320 
(0.5) 
80 
(0.125) 
640 
(1) 
TWK1 1280 160 
(0.125) 
1280 
(1) 
640 
(0.5) 
160 
(0.125) 
1280 
(1) 
TWK2 1280 160 
(0.125) 
2560 
(2) 
640 
(0.5) 
160 
(0.125) 
1280  
(1) 
TWK3 2560 320 
(0.125) 
2560 
(1) 
1280 
(0.5) 
160 
(0.0625) 
2560 
(1) 
TWK4 2560 320 
(0.125) 
2560 
(1) 
1280 
(0.5) 
160 
(0.0625) 
2560 
(1) 
Species FIC90 mean 
 
0.125 1.20 0.500 0.100 1.00 
P. aeruginosa NCTC 13359 2560 5 
(0.0020) 
1280 
(0.5) 
640 
(0.25) 
5 
(0.0020) 
1280 
(0.5) 
TWP1 2560 5 
(0.0020) 
2560 
(1) 
1280 
(0.5) 
0 
(N/A) 
2560 
(1) 
TWP2 2560 5 
(0.0020) 
2560 
(1) 
1280 
(0.5) 
5 
(0.0020) 
1280 
(0.5) 
TWP3 2560 5 
(0.0020) 
2560 
(1) 
1280 
(0.5) 
5 
(0.0020) 
1280 
(0.5) 
TWP4 2560 5 
(0.0020) 
2560 
(1) 
1280 
(0.5) 
0 
(N/A) 
2560 
(1) 
Species FIC90 mean 
 
0.00195 0.900 0.450 0.00195 0.700 
Mean Gram-negative FIC90 0.0652 1.00 0.392 0.0526 0.867 
Metal ion concentrations are 0.25 x modal MIC90: 0.625 mM Al3+, 0.0391 mM Co2+,  
0.625 mM Cu2+, 0.625 mM Fe2+ and 0.156 mM Ni2+. (n = 3) 
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Overall, Co2+ did not reduce the FNa MIC90 against GN organisms (p >0.05). The 
exceptions were the model organism E. coli NCTC 10418 and P. aeruginosa reference 
strain NCTC 13359 – the presence of 0.039 mM Co2+ halved the modal FNa MIC90 
against both. Conversely, the MIC90 of FNa against K. pneumoniae TWK2 was doubled 
by the presence of Co2+. However, these effects were not statistically significant 
(p >0.05). The mean FIC90s of FNa with Co2+ were 0.9, 1.2 and 0.9 against E. coli, 
K. pneumoniae and P. aeruginosa, respectively. 
FNa MIC90s against E. coli in the presence of 0.625 mM Cu2+ were reduced to between 
40 and 320 µM, with corresponding FIC90s ranging from 0.125 to 0.5. The most resistant 
E. coli strain was the MDR isolate TWE4 with an FIC90 of 0.5 which was significantly 
different to the reference strain (p <0.05), while the FIC90 against TWE3 was 0.25 and 
0.125 against all other strains. The MIC90 of FNa was halved against MDR isolates of 
K. pneumoniae and P. aeruginosa by Cu2+. The FNa FIC90 against K. pneumoniae 
reference strain NCTC 9633 was also halved, however, while not statistically significant, 
the P. aeruginosa reference strain NCTC 13359 was slightly more susceptible to the 
combination with an FIC90 of 0.25 (p >0.05). The susceptibility of E. coli isolates to FNa 
was increased more by the presence of Cu2+ than against either K. pneumoniae or 
P. aeruginosa (p >0.05). The mean GN FNa FIC90 with Cu2+ was 0.392. 
Fe2+ was also very effective at reducing the FNa MIC90 against P. aeruginosa, producing 
a mean FIC90 of ≤0.00195, the same as Al3+. However, two strains of P. aeruginosa were 
omitted from the analysis as the 0.625 mM Fe2+ used was ≥90 % inhibitory to them. The 
mean FNa FIC90 against both E. coli and K. pneumoniae with Fe2+ were both lower than 
for any other metal at 0.0355 and 0.100, respectively (p <0.05), however, these were 
significantly greater than the FIC90 against P. aeruginosa (p <0.05). Interestingly, the 
MIC90 of FNa against E. coli reference strain NCTC 10418 was significantly less affected 
by the presence of Fe2+ compared to the MDR E. coli isolates (p <0.05). The overall 
mean FNa FIC90 with 0.625 mM Fe2+ against GNs was 0.0526. 
The presence of 0.156 mM Ni2+ did not have a significant impact on the FNa MIC90 
against GN organisms (p >0.05). While the modal MIC90 of FNa against the model 
organism E. coli NCTC 10418 and three P. aeruginosa strains: NCTC 13359, TWP2 and 
TWP3 were halved by its presence, these were not statistically significant (p >0.05) and 
there was no change against any other strain tested. The mean FIC90s in the presence 
of Ni2+ were 0.9, 1.0 and 0.7 against E. coli, K. pneumoniae and P. aeruginosa, 
respectively.  
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Figure 6.2 – Fold reduction in sodium fusidate MIC90 when in the presence of metal ions 
Metal ion were each present at 0.25 x their modal MIC90: 0.625 mM Al3+, 0.039 mM Co2+, 
0.625 mM Cu2+, 0.625 mM Fe2+ and 0.156 mM Ni2+. Greater fold reduction in sodium fusidate 
MIC90 indicates increased inhibition when combined with metal ion.  
(n = 3, y axis = log2 scale) 
Figure 6.2 illustrates the fold reduction in FNa MIC90 when combined with metal ions 
against each bacterial strain for visual comparison. Al3+ reduced the FNa MIC90 by ≥8-fold 
against all GN strains, while having no negative impact on S. aureus FNa susceptibility. 
Fe2+ also reduced the FNa MIC90 against GNs by ≥8-fold while the MIC90 against 
S. aureus was halved by its presence. While Cu2+ was not as effective as Al3+ or Fe2+, it 
consistently reduced the MIC90 of FNa by 2 to 8-fold against all GNs tested and had no 
negative effect on activity of FNa against S. aureus. Co2+and Ni2+ had no impact on the 
FNa MIC90 against the majority of bacterial strains. There was a two-fold reduction in 
FNa MIC90 against E. coli NCTC 10418, and three P. aeruginosa strains: NCTC 13359, 
TWP2 and TWP3 when in the presence of Ni2+. The same reduction was found against 
E. coli NCTC 10418 and P. aeruginosa NCTC 13359 with Co2+. However, the presence 
of Co2+ also doubled the FNa MIC90 against K. pneumoniae TWK2. 
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6.4 Discussion 
6.4.1 Activity of metal ions alone 
While literature values for other species could not be found, reported Al3+ MICs against 
E. coli varied from 0.5 mM in minimal media to 3 mM in Lennox lysogeny broth (LLB)[300]. 
The latter agreed quite well with the MIC90 of 2.5 mM Al3+ found in NB against all but two 
bacterial strains tested in this work (Table 6.2, page 167). Despite little variation in Al3+ 
MIC90 between species and isolates, the MBC ranged from 2.5 to 5 mM against the 
Enterobacteriaceae but 2.5 to >10 mM against P. aeruginosa. While all within one two-
fold dilution of one another, the observed MBCs against E. coli and K. pneumoniae in 
NB were lower than the reported values of both 7 and 11 mM against E. coli in minimal 
media and LLB, respectively[300]. As previously discussed, the composition of 
bacteriological growth media can have a substantial impact on antimicrobial activity due 
to factors such as bacterial metabolism or phenotypic changes (Chapter 3) and agent 
solubility (Chapter 5). The inconsistencies between employed growth medium may, 
therefore, explain the difference between reported and observed MBC values. 
Conversely, the differences in Al3+ MBC against P. aeruginosa cannot be attributed to 
differences in culture medium and may be a result of phenotypic or genetic variation 
between strains. As mentioned in Section 6.1, P. aeruginosa lacks large general porins 
in its OM and instead relies on small substrate-specific membrane channels which 
increase membrane stability and reduce permeability compared to the 
Enterobacteriaceae. It is conceivable that differences in the number or type of membrane 
channels between P. aeruginosa strains would result in differences in OM stability and 
consequently Al3+ susceptibility. In addition, the structure of lipid A – a known Al3+ 
target[318],[319] – differs between the Enterobacteriaceae and P. aeruginosa. While the 
majority of lipid A of both E. coli[459] and K. pneumoniae[460] is acylated with six fatty acids 
of C12-C14, a penta-acylated form with shorter C10-C12 fatty acids generally 
predominates alongside both hexa- and hepta-acylated lipid A in P. aeruginosa[461]. 
However, all three bacterial species possess the ability to add positively charged 
residues such as 4-aminoarabinose to their lipid A in order to decrease their susceptibility 
to cations which would otherwise displace Ca2+ and Mg2+ from between LPS molecules 
and compromise membrane structure[71]. The PmrA/PmrB pathway responsible for this 
modification has been shown to be induced by and mediate resistance to Al3+ exposure 
in Salmonella[462]. The observed variation in survival of these few P. aeruginosa strains 
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may be due differences in combinations of lipid A forms and the consequent differences 
in the charge-modification effects of aminoarabinose addition. 
The MIC90 of Co2+ determined in NB against E. coli was 0.156 or 0.313 mM for all five 
strains investigated (Table 6.2, page 167) which was considerably lower than reported 
values of 1[301] and >134.5[463] mM in various rich media. Again, since the experimental 
values were within one two-fold dilution of one another, the difference to those reported 
is likely due to the different metabolic and solution chemistry effects of the varied growth 
media. Similarly, Co2+ MIC90s against the five K. pneumoniae strains were found to be 
0.078 or 0.156 mM in NB while an MIC of >134.5[463] mM has been reported in a variety 
of rich media. Interestingly, the same authors[463] also found a Co2+ MIC of >134.5 mM 
against P. aeruginosa in the various media employed, while 0.2 mM was demonstrated 
to produce approximately 85 % growth inhibition in NB[464], illustrating the effects of 
growth medium on antimicrobial activity. In addition, this value[464] is almost identical to 
the modal Co2+ MIC90 of 0.156 mM found against P. aeruginosa in NB in this work. 
Reported Cu2+ MICs against E. coli ranged from 4[301] or 5[271] mM in LB to 10 mM in 
MHB[307]. These values agree closely with Cu2+ MIC90s determined in LB and CAMHB 
during chequerboard incubation (see Chapter 3, Section 3.3.1, page 63). The present 
tests in NB yielded a modal MIC90 of 1.25 mM (Table 6.2, page 167), however, no reports 
of MIC determination in the same broth could be identified in the literature. Interestingly, 
Vaidya and colleagues[380] found a Cu2+ MIC of 0.25 mM against K. pneumoniae 
NCTC 9633 in NB which was only one twentieth of the 5 mM MIC90 found against the 
same strain in the same broth in this work. However, this difference may be due to 
differing assay techniques. Vaidya et al.[380] employed triphenyl tetrazolium chloride 
(TTC) as a colorimetric indicator of bacterial growth by adding 0.15 % w/v (1.5 mg mL-1) 
to the assay plate prior to the initiation of incubation. However, the early authors of this 
method[465] determined that 0.09 and 0.10 mg mL-1 TTC inhibited the growth of E. coli 
and S. aureus, respectively, when used in this way. Therefore, it is likely that 
K. pneumoniae growth was partially inhibited by the presence of 1.5 mg mL-1 TTC and, 
while the assay employed by Vaidya et al.[380] enabled comparison between metal ion 
activities in the same system, the results do not appear to be comparable to TTC-free 
conditions. Finally, a reported Cu2+ MIC of 1.2 mM against P. aeruginosa in NB[464] was 
approximately one two-fold dilution lower than the 2.5 mM MIC90 found against all five of 
the strains tested in this work. 
No Fe2+ MICs against K. pneumoniae or P. aeruginosa were identified in the literature. 
However, the reported MICs of Fe2+ against E. coli in minimal medium and LLB were 2 
and 5 mM, respectively[300]. While a different growth medium was employed, the Fe2+ 
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MIC90 in NB determined against all E. coli and K. pneumoniae strains in this work agreed 
with reported values at 2.5 mM (Table 6.2, page 167). Fe2+ exhibited a lower MIC90 
against P. aeruginosa strains of 0.625 or 1.25 mM, likely due to differences in the 
P. aeruginosa membrane structure compared to the Enterobacteriaceae. However, in 
contrast to the apparently protective effect of these differences on Al3+ exposure, 
P. aeruginosa was more vulnerable to inhibition by Fe2+ than E. coli or K. pneumoniae. 
As discussed in Chapter 4 (see Section 4.1.1.478, page 78), one of the major 
mechanisms of Fe antimicrobial activity is ROS generation via Fenton reactivity[336]. This 
is also a mechanism not associated with Al3+ due to its single oxidation state. In addition, 
P. aeruginosa may be more sensitive to ROS DNA damage due to its comparatively high 
guanine-cytosine (GC) content. Guanine has the lowest oxidation potential of the 
nucleotides, making it particularly susceptible to ROS attack[466]. Example genomes for 
P. aeruginosa, K. pneumoniae and E. coli indicate 66[467], 57[468] and 51[469] %, 
respectively, of these organisms’ DNA is GC. Furthermore, the presence of large general 
porins in the Enterobacteriaceae may serve as a sink for some Fe-generated ROS in the 
periplasm, thereby delaying the onset of membrane damage compared to P. aeruginosa. 
Finally, direct oxidative damage by Fe2+ may compromise the structure and function of 
P. aeruginosa’s small substrate-specific OM channels which are relied upon for both 
nutrient uptake and membrane stability. Compared to the Enterobacteriaceae which can 
internalise a wide variety of nutrients via their large general porins, this could more 
readily resulting in starvation as well as loss of OM integrity. 
The only reported MIC of Mn2+ was 20 mM against E. coli in a TRIS-buffered minimal 
salts medium with gluconate as carbon source[306]. While, Mn2+ exerted similar inhibitory 
activity across all bacterial strains tested in this work (Table 6.2, page 167), the modal 
MIC90 found was only 2.5 mM, further illustrating the impact of growth medium on 
responses to antimicrobial substances. Three of the E. coli isolates were slightly less 
susceptible than the other bacterial strains by a difference of one two-fold dilution with 
MIC90s of 2.5 and 5 mM. These variations could be due to genetic factors such as 
additional copies of genes encoding proteins targeted by Mn2+ or phenotypic differences 
in Mn2+ uptake, altering the rate of internalisation. 
The modal Ni2+ MIC90 across all strains was 0.625 mM. E. coli MDR isolates were the 
most variable in their susceptibility, with values of 1.25 and 2.5 mM against TWE1 and 
TWE4, respectively. The latter agreed closely with the reported Ni2+ MIC of 2 mM in 
LB[301]. Interestingly, the MIC of NI2+ was reported to be 0.60 mM in a minimal medium 
and 17 mM in LB against P. aeruginosa[470]. While the value in LB is more than 25 times 
the Ni2+ MIC90 observed against P. aeruginosa in NB, the reported activity in minimal 
media was very similar. 
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Reported values for the MIC of Pd2+ against E. coli varied from 0.015 mM in minimal 
medium[304] to 2.82 mM in LB[305]. However, the Pd2+ MIC90 in NB was determined to fall 
between these values at 0.625 mM (Table 6.2, page 167). The MIC of Pd2+ against 
P. aeruginosa in LB from the literature was only marginally higher than that found in NB 
at 1.94[305] compared to 1.25 mM, respectively. Finally, Vaidya and colleagues[380] found 
an MIC of 0.055 mM against K. pneumoniae using the TTC-based assay described 
above. This value was less than one tenth the modal Pd2+ MIC90 against K. pneumoniae 
strains, likely due to the same limitations discussed previously. 
Literature values for the MIC of Zn2+ against E. coli in LB and CAMHB were 6 and 12 
times the modal MIC90 in NB at 2[301] and 3.73[303] mM, respectively. No Zn2+ MICs against 
K. pneumoniae were identified in the literature, however, the modal MIC90 in NB was the 
same as against E. coli at 0.313 mM (Table 6.2, page 167). The reported MICs of Zn2+ 
against P. aeruginosa in LB and CAMHB were both ~60 times that determined in NB at 
78[470] and 73.74[303] mM, respectively. However, the Zn2+ MIC90 of 1.25 mM found in this 
work corresponded closely to the MIC of 1.5 mM reported against P. aeruginosa in NB 
elsewhere[464]. 
Overall, metal ions were similarly effective against MDR isolates and reference strains. 
There was no correlation between antimicrobial resistance and metal ion susceptibility, 
despite previous reports of co-localisation of metal and drug resistance 
determinants[307],[471]. While there were some differences in response to metal ions 
between species, individual strain MIC90s were never more than two two-fold dilutions 
apart, and modal species MIC90s differed by no more than one two-fold dilution. Only 
metals that had not been found to antagonise the activity of FNa against E. coli NCTC 
10418 or S. aureus NCTC 12973 (Chapter 4) – Al3+, Co2+, Cu2+, Fe2+ and Ni2+ – were 
tested against the additional GN strains in combination with FNa. 
6.4.2 Combined activity of sodium fusidate and metal ions 
As with metal ions alone, there was also no correlation between resistance to any 
antimicrobial class and susceptibility to FNa combined with various metal ions. At a 
concentration of 0.25 x their respective modal MIC90, Co2+ and Ni2+ were largely 
ineffective at increasing FNa activity against GN bacteria. The presence of neither metal 
reduced the growth AUC by more than 20 % (Figure 6.1, page 170) or the FNa MIC90 by 
more than two-fold (Figure 6.2, page 174). As discussed in Chapter 4, both metals have 
similar antimicrobial targets and are micronutrients managed by the same homeostasis 
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systems (see Section 4.4.1.2, page 97), and their antimicrobial effects do not appear to 
enhance bacterial susceptibility to FNa.  
The presence of 0.625 mM Cu2+ significantly enhanced FNa activity against all strains, 
however, the fold changes in FNa MIC90s were significantly less than with Fe2+ or Al3+. 
E. coli MDR isolates were the most susceptible to the combination of FNa and Cu2+, 
which was most likely because the concentration of Cu2+ employed was 50 % the modal 
MIC90 compared to 25 % for other species. There was no significant difference between 
the response of K. pneumoniae and P. aeruginosa strains to FNa in the presence of Cu2+ 
(p >0.05, Figure 6.1 and Figure 6.2). A difference might have been expected since 
increased membrane permeation due to reduced FNa solubility has been identified as a 
probable mediator of combined antimicrobial efficacy against E. coli (Chapter 5), and the 
difference in structure of the P. aeruginosa and Enterobacteriaceae OM is known to 
impact permeability. This may indicate that, despite decreased permeability to a wide 
range of substances, the P. aeruginosa OM presents no more of a barrier to low solubility 
FNa than that of E. coli or K. pneumoniae. While the presence of Fe2+ enhanced FNa 
activity against P. aeruginosa strains more than E. coli or K. pneumoniae, this was likely 
due to the metal ions concentration being 50-100 % the MIC90 compared to 25 % against 
both the other species. However, P. aeruginosa strains were significantly more 
susceptible to FNa in the presence of Al3+ than either E. coli or K. pneumoniae. All five 
P. aeruginosa strains were completely inhibited by 5 mM FNa when combined with 
0.625 mM Al3+. This was unexpected. A possible explanation could lie in the structure of 
P. aeruginosa LPS. Al3+ alone was not enough to perturb P. aeruginosa growth any more 
than that of the Enterobacteriaceae. However, Al3+ interaction with P. aeruginosa LPS 
may result in specific structural changes that more readily allow FNa entry than 
compared to Al-bound E. coli or K. pneumoniae LPS. Alternatively, Al3+ may act on an 
unidentified target present in P. aeruginosa but not the Enterobacteriaceae. The 
antimicrobial activity and mechanism of Al3+ has not been extensively studied and was 
beyond the scope of this work, however, investigation into this combined activity would 
be worthy of further study. 
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6.5 Conclusions 
Conclusions drawn from the work in this Chapter can be summarised as follows: 
1) Antimicrobial metal ions Al3+, Co2+, Cu2+, Fe2+, Mn2+, Ni2+, Pd2+ and Zn2+ exhibit 
similar activity against E. coli, K. pneumoniae and P. aeruginosa reference 
strains and MDR isolates. 
2) Co2+ and Ni2+ do not enhance the activity of FNa against intrinsically resistant 
E. coli, K. pneumoniae and P. aeruginosa reference strains and MDR isolates. 
3) Al3+, Cu2+ and Fe2+ enhanced the activity of FNa against intrinsically resistant 
E. coli, K. pneumoniae and P. aeruginosa reference strains and MDR isolates. 
4) The combination of FNa and Al3+ proved to be particularly effective against 
strains of P. aeruginosa.
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Chapter 7: Effect of sodium fusidate and 
metal ions on human corneal 
epithelial cell survival and 
proliferation 
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7.1 Introduction 
In vitro testing of novel drugs, excipients and formulations against cultured mammalian 
cells can enable early detection of potential toxicity, even before initiation of pre-clinical 
animal studies[472]. Selection of the cell type to be employed depends on the intended 
application site and route of administration. For example, since the liver is a major site 
of toxicological effects after systemic administration due to first pass metabolism, 
hepatocyte cell lines such as HepG2[473] are challenged with drugs in development for 
oral use. On the other hand, agents intended for topical use on the skin are commonly 
tested against an established spontaneously transformed immortal human keratinocyte 
cell line known as HaCaT[474]. The response of appropriately selected cell lines to 
potential topical therapies while grown in vitro can be used to determine indicative locally 
tolerable drug concentrations and those likely to cause toxicity[475],[476]. Tests for 
cytotoxicity and proliferation are used to determine whether the applied agent kills or 
modifies growth of mammalian cells, respectively. Cytotoxicity tests include the lactate 
dehydrogenase (LDH) assay which quantifies the proportion of a treated cell population 
that have died based on the release of usually intracellular LDH[477]. Conversely, cell 
proliferation tests such as those employing 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT)[472] or neutral red[478] quantify numbers of still 
metabolically active cells by measuring production of coloured degradation products in 
the mitochondria or internalisation of dye into lysosomes, respectively.  
Table 7.1 – Mammalian cell proliferation inhibition data from the literature  
Agent Cell type Exposure 
duration (h) 
IC50 (mM) 
FNa primary human hepatocytes 48 0.236[479] 
Al3+ primary rat astrocytes 72 0.343[480] 
Cu2+ human skin-derived cells 
rat skin derived-cells 
primary rat hepatocytes 
mouse embryo fibroblasts (3T3) 
primary human hepatocytes 
human hepatocytes (HepG2) 
24 
24 
24 
24 
24 
24 
0.29[481] 
0.25[481] 
0.268[482] 
0.444[482] 
0.969[482] 
1.716[482] 
Fe2+ mouse embryo fibroblasts (3T3) 
primary human hepatocytes 
primary rat hepatocytes 
24 
24 
24 
6.13[483] 
6.40[483] 
8.81[483] 
 
In this work, the LDH and MTT assays were chosen for use in combination in order to 
generate a more detailed understanding of the nature and degree of any negative effects 
183 
on cell viability. Based on the antimicrobial activity presented in Chapter 6, Al3+, Cu2+ and 
Fe2+ were selected for testing against an immortalised human corneal epithelial cell line 
with and without FNa. Published data for the effects of Al3+, Cu2+, Fe2+ and FNa on 
mammalian cell proliferation are listed in Table 7.1. 
It is apparent that the degree of proliferation inhibition can vary between species and cell 
type. For example, the IC50 of Cu2+ against primary rat and human hepatocytes is 0.268 
and 0.969 mM, respectively[482], while it is 0.29 mM against human skin-derived cells[481]. 
No published data on the effects of these metal ions or FNa on any eye-derived cell lines 
was identified. Therefore, the effects of Al3+, Cu2+, Fe2+ and FNa alone and in 
combination on the proliferation and survival of human corneal epithelial cells was 
investigated. 
7.1.1 Aim and objectives 
Aim: to determine whether FNa combined with metal ions may be suitable for further 
investigation as a treatment option in clinical bacterial keratitis based on the susceptibility 
of human corneal epithelial cells. 
Objectives: 
1) To determine inhibitory and cytotoxic activity of Al3+, Cu2+, Fe2+ and FNa 
individually against human corneal epithelial cells. 
2) To determine inhibitory and cytotoxic activity of FNa combined with Al3+, Cu2+ 
or Fe2+ against human corneal epithelial cells. 
3) To compare activity of Al3+, Cu2+ and Fe2+ each combined with FNa against 
human corneal epithelial cells and GN bacterial reference strains. 
4) To identify the FNa and metal ion combination with highest selectivity index 
and therefore best potential for clinical use. 
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7.2 Methods 
7.2.1 Cell line and standard culture conditions 
Human corneal epithelial cells immortalised with an Adenovirus 12-SV40 hybrid virus 
(HCE-2 [50.B1] ATCC® CRL-11135) were purchased from the American Type Culture 
Collection (ATCC) via LGC Standards (Teddington, UK) and received at passage 
number 26. Culture conditions for HCE-2 were per the manufacturer's instructions, as 
follows. 
A mixture of 0.01 mg mL-1 BSA, 0.01 mg mL-1 fibronectin and 0.03 mg mL-1 collagen was 
prepared in sterile PBS and used to coat Nunclon™ Delta treated polystyrene flasks and 
plates (Nunc/Thermo Scientific, Roskilde, Denmark). A stock solution of 1 mg mL-1 
bovine serum albumin (BSA) (Fisher Scientific, Loughborough, UK) was prepared in 
HPLC grade water and filter sterilised. Human fibronectin purchased from Roche 
Diagnostics (Mannheim, Germany) had been 0.2 µm filtered prior to lyophilisation and 
was suspended in sterile HPLC to make a 1 mg mL-1 stock solution. Aliquots of BSA and 
fibronectin were frozen at -20 °C for later use. Bovine collagen type I 5 mg mL-1 stock 
solution (Gibco, Paisley, UK) was stored at 4 °C and used as received. A minimal volume 
of 1.5 mL for 25 cm2 culture flasks and 30 μL per well for flat-bottomed 96 well plates 
was added to plasticware which was gently rocked to ensure surface coverage, sealed 
with plastic to prevent evaporation and incubated at 37 °C for 2 to 24 h. Coated flasks 
and plates were stored at 4 °C for up to 1 month and the coating mixture aspirated 15 min 
prior to use. 
Cells were grown on the coated polystyrene in keratinocyte serum-free medium (KSFM) 
(Gibco, Paisley, UK) supplemented with 0.05 mg mL-1 bovine pituitary extract (BPE) and 
5 ng mL-1 epidermal growth factor (EGF) as supplied, along with 0.005 mg mL-1 
recombinant human insulin (4 mg mL-1 stock solution, Gibco, Paisley, UK) and 
500 ng mL-1 hydrocortisone (96 µg mL-1 stock solution, Stemcell Technologies, 
Cambridge, UK) at 37 °C in humidified air with 5 % CO2. Growth medium was replaced 
twice per week and always warmed and equilibrated to 37 °C and 5 % CO2 for at least 
30 min prior to use to ensure correct pH and temperature was reached. Under these 
conditions, HCE-2 grew to 80-90 % confluence in 3-5 days, totalling approximately 
1 x 106 cells per 25 cm2 culture flask, at which point subcultivation was performed at a 
ratio of 1:3. The medium was removed and the cell layer rinsed twice with sterile PBS 
before adding 2 mL TrypLE™ Express dissociation reagent (Gibco, Paisley, UK). 
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TrypLE™ Express is a recombinant fungal trypsin-like protease and was selected in 
place of the more traditionally used animal trypsin due to its increased specificity, room 
temperature stability and inactivation by dilution rather than addition of an enzyme 
inhibitor[484]. Cells were incubated with TrypLE™ Express at room temperature for 15 min 
until detachment could be confirmed using a light microscope. The dissociation enzyme 
was neutralised using two volumes of warmed supplemented KSFM and the resulting 
cell suspension centrifuged for 8 min at 130 x g in a VWR Mega Star 600 centrifuge. 
After discarding the supernatant, cells were resuspended in 15 mL fresh warmed 
supplemented KSFM and seeded into 3 coated 25 cm2 culture flasks, 5 mL per flask. 
7.2.2 Preparation, storage and recovery of frozen cell stocks 
HCE-2 cells at 80-90 % confluence in 25 cm2 culture flasks were harvested using 
TrypLE™ Express, rinsed in supplemented KSFM and pelleted as described above. The 
whole population from one 25 cm2 culture flask (approximately 1 x 106 cells) was 
resuspended in 1 mL freezing medium composed of 85 % supplemented KSFM, 10 % 
foetal bovine serum (Gibco, Paisley, UK) and 5 % dimethyl sulfoxide (DMSO), ≥99% (MP 
Biomedicals, Solon, OH, USA) and transferred to a labelled cryovial. Cryovial stocks 
were cooled to -80 °C at a rate of 1 °C min-1 using a Mr Frosty™ Freezing Container 
(Fisher Scientific, Loughborough, UK) then transferred to the vapour phase of liquid 
nitrogen. 
Frozen stocks were thawed rapidly, rinsed with 15 mL warmed supplemented KSFM and 
centrifuged for 8 min at 130 x g. The collected cells were resuspended in fresh warmed 
supplemented KSFM, enumerated and seeded into coated culture vessels at 
approximately 1 x 104 cells per cm2. Post-freeze viability was approximately 60 %. 
7.2.3 Combined LDH and MTT assay procedure 
LDH and MTT assays were co-optimised to enable performance of both tests 
simultaneously using the same cell populations (see Appendix E). 
Coated flat-bottomed polystyrene 96 well plates were seeded with 8,000 HCE-2 in 
100 μL supplemented KSFM in wells B2 to D10. Supplemented KSFM was added to 
wells E2 to G10 and KSFM without bovine pituitary extract (BPE) was added to B11 to 
G11 serve as cell free controls (Figure 7.1A). Since tissue extracts can contain LDH[485], 
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a BPE-free control was included in order to determine any background activity 
attributable to its presence. Finally, wells in rows A and H and columns 1 and 12 were 
filled with 100 μL sterile PBS to maintain humidity and prevent evaporation. Prepared 
plates were incubated at 37 °C and 5 % CO2 in humidified air for 24 h. 
Exposure to test agents was initiated by adding 10 μL stock solution to three wells 
containing HCE-2 and three cell-free wells per concentration. The same volume of sterile 
HPLC grade water was added to the treatment-free control wells B8-G8 (Figure 7.1B). 
Lysis buffer from a Pierce™ LDH Cytotoxicity Assay Kit (Thermo Scientific, 
Loughborough, UK) x 10 μL was also added to wells B9 to G9 as a positive control for 
complete cytotoxicity to total cells at the point of exposure initiation. Plates were returned 
to the incubator for the 18 h exposure period. 
 
Figure 7.1 - Layout of 96 well plates for LDH and MTT assays 
An individual 96 well plate served as one replicate for 6 test agent concentrations or 
combinations with controls and internal technical triplication. 
The LDH assay was carried out per the manufacturer's instructions with minor 
modifications using the Pierce™ LDH Cytotoxicity Assay Kit and the MTT assay 
procedure was optimised based on reported protocols (see Appendix E). Both assays 
were carried out simultaneously, as follows: 
Aliquots of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Tocris 
Bioscience Bio-Techne, Bristol, UK) stock solution previously prepared in PBS and 
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frozen at -20 °C were thawed while protected from light. MTT stock solution was diluted 
in an uncoated 25 cm2 culture flask (with a filter lid) 1/5 with supplemented KSFM to a 
final concentration of 1 mg mL-1 and placed in the incubator to warm and equilibrate with 
5 % CO2 for 30-45 min before use. The LDH reaction mixture was prepared by dissolving 
one vial of Pierce™ substrate mix in 11.4 mL sterile HPLC grade water and adding one 
vial of Pierce™ assay buffer. Unused reaction mixture was stored at -20 °C for up to 
4 weeks with a maximum of 3 freeze/thaw cycles. 
After the 18 h test agent exposure duration, 10 μL Pierce™ lysis buffer was added to the 
maximum LDH activity (B10-D10), supplemented medium LDH activity (E10-G10) and 
BPE-free medium LDH activity (B11-D11) controls and the plate incubated at 37 °C and 
5 % CO2 for 45 min. A 50 μL aliquot of medium was transferred from each well to a fresh, 
uncoated, flat-bottomed 96 well plate for onward LDH assay processing. The remaining 
medium was aspirated from wells B2 to G9, carefully avoiding disturbance of the cell 
layer, and replaced with 100 μL warmed MTT dilution in supplemented KSFM. Following 
addition of the MTT reagent, plates were wrapped in aluminium foil to protect from light 
and returned to 37 °C and 5 % CO2 for 2 h[486],[487]. 
Meanwhile, Pierce™ LDH reaction mixture (50 μL) was added to and gently mixed with 
the contents of each well in the LDH assay plate, followed by incubation at room 
temperature for 30 min, protected from light. At the end of the reaction period, 50 μL 
Pierce™ stop solution was gently mixed into each well. LDH assay plates were 
centrifuged at 4000 rpm for 15 min at 25 °C in a Thermo Scientific Heraeus Megafuge 
40R fitted with well plate carriers in order to disperse bubbles. Any remaining bubbles 
were removed using a hot syringe needle. Plates were shaken orbitally for 10 s at 6 mm 
and the absorbance in each well was read at a measurement wavelength of 490 nm and 
reference wavelength of 680 nm with a Tecan Infinite M200 PRO microplate reader 
(wavelength accuracy ±1.5 nm[283]). 
After the 2 h incubation period, MTT-containing medium was removed from each well of 
the MTT assay plate and replaced with 100 μL DMSO, with gentle mixing. Plates were 
incubated at room temperature for 30 min, protected from light. The Tecan Infinite M200 
PRO microplate reader was used to measure absorbance in each well at 506 nm, the 
λmax for MTT formazan product solubilised in 100 % DMSO[472], preceded by 10 s orbital 
shaking at 6 mm. 
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7.2.4 Test concentrations and combinations 
LDH and MTT assays were initially performed with twofold serial dilutions of Al2(SO4)3, 
CuSO4, FeSO4 or FNa. The equivalent concentrations of EtOH to those present in the 
FNa dilutions were also tested to determine any background activity attributable to its 
presence. Concentration ranges were selected to reflect those previously used against 
bacteria (see Section 4.2.1, page 84) and are summarised in Table 7.2. 
Table 7.2 – Concentration range of each agent tested alone for cytotoxicity and 
proliferation effects on HCE-2 
Test agent Minimum concentration Maximum concentration 
Aluminium (as sulphate) 312.5 μM 10 mM 
Copper(II) sulphate 156.25 μM 5 mM 
Iron(II) sulphate 312.5 μM 10 mM 
Sodium fusidate 40 μM 1280 μM 
Ethanol 0.039 % v/v 1.25 % v/v 
 
Metal sulphates were found to interfere with the LDH reaction. The generation of 
coloured formazan product was not apparent despite evidence of complete cell death on 
direct observation using a light microscope and indicated by MTT assay results. The 
addition of EDTA at the end of the exposure period was investigated as a means to bind 
metal ions in order to prevent interaction with the LDH pathway but was found to be 
unsuccessful. Effects of metal sulphates on HCE-2 growth were therefore quantified only 
using the MTT assay. 
The MTT results were compared to bacteriology data and a concentration of 0.625 mM 
of each metal selected for testing against HCE-2 in combination with a range of FNa 
concentrations. In order to perform combined agent tests, double concentration stock 
solutions were prepared and only 5 μL of each added to the test wells so that the total 
addition volume was still 10 μL and the medium dilution factor equal to that when single 
agents were tested. Only the MTT assay was used to quantify effects of FNa with metals. 
Each individual agent and combination was tested in triplicate using three different 
HCE-2 passage numbers between 30 and 36. 
189 
7.2.5 Data processing 
7.2.5.1 Cytotoxicity 
Analysis of the LDH assay results was performed per the kit manufacturer's instructions. 
Raw data was background corrected before determining LDH activity by subtracting 
absorbance at 680 nm from absorbance at 490 nm for each well. Values were then 
adjusted for spontaneous LDH activity by subtracting the background corrected 
absorbance of the untreated control from each well. Mean values for each technical 
triplicate were calculated. Finally, cytotoxicity of each concentration of each test agent 
was calculated as percentage of maximal LDH activity from cells lysed at the point of 
treatment initiation using the following formula: 
% 𝑐𝑐𝑐𝑐𝑖𝑖𝑝𝑝𝑖𝑖𝑝𝑝𝑖𝑖𝑐𝑐𝑖𝑖𝑐𝑐𝑖𝑖𝑝𝑝𝑐𝑐 = [𝐿𝐿𝐿𝐿𝐿𝐿 𝑝𝑝𝑐𝑐𝑝𝑝𝑖𝑖𝑎𝑎𝑖𝑖𝑝𝑝𝑐𝑐 𝑓𝑓𝑝𝑝𝑖𝑖𝑐𝑐 𝑝𝑝𝑝𝑝𝑝𝑝𝑛𝑛𝑝𝑝 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑑𝑑 𝑐𝑐𝑝𝑝𝑎𝑎𝑎𝑎𝑠𝑠][𝐿𝐿𝐿𝐿𝐿𝐿 𝑝𝑝𝑐𝑐𝑝𝑝𝑖𝑖𝑎𝑎𝑖𝑖𝑝𝑝𝑐𝑐 𝑓𝑓𝑝𝑝𝑖𝑖𝑐𝑐 𝑐𝑐𝑝𝑝𝑎𝑎𝑎𝑎𝑠𝑠 𝑎𝑎𝑐𝑐𝑠𝑠𝑝𝑝𝑑𝑑 𝑝𝑝𝑝𝑝 𝑝𝑝𝑐𝑐𝑝𝑝𝑖𝑖𝑠𝑠𝑒𝑒𝑝𝑝𝑝𝑝 𝑖𝑖𝑛𝑛𝑖𝑖𝑝𝑝𝑖𝑖𝑝𝑝𝑝𝑝𝑖𝑖𝑖𝑖𝑛𝑛]   × 100 
Lysis at the point of exposure initiation was selected for use in the analysis because the 
untreated cell populations were found to increase during the 18 exposure period. This 
growth prevented accurate quantification of complete cell death when the maximal LDH 
activity from cells lysed at the point of assay was used in the calculations. 
7.2.5.2 Cell proliferation 
Percentage proliferation was calculated following a similar process. Raw data from the 
MTT assay were adjusted for baseline DMSO absorbance by subtracting the lysed cell 
control values from every well. Any additional background interference from residual test 
agent was corrected for by subtracting the adjusted cell-free values from their HCE-2 
containing equivalents (i.e. E2-G2 values were subtracted from B2-D2 values and so on, 
Figure 7.1). Mean values for each technical triplicate were calculated and proliferation 
as a percentage of untreated control determined for each test agent and concentration: 
% 𝑝𝑝𝑝𝑝𝑖𝑖𝑎𝑎𝑖𝑖𝑓𝑓𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑖𝑖𝑖𝑖𝑛𝑛 = [𝑓𝑓𝑖𝑖𝑝𝑝𝑐𝑐𝑝𝑝𝑓𝑓𝑝𝑝𝑛𝑛 𝑝𝑝𝑖𝑖𝑠𝑠𝑖𝑖𝑝𝑝𝑖𝑖𝑝𝑝𝑛𝑛𝑐𝑐𝑝𝑝 𝑓𝑓𝑝𝑝𝑖𝑖𝑐𝑐 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑑𝑑 𝑐𝑐𝑝𝑝𝑎𝑎𝑎𝑎𝑠𝑠][𝑓𝑓𝑖𝑖𝑝𝑝𝑐𝑐𝑝𝑝𝑓𝑓𝑝𝑝𝑛𝑛 𝑝𝑝𝑖𝑖𝑠𝑠𝑖𝑖𝑝𝑝𝑖𝑖𝑝𝑝𝑛𝑛𝑐𝑐𝑝𝑝 𝑓𝑓𝑝𝑝𝑖𝑖𝑐𝑐 𝑒𝑒𝑛𝑛𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑑𝑑 𝑐𝑐𝑖𝑖𝑛𝑛𝑝𝑝𝑝𝑝𝑖𝑖𝑎𝑎] × 100 
Percentage inhibition of cell proliferation was calculated as: 
% 𝑖𝑖𝑛𝑛ℎ𝑖𝑖𝑖𝑖𝑖𝑖𝑝𝑝𝑖𝑖𝑖𝑖𝑛𝑛 = 100 − (% 𝑝𝑝𝑝𝑝𝑖𝑖𝑎𝑎𝑖𝑖𝑓𝑓𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑖𝑖𝑖𝑖𝑛𝑛)  
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7.2.5.3 EC50, IC50 and IC90 calculation 
Cytotoxicity and inhibition data were used to calculate the mean agent concentrations to 
produce 50 % cytotoxicity (EC50), 50 % inhibition (IC50) and 90 % inhibition (IC90). The 
results for each individual replicate were fit to Boltzmann sigmoidal curves using the 
formula: 
𝑃𝑃 = 𝑐𝑐𝑚𝑚𝑚𝑚𝑐𝑐 + 𝑐𝑐𝑚𝑚𝑚𝑚𝑚𝑚 − 𝑐𝑐𝑚𝑚𝑚𝑚𝑐𝑐1 + 𝑝𝑝(𝑚𝑚−𝑐𝑐)/𝑡𝑡  
Where P = predicted cytotoxicity or inhibition, Amin = minimum observed cytotoxicity or 
inhibition, Amax = maximum observed cytotoxicity or inhibition, i = the sigmoidal inflection 
point, c = natural logarithm of the test agent concentration and s = the slope. 
Microsoft® Excel® (MSO Professional Plus 2016, Microsoft Corporation, WA, USA) 
Solver add-in was used to optimise the constants i and s to the fit the observed data by 
solving for the lowest sum of least squares between observed and predicted values. The 
determined constants were then used to identify the natural logarithm of the test agent 
concentration (c) predicted to produce 50 % or 90 % cytotoxicity or inhibition, as 
applicable. The resulting value was inverted to obtain the EC50, IC50 or IC90 for the given 
replicate and the mean and 95 % CI (p = 0.05) determined for each triplicate. The 
selectivity indices (SI) were calculated by dividing the IC50s by respective MIC90s against 
each of the GN reference strains. 
7.3 Results 
7.3.1 Inhibitory and cytotoxic effects of sodium fusidate, aluminium, 
copper and iron ions alone on corneal epithelial cells 
The inhibitory and cytotoxic effects of FNa on HCE-2 are illustrated in Figure 7.2. While 
FNa completely inhibited HCE-2 proliferation at concentrations of ≥640 µM, the 
maximum cytotoxicity was only 66.6 % with 1280 µM. Consequently, the EC90 of FNa 
could not be determined. The FNa EC50 was 425.30 µM (95 % CI = 63.23) which was 
statistically significantly greater (p <0.05) than both the IC50 and IC90 of 183.53 (95 % CI 
= 4.83) and 338.21 µM (95 % CI = 15.41), respectively. 
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Figure 7.2 - Sodium fusidate-induced cytotoxicity and growth inhibition of human corneal 
epithelial cells after 18±2 h incubation at 37 °C in 5 % CO2 
A cytotoxicity or inhibition value of <0 indicates enhanced proliferation compared to 
untreated control. 
(n = 3, error bars = 95 % CI) 
The IC50s of Al3+, Cu2+ and Fe2+ against HCE-2 were 8.27 (95 % CI = 3.03), 1.31 (95 % 
CI = 0.18) and 3.27 mM (95 % CI = 0.28), respectively. The proliferation inhibition profiles 
produced by these metal ions are illustrated in Figure 7.3. Al3+ at concentrations of 
≤5 mM enhanced HCE-2 growth by between 12.7 and 29.6 %. Even at 10 mM, the 
highest concentration of Al3+ tested, HCE-2 proliferation was inhibited by only 68.9 %, 
therefore, an IC90 could not be calculated. Cu2+ and Fe2+ also enhanced HCE-2 growth 
but at lower concentrations of ≤0.625 and ≤1.25 mM, respectively. The IC90s were 
2.38 mM (95 % CI = 0.93) Cu2+ and 4.45 mM (95 % CI = 0.83) Fe2+. 
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Figure 7.3 – Metal ion-induced growth inhibition of human corneal epithelial cells after 
18±2 h incubation at 37 °C in 5 % CO2 
An inhibition value of <0 indicates enhanced proliferation compared to untreated control. 
(n = 3, error bars = 95 % CI) 
7.3.2 Effects of sodium fusidate combined with metal ions on the 
proliferation of corneal epithelial cells 
The HCE-2 inhibition profiles produced by FNa with and without 0.625 mM Al3+, Cu2+ or 
Fe2+ are illustrated in Figure 7.4. There was no significant difference between the 
inhibition caused by ≥160 µM FNa alone and in the presence of Al3+ or Fe2+ (p >0.05). 
However, inhibition of HCE-2 by FNa combined with Cu2+ was significantly greater than 
by FNa alone (p <0.05). Inhibition was 33.3 % by 160 µM FNa alone and 51.2 % in the 
presence of 0.625 mM Cu2+. While also significant, the differences between inhibition 
with and without Cu2+ were less than 3 % with 320 and 640 µM FNa. There was no 
significant difference (p >0.05) between inhibition of HCE-2 proliferation by 80 µM FNa 
alone and in the presence of 0.625 mM Cu2+ which were 13.0 and 18.6 %, respectively. 
With Al3+ and Fe2+ inhibition by 80 µM FNa was -1.3 and 4.4 %, respectively, and both 
were significantly less than FNa alone (p <0.05). There was no significant difference 
between inhibition produced by 40 µM FNa alone and in the presence of any metal ion 
tested (p >0.05). 
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Figure 7.4 - Inhibition of human corneal epithelial cell growth by sodium fusidate combined 
with 0.625 mM metal ions after 18±2 h incubation at 37 °C in 5 % CO2 
An inhibition value of <0 indicates enhanced proliferation compared to untreated control. 
(n = 3, error bars = 95 % CI) 
There was no significant difference between the IC90s of FNa alone and in the presence 
of any of the metal ions tested (p>0.05, Table 7.3). There was also no significant 
difference between the IC50 of FNa alone and with Al3+ or Fe2+ (p>0.05). However, the 
IC50 of FNa was significantly lowered by the presence of Cu2+ at 146.5 µM compared to 
183.5 µM FNa when alone. 
 
Table 7.3 – Mean sodium fusidate IC50s and IC90s against human corneal epithelial cells, 
with and without 0.625 mM metal ions 
 IC50 ± 95 % CI (µM) IC90 ± 95 % CI (µM) 
Al3+ 187.17 ± 2.66 363.03 ± 68.47 
Cu2+ 146.53 ± 14.25 338.58 ± 43.74 
Fe2+ 195.57 ± 11.81 340.37 ± 31.61 
control 183.53 ± 4.83 338.21 ± 15.41 
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7.3.3 Comparison of antimicrobial activity versus corneal epithelial cell 
proliferation in the presence of sodium fusidate and metal ion 
combinations 
7.3.3.1 Inhibition profiles 
The inhibition profiles of HCE-2, E. coli NCTC 10418, K. pneumoniae NCTC 9633 and 
P. aeruginosa NCTC 13359 in response to FNa are illustrated in Figure 7.5. There were 
significant differences between the degree of inhibition of each cell type by FNa, 
however, HCE-2 and K. pneumoniae followed a similar pattern. E. coli was more 
sensitive to FNa than HCE-2 and the other bacterial species and P. aeruginosa was the 
least sensitive overall. 
 
Figure 7.5 - Comparison of growth inhibition of human corneal epithelial cells and bacterial 
reference strains E. coli NCTC 10418, K. pneumoniae NCTC 9633 and P. aeruginosa 
NCTC 13359 by sodium fusidate alone 
An inhibition value of <0 indicates enhanced proliferation compared to untreated control. 
(n = 3, error bars = 95 % CI) 
Conversely, P. aeruginosa was more inhibited by Al3+ than either E. coli, K. pneumoniae 
or HCE-2 (Figure 7.6A). In fact, all three bacterial species were 100 % inhibited by 5 mM 
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Al3+ while HCE-2 proliferation was enhanced by the same concentration with -12.7 % 
inhibition. 
 
 
Figure 7.6 – Comparison of growth inhibition of human corneal epithelial cells and bacterial 
reference strains E. coli NCTC 10418, K. pneumoniae NCTC 9633 and P. aeruginosa 
NCTC 13359 by aluminium ions alone (A) and sodium fusidate in the presence of 0.625 mM 
aluminium ions (B) 
An inhibition value of <0 indicates enhanced proliferation compared to untreated control. 
(n = 3, error bars = 95 % CI) 
The bacterial reference strains were also more inhibited by FNa in the presence of 
0.625 mM Al3+ than HCE-2 (Figure 7.6B). For example, 80 µM FNa with 0.625 mM Al3+ 
produced -1.3 % HCE-2 inhibition and the same combination inhibited E. coli 
NCTC 10418, K. pneumoniae NCTC 9633 and P. aeruginosa NCTC 13359 by >98 %. 
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There were more similarities between inhibition of bacterial species and HCE-2 by Cu2+ 
(Figure 7.7A). At Cu2+ concentrations of ≤0.625 mM HCE-2 were the least inhibited (-26.1 
to -17.0 %) followed by K. pneumoniae (13.0 to 17.4 %), P. aeruginosa (26.1 to 38.2 %) 
then E. coli (48.8 to 59.5 %). However, all cell types were >80 % inhibited by 2.5 mM 
Cu2+. 
 
 
Figure 7.7 - Comparison of growth inhibition of human corneal epithelial cells and bacterial 
reference strains E. coli NCTC 10418, K. pneumoniae NCTC 9633 and P. aeruginosa 
NCTC 13359 by copper(II) ions alone (A) and sodium fusidate in the presence of 0.625 mM 
copper(II) ions (B) 
An inhibition value of <0 indicates enhanced proliferation compared to untreated control. 
(n = 3, error bars = 95 % CI) 
The presence of 0.625 mM Cu2+ increased the inhibition of bacterial reference strains by 
FNa to a greater degree than HCE-2 (Figure 7.7B), however, the difference was not as 
notable as with the other metals. While 80 µM FNa with Cu2+ produced 18.6 % inhibition 
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of HCE-2, bacterial strains were inhibited by 60.3 to 95.0 % (p <0.05). However, while 
still significant (p <0.05) the difference between the effects of 160 µM FNa with Cu2+ on 
HCE-2 and bacterial strains was less with the combination inhibiting HCE-2 by 51.2 % 
and bacterial strains by between 73.4 and 99.0 %. Finally, 320 µM produced >95 % 
inhibition (p >0.05) of all but P. aeruginosa. 
 
 
Figure 7.8 - Comparison of growth inhibition of human corneal epithelial cells and bacterial 
reference strains E. coli NCTC 10418, K. pneumoniae NCTC 9633 and P. aeruginosa NCTC 
13359 by iron ions alone (A) and sodium fusidate in the presence of 0.625 mM iron ions (B) 
An inhibition value of <0 indicates enhanced proliferation compared to untreated control. 
(n = 3, error bars = 95 % CI) 
While Fe2+ (Figure 7.8A) was not as inhibitory as Al3+, a similar sensitivity pattern was 
observed with both metals. HCE-2 proliferation was not negatively impacted by ≤2.5 mM 
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Fe2+, however all three bacterial strains were 100 % inhibited (p <0.05). P. aeruginosa 
was also more sensitive to Fe2+ than E. coli and K. pneumoniae. 
At concentrations of ≤320 µM, FNa combined with 0.625 mM Fe2+ also inhibited the 
bacterial reference strains to a greater degree than HCE-2 (p <0.05, Figure 7.8B). HCE-2 
proliferation was inhibited by 4.4 % by 80 µM FNa with Fe2+ whereas E. coli 
NCTC 10418, K. pneumoniae NCTC 9633 and P. aeruginosa NCTC 13359 were all 
inhibited >97 % by the same combination. 
7.3.3.2 Selectivity indices 
The selectivity index (SI) is a measure of the ratio of the adverse effect of an agent on 
mammalian cell proliferation (IC50) to its antimicrobial efficacy (MIC). A value of ≥10 is 
used as an indicator of high clinical potential[488]. SIs for FNa alone and in the presence 
of metal ions against each GN reference strain are listed in Error! Reference source 
not found.. All SIs for FNa alone were <1, demonstrating its clinical ineffectiveness 
against GN organisms. Although the SIs for FNa with Al3+, Cu2+ and Fe2+ against E. coli 
NCTC 10418 – the original GN reference strain tested – were <10, all three values are 
similar to one another at 4.7, 3.7 and 4.9, respectively. However, against both 
K. pneumoniae NCTC 9633 and P. aeruginosa NCTC 13359, the SI for FNa with 
0.625 mM Cu2+ was <1. In addition, K. pneumoniae NCTC 9633 was more resistant to 
FNa in the presence of Al3+ or Fe2+ than the other two reference stains, resulting in SIs 
of 2.3 and 2.4, respectively. On the contrary, the SIs for FNa in the presence of Al3+ or 
Fe2+ against P. aeruginosa NCTC 13359 were 37.4 and 39.3, respectively, indicating 
potential for clinical use of these combinations against P. aeruginosa infections. 
 
Table 7.4 – Sodium fusidate selectivity indices against human corneal epithelial cells and 
Gram-negative reference strains, with and without metal ions 
 E. coli 
NCTC 10418 
K. pneumoniae 
NCTC 9633 
P. aeruginosa 
NCTC 13359 
Al3+ 4.679 2.340 37.434 
Cu2+ 3.663 0.4579 0.2290 
Fe2+ 4.879 2.445 39.306 
control 0.5735 0.2868 0.07169 
Selectivity index of ≥10 indicates suitability for consideration for clinical use high due to high 
ratio of antimicrobial activity to inhibition of mammalian cell proliferation (green, bold text). 
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7.4 Discussion 
7.4.1 Human corneal epithelial cell proliferation in the presence of sodium 
fusidate, metal ions and sodium fusidate combined with metal ions 
The IC50 of 183.53 µM FNa determined against HCE-2 after 18 h exposure was lower 
than that reported against primary human hepatocytes of 235.6 µM after 48 h[479]. The 
IC50 would normally be expected to decrease inversely to duration of exposure. However, 
this difference was not surprising due to the known variability between the susceptibility 
of cell types to toxic agents. Interestingly, while HCE-2 proliferation was completely 
inhibited by ≥640 µM FNa, 29.7 and 23.4 % of the cell populations were still alive after 
18 h in the presence of 640 and 1280 µM, respectively. The difference between inhibitory 
and cytotoxic effect was also exhibited by the statistically significantly larger EC50 of 
425.3 µM (p <0.05), indicating that FNa more readily inhibited growth than killed HCE-2. 
Due to the limitations found with the use of the LDH assay in the presence of metal ions, 
similar comparisons between inhibitory and cytotoxic effects could not be made for Al3+, 
Cu2+ and Fe2+. However, Al3+ was found to be substantially less inhibitory to HCE-2 than 
rat astrocytes, with an IC50 of 8.27 mM after 18 h exposure compared to 0.343 mM after 
72 h[480]. This may be explained by the similarities between astrocytes and neurons, the 
latter of which are known to be particularly vulnerable to Al3+ via interference with a 
variety of cellular functions including axonal transport and protein phosphorylation/de-
phosphorylation[489]. HCE-2 were also less susceptible to Cu2+ than most reported cell 
types with an IC50 of 1.31 mM falling between those reported against primary human 
hepatocytes and the human hepatocyte immortal cell line HepG2 (see Table 7.1, page 
182). Conversely, and despite a higher IC50 than Cu2+, HCE-2 were inhibited 
considerably more by Fe2+ (IC50 3.27 mM) than the mouse fibroblasts, human 
hepatocytes or rat hepatocytes reported in the literature (Table 7.1). Since the effects of 
metal ions on mammalian cells and their proliferation appear to be even less well studied 
than that of bacteria, the reasons for differences between cell type susceptibilities cannot 
be explained. However, this data clearly demonstrates the importance of selecting an 
appropriate cell type for investigations into potential toxicity of novel drugs or 
formulations. 
At a concentration of 0.625 mM, neither Al3+ nor Fe2+ had a significant impact on the 
inhibition profile, IC50 or IC90 of FNa against HCE-2 (p >0.05). However, the presence of 
0.625 mM Cu2+ increased inhibition when combined with 160 µM FNa by an additional 
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18 % (p <0.05) and reduced the IC50 to 146.5 µM (p <0.05). This may suggest some anti-
proliferative synergy between Cu2+ and FNa since the same concentration of Cu2+ alone 
had no impact on HCE-2 growth (p >0.05). However, the mechanism is, as yet, unclear 
due to lack of published information on the effects of these agents on mammalian cells. 
7.4.2 Comparison of human corneal epithelial cell and bacterial inhibition 
by sodium fusidate combined with metal ions  
While the response of HCE-2 to FNa alone followed a similar pattern to that of 
K. pneumoniae and P. aeruginosa (Figure 7.5, page 194), the mammalian cells were 
significantly less inhibited than bacterial reference strains by almost all combinations of 
metal ions and FNa tested (p <0.05). The only exceptions were in the presence of 
0.625 mM Cu2+ and 320 µM FNa which inhibited HCE-2 significantly more than 
P. aeruginosa (p <0.05, Figure 7.7B, page 196) and wherever HCE-2 and the bacterial 
strains were all ≥95 % inhibited (p >0.05). There are several factors which could explain 
the comparative lack of inhibition of mammalian cells to metal ion and FNa combinations. 
Firstly, mammalian cells are thought to be susceptible to FNa via inhibition of their 
mitochondrial ribosomes[490]. However, the IC50 of FNa against isolated mitochondrial 
ribosomes is 2020 µM compared to 33 µM against E. coli ribosomes[491]. Therefore, while 
the HCE-2 cell and mitochondrial membranes are more permeable to FNa than the OM 
of GN bacterial strains, their resulting susceptibility is similar. Secondly, the presence of 
metal ions increases the amount of FNa associated with bacterial cells (see Section 
5.3.4, page 150) which increases growth inhibition, while the same does not appear to 
occur in HCE-2. The presence of 0.625 mM Al3+ or Fe2+ had no significant impact on the 
activity of FNa against HCE-2 (Figure 7.4, page 193). However, these metal ions were 
the most effective in combination with FNa against GN isolates, reducing the FNa MIC90 
by 8 to ≥512-fold by their presence (see Chapter 6, Section 6.3.3, page 171). This may 
be attributable to either the comparatively low susceptibility of mitochondrial ribosomes 
to FNa or, possibly more likely, increased differential permeability of the LPS-containing 
bacterial OM to highly protonated FNa in the presence of metal ions. 
The selectivity indices (SI) unfortunately indicate little clinical potential for the majority of 
combinations of metal ions and FNa against GN bacteria. However, the exceptions were 
Al3+ and Fe2+ with significantly high ratios of antimicrobial activity against P. aeruginosa 
to HCE-2 toxicity of 37.4 and 39.3, respectively. While identification of a co-formulation 
with a wider spectrum of antimicrobial activity was the original aim of this study, a 
combination active against P. aeruginosa is an important finding. As discussed in 
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Chapter 1, P. aeruginosa is both widely resistant to commonly used antimicrobials and 
the most frequent cause of GN bacterial keratitis. In addition, this bacterium is a 
problematic cause of many other severe, difficult to treat infections such as in burn 
wounds[492] and cystic fibrosis[493]. If similar low toxicity is found in other cell types, 
co-formulation of FNa with either Al3+ or Fe2+ may have potential for application in the 
topical treatment of eye and wound infections or as an inhaled formulation for the 
treatment of infections in cystic fibrosis. 
7.5 Conclusions 
The following conclusions can be drawn from the work presented in this Chapter: 
1) The proliferation of human corneal epithelial cells was inhibited in the order 
Cu2+ > Fe2+ > Al3+.  
2) The presence of Cu2+, Fe2+ or Al3+ did not alter human corneal epithelial cell 
response to FNa. 
3) GN bacterial reference strains were more susceptible to growth inhibition by 
metal ion and FNa combinations than human corneal epithelial cells. 
4) The combinations of FNa with Al3+ or Fe2+ yielded selectivity indices of >10 
against P. aeruginosa indicating potential suitability for clinical use against this 
challenging opportunistic pathogen.
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Chapter 8: Anti-Gram-negative activity 
and solubility of sodium 
fusidate combined with metal 
ions in a novel simulated tear 
fluid 
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8.1 Introduction 
The human tear film is a complex structure, thoroughly described in a 2012 review by 
Franzco[494]. In brief, the tear film is composed of two discrete compartments (Figure 8.1). 
The lipid sealant film is a 100 nm layer of meibomian lipids on the outermost surface 
which serves to reduce evaporation. The muco-aqueous pool (MAP) is in contact with 
the anchored mucin and glycocalyx of the corneal epithelium and both lubricates the eye 
surface and provides protection from pathogens and foreign particles. The MAP is the 
larger compartment with a depth of 3000-9000 nm. It contains a complex mixture of 
electrolytes, metabolites, proteins, trace elements and mucin which creates a dense 
mucous layer at the cell surface to lubricate the eye and trap microbes and foreign 
particles. 
Simulated tear fluids (STFs) are widely used in the literature with the intention to mimic 
in situ conditions at the eye surface, thereby reducing the use of animals in research. 
Applications include the study of drug release from ocular preparations[495], spoilage of 
contact lenses[496] and the growth of microbial pathogens[497]. Published STF formulations 
range from simple solutions of electrolytes to complex mixtures of salts, proteins and 
lipids, with much variation in between. One of the most frequently used STF formulations 
is a simple electrolyte solution of sodium chloride, sodium bicarbonate and calcium 
chloride[498]–[501], devoid of many electrolytes and without any of the metabolites, proteins 
or lipids found in human tears. Other, more complex, formulations include a variety of 
proteins and lipids more closely resembling tear concentrations in vivo, but in a 
homogenous suspension[502],[503]. Disparity between the composition and structure of tear 
film and reported STF formulations may mean that studies employing these STFs do not 
consistently produce the desired in situ-like setting, reducing the predictive reliability of 
their results. 
Exposure to any individual or combination of molecules can initiate phenotypic changes 
in bacterial cells[504]. Exposure to individual components or the particular molecular 
mixtures encountered in tear fluid may induce the switching on or off of metabolic 
pathways and virulence mechanisms relied upon during infection which the same 
bacteria do not exhibit during growth in standard bacteriological broth. In particular, 
mucin has been shown to induce the expression of various virulence factors and 
metabolic processes in A. baumannii which increases the bacterium’s efficiency in 
infecting host cells[505] and to trigger production of toxins by Bacillus cereus[506]. 
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Therefore, it was decided to investigate the efficacy of the discovered antimicrobially 
active FNa and metal ion combinations in an STF designed to mimic the MAP. 
While the meibomian lipid layer is an important component of the tear film structure and 
may have an impact on a variety of ocular considerations, the aim of this investigation 
was to predict the solubility and activity of FNa delivered as an eyedrop to the infected 
cornea. Although the eyedrop will theoretically have to penetrate the exterior lipid film 
“sealant”, this layer is extremely thin (100 nm) and is likely considerably disrupted on 
addition of a 25-50 μL drop to the usual total tear volume of ~7 μL[498]. In addition, tear 
production increases in keratitis resulting in an even greater proportion of the tear film 
volume being comprised of MAP[507]. For these reasons, this work focussed on the 
rationalisation and employment of an STF representative of the physiological human 
MAP. Testing the identified anti-GN combinations of FNa and metal ions under these 
conditions may provide an indication as to efficacy in situ against bacteria habituated to 
survival and growth in tear fluid. In addition, since solubility can vary widely by solvent, 
investigations in STF may be particularly important to the current work due to the 
apparent relationship between the discovered combined antimicrobial activity and FNa 
solubility. 
8.1.1 Aim and objectives 
Aim: to investigate whether metal ion and FNa combinations found to be active against 
GN isolates in a bacteriological growth medium under standard laboratory conditions 
also exhibit anti-GN activity in a novel, rationally designed, physiologically representative 
STF and the relationship to solubility. 
Objectives: 
1) To rationally design a novel STF representative of the physiological human 
muco-aqueous pool and suitable for antimicrobial testing. 
2) To optimise a simple assay to investigate antimicrobial efficacy in the novel 
STF. 
3) To determine whether Al3+, Cu2+ and/or Fe2+ increase FNa activity against 
E. coli, K. pneumoniae and P. aeruginosa reference strains in the novel STF. 
4) To investigate whether the activity of FNa with and without metal ions in the 
novel STF is also related to FNa solubility. 
206 
 
Figure 8.1 - Scale diagram of the tear film structure 
The human squamous corneal epithelial cell diameter is 30-40 µm[508] with a microvillus 
surface[509]. Approximately 1/20 of a single corneal epithelial cell diameter is shown. Anchored 
mucin forms part of the glycocalyx of 300-600 nm depth[509] and covers the cell surface, 
increasing wettability[510]. Additional solubilised mucin in the muco-aqueous pool (9 µm[511]) 
lubricates the cell surface to prevent damage during blinking and traps foreign particles[512]. 
The outer lipid layer (100 nm) acts as a sealant to reduce evaporation[494],[513]. 
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8.2 Methods 
8.2.1 Development of a novel simulated tear fluid formulation 
8.2.1.1 Collation of published data 
The first task was a critical analysis of published STF formulae reported in the literature 
and understanding the rationale for inclusion of individual components. A literature 
search was undertaken for STF formulations used to mimic in situ conditions. For each 
STF formulation reported, the ingredients and concentrations were tabulated, with the 
units standardised (converted to mM or mg mL-1, as appropriate). Electrolytes were 
considered as individual ions and the final concentrations of each summated. Where 
multiple publications employed the same formulation, only one entry was made 
referencing the earliest reported use. Component concentrations were compared across 
all identified STF formulations to determine frequency of use and the mean and range of 
concentrations employed. 
The actual concentrations of electrolytes, metabolites and proteins measured in human 
tears was gathered through further literature searches. Data from the eyes of normal 
healthy subjects and, where available, eyes with bacterial keratitis or corneal ulceration 
were included. Information regarding collection method was also recorded allowing 
procedure-related differences in reported concentrations to be considered and 
rationalisation of inclusion or exclusion of each data point in the analysis. Selected 
literature values were tabulated, and the mean and range calculated for each 
component. Finally, the pH of each published STF formulation (where reported) and data 
for human tear fluid pH were also collated. 
8.2.1.2 Design and optimisation of a novel STF 
Each component as identified in 8.2.1.1 was reviewed and its inclusion in the novel STF 
rationalised. Where available, the reported human muco-aqueous pool component 
concentrations were used to deduce a formulation composed of commonly available 
salts and proteins. Where actual human tear fluid concentrations could not be identified, 
concentrations employed in published STF formulations were used as a guide.  
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8.2.1.2.1 Materials 
Calcium chloride dihydrate, magnesium chloride hexahydrate, potassium chloride, D-
glucose anhydrous, urea and BSA were purchased from Fisher Scientific 
(Loughborough, UK) while sodium phosphate dibasic, sodium phosphate tribasic, 
sodium bicarbonate, sodium chloride, sodium citrate tribasic dihydrate, sodium pyruvate, 
sodium DL-lactate, lysozyme from chicken egg white and mucin from porcine stomach 
were from Sigma Aldrich (Gillingham, UK). Sodium phosphate monobasic monohydrate 
was purchased from Acros Organics (Geel, Belgium). All materials were used as 
received. 
Stock solutions were prepared in HPLC grade water and, except for mucin, sterilised by 
filtration through 0.22 μm PES (Sartorius, Germany). As the viscous, polymeric nature of 
mucin makes solutions incompatible with sterilisation by filtration, the stock solution was 
autoclaved for 15 min at 121 °C[497]. STF formulations were prepared by sequential 
addition of stock solutions to sterile HPLC grade water and evaluated for their ability to 
support bacterial growth and replicate physiological pH. 
8.2.1.2.2 Initial assessment of bacterial growth 
The ability of test STF formulations to support quantifiable growth of GN organisms was 
initially assessed and compared to standard NB by generating optical density growth 
curves. STF formulations or NB aliquots in flat-bottomed 96 well plates were inoculated 
with E. coli NCTC 10418 to a final concentration of 5±3 x 105 CFU mL-1, in triplicate. 
Plates were incubated in a Tecan Infinite 200 PRO plate reader at 35 °C and absorbance 
at 595 nm was measured every 20 min preceded by 20 s orbital shaking at 6 mm 
amplitude for 60 h.  
8.2.1.2.3 Formulation refinement to mimic physiological pH 
Based on the findings in 8.2.1.2.2 one STF formulation was selected for further 
refinement. Since all test STF formulations were found to exhibit more alkaline pH in 
normal air than that reported for human tears in situ, alteration of the bicarbonate 
concentration and modification of the included phosphate were initially investigated as a 
means to replicate physiological pH. Nine variations of the selected novel STF were 
investigated: all permutations of 100, 50 or 0 % optimised HCO3- concentration combined 
with the optimised phosphate concentration as PO43-, HPO42- or H2PO4-. The STF 
variations were prepared in 1 mL aliquots in duplicate and left to equilibrate for 24 h in 
normal air at room temperature before measuring the pH. 
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The effects of incubation of the original selected STF formulation in 5 % CO2 on pH were 
also investigated. After the 24 h normal air pH measurement was performed, the tubes 
were loosely covered and incubated at 37 °C in 5 % CO2 for 48 h. To check for drift, the 
pH was measured after 6, 24 and 48 h of incubation. After removal from the incubator, 
both tubes were sealed, and the pH was measured again after cooling to room 
temperature for 6 h. One tube was left loosely covered for exposure to normal air while 
the other was resealed, and pH measured a final time after equilibration at room 
temperature for 18 h. A final novel STF formulation which reached physiological pH 
during incubation in 5 % CO2 was selected for use. 
8.2.2 Optimisation of an antimicrobial assay in novel simulated tear fluid 
Growth of E. coli NCTC 10418 in the novel STF over 24 hours was compared to that in 
a range of dilute concentrations of NB in order to select an appropriate bacteriological 
medium comparator. A flat-bottomed 96 well plate was prepared with 90 µL aliquots of 
STF, standard NB, NB diluted to 50 % standard concentration (50 % NB), 20 % NB, 10 % 
NB and 5 % NB and equilibrated overnight in 5 % CO2 at 37 °C. Aliquots were inoculated 
with approximately 2 x 106 CFU mL-1 bacteria grown on NA and returned to the CO2 
incubator for 24 h. After incubation, bacteria were enumerated using the Miles & Misra 
drop count method[280] and the NB dilution supporting most similar growth to the novel 
STF selected as a comparator. 
Growth curves of E. coli NCTC 10418, K. pneumoniae NCTC 9633 and P. aeruginosa 
NCTC 13359 were performed in novel STF and the selected comparator. Aliquots of 
90 µL were again equilibrated overnight in 5 % CO2 at 37 °C in duplicate before 
inoculation with approximately 5 x 105 CFU mL-1 bacteria grown on NA. Drop counts 
were performed immediately after inoculation and after 4, 8, 12, 16, 20, 24 and 28 h 
incubation in 5 % CO2 at 37 °C. The log10 CFU mL-1 increase since inoculation was 
calculated for each timepoint, plotted against incubation time and used to select duration 
of bacterial acclimatisation and treatment for the antimicrobial activity assay. 
8.2.3 Antimicrobial activity of sodium fusidate in novel simulated tear 
fluid, with and without metal ions 
Aliquots of the novel STF were transferred to flat-bottomed 96 wells plates, 90 μL per 
well, and incubated for 12-18 h at 37 °C and 5 % CO2 to equilibrate before use. 50 % NB 
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was used as a comparator. E. coli NCTC 10418, K. pneumoniae NCTC 9633 and 
P. aeruginosa NCTC 13359 were grown over night on NA at 37 °C. Bacteria were 
suspended in HPLC grade water and the OD adjusted. Equilibrated STF and 50 % NB 
was inoculated to a final concentration of 5±3 x 105 CFU mL-1 by adding 10 μL bacterial 
suspension. Mixing on addition was avoided in order to prevent disturbing the stratified 
STF structure and to ensure bacteria were presented with a similar gradient to that 
encountered when initiating an ocular infection. Initial concentration of bacteria was 
confirmed by adding 10 μL sterile HPLC grade water (the same volume of treatments to 
be later added to other wells), thoroughly mixing and performing a CFU count per the 
Miles & Misra method[280] from wells dedicated for this purpose. Inoculated plates were 
incubated at 37 °C and 5 % CO2 for 4 h to allow for acclimatisation to the new growth 
medium and establishment of actively growing bacterial populations. 
Treatment with metal sulphates, FNa and combinations was initiated by adding a total of 
10 μL to each well, comprising either 5 μL metal + 5 μL FNa, 5 μL metal + 5 μL water, 
5 μL FNa + 5 μL water or 10 μL water for untreated controls, without mixing. All metal 
ions were added to a final concentration of 625 μM and the final FNa concentration was 
80 μM. These concentrations were chosen for their combination of relatively low toxicity 
(see Chapter 7), considerable anti-GN activity determined previously in NB (see Chapter 
6) and, for FNa, similarity to trough concentrations in the tears and cornea during 
standard 12-hourly treatment with 1 % FA viscous eyedrops (see Discussion, Section 
8.4.2). Bacterial populations at the start of treatment were measured by CFU counting 
from additional dedicated wells diluted with 10 μL water. Plates were returned to 37 °C 
and 5 % CO2 for a further 4 h. A 4 h exposure period was selected to ensure there would 
be a measurable difference between bacterial populations in wells of actively growing, 
uninhibited organisms and those that were inhibited or killed by the treatment, while 
avoiding the potential skewing effects of reaching stationary phase. Viable CFU in all 
treated and untreated control wells were quantified at the end of the exposure period by 
the Miles & Misra method[280].  
All combinations of growth medium, organism and treatment were carried out in triplicate. 
CFU counts were used to calculate log10 change in bacterial numbers during the 4 h 
treatment period and the 95 % CIs compared to determine statistically significant 
differences (p ≤0.05). 
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8.2.4 Solubility of sodium fusidate in novel simulated tear fluid, with and 
without metal ions 
8.2.4.1 Sodium fusidate solubility in novel STF 
Solubility of both 80 μM and 1280 μM FNa with and without 625 μM Al3+, Cu2+ and Fe2+ 
as sulphate was determined in the novel STF and 50 % NB using a similar method to 
that described in Section 2.7. It was previously established that the solubility of 1280 μM 
FNa correlated well with bacteriostatic activity in NB (Section 5.3.3, page 127). However, 
the solubility of 80 μM – the concentration used in antimicrobial investigations in STF – 
was also investigated in the event the 1280 μM solubility : activity relationship did not 
follow the same pattern in this novel growth medium. 
Aliquots of 900 μL STF and 50 % NB were equilibrated in loosely covered 2 mL 
centrifuge tubes for 12-18 h at 37 °C and 5 % CO2 in triplicate. In order to mimic the 
conditions and time-course of the antimicrobial assay, 100 μL sterile HPLC grade water 
(in place of bacterial suspension) was added to each tube and incubation continued for 
4 h. FNa and metal sulphate stock solutions were added to the test media to a total of 
100 μL, comprising either 50 μL metal + 50 μL FNa or 50 μL FNa + 50 μL water and the 
tubes returned to 37 °C and 5 % CO2 for 4 h equilibration.  
After equilibration, tubes were removed from the incubator and immediately sealed to 
prevent loss of CO2 from solution and any resulting pH change. Tubes were then 
centrifuged for 20 min at 37 °C in a pre-warmed Heraeus Fresco 17 (Thermo Scientific) 
at 17,000 x g (13,300 rpm). Samples of 500 μL each supernatant were mixed with 
500 μL ethanol in HPLC vials to prevent FNa precipitation before analysis. 
Solubilised FNa concentration was quantified using HPLC separation method 1 (see 
Section 2.6.1) and converted to % solubility of the original concentration added. The 
mean and 95 % CI were used to identify statistically significant differences between FNa 
solubility in STF and 50 % NB with and without metal ions (p ≤0.05). 
8.2.4.2 pH of metal sulphates in novel STF 
Since previous results illustrated that pH directly influences FNa solubility, the effect of 
metal sulphates on the pH of the novel STF and 50 % NB was also investigated. As for 
solubility testing, triplicate 900 μL aliquots were equilibrated for 12-18 h at 37 °C and 5 % 
CO2 before the addition of 100 μL sterile HPLC grade water and continued incubation 
for 4 h. Metal sulphate stock solution x 100 μL was added to STF or 50 %NB to a final 
metal ion concentration of 625 μM, and 100 μL water added to the control tubes. After 
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equilibration at 37 °C and 5 % CO2 for a further 4 h, tubes were sealed to prevent CO2 
loss and only re-opened immediately prior to pH measurement. 
8.3 Results 
8.3.1  Development of a novel simulated tear fluid formulation for bacterial 
studies 
8.3.1.1 Collation of published data 
8.3.1.1.1 Components and concentrations in published STF formulations 
STF formulations described in the literature have been employed for a variety of 
applications including drug release, contact lens spoilage, corneal epithelial 
maintenance and microbial growth. Several authors used formulations previously 
published. The most widely used STF was found to be sodium chloride 0.67 g, sodium 
bicarbonate 0.2 g and calcium chloride dihydrate 0.008 g per 100 g water, originally 
reported by Rozier et al (1989)[498]. Only the earliest report of each formulation was 
included in the analysis; these publications are listed in Table 8.1. 
Table 8.1 - Published simulated tear fluid formulations included in the analysis 
Publication Context 
Bachman & Wilson 
(1985)[514] 
STF for optimal corneal epithelial surface maintenance 
Rozier et al (1989)[498] STF for sol-gel drug release assay 
Mirejovsky et al (1991)[515] STF for protein deposition on contact lenses 
Cowell et al (1997)[516] STF to study in vitro bacterial adhesion to contact lenses 
Prager & Quintana 
(1997)[502] 
STF for lipid deposition on contact lenses 
Rebeix et al (2000)[496] STF for component adsorption on/spoilage of contact lenses 
Aristoteli & Wilcox 
(2003)[497] 
STF to study mucin degradation by P. aeruginosa 
Hagigit et al (2008)[495] STF for nano-emulsion drug release assays 
Lorentz et al (2011)[503] STF for lipid deposition & stability testing of contact lenses 
Ng et al (2013)[517] STF for lysozyme deposition on contact lenses 
Lee et al (2017)[518] STF for protein deposition on contact lenses 
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Table 8.2 - Concentrations of electrolytes, metabolites and proteins employed in published simulated tear fluid formulations 
Component units 
Deposition on contact lenses Drug release Bacterial 
behaviour 
Corneal 
culture 
Mean 
used Range used 
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Na+ mM 130.6 144.6 147.4 166.5 143.1 165.2 138.5 138.0 145.0 150.0 143.6 146.6 130.6 - 166.5 
K+ mM 23.02 5.4 4.51 19.0 18.96 1.91 - 14.89 20.0 3.2 18.78 12.97 1.91 - 23.02 
Ca2+ mM 1.0 1.0 0.06 0.5 0.63 0.09 0.54 0.21 0.7 - 0.58 0.53 0.06 - 1.0 
Mg2+ mM - 0.9 0.04 - - - - - 0.44 - 1.27 0.66 0.04 - 1.27 
Cl- mM 138.4 148.0 142.8 133.0 133.0 149.2 155.7 130.4 176.5 139.7 138.8 140.5 130.4 - 176.5 
CO32- mM - - - 12.0 11.98 - - - - - - 14.85 11.98 - 20.57 
HCO3- mM 16.38 4.0 0.21 3.0 3.0 - 23.81 22.9 - - 25.95 12.41 0.21 - 25.95 
HPO42- mM - 0.30 5.14 24.0 24.02 8.09 - - - 6.5 - 11.34 0.3 - 24.02 
H2PO4- mM 0.72 0.40 1.70 - - 1.91 - - - 1.5 0.78 1.17 0.40 - 1.91 
SO42- mM - 0.4 0.02 - - - - - 0.44 - - 0.29 0.02 - 0.44 
NH4+ mM - - - - - - - - 10.0 - - 10.0 n/a† 
citrate mM - - - 1.50 1.71 - - - - - - 1.61 1.50 - 1.71 
lactate mg L-1 270 - - - - - - - - - - 270.0 n/a† 
urea mg L-1 - - - 72.07 72.0 - - - - - - 72.04 72.0 – 72.07 
glucose mg L-1 - 1000 50.0 36.03 36.0 - - 25.0 751.3* - - 316.4 25 - 1000 
albumin mg L-1 200 200 200 200 200 540 - 6690 - - - 1175.7 200 - 6690 
lysozyme mg L-1 1900 1900 2000 1900 1900 1300 - - 2000* - - 1842.9 1300 - 2000 
lactoferrin mg L-1 1800 1800 1000 1800 1800 - - - 2000* - - 1700.0 1000 - 1800 
α-acid glycoproteins mg L-1 500 500 500 - - - - - - - - 500.0 n/a† 
immunoglobulins mg L-1 100 100 300 20 20 - - - 100* - - 106.7 20 - 300 
mucin mg L-1 150 150 1000 150 150 1800 - - - 10,000 - 1914.3 150 - 10000 
*each carbon source was used alone 
†no variability between publications in concentrations employed 
- = not present. 
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A further STF formulation was also identified which was used to investigate 
P. aeruginosa biofilm formation on contact lenses. However, the authors employed a 
mixture of 20 % v/v human serum and 2 g L-1 lysozyme diluted in a commercial ocular 
irrigation solution[519]. This prevented accurate quantification of individual electrolyte, 
metabolite and protein concentrations due to inter-patient variation in serum 
composition. This formulation was therefore omitted from the analysis. 
Table 8.2 summarises the total concentration of each electrolyte, metabolite and protein 
incorporated into each published STF formulation, standardised to the same units, with 
the mean and range across all formulations. Mirejovsky et al (1991)[515] also included 
MOPS as an additional buffer in their formulation. Of particular interest was the 
formulation developed by Bachman & Wilson (1985)[514] which was derived from an 
investigation into the particular components required to maintain viability of the epithelial 
surface of ex vivo rabbit corneas. Their STF formula included only the electrolytes Na+, 
K+, Ca2+, Mg2+, Cl-, H2PO4- and HCO3- at optimised concentrations. In addition, the work 
of Cowell et al (1997)[516] showed that lysozyme, lactoferrin or IgA could be the sole 
carbon source for P. aeruginosa, E. coli, and two species of Serratia (formerly 
Stenotrophomonas), while Aristoteli & Wilcox (2003)[497] demonstrated that 
P. aeruginosa could also utilise mucin as the sole source of both carbon and nitrogen. 
8.3.1.1.2 Measurements from human tears 
The mean and range of concentrations of electrolytes, metabolites and proteins in both 
basal (non-stimulated) and induced (stimulated) human tears reported in the literature 
are listed in Table 8.3 and Table 8.4. Measurements made in patients with diabetes, liver 
cirrhosis and other conditions were also found but only values from the healthy controls 
for these studies were included. 
The concentration of Na+ [520],[521] and urea[521] in human tear fluid has been determined 
to be equal to that in plasma regardless of tear secretion rate, indicating passive diffusion 
of these components. However, concentrations of K+, Ca2+, Mg2+ and Cl- in tears are 
independent of secretion rate. K+ [520] and Cl- [521] are both actively exported into the tear 
fluid, resulting in concentrations higher than those in plasma. Conversely, Ca2+ and Mg2+ 
are found at lower concentrations in the tears than in plasma[520], indicating limited export 
or diffusion. Measured electrolyte and metabolite concentrations generally agreed well 
with the mean used in published STFs, particularly considering intra-patient variabilities 
reported. However, exceptions included citrate, urea, glucose and pyruvate. Where used 
in published STFs, citrate was at a mean concentration of 1.61 mM[503],[517] (Table 8.2, 
page 213) but only 0.03 mM[522] was found in human tears. Conversely, the range of 
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human tear concentrations of urea of 204.2 to 1385 mg L-1 [521],[523] was considerably 
higher than the mean 72.04 mg L-1 [503],[517] employed in published STFs. Glucose tear 
measurements ranged from 45 to 270.2 mg L-1 [523]–[525] while published STF 
concentrations varied from 25 to 1000 mg L-1 [495],[496],[502],[503],[516],[517] with a mean of 
316.4 mg L-1. Pyruvate was not included in any of the published STF formulations; 
however, it is present in basal tears at 4.4 - 30.8 mg L-1 [523] and is an essential, 
immediate precursor to acetyl-CoA, utilised in bacterial synthesis of ATP[161]. No human 
tear concentrations of CO32-, HPO42-, H2PO4-, SO42- or NH4+, or electrolytes or metabolites 
in infected eyes, were found in the literature. 
Table 8.3 - Concentrations of electrolytes and metabolites measured in human tears 
Electrolytes and 
metabolites 
Healthy subjects, non-
stimulated (mM) 
Healthy subjects, stimulated (mM) 
mean range mean range 
Na+ 122.9[526] n/a 144.0[521],[527] 142 - 146[521],[522],[527] 
K+ 15.5[528] n/a 22.0[521],[527] 14.9 - 29.0[521],[522],[527] 
Ca2+ 0.64[529],[530] 0.33 - 2.40[529]–
[531] 
- - 
Mg2+ 0.82[530] 0.3 - 1.1[520] - - 
Cl- 120[532] n/a 131.5[521],[527] 128 - 135[521],[527] 
HCO3- 26[520],[522] n/a - - 
citrate 0.03[522] n/a - - 
lactate (mg L-1) - 81.1 - 486.4[523] - - 
urea (mg L-1) - 204.2 - 450.5[523] - 328 - 1385[521] 
glucose (mg L-1) 74.5[524],[525] 45.0 - 90.1[523] - 90.1 - 270.2[523] 
pyruvate (mg L-1) - 4.4 - 30.8[523] - - 
- = not found, n/a = not applicable as only one reported value identified 
Three papers reported protein concentrations in infected eyes (Table 8.4). Lal et al 
(1991)[507] compared lysozyme in the tears of patients with bacterial, viral or fungal 
corneal ulcers, determining that the lowest level of lysozyme was present with bacterial 
infection at 1700 mg L-1. This value was consistent with that published by Saari et al 
(1983)[533] who found 1770 mg L-1 lysozyme in the tears of patients with keratitis and 
similar to the mean concentration of 1842.9 mg L-1 employed in STFs (Table 8.2). Sen & 
Sarin (1979)[534] determined that immunoglobulin tear concentration was decreased in 
cases of bacterial corneal ulcers compared to healthy controls with 204 and 260 to 
288 mg L-1 found, respectively (whereas concentration increased with bacterial 
conjunctivitis). However, Fullard & Snyder (1990)[535] measured only 1.5 to 12.2 mg L-1 
immunoglobulin in non-stimulated tears and 0 to 94.8 mg L-1 in stimulated tears, both 
considerably less than Sen & Sarin’s controls. Therefore, any of the employed range of 
20 to 300 mg L-1 immunoglobulin in STF formulations could be considered reasonable. 
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Table 8.4 – Concentrations of proteins measured in human tears 
Proteins Healthy subjects, non-
stimulated (mg L-1) 
Healthy subjects, 
stimulated (mg L-1) 
Ocular infections and 
comparators (mg L-1: condition 
details) mean range mean range 
albumin 
/pre-
albumin 
585.8 
[524],[535] 
38.0 – 
1677.4 
[524],[535] 
732.6 
[524],[535],[5
36] 
12.2 - 1830 
[524],[535],[536] - 
lysozyme 1486.8 
[524],[535],[5
37],[538] 
650 – 3297 
[524],[535],[537]
,[538] 
2580.3 
[507],[524],[5
35]–
[537],[539] 
1500 – 5140 
[507],[524],[535]–
[537],[539] 
1700: bacterial corneal ulcer[507] 
1770: all cause keratitis[533] 
2850: viral corneal ulcer[507] 
3020: fungal corneal ulcer[507] 
lactoferrin 1990.5 
[524],[535],[5
37] 
1370 – 
2860 
[524],[535],[537] 
3071.5 
[524],[535]–
[537] 
1587.5 – 
4000 
[524],[535]–[537] 
- 
other 
transferrins 
0.99[535] n/a 0.50[535] n/a - 
immuno-
globulins 
- 1.5 - 
12.2[535] 
- 0 - 94.8[535] 204: bacterial corneal ulcer[534] 
260 - 288: infection-free 
controls[534] 
339: bacterial conjunctivitis[534] 
- = not found, n/a = not applicable as only one reported value identified 
Concentrations of α-acid glycoproteins and mucin in human tears were not identified 
from the literature. However, albumin or tear-specific pre-albumin concentrations have 
been determined as ranging between 12.2 and 1830 mg L-1, with means of 585.8 and 
732.6 mg L-1 in non-stimulated and stimulated tears, respectively[524],[535],[536]. While the 
mean albumin concentration incorporated in STFs was 1175.7 mg L-1, it was only 
200  mg L-1 in five of the seven formulations in which it was employed[496],[502],[503],[515],[517]. 
Another formulation closely reflected the mean non-stimulated tear concentration of 
albumin at 540 mg L-1 [518], while the last was higher than any measured value at 
6690 mg L-1 [495]. Conversely, at 1000 to 1800 mg L-1, lactoferrin concentrations in STF 
formulations were not overly dissimilar to the 1990.5 mg L-1mean of measurements in 
non-stimulated tears[524],[535],[537]. Finally, other transferrins were not included in any 
published STF but are present in non-stimulated and stimulated human tears at 0.99 and 
0.50 mg L-1, respectively[535].  
8.3.1.1.3 The pH of published STFs and human tears 
Where reported, the pH of reported STF formulations are listed in Table 8.5. Three of 
the 11 authors failed to disclose the pH of their STF formulation. Published STF pHs 
were between 7.4 and 7.5, however, Prager & Quintana (1997)[502] reported only the pH 
of the salt solution prior to the addition of proteins and lipids and Rebeix et al (2000)[496] 
stated only that pH 7.4 was “maintained” without further explanatory details. Four of the 
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formulations were adjusted manually after preparation using HCl or NaOH[495],[515],[516],[518]. 
Bachman & Wilson (1985)[514] purged the prepared STF with 5 % CO2 to achieve pH 7.5, 
whereas Lorentz et al (2011)[503] found that equilibration of their STF at room temperature 
for at least 3 days resulted in a pH of 7.4 which was stable for 4 weeks. 
Table 8.5 - Reported pH of eight simulated tear fluid formulations 
Publication pH Notes on pH adjustment 
Bachman & Wilson 
(1985)[514] 
7.5 adjusted by bubbling with 95 % air, 5 % CO2 
Mirejovsky et al 
(1991)[515] 
7.4 adjusted after preparation 
Cowell et al 
(1997)[516] 
7.4 adjusted after preparation 
Prager & Quintana 
(1997)[502] 
7.4 initial pH of Hank’s buffered salts solution before protein 
& lipid addition 
Rebeix et al 
(2000)[496] 
7.4 listed as "maintained" 
Hagigit et al 
(2008)[495] 
7.4 adjusted after preparation 
 
Lorentz et al 
(2011)[503]  
7.15 initial pH after mixing of salt base solution 
7.35 pH of complete STF immediately after preparation 
7.4 pH after equilibration at room temp for 3+ days 
7.49 max pH of complete STF up to 28 days after incubation 
Lee et al (2017)[518] 7.4 adjusted after preparation 
 
 
Interestingly, the pH of human tear film is more variable than the consistency between 
published STF formulations would suggest. Figure 8.2 summarises the reported pH of 
the human tear film at two different locations on the ocular surface and various times 
after opening the lid, along with that of collected tears. While the pH of collected tears 
stored with a minimal volume of air was found to range from 7.14 to 7.82[540],[541], the in 
vivo human tear film was between pH 6.5[542] and 9.3[543]. The lowest readings were from 
the inferior fornix, the fold behind the lower eyelid. Abelson et al (1981)[542] originally 
found a range of pH 6.5 to 7.6 in the inferior fornix. Coles & Jaros (1984)[544] later 
determined that in the open eye, the inferior fornix tear film pH was 7.19±0.16 whereas 
this decreased to 7.06±0.16 when measured immediately after the eye lid had been kept 
closed for 1 h. However, Fischer & Wiederholt (1982)[543] found a mean pH of 7.5 in the 
precorneal tear film within 2 to 4 s of opening the eye, and a maximum of pH 9.3 after 30 
to 60 s. Similarly, Chen & Maurice (1990)[545] measured a precorneal tear film pH of 
7.83±0.33 1 min after opening the eye.  
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Figure 8.2 – The in vivo pH of human tear fluid and its variation in response to air exposure 
[542] [544] [543] [545] [540] [541] 
Central ocular surface 
Electrode measurement, 2-4 s after opening 
eye: pH 7.5±0.1 (range 7.0-8.1)[527] 
Fluorescent probe measurement, equilibration 
1 min after opening eye: pH 7.83±0.33[529] 
Electrode measurement, max value 30-60 s 
after opening eye: pH 9.3[527] 
Collected tears (sealed until measurement) 
Mean over waking hours: pH 7.45 (range 7.14-7.82)[524] 
Pre-treatment control: pH 7.5±0.16[525] 
Inferior fornix 
Electrode measurement: pH 7.0 
(range 6.5-7.6)[526] 
Electrode measurement, open 
eye: pH 7.19±0.16[528] 
Electrode measurement, after 
1 h of closure: pH 7.06±0.16[528] 
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8.3.1.2 Rational design of a novel simulated tear fluid 
8.3.1.2.1 Novel STF formulation and initial evaluation 
Lipid and lipid-soluble components (Appendix F) were not considered for inclusion since 
the focus was to develop an STF physiologically representative of the human muco-
aqueous pool. Immunoglobulins, α-acid glycoprotein and transferrins were also omitted 
due to their potential to interfere with antimicrobial activity (see Section 8.4.1). Finally, 
ammonium was not considered for inclusion since its use in the single STF formulation 
was to ensure a nitrogen source[516]. 
A base salt solution was rationally designed to reflect the electrolyte values recorded in 
tears. Metabolites lactate, pyruvate and urea along with BSA were also added to the 
base solution. Since their inclusion or concentration may impact bacterial growth, the 
effects of the presence or absence of mucin and lysozyme and the concentration of 
glucose was investigated. Table 8.6 lists the rationale for the individual component 
concentrations tested. 
Table 8.6 - Rationalised concentrations of novel STF components 
Component Concentration 
(mM) 
Rationale 
Na+ 142.75 
Mean of stimulated tear concentrations and published STF 
formulations; similar to optimal concentration for corneal 
epithelium maintenance 
K+ 19.31 Mean of all reported tear concentrations; similar to optimal concentration for corneal epithelium maintenance 
Ca2+ 0.60 Mean of reported tear concentrations and optimal concentration for corneal epithelium maintenance 
Mg2+ 0.94 Mean of reported tear concentrations and optimal concentration for corneal epithelium maintenance 
Cl- 134.32 Mean of all reported tear concentrations; similar to optimal concentration for corneal epithelium maintenance 
HCO3- 25.95 Optimal concentration for corneal epithelium maintenance 
H2PO4- 0.78 Optimal concentration for corneal epithelium maintenance 
citrate 0.03 Concentration recorded in tears 
lactate (mg L-1) 270.0 As used in one STF formulation and within measured concentration range 
pyruvate (mg L-1) 17.60 Approximate median of reported tear concentration range 
urea (mg L-1) 250.0 Approximate median of reported tear concentration range 
BSA (mg L-1) 735.0 Based on mean of reported concentration in stimulated tears 
glucose (mg L-1) 90.0 or 1000 
90 mg L-1 = minimum concentration in stimulated tears; 
1000 mg L-1 = ¼ carbon source concentration utilised in 
minimal bacteriological media such as M9[546] 
lysozyme (mg L-1) 1700.0 Reported value from eyes with bacterial corneal ulcer 
mucin (mg L-1) 1500.0 No reported tear concentration; between values used in STFs 
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During growth curve set-up, it was observed that mixing wells containing both lysozyme 
and mucin on addition of E. coli resulted in alteration of the solution opacity. Therefore, 
all bacteria-free control wells were similarly mixed on addition of the same volume of 
sterile water and immediately after the corresponding inoculated well. This apparent 
interaction between lysozyme and mucin limited the accuracy of growth curve results 
based on optical density since opacity in all wells (including bacteria-free controls) 
fluctuated over time. Figure 8.3 illustrates the mean absorbance of bacteria-free control 
STFs over time. E. coli growth data (Figure 8.4) was therefore baseline corrected against 
the lowest OD observed in the corresponding bacteria-free control well to account for 
this equilibration. 
 
Figure 8.3 - Mean absorbance of STF formulations and nutrient broth at 595 nm over 60 h 
incubation at 35 °C 
(n=3) 
Figure 8.4 illustrates E. coli NCTC 10418 growth curves in the STF formulations and NB 
comparator. While not as rapid or achieving the same density as in NB, all STF 
formulations were able to support E. coli growth, with cell numbers reaching levels 
detectable by the plate reader within 6 h. However, the growth curves were unusually 
shaped, and absorbance was found to decrease after the initial growth phase. E. coli OD 
peaked after 12-13 h in STF containing 1000 mg L-1 glucose, followed by a steep decline 
up to 16-18 h. Growth in STF formulations with 90 mg L-1 glucose was apparently slower 
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and steadier than in the 1000 mg L-1-containing counterparts, peaking between 20 and 
24 h. There was reduction in absorbance between 30 and 60 h in all formulations, 
however, this was least pronounced with both mucin and lysozyme combined with 
90 mg L-1 glucose. The formulation containing mucin, lysozyme and 90 mg L-1 glucose 
was therefore selected for further investigation as it most closely resembled reported tear 
composition and supported detectable bacterial growth. 
 
Figure 8.4 - Growth of E. coli NCTC 10418 in STF formulations and nutrient broth as 
determined by absorbance at 595 nm over 60 h incubation at 35 °C 
(n=3) 
8.3.1.2.2 Novel STF pH issues and resolution 
The pH of the novel STF formulation in normal air was 8.6. Two options for pH correction 
to approximate physiological conditions were investigated: 1) alteration of bicarbonate 
concentration combined with phosphates of different protonation states, and 2) 
incubation in 5 % CO2. Table 8.7 lists the measured pH of STF formulations incorporating 
varying HCO3- concentrations and phosphates. Even with half the original concentration, 
the buffering effect of HCO3- could not be overcome by changing the phosphate anion 
(while using the concentration of phosphates found in tears). With complete omission of 
HCO3- and use of PO43-, the STF pH after 24 h at room temperature in normal air was 
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very similar to human tear pH at 7.58. However, inclusion of HCO3- was deemed 
preferable in order to replicate actual tear composition as closely as possible. 
Table 8.7 - Effect of bicarbonate concentration and phosphate protonation state on STF pH 
in normal air at room temperature 
Bicarbonate concentration 
(% rationalised value) 
Phosphate anion 
(0.78 mM) 
pH after 24 h 
equilibration 
25.95 mM (100 %) PO43- 8.88 
25.95 mM (100 %) HPO42- 8.84 
25.95 mM (100 %) H2PO4- 8.82 
12.975 mM (50 %) PO43- 8.77 
12.975 mM (50 %) HPO42- 8.72 
12.975 mM (50 %) H2PO4- 8.68 
0 mM (0 %) PO43- 7.58 
0 mM (0 %) HPO42- 6.75 
0 mM (0 %) H2PO4- 5.90 
 
 
Figure 8.5 - Change in pH of novel STF before, during and after incubation at 37 °C with 5 % 
CO2 
 
Figure 8.5 illustrates the change in pH of 1 mL aliquots of the selected formulation 
without modification (containing 25.95 mM HCO3- and HPO42-) on incubation in 5 % CO2. 
The pH substantially decreased from 8.6 to 7.6 during the incubation period, very similar 
to human tear pH. After removal from 5 % CO2, an increase in pH was observed in all 
samples. However, those allowed to equilibrate to normal air reached pH 9.15 compared 
lid open
room 
temperature
incubation at 
37 °C with 
CO2 start
return to room 
temperature & 
atmosphere
lid opened
lid closed
7.0
7.5
8.0
8.5
9.0
9.5
0 20 40 60 80 100
pH
time since mixing (h)
223 
to 8.29 with the lid closed. In addition, during incubation at 37 °C in CO2, the selected 
STF formulation developed mucin stratification similar to that reported for tear film 
structure in vivo (Figure 8.6). 
 
Figure 8.6 - Photograph of novel STF after overnight incubation at 37 °C and 5 % CO2 
Stratification of mucin in the optimised STF formulation after incubation after 18-24 h 
mimicked tear film structure (compare to Figure 8.1, page 206). 
 
A combination of the STF containing mucin, lysozyme, 90 mg L-1 glucose, 25.95 mM 
HCO3- and phosphate as HPO42- along with incubation in 5 % CO2 was, therefore, 
selected for further use. The composition of the optimised novel STF formulation is listed 
in Table 8.8. 
Table 8.8 - Composition of optimised novel STF 
Material Concentration 
in STF 
Sodium bicarbonate# 25.95 mM 
Calcium chloride (dihydrate)$ 0.596 mM 
Magnesium chloride (hexahydrate)$ 0.935 mM 
Potassium phosphate monobasic# 0.775 mM 
Potassium chloride$ 18.54 mM 
Sodium chloride# 113.20 mM 
Sodium citrate tribasic (dihydrate)# 0.031 mM 
Sodium DL-lactate# 270.0 mg L-1 
Sodium pyruvate# 17.6 mg L-1 
Urea$ 250.0 mg L-1 
D-glucose (anhydrous)$ 90.0 mg L-1 
BSA$ 735.0 mg L-1 
Lysozyme from hen's egg# 1700 mg L-1 
Porcine stomach mucin# 1500 mg L-1 
Suppliers: #Sigma Aldrich (Gillingham, UK), $Fisher Scientific (Loughborough, UK) 
Aqueous layer 
 
 
 
 
Mucin gradient 
 
Dense mucin layer 
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8.3.2 Optimisation of an antimicrobial assay in novel simulated tear fluid 
After 24 h at 37 °C and 5 % CO2, growth of E. coli in the novel STF was most similar to 
that in NB diluted to 50 % the standard concentration (Figure 8.7). The total CFU present 
in the novel STF was 3.4 x 109 mL-1 and in 50 % NB was 3.8 x 109 mL-1. Standard 100 % 
NB yielded 5.6 x 109 CFU mL-1, while in 20, 10 and 5 % NB E. coli grew to 2.2 x 109, 
2.3 x 109 and 1.3 x 109 CFU mL-1, respectively. Therefore, 50 % NB was selected as an 
STF comparator. 
 
Figure 8.7 - Growth of E. coli NCTC 10418 after 24 h at 37 °C and 5 % CO2 in novel STF 
compared to various dilutions of nutrient broth 
 
E. coli and K. pneumoniae reached stationary phase in both novel STF and 50 % NB 
after approximately 8 h, while P. aeruginosa took 12 h (Figure 8.8). During the first 4 h, 
both Enterobacteriaceae populations increased by between 2.2 and 2.5 log10 CFU mL-1 
in both media, and P. aeruginosa increased by 0.8 and 0.9 log10 CFU mL-1 in novel STF 
and in 50 % NB. However, between 4 and 8 h incubation, all species increased by 
0.97±0.16 log10 CFU mL-1 in both media. Therefore, an initial acclimatisation phase of 
4 h was selected, followed by an exposure period of a further 4 h. 
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Figure 8.8 - Bacterial growth curves in novel STF and 50 % nutrient broth comparator over 
28 h at 37 °C and 5 % CO2 
A: E. coli NCTC 10418, B: K. pneumoniae NCTC 9633, C: P. aeruginosa NCTC 13359 
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8.3.3 Antimicrobial activity of sodium fusidate and metal ion combinations 
in novel simulated tear fluid 
 
  
  
 
 
 
 
 
 
Figure 8.9 – Activity of sodium fusidate and metal sulphates against E. coli, K. pneumoniae 
and P. aeruginosa reference strains in novel STF and 50 % nutrient broth 
A: metal-free controls, B: 625 µM aluminium as sulphate, 
C: 625 µM copper(II) sulphate, D: 625 µM iron(II) sulphate. 
Incubation conditions: 4 h at 37 °C and 5 % CO2. Sodium fusidate concentration: 80 µM. 
Positive values indicate bacterial growth during exposure period whereas negative values 
indicate bacterial death and a value of zero indicates bacteriostasis. 
* = significant difference to metal-free control (p≤0.05); 
† = significant difference to metal alone (p≤0.05). 
(n = 3, error bars = 95 % CI) 
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Without any antimicrobial agent, E. coli, K. pneumoniae and P. aeruginosa reference 
strains grew similarly in both the novel STF and 50 % NB over 4 h (Figure 8.9A). Total 
mean growth ranged from 0.73 to 1.59 log10 CFU with P. aeruginosa exhibiting greater 
final numbers than E. coli and K. pneumoniae, however, there was no statistically 
significant difference between organisms or growth medium (p >0.05). The presence of 
80 μM FNa alone had little impact on bacterial growth in either medium: while mean 
growth of each organism was slightly reduced compared to the agent-free control, 
variation between replicates meant that there was no significant difference between any 
of the control conditions, with or without FNa (p >0.05, Figure 8.9A). 
For most metal and organism combinations, the ability of metal sulphates to inhibit 
bacterial growth over the 4 h exposure period differed greatly between the novel STF 
and 50 % NB. Al3+ killed all three species when 625 μM was added to 50 % NB (p <0.05), 
however, the same concentration in STF resulted in no significant difference in growth 
compared to the agent-free controls (p >0.05, Figure 8.9B). In a similar fashion, 625 μM 
Fe2+ had no net effect on growth of any organism in STF (p >0.05) but produced ≥6 log10 
CFU reductions of both E. coli and P. aeruginosa in 50 % NB (p <0.05, Figure 8.9D). 
Conversely, Cu2+ produced a significant and comprehensive reduction in bacterial 
numbers when added to STF (p <0.05) but less dramatic reductions in 50 % NB (Figure 
8.9C). 
In only one case was there a statistically significant difference between log10 CFU change 
caused by FNa with metal ions and metal ions alone. The log10 reduction of 
K. pneumoniae when exposed to Al3+ alone in 50 % NB was 5.3, while the combination 
of FNa and Al3+ reduced bacterial numbers by 7.9 log10 CFU mL-1 (p <0.05). There was 
no significant difference between activity of any other metal ion and FNa combination 
compared to the same metal ions alone (p >0.05). 
8.3.4 Effect of metal ions on sodium fusidate solubility in and pH of 
simulated tear fluid 
There was no significant difference between the solubility of either 80 or 1280 µM FNa 
in STF when alone or with 625 µM Al3+, Cu2+ or Fe2+ (p >0.05), therefore, only data for 
the solubility of 1280 µM FNa was used in the analysis. 
FNa at a concentration of 1280 µM was freely soluble in the novel STF after 4 h at 37 °C 
and 5 % CO2. While mean values varied from 91.9 to 97.3 %, there was no significant 
difference between FNa solubility in STF in the presence of any of the metal ions tested 
228 
and without (p >0.05, Figure 8.10). In 50 % NB, on the other hand, there was significantly 
reduced solubility of 1280 µM FNa with all three metal ions compared to the control 
(p <0.05). FNa solubility alone in 50 % NB was 81.4 %, whereas it was 26.5, 47.3 and 
28.8 % in 50 % NB with 625 µM Al3+, Cu2+ or Fe2+, respectively. 
 
Figure 8.10 - Solubility of 1280 µM sodium fusidate in novel STF or 50 % nutrient broth with 
or without metal sulphates after 4 h at 37 °C and 5 % CO2 
(n = 3, error bars = 95 % CI, * = p≤0.05 compared to solvent control) 
Table 8.9 - pH of novel STF and 50 % NB with and without 625 μM metal ions after 4 h at 
37 °C and 5 % CO2 
Metal sulphate STF 50 % NB 
Control 7.54 ± 0.03 6.31 ± 0.06 
Al 7.38 ± 0.02 4.95 ± 0.02 
Cu 7.53 ± 0.04 5.47 ± 0.01 
Fe 7.39 ± 0.05 5.66 ± 0.01 
Data is shown as mean of n = 3 ± 95 % CI. Apparatus accurate to ±0.02 pH units. 
As with previous investigations (see Chapter 5), FNa solubility appeared to be related to 
solution pH. The pH of novel STF and 50 % NB after 4 h at 37 °C and 5 % CO2 with and 
without 625 µM each metal is listed in Table 8.9. Figure 8.11 illustrates the relationship 
between pH of the novel STF or 50 % NB and the solubility of FNa. The pH and FNa 
solubility in the STF was very similar across all metals and the control with differences 
of no more than 0.16 pH units and 8.1 % FNa solubility between them. Conversely, 50 % 
NB pH significantly varied with the addition of each of the metal sulphates which also 
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had a significant impact on FNa solubility (p <0.05). Solubility of FNa compared to pH of 
50 % NB containing Fe2+ appears to fall outside of the overall correlation between these 
parameters. This may be due to incomplete equilibration during the short 4 h incubation 
period, as observed in previous solubility studies (see Chapter 5). 
 
Figure 8.11 - Solubility of 1280 μM sodium fusidate sodium salt compared to pH of metal 
sulphates in novel STF and 50 % NB after 4 h at 37 °C and 5 % CO2 
(n = 3, error bars = SD) 
8.4 Discussion 
8.4.1 Novel simulated tear fluid formulation development 
8.4.1.1 Omission of components found in reported formulations or human tears 
The rational for exclusion of lipid film components from the novel STF formulation is 
presented in Section 8.1. However, several proteins known to be present in the human 
muco-aqueous pool were also omitted, namely immunoglobulins, α-acid glycoproteins 
and transferrins. In addition, ammonium was not considered for inclusion. 
The single published STF formulation found to contain ammonium in the literature[516] 
included it as the only source of nitrogen, essential to bacterial growth. However, no 
evidence of ammonium in human tears was identified in the literature, indicating inclusion 
was not necessary to mimicking the human muco-aqueous pool. Since the developed 
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formulation included several nitrogen-containing proteins, any requirement for the 
addition of ammonium in order to support bacterial growth was negated. 
The role of immunoglobulins in vivo is to adhere to foreign bodies such as bacterial cells, 
marking them for phagocytosis by neutrophils[547]. While this process acts as an effective 
bacterial clearing mechanism in healthy eyes, an in vitro model involving immune cells 
was not the aim of this work. Therefore, the presence of immunoglobulins was not 
deemed as required in the STF formulation for its intended use. 
While α-acid glycoproteins were used in several reported STF formulations and are 
known to be contributors to drug binding in the blood[548],[549], no published tear 
concentrations were found. Alpha-acid glycoproteins were not included in novel STF 
formulation development since their presence in tear fluid could not be substantiated. In 
addition, albumin is the most abundant drug-binding protein in both the blood[550] and tear 
fluid[551] and BSA was included in the STF formulation at a concentration equivalent to 
pre-albumin documented in tear fluid. 
Lactoferrin, along with other transferrins, is an iron chelator and mammalian siderophore, 
utilised in cellular uptake, processing and storage under normal conditions as well as 
iron sequestration during infection[552]. However, some bacterial species are able to 
acquire iron via human transferrins, including P. aeruginosa[553]. The presence of 
transferrins could either reduce or enhance the activity of metal ion and FNa 
combinations, particularly with Fe2+. Sequestration of the solubilised metal ions may 
reduce antimicrobial activity by disrupting the mechanism of action or increase it by 
limiting available nutrients and therefore bacterial recovery. Alternatively, bacterial 
uptake of iron-loaded mammalian siderophores may reduce antimicrobial activity 
enabling bacteria to acquire non-toxic iron essential to cellular processes or increase it 
by supporting increase growth rate and therefore FNa susceptibility. While these effects 
may have an important impact on the activity of FNa and metal ions combinations, the 
transferrins were excluded in order to minimise potential complication in interpretation of 
bacterial growth assay results. 
8.4.1.2 Novel simulated tear fluid opacity change on bacterial inoculation 
The opacity of the STF test formulations after the addition of bacteria precluded 
microplate reader use during assessment of growth curves and antimicrobial 
susceptibility. This phenomenon was most apparent with the test STF formulation 
containing 1000 mg L-1 glucose and both lysozyme and mucin (Figure 8.4, page 221). In 
part, this could have been due to rapid bacterial growth compared to the 90 mg L-1 
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glucose formulations through utilisation of this easily accessible and comparatively 
abundant energy source. However, the reaction of mucin in response to increasing 
bacterial numbers was most likely to have contributed to the dramatic increase in optical 
density, since the opacity of solutions containing mucin were observed to dramatically 
increase immediately on introduction of E. coli. This change may have been due to 
bacterium-initiated adherence or aggregation of mucin, as occurs in vivo in order to 
immobilise and clear foreign particles from the eye surface[554],[555]. Subsequent reduction 
of absorbance during growth curve investigations may, therefore, be the result of either 
spontaneous or E. coli-mediated breakdown of these aggregated structures. 
Interestingly, this process was not as apparent with test STF formulations containing 
90 mg L-1 glucose. However, comparison of microplate reader-monitored and CFU 
count-based growth curves revealed that while E. coli population increase ceased after 
12 h (Figure 8.8A, page 225), absorbance continued to increase for a further 12 h in the 
same STF formulation (Figure 8.4, mucin, lysozyme and 90 mg L-1 glucose). In addition, 
the absorbance curve for the STF formulation containing mucin and 90 mg L-1 glucose 
(without lysozyme) followed a very similar trend, whereas that for STF with lysozyme and 
90 mg L-1 glucose (without mucin) was dissimilar, peaking around 20 h and then steadily 
decreasing over the remaining incubation period. This may indicate that, where present, 
mucin-mediated bacterial aggregation continued to increase after the E. coli population 
reached stationary phase. However, since the microplate reader-monitored growth curve 
cultures were incubated at 35 °C in normal air whereas the CFU count-based growth 
curve cultures were performed at 37 °C in 5 % CO2, actual bacterial growth is likely to 
have proceeded differently under each incubation condition. 
Therefore, the observed absorbance changes may have reflected bacterial numbers in 
test STF where only 90 mg L-1 glucose was included. However, all growth curves in 
Figure 8.4 were performed under the same culture conditions and the differences 
between 90 mg L-1 glucose test STF formulations demonstrate that either aggregation or 
bacterial population decrease when mucin is not present. Since this phenomenon was 
not the focus of the assay performed, an STF formulation without mucin or lysozyme was 
not tested, however, this would allow determination of whether absorbance reduced due 
to the lytic activity of lysozyme or breakdown of less stable mucin-free bacterial 
aggregation. 
8.4.1.3 Optimisation of incubation conditions to achieve physiological pH 
While tears have long been known to exert an appreciable buffering capacity[540],[541],[556], 
empirical pH measurements vary with exposure to air. The literature data illustrated in 
Figure 8.2 (page 218) clearly demonstrated a range of tear pHs which correspond to 
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exposure to air. This is because the tear film of closed eyes is equilibrated with the 
surrounding tissue, particularly the CO2 the tissue is producing. On eye opening, the CO2 
partial pressure the tear film is exposed to reduces to that of normal atmosphere (0.2 %). 
This leads to alkalinisation of the tear film as solubilised CO2 is released to equilibrate 
with the surrounding air.[511],[543],[557] Therefore, the pH of 8.6 for the novel rationalised 
STF formulation in normal air was to be expected and can be primarily attributed to the 
alkalising effects of bicarbonate[544]. While elimination of sodium bicarbonate from the 
STF formulation proved effective in achieving physiological pH (Table 8.7, page 222), 
incubation in 5 % CO2 was investigated as a means to more closely replicate in vivo 
conditions. The novel rationalised STF formulation containing the originally deduced 
bicarbonate concentration during and after incubation in 5 % CO2 demonstrated very 
similar pH change (Figure 8.5, page 222) to those documented in in vivo tear film and 
collected tears (Figure 8.2, page 218). The pre-incubation pH of STF was 8.60 while the 
pH of tear film after 1 min air exposure was reported to be 7.83[545] to 9.3[543]. During 
incubation in 5 % CO2, the STF pH dropped to 7.62, slightly higher than found in collected 
tears (7.45[540] to 7.5[541]) and in vivo tear film after brief air exposure (7.5[543]). This 
difference was likely due to the short exposure to normal air during pH measurement. In 
addition, after CO2 incubation, STF equilibrated to normal air for 24 h increased to pH 
9.15, similar to the tear film after 1 min exposure to air. A pH increase was also observed 
in samples with closed lids post-incubation, however, this can also be explained by 
minimal normal air exposure during pH measurement. Therefore, incubation in 5 % CO2 
was selected to best recreate in vivo conditions and physiological pH of the novel STF. 
8.4.2 Antimicrobial assay optimisation 
8.4.2.1 Bacterial addition, acclimatisation and antimicrobial exposure duration in 
novel simulated tear fluid 
Bacteria were carefully added to the CO2-equilibrate novel STF without mixing in order 
to avoid disturbing the observed stratification (Figure 8.6, page 223) or inducing overt 
mucin aggregation (Figure 8.4, page 221 and Section 8.4.1.2, page 230). While mucin-
mediated immobilisation is a rapid response to arriving bacteria in vivo, this process is 
overcome during the initiation of infection and bacteria are not cleared from the ocular 
surface. Therefore, it was desirable to avoid excessive aggregation on addition of 
inoculum so that bacterial growth was not overly perturbed nor cells protected from 
antimicrobial exposure by too much mucin coating. 
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All three bacterial species took at least 8 h to reach stationary phase in the novel STF 
and, while growth rate over the initial 4 h varied, all populations increased by 
approximately 1 log10 CFU mL-1 between 4 and 8 h (Figure 8.8). Therefore, an initial 
acclimatisation period of 4 h followed by a 4 h exposure period was selected. This 
allowed for bacteria to express metabolic and phenotypic characteristics induced by STF 
and applicable to the in vivo environment prior to application of the metal ion and FNa 
treatments. Further, while bacterial growth would not be limited by nutrient depletion in 
vivo as the tear fluid is continually replenished, limiting the exposure duration to the log 
period of rapid growth in vitro was chosen to increase sensitivity and reduce any skewing 
effects of the potentially limited nutrition available in STF.  
8.4.2.2 Calculation of sodium fusidate test concentration 
The test concentration of 80 µM FNa was determined using calculations based on 
pharmacokinetic literature data. The half-life of 1 % FA viscous eye drops in the tear fluid 
of healthy volunteers was reported to be 7.3 h by Thorn & Johansen[558] using a single 
sampling protocol repeated at different post-administration timepoints on separate days. 
The authors used this method to prevent any washout effect of repeated tearing in 
response to sampling at multiple timepoints over the course of one day. However, since 
keratitis and other eye infections increase tear production[507], results of earlier work by 
van Bijsterveld et al[559] where multiple sampling was performed sequentially on the same 
day were determined to be more relevant to conditions in the infected eye. By this 
method, a half-life of 1.9 h in human tears was determined. At this elimination rate and 
assuming initial retention of 5  % of the applied dose[63], the tear concentration 12 h after 
administration of a 50 µL drop of standard 1 % FA viscous eye drops can be expected 
to be 83 µM. FNa concentrations within the human cornea have not been measured, 
however, 24 h after a single dose to the rabbit eye, the concentration of FA in the tear 
fluid and cornea were found to be quite similar at 9.28[559] and 11.95[560] µM (as calculated 
based on rabbit corneal tissue comprising 77.67 % water[561]), respectively. The corneal 
epithelium creates a barrier to hydrophilic drugs whereas the corneal stroma is 
impenetrable to lipophilic molecules[562]. The similarity between tear and corneal FA 
concentrations indicates that the amphiphilic nature of FA enables it to both cross the 
epithelium and reside in the cornea. A 12 h trough concentration of approximately 80 µM 
could therefore be expected in the human cornea. 
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8.4.3 Antimicrobial activity of sodium fusidate and metal ions in novel 
simulated tear fluid and 50 % nutrient broth comparator 
8.4.3.1 Sodium fusidate or metal ions alone 
At 80 µM, FNa had no effect on the growth of E. coli, K. pneumoniae or P. aeruginosa 
reference strains in the novel STF or 50 % NB over 4 h (p >0.05, Figure 8.9A, page 226). 
This was to be expected as this concentration was not found to inhibit growth of any GN 
organism tested using the microdilution assay (see Chapter 6) and all three species are 
considered clinically resistant to FNa. However, metal ions alone in 50 % NB and 5 % 
CO2 for 4 h exhibited interesting antimicrobial activity, without apparent correspondence 
to previously determined 18 h MIC90s in NB and normal air. Al3+ exerted cidal activity on 
all three species (Figure 8.9B, page 226) and Fe2+ was cidal against E. coli and 
P. aeruginosa (Figure 8.9D, page 226). This may have been due to a combination of 
increased osmotic pressure in 50 % NB compared to standard NB and further reduced 
pH during incubation in 5 % CO2. However, K. pneumoniae was not killed by Fe2+ and 
populations remained static during the 4 h exposure period. In addition, Cu2+ was less 
dramatically cidal to E. coli and P. aeruginosa than the other two metals and, again, had 
no effect on K. pneumoniae numbers (Figure 8.9C, page 226). This suggests nuanced 
differences in bacterial metabolism or homeostatic mechanisms may be the more likely 
determinant of metal ion susceptibility over 4 h in 50 % NB under 5 % CO2. 
Interestingly, bacterial responses to metal ions in STF were quite different to in 50 % NB. 
None of the three bacterial species were inhibited by Al3+ or Fe2+ and growth was no 
different to the controls (p >0.05, Figure 8.9A and C, respectively, page 226). However, 
Cu2+ was cidal to all three after 4 h in STF under 5 % CO2 (Figure 8.9B, page 226). Lack 
of activity of Al3+ or Fe2+ may be readily explained by sequestration of metal ions by 
mucin[563],[564]. Mucin is known to bind metal ions, with highest affinity to harder Lewis 
acids such as Al3+, Na+ and Mg2+ [563]. Since Cu2+ is a softer Lewis acid than many of the 
metal ions included in the STF formulation[565], it may have been outcompeted for mucin 
binding therefore producing a high thermodynamic activity of the free ions. However, 
other ligands, including lactate, pyruvate and bicarbonate, have been shown to be 
involved in metal-mucin binding in the gastrointestinal fluids[563]. Differential binding to 
these components – or, indeed, lysozyme, BSA or other metabolites – may also impact 
the antimicrobial activity of metal ions in STF. Further investigation would be required in 
order to tease out these interactions. 
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8.4.3.2 Sodium fusidate combined with metal ions 
In the novel STF, FNa combined with metal ions was no more antimicrobially active than 
the same metal ions alone (p >0.05). A similar pattern was seen in 50 % NB, with the 
exception of Al3+ against K pneumoniae (p <0.05). This may have been because all metal 
ions alone exerted either a cidal or completely bacteriostatic effect over the 4 h exposure 
period. Since no bacteria were growing in the presence of the metals, there was no active 
protein synthesis for FNa to inhibit even if it was able to more effectively access the 
ribosome due to the action of the metal ions. However, lack of detection of differences 
may have been due to the assay design and a longer exposure period may produce a 
different pattern. For example, during the first 4 h of exposure to metal ions alone 90 % 
of a bacterial population might be killed while the remaining 10 % is able to upregulate 
the required homeostatic processes, survive and continue to multiply. However, another 
population exposed to metal ions and FNa is similarly reduced during the first 4 h but 
regrowth of the survivors is inhibited by the combination. Alternatively, 80 µM might 
simply be too low a concentration of FNa to produce a combined antimicrobial effect, 
particularly in STF due its high level of protein binding[566]. This concentration was 
modelled on the concentration of 1 % viscous eye drops and frequency of dosing used 
in conjunctivitis (every 12 h, Section 8.4.2.2). However, in the few reported cases of the 
use of FA for the treatment of bacterial keratitis, application was performed every 2 to 
6 h[567], which would produce trough values of 0.75 to 3.2 mM. Such concentrations may 
prove more active in combination with metal ions in STF. 
8.4.4 Solubility of sodium fusidate in novel simulated tear fluid and 50 % 
nutrient broth comparator 
FNa was significantly less soluble in 50 % NB than the novel STF after 4 h at 37 °C in 
5 % CO2 (p <0.05, Figure 8.10, page 228). Solubility of 1280 µM FNa in 50 % NB with 
metal ions followed a similar pattern to that observed in standard NB (see Chapter 5) 
while there was no significant difference between with and without metal ions in STF 
(p >0.05). However, while variation between replicates meant there was no significant 
difference between solubility of 1280 µM FNa in STF in any of the conditions tested and 
solubility of FNa alone or with Al3+ or Fe2+ was not significantly different from 100 %, the 
presence of Cu2+ reduced FNa solubility to 91.9 % which was significantly different from 
100 %. This reduction in solubility may be related to the reduced mucin binding of Cu2+, 
as hypothesised above. However, since Cu2+ was found to be cidal in STF, the possible 
increase in FNa activity due to reduced solubility was masked. Interestingly, apart from 
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with Fe2+ in 50 % NB (likely due to insufficient equilibration time), the relationship 
between medium pH and 1280 µM FNa solubility (Figure 8.11, page 229) appeared to 
follow the same pattern as presented in Chapter 5 (Figure 5.21, page 140). However, 
this did not correspond to the antimicrobial activities determined after 4 h exposure. As 
discussed above, this may be due to limitations of the present assay or an activity pattern 
that does not translate to other growth media or bacterial species. 
8.5 Conclusions 
Conclusions drawn from the work presented in this Chapter are: 
1) A novel STF representative of the human muco-aqueous pool and suitable for 
antimicrobial testing was successfully developed. 
2) The optimised novel STF was successfully utilised in simple antimicrobial 
efficacy assay. 
3) Neither Al3+, Cu2+ nor Fe2+ were found to increase FNa activity against E. coli, 
K. pneumoniae and P. aeruginosa reference strains in STF. 
4) No relationship between FNa solubility and activity in STF could defined from 
the data generated.
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9.1 Reflections on findings and context 
This thesis presents the first investigations into the combination of FNa with metal ions 
as a strategy to overcome intrinsic GN resistance. The primary hypothesis was that one 
or more antimicrobial metal ion(s) would enhance the activity of FNa against GN bacteria 
without reducing anti-GP efficacy. This was tested using an optimised chequerboard 
assay which revealed synergy between FNa and Al3+, Cu2+ or Fe2+ against E. coli 
reference strain NCTC 10418 (Chapter 4). Testing against other GN species 
demonstrated that, while some variation in efficacy was observed, this activity was not 
specific only to E. coli or the reference strain originally employed (Chapter 6). There was 
also no apparent link between resistance genes harboured by MDR isolates and their 
susceptibility to metal ion and FNa combinations. Taken together, this is promising 
evidence for a potential novel antimicrobial combination. FNa combined with metal ions, 
particularly Al3+, produced increased inhibition of all MDR and reference strains of E. coli, 
K. pneumoniae and P. aeruginosa – GN species capable of causing bacterial keratitis. 
In addition, the presence of metal ions did not reduce the antimicrobial efficacy of FNa 
against S. aureus, a common GP cause of keratitis. Investigations using UV-Vis 
spectrophotometry and ITC indicated lack of interaction between metal ions and FNa 
(Chapter 5). The enhanced FNa activity could be correlated with reduced solubility due 
to pH change and total antimicrobial effect was successfully modelled as additive 
between this and the independent activity of the metal ions. 
This work sits at the crossroads of two antimicrobial development approaches: 
combinations of antimicrobial agents and adjuvants targeting resistance mechanisms. 
The metal ions used were, themselves, antimicrobially active, therefore combination with 
FNa could be considered concomitant use of two antimicrobials. However, experimental 
results indicated part of that the mechanism by which the metals synergised with FNa 
was by overcoming an intrinsic resistance mechanism – OM impermeability (Chapter 5). 
Due to widespread and ever-growing antimicrobial resistance, the employment of 
antimicrobial adjuvants to overcome resistance mechanisms is increasing in recognition. 
As mentioned in Chapter 1 (Section 1.4.3.2, page 34), one of the earliest adjuvants 
brought to market was the β-lactamase inhibitor clavulanic acid[210]. This has led to the 
development of the ESBL-inhibitors which have more recently been approved, such as 
avibactam[216], and ensure ongoing usability of carbapenems. While antimicrobial 
adjuvants as a field of research is still quite young, many more approaches to negating 
antimicrobial resistance mechanisms have been investigated or are in development[568]. 
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In fact, very recent reports include agents capable of OM permeabilisation[569] or efflux 
inhibition[570],[571], the same mechanisms that were principal in guiding metal ion selection 
for use in this work. With regards to the antimicrobial activity investigations presented, 
this thesis agrees with published works in illustrating that efficacy of agents intrinsically 
resisted by low permeability can be enhanced. While the discovered mechanism of 
overcoming the OM barrier – increased protonation via reduced pH – may not be 
practical for direct translation to clinical application (see Section 9.2), other 
permeabilisers or formulation approaches could be employed to the same result (see 
Section 9.3.1.2). 
It is interesting that this work also identified factors which could lead to potential topical 
antimicrobial agents being overlooked or undiscovered during early investigations and 
development. By optimising the chequerboard assay to employ NB rather than CAMHB, 
the synergistic anti-GN activity of a select few metal ions and FNa was discovered and 
determined to be related to reduced FNa solubility. If the assay had been performed in 
standard CAMHB, this activity would likely have been missed, particularly since acid 
hydrolysate of casein is known to sequester metal ions[310]. In addition, low solubility was 
observed in the NB used, which is generally considered an undesirable characteristic of 
novel antimicrobials. In fact, this work demonstrated that, in some cases, low solubility 
can be advantageous to antimicrobial activity. Solubility considerations are of paramount 
importance when considering systemic administration, since the ingested or injected 
drug must reach its site of activity without precipitating. However, topical agents are 
usually applied directly to the infected tissue and do not need to travel far in aqueous 
solution in order to reach the target cells. Less soluble, more lipophilic molecules in an 
aqueous solution or suspension are more likely to associate with the lipids of membranes 
and thereby gain access the intracellular target. In addition, if insolubility becomes 
problematic to drug delivery the formulation may be able to be optimised, capitalising on 
what would otherwise have been an abandoned potential drug. An excellent example of 
this is the use of cyclodextrin and surfactant to solubilise and deliver a very poorly soluble 
antifungal (4 ng mL-1) through the cornea[572]. Other approaches are also discussed in 
Section 9.3.1.2. The standardised CAMHB culture conditions are excellent for producing 
comparable, reproducible diagnostic antimicrobial susceptibility data. However, it should 
be recognised that this is both 1) an artificial system which does not closely represent 
the conditions bacteria experience in the host, and 2) may be limiting the discovery of 
usual agents and mechanisms which we now have the formulation strategies to be able 
to employ clinically. 
As with many bacterial infections, keratitis has been shown to develop as a 
biofilm[573],[574]. These are slow-growing communities of adherent bacteria surrounded by 
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a polymeric extracellular matrix with very low permeability to antimicrobials[575]. 
Determination of the anti-biofilm efficacy of new drugs or formulations in vitro may 
provide sensitivity data more in line with in vivo efficacies. While ineffective alone, FNa 
has been shown to synergise with vancomycin against established S. aureus biofilms in 
vitro[566]. Cu2+ can eradicate K. pneumoniae biofilms[380], however, the concentration used 
was equivalent to 17.25 mM which is ~7 times the IC90 found against HCE-2 in this work 
(Section 7.2.5.3). In addition, >304 mM Al3+ could not disperse a biofilm of E. coli[576]. 
This may indicate that the free metal ion and FNa combinations will be ineffective against 
biofilms. However, formulation strategies may be able to combat this issue (see Section 
9.3.1.2). In addition, due to the severity of bacterial keratitis, the FNa and metal ion 
combination could be included with more effective anti-biofilm agents in order to slow the 
growth of cells released from the biofilm.  
The secondary hypothesis of this work was that the combination would exhibit low toxicity 
against mammalian cells and good activity in an STF mimicking the ocular environment. 
Indeed, metal ion IC90s against HCE-2 were higher than the MIC90s against GN isolates, 
and FNa with Al3+ in particular exhibited an excellent selectivity index of 37.4 against 
P. aeruginosa (Chapter 7). However, combined antimicrobial activity in a novel STF, 
rationally designed as physiologically representative of the human muco-aqueous pool, 
was not detected (Chapter 8). Lack of activity detection may have been due to the 
concentration of FNa and metal ions selected for testing, however, as discussed 
previously, protein binding in STF is likely to have been the key mediator in suppression 
of bacterial inhibition. This is an issue faced by many pharmacological agents. FNa is 
already known to be >95 % protein bound in human plasma when administered 
systemically[566], however, this does not prevent in vivo antimicrobial activity. Metals also 
bind proteins, as discussed in Section 9.2, below. Despite this, there may be formulation 
strategies that can prevent loss of active drug to protein binding such as encapsulation 
in liposomes (see Section 9.3.1.2). 
9.2 Limitations in application of this work 
Due to the combinational nature of this system, the new activities are bimolecular events 
relying on FNa and metal arriving at and acting on the bacterial OM simultaneously. This 
excludes use systemically in vivo, where the likelihood of a bimolecular event is 
extremely unlikely, due to dilution in the bloodstream. However, topical delivery onto the 
surface of infection, where there is little or no such dilution, is more likely to result in the 
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observed potentiation. Nonetheless, there are a number of challenges to safely and 
effectively utilise the combination of FNa and metal ions in vivo. 
The use of free metal ions clinically may be limited by the innate sequestration used in 
mammalian immune processes. Transferrins are present in human serum and 
secretions, including tear fluid, while activated macrophages specifically withhold iron 
during infection using ferritin, and recruited neutrophils release lactoferrin[577]. In addition, 
and as discussed in Chapter 8 (Section 8.4.3, page 234), mucin present on the ocular 
surface is known to bind metal ions[563],[564]. Similarly, while there is no such specifically 
identified sequestration process for Al3+, its high affinity to a variety of moieties present 
on glycoproteins such as mucin is likely to remove free aluminium ions from the site of 
application[563],[564]. On the other hand, no extracellular proteins with copper sequestering 
function have been identified and known Lewis acid binding order[565] combined with 
results presented in Chapter 8 indicate that other metal ions naturally present in tear fluid 
may outcompete copper for mucin binding. However, copper ions are efficiently taken up 
into mammalian cells by high affinity transporters[578],[579], which could reduce their local 
concentration. These processes may rapidly alter the free metal ion concentration in an 
applied dose, eliminating its antimicrobial activity. However, this may be able to be 
overcome through formulation strategies (Section 9.3.1.2) or further characterisation of 
the mechanism of combined action (Section 9.3.1.1) allowing identification of an 
alternative agent to metal ions. 
Another factor potentially limiting the clinical use of metal ions is their undesirable effects 
besides discomfort on application, since their toxicity is not limited to bacteria. Although 
cultured human corneal epithelial cells tolerated exposure to Al3+, Cu2+ and Fe2+ at 
concentrations above those required in combination with FNa to inhibit bacterial growth, 
the response of other cell types and whole tissues might be quite different. For example, 
retinal degeneration has been observed in the rat after systemic administration of 
AlCl3[580] and intraocular injection of CuSO4 produced inflammation and lowered 
intraocular pressure in the rabbit[581]. While these routes of administration were different 
to the intended application, the risk of damaging ocular function must be understood prior 
to clinical use in order to weigh any risk against the benefits. Methods to investigate this 
are discussed in Section 9.3.1.3. 
In addition, while solutions below pH 6 can cause discomfort, the human eye can tolerate 
application of preparations with pH ranging from 4 to 8[582] and, in sight-threatening 
keratitis, pain on application would be far outweighed by the potential benefit. However, 
as discussed in Chapter 8, the tear fluid has considerable buffering capacity. Human 
tears have been shown to maintain pH 7.0 to 7.7 on titration with the same concentrations 
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of HCl or NaOH that produced pH 3.5 to 8.0 in unbuffered water[541]. The employment of 
reduced solution pH as a means to increase FNa activity at the ocular surface is, 
therefore, likely untenable. However, other formulation approaches may be employed to 
increase the delivery of fusidate through the bacterial OM, as discussed in Section 
9.3.1.2, below. 
As discussed in Chapter 1 (Section 1.4.2), the risk of development of resistance is 
universal to the use of antimicrobial drugs. Rates of resistance emergence are generally 
lower when agents are combined due to greater efficacy and consequently shorter 
exposure duration[187],[202]–[204]. However, only one point mutation is required to render EF-
G impervious to FNa binding[583]. Furthermore, when used systemically, FNa is always 
combined with at least one other agent in order to limit resistance induction[584]. 
Treatment of corneal infections takes considerably longer than conjunctivitis[1],[585], the 
approved ocular indication of FNa, which would result in prolonged exposure of infecting 
bacteria to FNa. Therefore, addition of another antimicrobial agent to the formulation may 
be appropriate. In fact, a broad spectrum triple antibiotic formulation for the treatment of 
bacterial corneal ulcers combining polymyxin B, trimethoprim and rifampin has recently 
been proposed[586]. The authors not only demonstrated synergy against planktonic 
P. aeruginosa and S. aureus, but also activity against established in vitro biofilms and a 
murine model of S. aureus keratitis. All additions to the antimicrobial arsenal are valuable 
in the face of ever-increasing resistance, however, polymyxins are still considered drugs 
of last resort in the treatment of MDR infections of all types[587]. In order to limit the 
chances of development and spread of resistance to these important agents, the 
employment of the polymyxin B, trimethoprim and rifampin combination may need to be 
reserved only for keratitis cases of extreme severity or with resistance to other available 
agents. However, a formulation based on the combination of metal ions and FNa with 
the addition of another agent could serve as an initial first line treatment for early 
presenting cases with broader spectrum than current options. This could be followed by 
amendment to a second line combination including polymyxin B, if necessary. Such an 
approach would still streamline bacterial keratitis management while preserving 
effectiveness of precious last line antimicrobials. 
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9.3 Future directions 
9.3.1 Further research 
9.3.1.1 Mechanism of action 
The evidence gathered in this thesis suggests OM damage caused by metal ions plays 
a role in their synergistic activity with FNa. In most circumstances, OM disruption can be 
detected by assaying alkaline phosphatase activity in the medium[588]. Alkaline 
phosphatase is a periplasmic enzyme which can convert p-nitrophenyl phosphate into a 
coloured product, spectrophotometrically quantifiable at 410 nm. However, divalent 
metal ions non-competitively inhibit the enzymatic activity[589] by inducing conformational 
changes and aggregation[590] while Al3+ also inhibits its activity[591] by strong but reversible 
binding[592]. Modification to the assay using a metal chelation or quenching step prior to 
substrate addition may be able to overcome these issues providing the enzyme structure 
is not irreversibly denatured. 
Alternatively, increased OM penetration of FNa as the mechanism of synergistic activity 
with metal ions could be verified by comparison to the effects of an agent known to 
disrupt the OM with no other antimicrobial mechanisms. For example, recently 
discovered B2088 specifically binds to lipid A to disrupt the LPS and has been shown to 
synergise with a variety of antimicrobials normally hindered by the OM[569]. In addition, 
the involvement of efflux inhibition could be investigated using AcrAB-TolC 
inhibitors[570],[571] in place of metal ions in combination with FNa. Furthermore, 
combinations of membrane disruptor and efflux inhibitor could be used to further 
characterise the involvement of each mechanism. 
The work in Chapter 5, Section 5.4.4, demonstrates that the amount of FNa associated 
with E. coli cells increased as pH is reduced. Experimental parameters were selected to 
ensure similar numbers of live bacteria would be present across all test conditions so 
that results would not be skewed by passive diffusion into dead cells unable to efflux. 
However, the concentration of Cu2+ employed was not sufficient to lower pH. Therefore, 
the effect of metal ions and acidity could not be fully quantified by this method. An 
alternative method could have been to utilise fluorescent microscopy in order to quantify 
FNa with greater sensitivity and after a shorter exposure time[593]. However, such an 
approach requires the drug of interest to fluoresce. Some antimicrobial drugs, such as 
quinolones[594], contain a fluorophore which can be employed in fluorescent microscopy, 
however, FNa does not. Non-fluorescing drugs can be modified by chemical substitution 
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in order to produce fluorescence[595]. However, production can be complex and the 
substitution positioning is crucial, frequently impacting the drug affinities for uptake, efflux 
or target, compromising the validity of such studies[595]. Radio-labelling may be a suitable 
alternative since substitution with a radioactive isotope should not alter the overall 
properties of FNa. Microautoradiography has been used to determine the intracellular 
localisation of radionuclides mammalian cells[596] and uptake of radio-labelled nutrients 
in environmental bacteria[597]. The same approach may be used to explore the bacterial 
localisation of FNa, with and without the presence of metal ions. 
Another option which would enable simultaneous 3D localisation studies of both FNa 
and metal ions is Time-of-Flight secondary ion mass spectrometry (TOF-SIMS). TOF-
SIMS can be used to determine the 3D positioning of molecules and atoms[598] within 
bacterial cells to a resolution of ~200 nm[599]. In addition to enabling visualisation of metal 
ions as well as FNa and rendering information in 3D, another key advantage of this 
relatively new technique over microscopy-based methods is that no labelling or 
fluorescence of the target drug or cellular components is required[598],[599]. Drugs, metal 
ions, important cellular components and/or mounting material can be characterised 
alone and resulting signal information applied to the experimental output[598],[599]. The 
method has already been used to demonstrate the internalisation of tetracycline and 
ampicillin in E. coli[599], localisation of quinolones in P. aeruginosa biofilms inside infected 
tissues[600], and presence of cystic fibrosis-specific lipid markers in lung and intestinal 
tissue of a murine model[601]. 
The mechanism of Al3+ in sensitising P. aeruginosa to FNa is a particular area of interest 
for future research since the combination was so unexpectedly efficacious. As discussed 
in Chapter 6, this may be due to increased susceptibility of the P. aeruginosa LPS to Al3+ 
attack compared to that of the Enterobacteriaceae, or increased OM permeabilisation 
due to different protein and porin arrangement. The aim of the investigations using MDR 
representatives of GN organisms capable of causing keratitis was to determine whether 
they were inhibited by metal ion and FNa combinations in a similar way to the E. coli 
reference strain. It was beyond the scope of the present work to characterise any 
differences in responses between species other than by comparison to known carriage 
of resistance genes. However, it may be hypothesised that, unlike against the 
Enterobacteriaceae, Al3+ interferes with one or more of P. aeruginosa's mechanisms of 
FNa tolerance. This could indicate a novel drug target in an organism the US Centers for 
Disease Control and Prevention lists as a serious threat to public health[602]. Wellcome 
Trust funding has been awarded for a project to investigate this hypothesis utilising 
genome-wide association studies. The MICs of FNa and Al3+ alone and in combination 
will be determined against a library of 145 genetically varied P. aeruginosa isolates. 
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Whole genome sequencing of isolates will be performed and the data used to map the 
degree of combination sensitivity to the presence, absence or particular allele of genes 
of potential targets across the isolate library. This may reveal a novel mechanism through 
which P. aeruginosa can be inhibited and a focus for future development of antimicrobial 
agents against this increasingly resistant organism. 
9.3.1.2 Formulation 
A variety of formulation strategies may be able to be employed to increase FNa delivery 
to bacterial cells without relying on lowering of the local pH. Two of these approaches 
are complexation with cyclodextrins and inclusion within liposomes, the results of both 
requiring less energy to successfully interact with the target membranes compared to the 
free drug. The lower energy requirement is due to a reduction of repulsive double layer 
force or increase of attractive van der Waals forces or both, as described by the 
Derjaguin Landau Verwey Overbeek (DLVO) theory[603],[604]. Cyclodextrins are cyclic 
oligosaccharides composed of 6 to 8 glucose units. Their structure enables the formation 
of inclusion complexes with a variety of organic molecules, shielding a portion of the 
guest molecule and increasing its effective solubility and bioavailability[605]. FNa can form 
1:1 and 1:2 complexes with β- and ɣ-cyclodextrin, respectively[606]. Complexation with 
cyclodextrins has been shown to enhance the permeation of a variety of drugs across 
mammalian corneas, including pilocarpine[607], riboflavin[608] and voriconazole[609]. In 
addition, the highly lipophilic itraconazole has been successfully solubilised by 
complexation with cyclodextrins, significantly enhancing both its corneal penetration and 
antifungal activity[572]. Addition of a mucoadhesive polymer can has also been shown to 
increase the residence time and therefore corneal concentration of cyclodextrin 
complexed drugs by slowing elimination due to lacrimation and blinking[610]. Liposomes 
are synthetic phospholipid bilayer vesicles which can be used to encapsulate drug 
molecules. Incorporation into liposomes can increase the drug residency time at the site 
of administration[562], overcome issues of solubility[562] and increase biofilm 
penetration[611]. In particular, fusogenic liposomes are specifically designed with the 
inclusion of specific lipids to enhance fusion with biological membranes and more 
efficiently deposit the cargo into the target cells[612]. Fusogenic liposomes containing FA 
have been shown to be more antimicrobially active against both GP and GN bacteria 
than FA encapsulated in standard liposomes in vitro, however, the authors did not 
determine MICs of free FA against the GN strains used, preventing comparison[612]. In 
addition, liposomal encapsulation has been shown to increase the penetration of FA into 
mouse skin[613], indicating potential for enhancing delivery into other low permeability 
tissues such as the cornea. Both these approaches could reduce the protein binding and 
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increase the bioavailability of FNa, increasing antimicrobial activity in keratitis. In 
addition, the incorporation of metal ions alongside FNa into liposomes could produce 
similar or even greater activity to that observed in NB in this work by enhancing delivery 
both agents directly into the bacterial periplasm. 
9.3.1.3 Efficacy and toxicity 
While cell culture can provide early indicative toxicity data, the effects of an agent on 
whole tissues has been shown to more closely correlate to in vivo results. An in vitro 
method to assess potential ocular irritation is to use the chorioallantoic membrane of a 
hen’s egg as a model[614]–[616]. There are several versions of the hen’s egg test, all of 
which involve the application of the investigative substance to the exposed 
chorioallantoic membrane of fertilised hens’ eggs and assessment of damage to the 
vasculature indicative of irritation[614]–[616]. This model is effective due to the similarly 
between the vascularisation and inflammatory processes exhibited by the chorioallantoic 
membrane and the conjunctiva[617]. The assay therefore enables prediction of the irritant 
effects of a potential ocular drug or formulation and optimisation of safe dosing ranges 
without the use of experimental animals. However, the hen’s egg test would not be 
suitable for modification as a model of infectious keratitis due to gross differences in 
structure and tissues of the hen’s egg compared to the eye. 
Excised corneas from rabbit[618],[619], porcine[620], canine[621], caprine[622] and human[623],[624] 
eyes have been utilised in various ex vivo models of infectious keratitis. Such models 
enable the study of antimicrobial efficacy against microbes resident in tissue closely 
mimicking in vivo conditions. In addition, the use of eyes from slaughtered food animals 
such as pigs or from human donors negates the use and sacrifice of experimental 
animals. However, while ex vivo investigations may provide a good indication of in situ 
drug or formulation antimicrobial efficacy, isolation from systemic immune functions can 
limit the accuracy of simulated keratitis and progression. For example, ex vivo corneas 
do not develop ulceration after infection due to lack of recruitment of inflammatory and 
other immune cells from the circulation[624]. This may impact the interpretation of 
antimicrobial efficacy since drug penetration of an ulcer presents additional challenges. 
For similar reasons, the infection can also progress more rapidly than often observed in 
vivo[622]. Despite these limitations, an ex vivo model could be used to determine indicative 
spectrum of activity and, alongside the hen’s egg test, used to optimise parameters such 
as dosing prior to in vivo testing, thereby limiting animal use. 
Organotypic modelling of the human cornea has also been achieved using 3D culture of 
keratocytes embedded in a collagen gel supported by a polycarbonate filter and overlaid 
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with corneal epithelial cells a the air-liquid interface[625]. A 3D culture of human corneal 
epithelial cells has also been shown to exhibit similar permeability and drug-metabolising 
enzyme expression as ex vivo tissue[626],[627]. Such models could be used investigate the 
corneal penetration and cytotoxicity of FNa and metal ion combinations to the ocular 
tissues without the use of experimental animals. In addition, this system could be 
modified to produce an in vitro keratitis model. While this would lack the immune 
response, as with ex vivo corneal models, it would provide a standardised, animal-fee 
system enabling the simultaneous study of bacterial and mammalian responses to early 
stage developmental drugs and formulations. 
Novel drugs or formulations can be tested in vivo using a model of bacterial keratitis. 
Most commonly, rabbits are employed[628], however, a recent mouse model has also 
been developed[573]. In both animals, keratitis is induced by scratching the cornea and 
introducing a small volume of bacterial suspension. Experimental treatment is initiated 
within 24 h of the infection procedure and outcomes measured by clinical scoring of the 
resulting ulcer and/or CFU count from homogenised excised corneas . While rabbits are 
the more widely accepted keratitis model, the nictitating membrane must be removed in 
order to more mimic the human eye structure which is devoid of this third eyelid[628]. The 
mouse model negates this requirement, reducing some of the time, costs and animal 
welfare concerns associated with such investigations. 
9.3.2 Additional and alternative clinical applications 
Helicobacter pylori is a GN bacterium capable of colonising the acid environment of the 
stomach[629]. Infection itself is often without symptoms, however, the presence of H. pylori 
is strongly correlated with gastric ulcer and gastric cancer[630]. Current treatment 
regimens involve multiple antimicrobials along with suppression of stomach acid 
production, which can lead to secondary infections and other complications[631]. 
However, the acid environment could be utilised to enhance FNa activity against 
H. pylori. In addition, several steroid-like compounds with similar structure to FNa have 
been isolated from a variety of gums and shown to exhibit some antimicrobial activity 
against H. pylori[632]. Therefore, the addition of FNa and metal ions to treatment regimens 
could increase H. pylori eradication efficacy while reducing the need for long term acid 
suppression and associated secondary infection risk. 
With appropriate formulation optimisation, the combination of FNa and Al3+ may be useful 
in other infections caused by P. aeruginosa. Aside from keratitis, P. aeruginosa can 
248 
cause severe infection secondary to other conditions including cystic fibrosis[493] and 
burn[633] or surgical[634] wounds. These groups of vulnerable patients often suffer from 
long duration or refractory infections. A treatment regimen including a novel anti-
P. aeruginosa agent from the work described in 9.3.1.1 or even combined FNa and Al3+ 
formulation could make a significant impact on early infection management and recovery. 
9.4 Closing remarks 
In this work, the presence of Al3+, Cu2+ or Fe2+ ions was found to increase the activity of 
FNa against a selection of intrinsically resistant E. coli, K. pneumoniae and 
P. aeruginosa reference strains and MDR isolates in NB, without interfering with anti-
S. aureus efficacy. The mechanism of action was determined to be a combination of 
reduced FNa solubility enabling increased access through bacterial membranes and the 
independent antimicrobial activity of the metal ions. There was no apparent link between 
the carriage of any individual or combination of antimicrobial resistance determinants 
and susceptibility to the FNa and metal ion combinations in the MDR isolates tested. In 
addition, while exposure to metal ions can result in mammalian toxicity, human corneal 
epithelial cells were less inhibited by Al3+, Cu2+ or Fe2+ alone than GN reference strains. 
Of particular interest, Al3+ decreased FNa MIC90s against P. aeruginosa strains by at 
least 512-fold and was least toxic to human corneal epithelial cells yielding a selectivity 
index indicative of potential suitability for clinical use. Unfortunately, the combination of 
FNa and Al3+ proved to be antimicrobially inactive against GN reference strains in a novel 
STF, likely due to protein binding of both agents. Further hurdles regarding penetration 
of the infective biofilm and development of resistance may also prove problematic. 
However, formulation strategies such as encapsulation of FNa and metal ion 
combinations in fusogenic liposomes and inclusion of an additional antimicrobial may 
enable direct delivery of an active drug cocktail to bacterial cells and minimise resistance 
induction. Furthermore, investigation into the specific mechanism of Al3+ in combination 
with FNa against P. aeruginosa could identify a novel antimicrobial target and guide 
design of a new drug to treat infections caused by this important opportunistic pathogen.
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Appendix A: Personal and environmental safety 
Safety assessments were completed prior to commencement of experimentation. All 
microbiology and aseptic procedures were carried out in a designated biosafety level 
2 (BSL2) laboratory inside an MSC-Advantage laminar flow safety cabinet (Thermo 
Fisher Scientific, Loughborough, UK). All surfaces used during microbiology work were 
decontaminated before and after use with 70 % ethanol (EtOH) or 10 % sodium 
hypochlorite, as appropriate. Contaminated microbiological waste was autoclaved on-
site, prior to collection for incineration, per School of Pharmacy and Pharmaceutical 
Sciences procedures. Cell culture work was carried out in a separate, designated BSL2 
laboratory in a Heraeus HeraSafe HS12 laminar flow safety cabinet (Thermo Fisher 
Scientific, Loughborough, UK) with 70 % EtOH as a decontaminant. Cell culture waste 
was sterilised using Presept™ per local procedure. A 10x Presept™ solution, prepared 
by dissolving one 2.5 g tablet in 1 L water, was mixed 1:9 with liquid waste at least 
30 min before disposal. All flammable, volatile and/or corrosive chemicals were stored 
and handled per School and labelling safety guidelines. Personal protective equipment 
(PPE) comprising of laboratory coat, nitrile gloves and safety glasses was employed 
during laboratory work, as appropriate. 
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Appendix B: Calibration curves for quantification of fusidate 
by RP-HPLC 
The linear regression equations for peak area : fusidate concentration were determined 
for both RP-HPLC separation methods (Section 2.6, page 53) using serial twofold 
dilutions of FNa in 50 % v/v EtOH, in triplicate. Example chromatograms for separation 
methods 1 and 2 are presented in Figure 10.1 and Figure 10.2, respectively. 
 
Figure 10.1 - Example chromatogram for fusidate resolved by RP-HPLC separation 
method 1[287] 
Sample analysed was 1280 µM sodium fusidate in 50 % EtOH 
 
Figure 10.2 - Example chromatogram for fusidate resolved by RP-HPLC separation 
method 2[288] 
Sample analysed was 400 µM sodium fusidate in 50 % EtOH 
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Peak areas of lower LOQ and above were plotted against FNa concentration and the 
linearity of the relationship assessed. Accuracy of the linear regression equations was 
verified by using the detected peak areas and comparing the calculated fusidate 
concentration to that in the originally analysed samples. 
The correlation between peak area produced by separation method 1 and FNa 
concentration was linear from 10 to 2,560 μM with an R2 value of 0.9997 (Figure 10.3) 
and calculation error of ±3.34 %. 
 
Figure 10.3 - Calibration curve for fusidate quantification by RP-HPLC separation 
method 1[287] 
LOD: 5 μM, LOQ: 10 μM, 
range: 10-2,560 μM (69.5-19,877.8 mAU2), in-range error: ±3.34 % 
The linear correlation was found to cover all FNa concentrations analysed by separation 
method 2 (1.5625 to 800 μM) and intersected at 0,0. The equation and R2 value are 
shown in Figure 10.4. The calculation error across all concentrations used was ±2.28 %. 
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Figure 10.4 - Calibration curve for fusidate quantification by RP-HPLC separation 
method 2[288] 
LOD: ≤1.5625 μM, LOQ: ≤1.5625 μM, 
range: 1.5625-800 μM (45.0-23,048.7 mAU2), in-range error: ±2.28 % 
The inverted linear regression formula for calculation of fusidate concentration from peak 
areas obtained by separation method 1 was:  
[𝑓𝑓𝑒𝑒𝑠𝑠𝑖𝑖𝑑𝑑𝑝𝑝𝑝𝑝𝑝𝑝 (𝜇𝜇𝑀𝑀)] = (𝑐𝑐𝑐𝑐𝑚𝑚2 + 8.1675)7.768  
While by separation method 2, the inverted linear regression formula was: 
[𝑓𝑓𝑒𝑒𝑠𝑠𝑖𝑖𝑑𝑑𝑝𝑝𝑝𝑝𝑝𝑝 (𝜇𝜇𝑀𝑀)] = 𝑐𝑐𝑐𝑐𝑚𝑚228.811 
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Appendix C: Optimisation of assay parameters for study of 
sodium fusidate association with E. coli cells 
C(i): Verification of bacterial pellet processing and sodium fusidate 
extraction 
E. coli NCTC 10418 was grown overnight on NA and used to inoculate six 40 mL 
volumes of standard NB. After incubation at 35 °C and 120 rpm for 18 to 24 h, liquid 
cultures were centrifuged in a Heraeus Megafuge 8R centrifuge (Thermo Scientific, 
Osterode am Harz, Germany) for 20 min at 3260 g (4500 rpm) at room temperature and 
the supernatants carefully decanted. Three of the six bacterial pellets were pooled and 
resuspended in 30 mL NB containing 160 µM FNa while the other three were pooled and 
resuspended 30 mL NB without FNa. Resuspended bacterial were incubated at 35 °C 
and 120 rpm for 30 min. After the exposure duration, the suspensions were centrifuged 
at 4 °C (pre-cooled) for 20 min at 4500 rpm. Post-exposure pellets were resuspended in 
3 mL HPLC-grade water to which 3 mL absolute EtOH was added and thoroughly mixed. 
Suspensions of S. aureus NCTC 12973 were prepared in sterile PBS from cultures 
grown overnight on NA and the optical density adjusted to 0.1±0.02 at 625 nm. Sterile 
cotton swabs were used to spread S. aureus suspension evenly over the surface of NA 
plates and allowed to dry for 15 min. Wells of 7.5 mm diameter were made aseptically in 
the centre of each inoculated plate. 
Ten minutes after addition of EtOH to resuspended, FNa-exposed and control E. coli, 
50 µL aliquots were transferred to the wells of agar diffusion plates prepared with 
S. aureus. Simultaneously, approximately 1.5 mL of the E. coli suspension in 50 % EtOH 
was syringe filtered and 50 µL filtrate also added to diffusion wells. This process was 
repeated 30, 60 and 120 min after EtOH addition. Control diffusion plates of 50 % EtOH 
without E. coli or FNa and 20, 40 and 80 µM FNa in 50 % EtOH without E. coli were also 
prepared. Ager plates were incubated overnight at 37 °C and the zones of inhibition 
measured in mm. Where confluent growth was observed up to the well edge, the zone 
of inhibition was recorded as 0 mm. 
The growth of S. aureus was not inhibited by the 50 % EtOH control (Table 10.1). All 
three FNa concentrations produced measurable zones of inhibition and zone diameter 
increased FNa concentration. 
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Table 10.1 - Control inhibition zone diameters produced by sodium fusidate against 
S. aureus NCTC 12973 on nutrient broth 
Control condition Inhibition zone diameter 
(mm) 
50 % EtOH 0 
20 µM FNa in 50 % EtOH 28 
40 µM FNa in 50 % EtOH 30 
80 µM FNa in 50 % EtOH 31 
 
There was no growth of E. coli after exposure to 50 % EtOH for ≥10 min, demonstrating 
the bacteria were rapidly and completely killed. No inhibition was produced by lysed raw 
or filtered E. coli (Table 10.2), indicating that S. aureus was not perturbed by any 
remaining metabolites or other E. coli products. There was no apparent difference 
between zone sizes produced by filtrate or raw lysed E. coli after FNa exposure. This 
indicates FNa concentration before and after filtration is similar and FNa is not highly 
bound to the particulate matter remaining after E. coli lysis by exposure to 50 % EtOH. 
 
Table 10.2 - Zones of inhibition of S. aureus NCTC 12973 on nutrient broth produced by 
lysate of E. coli NCTC 10418 exposed to sodium fusidate  
Time after 
addition of EtOH 
(min) 
Inhibition zone diameter (mm) 
FNa-exposed E. coli Control E. coli 
unfiltered filtered unfiltered filtered 
10 20 19.5 0 0 
30 20 20 0 0 
60 20 21 0 0 
120 18.5 19.5 0 0 
 
Exposure to 50 % EtOH produces rapid killing of E. coli and effective solubilisation of 
FNa from the bacterial pellet. Filtration of the lysed, FNa-treated E. coli without 
detectable FNa loss makes this simple process amenable to employment for HPLC 
sample preparation. 
C(ii): Selection of RP-HPLC method for quantification of fusidate 
Separation method 1 did not adequately resolve fusidate when in the presence of 
bacterial lysate (Figure 10.5-1). However, separation method 2 was effective (Figure 
10.5-2). Therefore, while the 10 min isocratic separation method 1 was employed for 
most fusidate quantification purposes, the 45 min gradient separation method 2 was 
required for the analysis of samples containing bacterial lysate. 
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Figure 10.5 - Example chromatograms for fusidate in bacterial lysate resolved by RP-HPLC 
separation method 1 and separation method 2 
Sample analysed by both methods was E. coli in 50 % v/v EtOH after exposure to 160 µM 
sodium fusidate in nutrient broth for 30 min. There was insufficient separation of fusidate 
(black box) and the adjoining peak when using method 1 (upper panel), while fusidate 
(labelled peak) was well resolved and quantifiable by method 2 (lower panel).  
1 
2 
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Appendix D: Isothermal titration calorimetry (ITC) 
performance validation and additional replicates 
D(i): EDTA-CaCl2 performance validation standard 
 
Figure 10.6 – Example of EDTA-CaCl2 ITC performance validation data 
Data generated during performance validation testing was fit to a one site interaction model 
using the MicroCal Origin software. 
The EDTA-CaCl2 performance validation standard was carried out at the start of each 
day prior to initiation of experimentation. If the results of the EDTA-CaCl2 test did not fit 
the required parameters, the instrument syringe, sample cell and reference cell were 
thoroughly cleaned per the manufacturer’s instructions and the validation run repeated 
until acceptable results were obtained. No more than two runs were required on any one 
day to achieve successful performance validation. 
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All solutions used in the performance validation tests were pre-made and provided by 
the manufacturer. The injectant was 5 mM CaCl2 in 10 mM 2-(N-
morpholino)ethanesulfonic acid (MES) at pH 5.6, the sample was 0.4 mM EDTA in 
10 mM MES at pH 5.6 and 10 mM MES at pH 5.6 was used in the reference cell. The 
run parameters were 25 °C cell temperature, 1000 rpm stirring speed, injection interval 
of 150 s, and 20 injections with initial injection of 0.4 μL over 0.8 s and subsequent 
injections of 2 μL over 4 s. After completion of data collection, the MicroCal Origin 
software was used to fit the data to the one site interaction model. An example of the 
typical results of a successful EDTA-CaCl2 performance validation test are shown in 
Figure 10.6. 
D(ii): Additional experimental ITC replicates 
 
  
Figure 10.7 –ITC thermograms of sodium fusidate with copper(II) sulphate 
Upper panels show enthalpy change at each injection over time and lower panels show the 
integrated enthalpy curve points normalized per mole of injectant as a function of molar ratio. 
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Figure 10.8 –ITC thermogram of sodium fusidate with copper(II) D-gluconate at native pH 
Upper panels show enthalpy change at each injection over time and lower panels show the 
integrated enthalpy curve points normalized per mole of injectant as a function of molar ratio. 
 
Figure 10.9 –ITC thermogram of sodium fusidate with copper(II) gluconate at pH 6.12 
Upper panels show enthalpy change at each injection over time and lower panels show the 
integrated enthalpy curve points normalized per mole of injectant as a function of molar ratio. 
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Figure 10.10 –ITC thermograms of sodium fusidate with sodium D-gluconate 
Upper panels show enthalpy change at each injection over time and lower panels show the 
integrated enthalpy curve points normalized per mole of injectant as a function of molar ratio. 
 
 
 
Figure 10.11 - ITC thermogram of sodium fusidate with dilute sulphuric acid 
Upper panels show enthalpy change at each injection over time and lower panels show the 
integrated enthalpy curve points normalized per mole of injectant as a function of molar ratio. 
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Appendix E: Co-optimisation of LDH and MTT assays 
LDH and MTT assays were co-optimised to enable performance of both tests 
simultaneously using the same cell populations. Human corneal epithelial cells (HCE) 
were selected for use as these are the most common in vitro model for ocular toxicity 
testing[635]–[637]. The adenovirus-immortalised HCE-2 [50.B1] CRL-11135 from ATCC 
(HCE-2) cell line was chosen as opposed to primary cells. Compared to primary cells, 
adenovirus-immortalised HCE exhibit increased stability with normal growth and 
behaviour being observed for up to 400 generations rather than the one or two 
generations common with primary cells[638]. In addition, employment of an establish cell 
line negated lengthy isolation procedures and guaranteed intra-lot standardisation. 
While the MTT assay is one of the most commonly used measures of in vitro cell 
proliferation, there are several parameters which lack standardisation. For example, the 
wavelength employed to quantify MTT formazan solubilised in DMSO has been reported 
as 490[639]–[642], 540[481],[643],[644] and 570[645]–[648] nm, however, its λmax in this solvent is 
506 nm[472]. This and other elements therefore required investigation in order to optimise 
the MTT assay.  
The LDH assay is performed using aliquots of cell culture medium into which the enzyme 
is released from dying cells during exposure to the test agents. Since the collection of 
these aliquots does not disturb the monolayer at the bottom of the wells, surviving cells 
can also be used to perform the MTT assay. As such, cell seeding density was optimised 
to allow simultaneous performance of both the LDH and MTT assay on the same cell 
populations. In addition, other elements of the LDH assay were investigated and refined. 
Cells used for all optimisation tests were grown and harvested as described in Section 
7.2.1. All 96 well plates were coated as also described in the same section. 
E(i): Pilot investigations 
Eight columns of two 96 well plates were seeded with two-fold dilutions of HCE-2 ranging 
from 106 down to 781 cells per well in 100 µL KSFM. Another column was filled with 
100 µL complete KSFM per well and a final column with 100 µL BPE-free KSFM per well. 
The outer edges (columns 1 and 12 and rows A and H) were filled with 100 µL sterile 
PBS to limit evaporation. Plates were incubated at 37 °C and 5 % CO2. One plate was 
incubated for 18 h and the other for 42 h to mimic the planned 24 h period of cell 
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acclimatisation and growth followed by 18 h test agent exposure. Comparison between 
the two was used to confirm growth over a 24 h period. 
The LDH assay was first carried out per the Pierce™ LDH Cytotoxicity Assay Kit 
instruction manual[649]. Sterile HPLC grade water (10 µL) was added to each well of three 
rows of the 96 well plate as controls for spontaneous LDH release from the respective 
cell populations and medium. To the other three rows, 10 µL Pierce™ lysis buffer was 
added in order to quantify maximum LDH for each cell population and medium. The plate 
was incubated for 45 min before 50 µL aliquots from each well were transferred to a 
fresh, uncoated flat-bottomed 96 well plate. The LDH reaction mixture was prepared by 
dissolving one vial of Pierce™ substrate mix in 11.4 mL sterile HPLC grade water and 
adding one vial of Pierce™ assay buffer. Fifty µL LDH reaction mixture was added to 
each well of the reaction plate (without mixing), followed by incubation at room 
temperature for 30 min, protected from light. At the end of the reaction period, 50 μL 
Pierce™ stop solution was added to each well (without mixing). Absorbance in each well 
was read at 490 and 680 nm with a Tecan Infinite M200 PRO microplate reader 
(wavelength accuracy ±1.5 nm[283]) preceded by 30 s orbital shaking at 6 mm. The 
background corrected absorbance from spontaneous LDH release wells was subtracted 
from that of the lysed cell wells of the same seeding density and the mean±SD LDH 
activity calculated as an absolute absorbance value. 
MTT 5 mg mL-1 stock solution was prepared in PBS and filter sterilised. The stock 
solution was diluted 1/10 in supplemented KSFM in an uncoated 25 cm2 culture flask 
(with a filter lid) and placed in the incubator to warm and equilibrate with 5 % CO2 for 30-
45 min before use. The final concentration of 0.5 mg mL-1 MTT used in initial testing was 
selected based on the concentration used in several reported HCE-2 proliferation 
investigations[486],[650],[651]. The remaining medium was aspirated from the cell culture 
plate, carefully avoiding disturbance of the cell layer, and replaced with 100 μL of the 
MTT dilution. The plates were wrapped in foil to protect from light and returned to 37 °C 
and 5 % CO2 for 2 h, an incubation period previously reported for MTT on HCE-
2[486],[487],[650]. After the 2 h incubation, the MTT containing medium was removed and 
replaced with 100 μL DMSO per well (without mixing). Plates were incubated at room 
temperature for 20 min, protected from light. The Tecan Infinite M200 PRO microplate 
reader was used to measure absorbance in each well at 540 nm, a wavelength frequently 
used for the quantification of MTT formazan product solubilised in 100 % 
DMSO[481],[643],[644], with each read preceded by 30 s orbital shaking at 6 mm. The values 
from cell-free controls were subtracted from all other wells and the mean±SD absolute 
absorbance was calculated for each cell density. 
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Figure 10.12 illustrates the growth of HCE-2 over 24 h, between the 18 and 42 h post-
seeding time points, as quantified by total LDH release on lysis. All cell populations were 
found to increase; for example, the absorbance of LDH released from cells 18 h after 
seeding 6,250 per well was 0.578 AU which increased to 0.977 AU after 42 h. 
Consequently, the LDH assay procedure was modified to include addition of the lysis 
buffer to a triplicate of maximal LDH release wells at the time of test agent addition in 
order to be able to normalise against the exposed population. 
 
Figure 10.12 – Maximal LDH release from HCE-2 after 18 or 42 h 
 
No linear portion in the relationship between seeded cell density and maximal LDH 
release absorbance was obtained with the generated data. In addition, the variance 
between absorbance in wells of the same technical triplicate was inconsistent and quite 
large in some cases, possibly indicating insufficient or varying degrees of mixing. 
The quality of the MTT results were also insufficient to determine a relationship between 
absorbance at 540 nm and seeded cell density. In addition, variability in absorbance over 
time was incidentally observed while collecting readings. 
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Figure 10.13 - Absorbance of MTT formazan produced by HCE-2 seeded at 12,500 cells per 
well over time after solubilisation in DMSO at 540 nm 
Figure 10.13 illustrates the change in absorbance of MTT formazan produced by HCE-2 
seeded at 12,500 cells per well over time. Observations were continued for more than 
50 min, at which point absorbance started reducing. Since orbital shaking was employed 
before each read, the increase in absorbance could have been due to insufficient mixing 
prior to reading, whereas the subsequent reduction could be due to MTT formazan 
breakdown. 
E(ii): MTT optimisation 
Based on the results of the pilot test, several parameters of the MTT assay were 
identified as requiring optimisation: MTT concentration, whether to mix DMSO on 
addition, DMSO incubation duration, and the reading wavelength. While many 
investigators use 0.5 mg mL-1 MTT, others employ a concentration of 1 mg mL-1 [648],[652]–
[654]. The higher concentration may yield greater MTT formazan production, increasing 
sensitivity of the assay. Since the absorbance of MTT formazan in DMSO was 
incidentally found to change over time during the pilot test, the incubation duration and 
effect of mixing the solvent on addition were selected for investigation. Finally, five read 
wavelengths were selected for investigation in order to identify the most appropriate in 
terms of sensitivity and variability. 
Eight columns of two 96 well plates were seeded with two fold dilutions of HCE-2, from 
37,000 down to 578 cells per well. A ninth column was filled with 100 µL complete KSFM 
per well as a cell-free control and the remaining columns (1, 11 and 12) and the top and 
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bottom rows (A and H) were filled with 100 µL sterile PBS. Plates were incubated at 
37 °C and 5 % CO2 for 42 h. 
MTT stock solution in PBS was diluted in separate volumes of supplemented KSFM to 
final concentrations of 0.5 and 1 mg mL-1. Both were equilibrated to 37 °C with 5 % CO2 
in filter-capped tissue culture flasks for 30-45 min before use. The medium from both 
plates was removed, replaced with MTT dilution and the plates returned to the incubator 
for 2 h. After incubation, the MTT-containing medium was removed and 100 µL DMSO 
added to each well, half with mixing and half without. The combination of MTT 
concentration and DMSO mixing status was arranged so that triplicate rows of serially 
diluted cells were each treated to every possible combination, as listed in Table 10.3. 
Table 10.3 - Combinations of optimisation test conditions 
 MTT concentration DMSO mixing on 
addition 
Set 1 0.5 mg mL-1 yes 
Set 2 0.5 mg mL-1 no 
Set 3 1.0 mg mL-1 yes 
Set 4 1.0 mg mL-1 no 
 
After DMSO addition, plates were protected from light and incubated at room 
temperature for 15 min. The Tecan Infinite M200 PRO microplate reader was used to 
measure absorbance in each well at 490, 506, 520, 553 and 570 nm. Wavelengths of 
490 and 570 nm were selected based on previously reported use[639]–[642],[645]–[648]; 506 nm 
was selected as it is the λmax of MTT formazan in 100 % DMSO[472]; 553 nm was used as 
it is the λmax of MTT formazan in DMSO with 1 % serum which may be more appropriate 
to account for small volumes of medium carry-over[472]; 520 nm was selected as it falls 
between 506 and 553 nm. Absorbance was read again after 30, 45, 60, 75, 90 and 120 
min incubation in the dark at room temperature. Each read was preceded by 10 s orbital 
shaking at 6 mm. The mean±SD cell-free corrected absorbance was calculated for each 
cell seeding density, combination of assay conditions, timepoint and wavelength. 
While absorbance of MTT formazan in DMSO was highest in more than 50 % of the test 
condition combinations at the 15 min timepoint, the variance was also the highest (mean 
SD 0.0189). The highest absorbance was observed after 30 min for 25 % of the test 
condition combinations and the variance was substantially lower with a mean SD of 
0.0104. Therefore, 30 min was selected as the incubation duration for solubilising MTT 
formazan in DMSO and only data for the 30 min timepoint used in subsequent analyses. 
The absorbance of MTT formazan in DMSO produced by cells exposed to either 05 or 
1 mg mL-1 MTT was plotted against the cell seeding density for each wavelength; mixed 
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and unmixed test data were assessed separately. The strength of the linear relationship 
between cell number and absorbance was compared between MTT concentrations. The 
R2 value for 1 mg mL-1 results was greater than those produced by 0.5 mg mL-1 in every 
case (Table 10.4). An MTT exposure concentration of 1 mg mL-1 was selected. 
Table 10.4 - R2 values for linear relationship between cell seeding density and absorbance 
of MTT formazan in DMSO produced by HCE-2 exposed to 0.5 or 1.0 mg mL-1 MTT with or 
without mixing of DMSO on addition 
Wavelength 
(nm) 
DMSO mixed on addition DMSO not mixed on addition 
0.5 mg mL-1 1.0 mg mL-1 0.5 mg mL-1 1.0 mg mL-1 
490 0.9895 0.9938 0.9699 0.9887 
506 0.9863 0.9927 0.9728 0.9826 
520 0.9825 0.9915 0.9726 0.9812 
553 0.9752 0.9893 0.9708 0.9804 
570 0.9759 0.9893 0.9712 0.9799 
Linear relationships were calculated for cell seeding densities of for 2,000-20,000 per well. 
The correlation between cell seeding density and absorbance was found to be stronger 
where DMSO had been mixed on addition than without mixing (Table 10.4). In addition, 
the variance between absorbance of individual replicates was less when DMSO had 
been mixed on addition with a mean SD across all cell densities and read wavelengths 
of 0.00681 compared to 0.0129 without mixing. 
The absorbance (at each wavelength investigated) of formazan produced by HCE-2 after 
exposure to 1 mg mL-1 MTT, mixing of DMSO on addition and 30 min DMSO incubation 
is plotted against seeded cell density in Figure 10.14. The R2 for the linear portion of 
every curve was >0.99. However, the variance increased with wavelength with a mean 
SD of absorbance at 570 nm for 2,000-20,000 cells per well of 0.0131 but 0.00418 for 
absorbance over the same range at 490 nm. A read wavelength of 506 nm was selected 
due to its combination of lower variability than 520, 553 or 570 nm but higher absorbance 
and therefore sensitivity than 490 nm. 
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Figure 10.14 - Absorbance at a variety of wavelengths of formazan produced by HCE-2 after exposure to 1 mg mL-1 MTT for 2 h and correlations with seeding density 
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E(iii): LDH optimisation 
In response to observations during the pilot test, mixing of reaction mixture and stop 
solution on addition were investigated as modifications to the LDH assay. Two 96 well 
plates were prepared and seeded with HCE-2, as described in E(ii) above. Plates were 
also incubated at 37 °C and 5 % pp CO2 for 42 h. 
Sterile HPLC grade water (10 µL) was added to each well in half of each plate and 10 µL 
Pierce™ lysis buffer was added to the other half. After 45 min incubation at 37 °C and 
5 % pp CO2, 50 µL aliquots were transferred from every well to a fresh, uncoated flat-
bottomed 96 well plate. To one reaction plate, 50 µL LDH reaction mixture was added to 
each well without mixing. To the second reaction plate, the same volume of LDH reaction 
mixture was added but with mixing on addition by gently pipetting up and down 4-5 times. 
Both plates were incubated at room temperature for 30 min, protected from light. At the 
end of the reaction period, 50 μL Pierce™ stop solution was added to each well, without 
mixing in the first plate and with mixing in the second. Absorbance read at 490 and 
680 nm after 10 s orbital shaking at 6 mm and the mean±SD absolute LDH activity 
calculated as described above in Section E(i). 
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Figure 10.15 – LDH activity from HCE-2 with and without mixing on addition of assay 
reagents and correlations with seeding density 
(n = 3, error bars = SD) 
In order to disperse bubbles in the LDH reaction plate that reagents had been mixed in 
on addition, centrifugation for 15 min at 25 °C at 4000 rpm was found to be sufficient for 
the majority. The remainder were efficiently popped with a hot syringe needle. 
While absorbance was generally higher when LDH reagents were not mixed on addition, 
the variance between technical replicates was larger and the strength of correlation of 
the linear portion was less than when reagents were mixed (Figure 10.15). As such, the 
LDH assay was modified to include mixing of reaction mixture and stop solution on 
addition. 
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E(iv): Seeding density selection 
 
Figure 10.16 – Comparison of optimised LDH and MTT assay results and linear relationships 
between HCE-2 seeding density and absorbance 
 
The absolute absorbance results from the optimised MTT and LDH assays were plotted 
against cell seeding density and the linear portions identified and compared (Figure 
10.16). The linear portion for the LDH assay spanned 4,625 to 18,500 cells per well, 
while it was 1,156 to 9,250 cells per well for MTT. This corresponded well with the cell 
densities reported in MTT assays employing HCE-2, listed in Table 10.5. Falling within 
both linear portions, a cell seeding density of 8,000 per well was selected. 
Table 10.5 - Published cell seeding densities used in MTT assay 
Paper Plate type Seeding density Pre-MTT 
growth time 
Paimela et al, 
2012[650] 
12 well 
(4 cm2) 
100,000 per well 
(25,000/cm2) 
48 h 
Lee et al, 
2014[486] 
35-mm dish 
(9 cm2) 
200,000 per plate 
(22,222/cm2) 
24 h 
Zheng et al, 
2015[487] 
96 well 
(0.32 cm2) 
5,000 per well 
(15,625/cm2) 
3 days 
Yu et al, 
2018[651] 
96 well 
(0.32 cm2) 
8,000 per well 
(25,000/cm2) 
24 h 
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E(v): Combined assay procedure 
Table 10.6 lists the timing of each task, illustrating the convenience of the dual process. 
Table 10.6 - Timepoints and tasks for the combined LDH and MTT assay procedure 
Time Task 
0 h addition of lysis buffer 
0.75 h removal of aliquots for LDH assay 
1 h replacement of medium with MTT dilution 
1.25 h addition of LDH reaction mixture 
1.75 h addition of LDH stop solution 
2 h centrifugation of LDH reaction plate and dispersal of bubbles 
2.5 h read LDH absorbance results 
3 h replacement of MTT dilution with DMSO 
3.5 h read MTT absorbance results 
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Appendix F: Concentrations of lipids and trace elements in 
STF formulations and human tears 
 
Table 10.7 - Concentrations of lipids in eleven published simulated tear fluid formulations 
Lipids Concentrations in STF formulations (mg L-1) Frequency of use 
(out of 11 
formulations) mean (SD) median range 
cholesterol 1.68 (0.1) 1.6 1.6 - 1.8 5[496],[502],[503],[515],[517] 
cholesteryl linoleate 24 (0) 24 24 - 24 2[496],[515] 
cholesteryl oleate 24.73 (1.04) 24 24 - 26.2 3[502],[503],[517] 
dicaproin 3.2 (0) 3.2 3.2 - 3.2 2[496],[515] 
linalyl acetate 20 (0) 20 20 - 20 2[496],[515] 
oleic acid 7.2 (7.64) 1.8 1.8 - 18 3[502],[503],[517] 
oleic acid methyl ester 12 (0) 12 12 - 12 2[503],[517] 
oleic acid oleyl ester 31.1 (0) 31.1 31.1 - 31.1 1[502] 
oleic acid propyl ester 12 (0) 12 12 - 12 2[496],[515] 
phosphatidyl choline 5.07 (6.46) 0.5 0.5 - 14.2 3[502],[503],[517] 
triolein 13.5 (5) 16 3.5 - 16 5[496],[502],[503],[515],[517] 
undecylenic acid, sodium salt 3.1 (0.1) 3.1 3 - 3.2 2[496],[515] 
 
Table 10.8 - Concentrations of trace elements in eleven published simulated tear fluid 
formulations 
Trace elements Concentrations in STF formulations (nM) Frequency of 
use (out of 11 
formulations) mean (SD) median range 
Co 924.22 (0) 924.22 924.22 - 924.22 1[516] 
Cu 87.99 (0) 87.99 87.99 - 87.99 1[516] 
Fe 29.6 (0) 29.6 29.6 - 29.6 1[516] 
Mn 505.28 (0) 505.28 505.28 - 505.28 1[516] 
Ni 105.18 (0) 105.18 105.18 - 105.18 1[516] 
Zn 513.63 (0) 513.63 513.63 - 513.63 1[516] 
BO3 1617.34 (0) 1617.34 1617.34 - 1617.34 1[516] 
MoO4 103.33 (0) 103.33 103.33 - 103.33 1[516] 
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Table 10.9 - Concentrations of trace elements measured in human tears 
Trace 
elements 
Concentrations measured in human tears (nM) 
reported values (patient population and 
collection conditions) 
mean of 
exact values 
max range 
As 0.33 (healthy, urban residents)[522] 
3.87 (healthy, rural residents)[522] 
2.1 0.33 to 3.87 
Ba 8.0 (healthy, rural residents)[522] 
17.6 (healthy, urban residents)[522] 
18.9 (healthy)[655] 
14.8 8.0 to 18.93 
Co 23.8 (healthy, urban residents)[522] 
28.0 (healthy, rural residents)[522] 
30.0 (healthy)[655] 
27.3 23.8 to 30.0 
Cr 0.96 (healthy, urban residents)[522] 
4.8 (healthy)[655] 
13.2 (healthy, rural residents)[522] 
6.3 0.96 to 13.2 
Cu 97.6 (healthy)[655] 
196.7 (healthy, rural residents)[522] 
200.6 (healthy, urban residents)[522] 
165.0 97.6 to 200.6 
Fe None reported N/A N/A 
Mn 70.4 (healthy)[655] 
344.0 (healthy, stimulated)[656] 
347.7 (Proteus spp corneal ulcer, stimulated)[656] 
349.5 (S. aureus corneal ulcer, stimulated)[656] 
353.1 (P. aeruginosa corneal ulcer, 
stimulated)[656] 
384.1 (Pneumococcal corneal ulcer, 
stimulated)[656] 
308.1 70.4 to 384.1 
Ni None reported N/A N/A 
Pb 2.4 (healthy)[655] 
5.3 (healthy, rural residents)[522] 
8.2 (healthy, urban residents)[522] 
5.4 2.4 to 8.2 
Rb 141.2 (healthy)[655] 
210.6 (healthy, rural residents)[522] 
265.0 (healthy, urban residents)[522] 
205.6 141.2 to 265.0 
Se 6.3 (healthy)[655] 
30.4 (healthy, urban residents)[522] 
38.0 (healthy, rural residents)[522] 
24.9 6.3 to 38.0 
Zn 270.0 (healthy, urban residents)[522] 
321.2 (healthy, rural residents)[522] 
508.6 (healthy)[655] 
366.6 270.0 to 508.6 
BO3 None reported N/A N/A 
MoO4 None reported N/A N/A 
 
